WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, August 31, 2004

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	
☐	L11	L10 AND beta-amyloid 1-28	8
☐	L10	L9 AND antibody	1848
☐	L9	(beta-amyloid OR amyloid-beta OR Abeta)	2993
☐	L8	L7 AND beta	176
☐	L7	L6 AND amyloid	187
☐	L6	(530/387.1,388.1,388.2,389.1,390.5.CCLS.)	4382
☐	L5	L4 AND amyloid	83
☐	L4	424/130.1,135.1,141.1.CCLS.	1905
☐	L3	Solomon.IN.	5805
☐	L2	Solomon-B.IN.	19
☐	L1	(Solomon-Beka.IN.)	17

END OF SEARCH HISTORY

h e b b cg b chh e f c e c ch

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for beta-amyloid AND antibody AND 1-28 Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Summary Show: 500 Sort Send to Text

Items 1-8 of 8 One page.

1: Miller DL, Currie JR, Mehta PD, Potempska A, Hwang YW, Wegiel J. Related Articles, Links

Humoral immune response to fibrillar beta-amyloid peptide.
Biochemistry. 2003 Oct 14;42(40):11682-92.
PMID: 14529278 [PubMed - indexed for MEDLINE]

2: Winkler K, Scharnagl H, Tisljar U, Hoschutzky H, Friedrich I, Hoffmann MM, Huttinger M, Wieland H, Marz W. Related Articles, Links

Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis.
J Lipid Res. 1999 Mar;40(3):447-55.
PMID: 10064733 [PubMed - indexed for MEDLINE]

3: Arai Y, Suzuki A, Mizuguchi M, Takashima S. Related Articles, Links

Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains.
Brain Dev. 1997 Jun;19(4):290-4.
PMID: 9187481 [PubMed - indexed for MEDLINE]

4: Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Related Articles, Links

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4109-12.
PMID: 9108113 [PubMed - indexed for MEDLINE]

5: Xu S, Gaskin F. Related Articles, Links

Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease.
Mech Ageing Dev. 1997 Mar;94(1-3):213-22.
PMID: 9147373 [PubMed - indexed for MEDLINE]

6: Tamaoka A, Endoh R, Shoji S, Takahashi H, Hirokawa K, Teplow DB, Selkoe DJ, Mori H. Related Articles, Links

Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Neurobiol Aging. 1996 May-Jun;17(3):405-14.
PMID: 8725902 [PubMed - indexed for MEDLINE]

7: Solomon B, Koppel R, Hanan E, Katzav T. Related Articles, Links

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):452-5.
PMID: 8552659 [PubMed - indexed for MEDLINE]

8: Gaskin F, Finley J, Fang Q, Xu S, Fu SM. Related Articles, Links

Human antibodies reactive with beta-amyloid protein in Alzheimer's disease.
J Exp Med. 1993 Apr 1;177(4):1181-6.
PMID: 8459212 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

h cb h g e e e fcg e ch b e

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for Stern AND 1989 AND beta Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Summary Show: 500 Sort Send to Text

Items 1-15 of 15 One page.

1: Greenwald P, Stern HR. Related Articles, Links

Role of biology and prevention in aerodigestive tract cancers.
J Natl Cancer Inst Monogr. 1992;(13):3-14.
PMID: 1389693 [PubMed - indexed for MEDLINE]

2: Gronke RS, Welsch DJ, VanDusen WJ, Garsky VM, Sardana MK, Stern AM, Friedman PA. Related Articles, Links

Partial purification and characterization of bovine liver aspartyl beta-hydroxylase.
J Biol Chem. 1990 May 25;265(15):8558-65.
PMID: 2187868 [PubMed - indexed for MEDLINE]

3: Moore BJ, Inokuchi T, Horwitz BA, Stern J. Related Articles, Links

Maternal brown fat metabolism returns to control level by four weeks postweaning in rats.
J Nutr. 1989 Dec;119(12):1992-8.
PMID: 2695604 [PubMed - indexed for MEDLINE]

4: Rutka JT, Rosenblum ML, Stern R, Ralston HJ 3rd, Dougherty D, Giblin J, DeArmond S. Related Articles, Links

Isolation and partial purification of growth factors with TGF-like activity from human malignant gliomas.
J Neurosurg. 1989 Dec;71(6):875-83.
PMID: 2585080 [PubMed - indexed for MEDLINE]

5: Stern MH, Lipkowitz S, Aurias A, Griscelli C, Thomas G, Kirsch IR. Related Articles, Links

Inversion of chromosome 7 in ataxia telangiectasia is generated by a rearrangement between T-cell receptor beta and T-cell receptor gamma genes.
Blood. 1989 Nov 1;74(6):2076-80.
PMID: 2529926 [PubMed - indexed for MEDLINE]

6: Stern N, Eggena P, Chandler W, Tuck ML. Related Articles, Links

Effects of central and peripheral dopamine antagonism on aldosterone secretion: evidence for adrenal mechanism.
Am J Physiol. 1989 Oct;257(4 Pt 1):E588-94.
PMID: 2679132 [PubMed - indexed for MEDLINE]

7: Brewster ME, Simpkins JW, Hora MS, Stern WC, Bodor N. Related Articles, Links

The potential use of cyclodextrins in parenteral formulations.
J Parenter Sci Technol. 1989 Sep-Oct;43(5):231-40. Review.
PMID: 2681643 [PubMed - indexed for MEDLINE]

8: Goldey SH, Stern GA, Oblon DJ, Mendenhall NP, Smith LJ, Duque RE. Related Articles, Links

Immunophenotypic characterization of an unusual T-cell lymphoma presenting as anterior uveitis. A clinicopathologic case report.

h cb h g e e e fcg e ch b e

Arch Ophthalmol. 1989 Sep;107(9):1349-53.
PMID: 2675806 [PubMed - indexed for MEDLINE]

9: Rinke de Wit TF, Vloemans AA, van den Elsen PJ, Ward J, Sutcliffe RC, Glazebrook J, Haworth A, Stern PL. Related Articles, Links

Novel human MHC class I genes are expressed by tumour cell lines representing embryonic and extraembryonic tissues.
J Immunogenet. 1989 Aug-Oct;16(4-5):391-6.
PMID: 2639910 [PubMed - indexed for MEDLINE]

10: Stern MD, Weisman HF, Renlund DG, Gerstenblith G, Hano O, Blank PS, Lakatta EG. Related Articles, Links

Laser backscatter studies of intracellular Ca2+ oscillations in isolated hearts.
Am J Physiol. 1989 Aug;257(2 Pt 2):H665-73.
PMID: 2504061 [PubMed - indexed for MEDLINE]

11: Gronke RS, VanDusen WJ, Garsky VM, Jacobs JW, Sardana MK, Stern AM, Friedman PA. Related Articles, Links

Aspartyl beta-hydroxylase: in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX.
Proc Natl Acad Sci U S A. 1989 May;86(10):3609-13.
PMID: 2726737 [PubMed - indexed for MEDLINE]

12: Dover JS, McEvoy MT, Rosen CF, Arndt KA, Stern RS. Related Articles, Links

Are topical corticosteroids useful in phototherapy for psoriasis?
J Am Acad Dermatol. 1989 May;20(5 Pt 1):748-54.
PMID: 2654215 [PubMed - indexed for MEDLINE]

13: Stern RA, Otvos L Jr, Trojanowski JQ, Lee VM. Related Articles, Links

Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer's disease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system.
Am J Pathol. 1989 May;134(5):973-8.
PMID: 2524164 [PubMed - indexed for MEDLINE]

14: Bantleon HP, Droschl H, Stern G. Related Articles, Links

[Different applications of various wire alloys in fixed appliance technic]
Inf Orthod Kieferorthop. 1989 2D QUARTER;21(2):173-83. German.
PMID: 2639865 [PubMed - indexed for MEDLINE]

15: Daems D, Boens N, De Schryver FC. Related Articles, Links

Fluorescence quenching with lindane in small unilamellar L,alpha-dimyristoylphosphatidylcholine vesicles.
Eur Biophys J. 1989;17(1):25-36.
PMID: 2473894 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

h cb hg e e e fcg e ch b e

1: Am J Pathol. 1989 May;134(5):973-8.

Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer's disease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system.

Stern RA, Otvos L Jr, Trojanowski JQ, Lee VM.

Department of Pathology and Laboratory Medicine (Neuropathology), University of Pennsylvania School of Medicine.

Studies were conducted to identify neural cells that synthesize and/or process cerebral amyloid using antisera and monoclonal antibodies (MAbs) raised to synthetic peptides based on the first 28 amino acids of the amyloid beta-protein. Using rabbit and mouse antisera, and 7 MAbs, sections of neocortex, hippocampus, cerebellum, and spinal cord from Alzheimer's disease (AD), Down's syndrome (DS), and control cases were probed. The antibodies produced 3 distinct immunohistochemical patterns: 1) staining restricted to neuritic plaque and blood vessel amyloid only (antisera, 1 of 7 MAbs); 2) immunoreactivity confined to cytoplasmic granules in diverse neuronal, glial (astrocytes, ependyma) and other (leptomeningeal, perivascular, choroid plexus) cells (1 of 7 MAbs); 3) a summation of these 2 patterns (5 of 7 MAbs). Controls resembled the AD and DS cases, except for a paucity of immunoreactive plaques and blood vessels in the controls. Immunoreactivity was reduced or removed by the peptides used to produce these antibodies. Formalin- and Bouins-fixed tissues reacted weakly or not at all with these antibodies while microwave denatured tissues reacted very intensely with them. Specific staining was enhanced by treatment of the tissue sections with Triton X-100, NaDodSO4, or trypsin. These studies significantly extend earlier studies that localized amyloid beta-protein precursor mRNA to human brain cells, and they suggest that the beta-protein, its precursor, and/or fragments thereof may exist in diverse neural cell types in AD, DS, and control brains.

PMID: 2524164 [PubMed - indexed for MEDLINE]

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for 10D5 Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display Summary Show: 500 Sort Send to Text

Items 1-12 of 12 One page.

1: Fernandez-Vizarra P, Fernandez AP, Castro-Blanco S, Serrano J, Bentura ML, Martinez-Murillo R, Martinez A, Rodrigo J. Related Articles, Links

Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease.
Histol Histopathol. 2004 Jul;19(3):823-44.
PMID: 15168346 [PubMed - indexed for MEDLINE]

2: Yamaguchi H, Harada A. Related Articles, Links

Supramolecular formation of antibodies with viologen dimers: utilization for amplification of methyl viologen detection signals in surface plasmon resonance sensor.
Biomacromolecules. 2002 Nov-Dec;3(6):1163-9.
PMID: 12425652 [PubMed - indexed for MEDLINE]

3: Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT. Related Articles, Links

Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.
J Neurosci. 2002 Sep 15;22(18):7873-8.
PMID: 12223540 [PubMed - indexed for MEDLINE]

4: Ramos DM, But M, Regezi J, Schmidt BL, Atakilit A, Dang D, Ellis D, Jordan R, Li X. Related Articles, Links

Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma.
Matrix Biol. 2002 Apr;21(3):297-307.
PMID: 12009335 [PubMed - indexed for MEDLINE]

5: Parvizi J, Van Hoesen GW, Damasio A. Related Articles, Links

The selective vulnerability of brainstem nuclei to Alzheimer's disease.
Ann Neurol. 2001 Jan;49(1):53-66.
PMID: 11198297 [PubMed - indexed for MEDLINE]

6: Parvizi J, Van Hoesen GW, Damasio A. Related Articles, Links

Selective pathological changes of the periaqueductal gray matter in Alzheimer's disease.
Ann Neurol. 2000 Sep;48(3):344-53.
PMID: 10976641 [PubMed - indexed for MEDLINE]

7: Jackson T, Sheppard D, Denyer M, Blakemore W, King AM. Related Articles, Links

The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus.
J Virol. 2000 Jun;74(11):4949-56.
PMID: 10799568 [PubMed - indexed for MEDLINE]

8: Frenkel D, Balass M, Katchalski-Katzir E, Solomon B. Related Articles, Links

High affinity binding of monoclonal antibodies to the sequential epitope

h cb h g e e e fcg e ch b e

EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation.
J Neuroimmunol. 1999 Mar 1;95(1-2):136-42.
PMID: 10229123 [PubMed - indexed for MEDLINE]

9: Frenkel D, Balass M, Solomon B. Related Articles, Links

N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies.
J Neuroimmunol. 1998 Aug 1;88(1-2):85-90.
PMID: 9688328 [PubMed - indexed for MEDLINE]

10: Huang X, Wu J, Spong S, Sheppard D. Related Articles, Links

The integrin alphavbeta6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin.
J Cell Sci. 1998 Aug;111 (Pt 15):2189-95.
PMID: 9664040 [PubMed - indexed for MEDLINE]

11: Johnstone EM, Babbey LE, Stephenson D, Paul DC, Santerre RF, Clemens JA, Williams DC, Little SP. Related Articles, Links

Nuclear and cytoplasmic localization of the beta-amyloid peptide (1-43) in transfected 293 cells.
Biochem Biophys Res Commun. 1996 Mar 27;220(3):710-8.
PMID: 8607830 [PubMed - indexed for MEDLINE]

12: Walker LC, Price DL, Voytko ML, Schenk DB. Related Articles, Links

Labeling of cerebral amyloid in vivo with a monoclonal antibody.
J Neuropathol Exp Neurol. 1994 Jul;53(4):377-83.
PMID: 8021711 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

h cb hg e e e fcg e ch b e

1: J Neuropathol Exp Neurol. 1994 Jul;53(4):377-83. Related Articles, Links

Labeling of cerebral amyloid in vivo with a monoclonal antibody.

Walker LC, Price DL, Voytko ML, Schenk DB.

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205-2196.

We assessed the ability of a murine monoclonal antibody to bind selectively to beta-amyloid in the brains of living nonhuman primates. To circumvent the blood-brain barrier, we injected unlabeled antibody 10D5 (murine whole IgG1 and/or Fab fragments) into the cerebrospinal fluid of the cisterna magna in three aged monkeys. A control animal was given an intracisternal injection of nonimmune mouse whole IgG plus Fab. Twenty-four hours later, the animals were perfused and prepared for immunohistochemical detection of bound murine immunoglobulin in brain. All three experimental animals showed selective binding of 10D5 to approximately 5-15% of amyloid deposits in cerebral cortex, primarily near the cortical surface. There was no labeling in the control animal. In vivo-labeled deposits were confirmed to be beta-amyloid by electron microscopy and by in vitro immunohistochemistry in adjacent sections. The animals tolerated the injection well, although some polymorphonuclear leukocytes infiltrated portions of the subarachnoid space and superficial neocortex. These results provide the first demonstration that it may be feasible to selectively direct a tagged monoclonal antibody to beta-amyloid in the brain for therapeutic or diagnostic purposes. With enhancement of labeling efficiency, the method also may be useful for studying the progression of beta-amyloidosis in experimental animals using emission tomography.

PMID: 8021711 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Display Summary Show: 500 Sort Send to Text

Items 1-471 of 471 One page.

1: De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia-Abreu J, Liu R, Chang L, Klein WL, Ferreira ST. Links

Targeting the neurotoxic species in Alzheimer's disease: inhibitors of A {beta} oligomerization.
FASEB J. 2004 Sep;18(12):1366-1372.
PMID: 15333579 [PubMed - as supplied by publisher]

2: Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, Wisniewski T. Related Articles, Links

A Synthetic Peptide Blocking the Apolipoprotein E/{beta}-Amyloid Binding Mitigates {beta}-Amyloid Toxicity and Fibril Formation in Vitro and Reduces {beta}-Amyloid Plaques in Transgenic Mice.
Am J Pathol. 2004 Sep;165(3):937-948.
PMID: 15331417 [PubMed - as supplied by publisher]

3: Sortino MA, Chisari M, Merlo S, Vancheri C, Caruso M, Nicoletti F, Canonico PL, Copani A. Related Articles, Links

Glia mediates the neuroprotective action of estradiol on {beta}-amyloid-induced neuronal death.
Endocrinology. 2004 Aug 12 [Epub ahead of print]
PMID: 15308615 [PubMed - as supplied by publisher]

4: Yasuoka K, Hirata K, Kuraoka A, He JW, Kawabuchi M. Related Articles, Links

Expression of amyloid precursor protein-like molecule in astroglial cells of the subventricular zone and rostral migratory stream of the adult rat forebrain.
J Anat. 2004 Aug;205(2):135-46.
PMID: 15291796 [PubMed - in process]

5: Liu R, McAllister C, Lyubchenko Y, Sierks MR. Related Articles, Links

Proteolytic Antibody Light Chains Alter beta-Amyloid Aggregation and Prevent Cytotoxicity.
Biochemistry. 2004 Aug 10;43(31):9999-10007.
PMID: 15287727 [PubMed - in process]

6: Liu R, Yuan B, Emadi S, Zameer A, Schulz P, McAllister C, Lyubchenko Y, Goud G, Sierks MR. Related Articles, Links

Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity.
Biochemistry. 2004 Jun 8;43(22):6959-67.
PMID: 15170333 [PubMed - indexed for MEDLINE]

7: Schultz C, Ghebremedhin E, Del Tredici K, Rub U, Braak H. Related Articles, Links

High prevalence of thorn-shaped astrocytes in the aged human medial temporal lobe.
Neurobiol Aging. 2004 Mar;25(3):397-405.
PMID: 15123344 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

8: Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK. Related Articles, Links

Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain.
J Neurosci. 2004 Apr 7;24(14):3592-9.
PMID: 15071107 [PubMed - indexed for MEDLINE]

9: Kung MP, Hou C, Zhuang ZP, Cross AJ, Maier DL, Kung HF. Related Articles, Links

Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice.
Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1136-45. Epub 2004 Mar 09.
PMID: 15007564 [PubMed - in process]

10: Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, Moller HJ. Related Articles, Links

Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
J Neural Transm. 2004 Mar;111(3):247-72. Epub 2003 Dec 03. Review.
PMID: 14991453 [PubMed - indexed for MEDLINE]

11: Bozzo C, Lombardi G, Santoro C, Canonico PL. Related Articles, Links

Involvement of beta(1) integrin in betaAP-induced apoptosis in human neuroblastoma cells.
Mol Cell Neurosci. 2004 Jan;25(1):1-8.
PMID: 14962735 [PubMed - indexed for MEDLINE]

12: Sondag CM, Combs CK. Related Articles, Links

Amyloid precursor protein mediates proinflammatory activation of monocytic lineage cells.
J Biol Chem. 2004 Apr 2;279(14):14456-63. Epub 2004 Jan 19.
PMID: 14732706 [PubMed - indexed for MEDLINE]

13: Muresan Z, Muresan V. Related Articles, Links

A phosphorylated, carboxy-terminal fragment of beta-amyloid precursor protein localizes to the splicing factor compartment.
Hum Mol Genet. 2004 Mar 1;13(5):475-88. Epub 2004 Jan 13.
PMID: 14722157 [PubMed - in process]

14: Yang W, Sopper MM, Leystra-Lantz C, Strong MJ. Related Articles, Links

Microtubule-associated tau protein positive neuronal and glial inclusions in ALS.
Neurology. 2003 Dec 23;61(12):1766-73.
PMID: 14694044 [PubMed - indexed for MEDLINE]

15: Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, Kong Q, Chen D, Ba D, He W. Related Articles, Links

A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease.
Neurobiol Dis. 2003 Dec;14(3):365-79.
PMID: 14678754 [PubMed - indexed for MEDLINE]

16: Cai J, Wang SZ, Peng Y, Zhong YW, Ji ZJ, Yuan JG, Qiang BQ. Related Articles, Links

[Cloning and expression of human single-chain Fv antibody against amyloid beta peptide involved in Alzheimer's disease]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003 Oct;25(5):557-62. Chinese.
PMID: 14650158 [PubMed - indexed for MEDLINE]

17: Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR. Related Articles, Links

Degradation of beta-amyloid by proteolytic antibody light chains.
Biochemistry. 2003 Dec 9;42(48):14328-34.
PMID: 14640701 [PubMed - indexed for MEDLINE]

18: Ghochikyan A, Vasilevko V, Petrushina I, Movsesyan N, Babikyan D, Tian W, Sadzikava N, Ross TM, Head E, Cribbs DH, Agadjanyan MG. Related Articles, Links

Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene.
Eur J Immunol. 2003 Dec;33(12):3232-41.
PMID: 14635031 [PubMed - indexed for MEDLINE]

19: Kojouharova MS, Tsacheva IG, Tchorbadjieva MI, Reid KB, Kishore U. Related Articles, Links

Localization of ligand-binding sites on human C1q globular head region using recombinant globular head fragments and single-chain antibodies.
Biochim Biophys Acta. 2003 Nov 3;1652(1):64-74.
PMID: 14580997 [PubMed - indexed for MEDLINE]

20: Miller DL, Currie JR, Mehta PD, Potempska A, Hwang YW, Wegiel J. Related Articles, Links

Humoral immune response to fibrillar beta-amyloid peptide.
Biochemistry. 2003 Oct 14;42(40):11682-92.
PMID: 14529278 [PubMed - indexed for MEDLINE]

21: Wang DS, Iwata N, Hama E, Saido TC, Dickson DW. Related Articles, Links

Oxidized neprilysin in aging and Alzheimer's disease brains.
Biochem Biophys Res Commun. 2003 Oct 10;310(1):236-41.
PMID: 14511676 [PubMed - indexed for MEDLINE]

22: Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, Dolios G, Wang R, Younkin SG, Lamb BT. Related Articles, Links

Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse.
Hum Mol Genet. 2003 Nov 15;12(22):2949-56. Epub 2003 Sep 23.
PMID: 14506131 [PubMed - indexed for MEDLINE]

23: Xu D, Yang CH, Wang LN. Related Articles, Links

[Prevalence and characteristics of cerebral amyloid angiopathy in the elderly]
Zhonghua Nei Ke Za Zhi. 2003 Aug;42(8):541-4. Chinese.
PMID: 14505543 [PubMed - indexed for MEDLINE]

24: Solomon B. Related Articles, Links

Immunological approach for the treatment of Alzheimer's disease.
J Mol Neurosci. 2003;20(3):283-6.
PMID: 14501009 [PubMed - indexed for MEDLINE]

25: Chauhan NB, Siegel GJ. Related Articles, Links

Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576.
J Neurosci Res. 2003 Oct 1;74(1):142-7.
PMID: 13130516 [PubMed - indexed for MEDLINE]

26: Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C. Related Articles, Links

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid

peptide42.
Arch Neurol. 2003 Sep;60(9):1202-6.
PMID: 12975284 [PubMed - indexed for MEDLINE]

27: Celsi F, Ferri A, Casciati A, D'Ambrosi N, Rotilio G, Costa A, Volonte C, Carri MT. Related Articles, Links

Overexpression of superoxide dismutase 1 protects against beta-amyloid peptide toxicity: effect of estrogen and copper chelators.
Neurochem Int. 2004 Jan;44(1):25-33.
PMID: 12963085 [PubMed - indexed for MEDLINE]

28: LeVine H 3rd. Related Articles, Links

Y10W beta(1-40) fluorescence reflects epitope exposure in conformers of Alzheimer's beta-peptide.
Arch Biochem Biophys. 2003 Sep 1;417(1):112-22.
PMID: 12921787 [PubMed - indexed for MEDLINE]

29: Mazur-Kolecka B, Kowal D, Sukontasup T, Dickson D, Frackowiak J. Related Articles, Links

The effect of oxidative stress on accumulation of apolipoprotein E3 and E4 in a cell culture model of beta-amyloid angiopathy (CAA).
Brain Res. 2003 Sep 5;983(1-2):48-57.
PMID: 12914965 [PubMed - indexed for MEDLINE]

30: Okuyama R, Marshall S. Related Articles, Links

UDP-N-acetylglucosaminyl transferase (OGT) in brain tissue: temperature sensitivity and subcellular distribution of cytosolic and nuclear enzyme.
J Neurochem. 2003 Sep;86(5):1271-80.
PMID: 12911634 [PubMed - indexed for MEDLINE]

31: Torp R, Ottersen OP, Cotman CW, Head E. Related Articles, Links

Identification of neuronal plasma membrane microdomains that colocalize beta-amyloid and presenilin: implications for beta-amyloid precursor protein processing.
Neuroscience. 2003;120(2):291-300.
PMID: 12890502 [PubMed - indexed for MEDLINE]

32: Schwab C, Hosokawa M, Akiyama H, McGeer PL. Related Articles, Links

Familial British dementia: colocalization of furin and ABri amyloid.
Acta Neuropathol (Berl). 2003 Sep;106(3):278-84. Epub 2003 Jul 16.
PMID: 12883829 [PubMed - indexed for MEDLINE]

33: Tang K, Wang C, Shen C, Sheng S, Ravid R, Jing N. Related Articles, Links

Identification of a novel alternative splicing isoform of human amyloid precursor protein gene, APP639.
Eur J Neurosci. 2003 Jul;18(1):102-8.
PMID: 12859342 [PubMed - indexed for MEDLINE]

34: Kishore U, Gupta SK, Perdikoulis MV, Kojouharova MS, Urban BC, Reid KB. Related Articles, Links

Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains.
J Immunol. 2003 Jul 15;171(2):812-20.
PMID: 12847249 [PubMed - indexed for MEDLINE]

35: Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Related Articles, Links

Subacute meningoencephalitis in a subset of patients with AD after

Abeta42 immunization.
Neurology. 2003 Jul 8;61(1):46-54.
PMID: 12847155 [PubMed - indexed for MEDLINE]

36: Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M. Related Articles, Links

Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity.
Brain. 2003 Sep;126(Pt 9):1935-9. Epub 2003 Jun 23.
PMID: 12821522 [PubMed - indexed for MEDLINE]

37: Austin L, Arendash GW, Gordon MN, Diamond DM, DiCarlo G, Dickey C, Ugen K, Morgan D. Related Articles, Links

Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice.
Behav Neurosci. 2003 Jun;117(3):478-84.
PMID: 12802876 [PubMed - indexed for MEDLINE]

38: Farr SA, Banks WA, Uezu K, Sano A, Gaskin FS, Morley JE. Related Articles, Links

Antibody to beta-amyloid protein increases acetylcholine in the hippocampus of 12 month SAMP8 male mice.
Life Sci. 2003 Jun 20;73(5):555-62.
PMID: 12770611 [PubMed - indexed for MEDLINE]

39: Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Related Articles, Links

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.
Neuron. 2003 May 22;38(4):547-54.
PMID: 12765607 [PubMed - indexed for MEDLINE]

40: Li G, Percontino L, Sun Q, Qazi AS, Frederikse PH. Related Articles, Links

Beta-amyloid secretases and beta-amloid degrading enzyme expression in lens.
Mol Vis. 2003 May 1;9:179-83.
PMID: 12740567 [PubMed - indexed for MEDLINE]

41: Taylor BM, Sarver RW, Fici G, Poorman RA, Lutzke BS, Molinari A, Kawabe T, Kappenman K, Buhl AE, Epps DE. Related Articles, Links

Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta1-40: a kinetic model.
J Protein Chem. 2003 Jan;22(1):31-40.
PMID: 12739896 [PubMed - indexed for MEDLINE]

42: Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. Related Articles, Links

Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.
J Neurosci. 2003 May 1;23(9):3745-51.
PMID: 12736345 [PubMed - indexed for MEDLINE]

43: Pasternak SH, Bagshaw RD, Guiral M, Zhang S, Ackerley CA, Pak BJ, Callahan JW, Mahuran DJ. Related Articles, Links

Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane.
J Biol Chem. 2003 Jul 18;278(29):26687-94. Epub 2003 May 07.
PMID: 12736250 [PubMed - indexed for MEDLINE]

☐ **44:** Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM. Related Articles, Links

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
JAMA. 2003 Apr 23-30;289(16):2094-103.
PMID: 12709467 [PubMed - indexed for MEDLINE]

☐ **45:** Leverone JF, Spooner ET, Lehman HK, Clements JD, Lemere CA. Related Articles, Links

Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting".
Vaccine. 2003 May 16;21(17-18):2197-206.
PMID: 12706711 [PubMed - indexed for MEDLINE]

☐ **46:** Patel JR, Brewer GJ. Related Articles, Links

Age-related changes in neuronal glucose uptake in response to glutamate and beta-amyloid.
J Neurosci Res. 2003 May 15;72(4):527-36.
PMID: 12704814 [PubMed - indexed for MEDLINE]

☐ **47:** Hirayama A, Horikoshi Y, Maeda M, Ito M, Takashima S. Related Articles, Links

Characteristic developmental expression of amyloid beta40, 42 and 43 in patients with Down syndrome.
Brain Dev. 2003 Apr;25(3):180-5.
PMID: 12689696 [PubMed - indexed for MEDLINE]

☐ **48:** Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG. Related Articles, Links

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid.
Int Immunol. 2003 Apr;15(4):505-14.
PMID: 12663680 [PubMed - indexed for MEDLINE]

☐ **49:** Dodart JC, Bales KR, Paul SM. Related Articles, Links

Immunotherapy for Alzheimer's disease: will vaccination work?
Trends Mol Med. 2003 Mar;9(3):85-7. Review.
PMID: 12657428 [PubMed - indexed for MEDLINE]

☐ **50:** Cantarella G, Uberti D, Carsana T, Lombardo G, Bernardini R, Memo M. Related Articles, Links

Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity.
Cell Death Differ. 2003 Jan;10(1):134-41.
PMID: 12655302 [PubMed - indexed for MEDLINE]

☐ **51:** Li Y, Liu L, Barger SW, Griffin WS. Related Articles, Links

Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway.
J Neurosci. 2003 Mar 1;23(5):1605-11.
PMID: 12629164 [PubMed - indexed for MEDLINE]

☐ **52:** Cai J, Wang S, Zhong Y, Cheng J, Ji Z, Sheng S, Zhang C. Related Articles, Links

Screening and characterization of human single-chain Fv antibody against beta-amyloid peptide 40.
Neuroreport. 2003 Feb 10;14(2):265-8.
PMID: 12598743 [PubMed - indexed for MEDLINE]

☐ **53:** Luo X, Weber GA, Zheng J, Gendelman HE, Ikezu T. Related Articles, Links

C1q-calreticulin induced oxidative neurotoxicity: relevance for the neuropathogenesis of Alzheimer's disease.
J Neuroimmunol. 2003 Feb;135(1-2):62-71.
PMID: 12576225 [PubMed - indexed for MEDLINE]

☐ **54:** Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T. Related Articles, Links

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. Epub 2003 Feb 03.
PMID: 12566568 [PubMed - indexed for MEDLINE]

☐ **55:** Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH. Related Articles, Links

Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice.
Neurosci Lett. 2003 Feb 20;338(1):5-8.
PMID: 12565127 [PubMed - indexed for MEDLINE]

☐ **56:** Frenkel D, Dewachter I, Van Leuven F, Solomon B. Related Articles, Links

Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization.
Vaccine. 2003 Mar 7;21(11-12):1060-5.
PMID: 12559780 [PubMed - indexed for MEDLINE]

☐ **57:** Meske V, Albert F, Richter D, Schwarze J, Ohm TG. Related Articles, Links

Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease.
Eur J Neurosci. 2003 Jan;17(1):93-102.
PMID: 12534972 [PubMed - indexed for MEDLINE]

☐ **58:** Blasko I, Grubeck-Loebenstein B. Related Articles, Links

Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.
Drugs Aging. 2003;20(2):101-13. Review.
PMID: 12534311 [PubMed - indexed for MEDLINE]

☐ **59:** Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Related Articles, Links

Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts.
J Cell Biol. 2003 Jan 6;160(1):113-23. Epub 2003 Jan 06.
PMID: 12515826 [PubMed - indexed for MEDLINE]

☐ **60:** Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K. Related Articles, Links

Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid.
J Neurosci. 2003 Jan 1;23(1):29-33.
PMID: 12514198 [PubMed - indexed for MEDLINE]

☐ **61:** Friedland RP. Related Articles, Links

Lipid metabolism, epidemiology, and the mechanisms of Alzheimer's disease.
Ann N Y Acad Sci. 2002 Nov;977:387-90. Review.

PMID: 12480777 [PubMed - indexed for MEDLINE]

☐ **62:** Solomon B, Frenkel D. Related Articles, Links

Generation and brain delivery of anti-aggregating antibodies against beta-amyloid plaques using phage display technology.
J Neural Transm Suppl. 2002;(62):321-5.
PMID: 12456075 [PubMed - indexed for MEDLINE]

☐ **63:** Kienzl E, Jellinger K, Janetzky B, Steindl H, Bergmann J. Related Articles, Links

A broader horizon of Alzheimer pathogenesis: ALZAS--an early serum biomarker?
J Neural Transm Suppl. 2002;(62):87-95.
PMID: 12456054 [PubMed - indexed for MEDLINE]

☐ **64:** Leclercq PD, Stephenson MS, Murray LS, McIntosh TK, Graham DI, Gentleman SM. Related Articles, Links

Simple morphometry of axonal swellings cannot be used in isolation for dating lesions after traumatic brain injury.
J Neurotrauma. 2002 Oct;19(10):1183-92.
PMID: 12427327 [PubMed - indexed for MEDLINE]

☐ **65:** Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, Mori T, Smeed R, Crawford F, Klein T, Tan J, Mullan M. Related Articles, Links

Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42).
J Neuroimmunol. 2002 Nov;132(1-2):49-59.
PMID: 12417433 [PubMed - indexed for MEDLINE]

☐ **66:** Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ. Related Articles, Links

Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice.
Nat Neurosci. 2002 Dec;5(12):1288-93.
PMID: 12402041 [PubMed - indexed for MEDLINE]

☐ **67:** Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM. Related Articles, Links

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.
Nat Med. 2002 Nov;8(11):1270-5. Epub 2002 Oct 15.
PMID: 12379846 [PubMed - indexed for MEDLINE]

☐ **68:** Capsoni S, Giannotta S, Cattaneo A. Related Articles, Links

Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies.
Mol Cell Neurosci. 2002 Sep;21(1):15-28.
PMID: 12359148 [PubMed - indexed for MEDLINE]

☐ **69:** Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jackel S, Wei X, Buerger K, Hoft C, Hemmer B, Moller HJ, Farlow M, Oertel WH, Sommer N, Du Y. Related Articles, Links

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.
Ann Neurol. 2002 Aug;52(2):253-6.
PMID: 12210803 [PubMed - indexed for MEDLINE]

☐ **70:** Pan W, Solomon B, Maness LM, Kastin AJ. Related Articles, Links

Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide.
Exp Biol Med (Maywood). 2002 Sep;227(8):609-15.
PMID: 12192102 [PubMed - indexed for MEDLINE]

☐ **71:** Kovacs GG, Zerbi P, Voigtlander T, Strohschneider M, Trabattoni G, Hainfellner JA, Budka H. Related Articles, Links

The prion protein in human neurodegenerative disorders.
Neurosci Lett. 2002 Sep 6;329(3):269-72.
PMID: 12183028 [PubMed - indexed for MEDLINE]

☐ **72:** Giri R, Selvaraj S, Miller CA, Hofman F, Yan SD, Stern D, Zlokovic BV, Kalra VK. Related Articles, Links

Effect of endothelial cell polarity on beta-amyloid-induced migration of monocytes across normal and AD endothelium.
Am J Physiol Cell Physiol. 2002 Sep;283(3):C895-904.
PMID: 12176746 [PubMed - indexed for MEDLINE]

☐ **73:** Beher D, Wrigley JD, Owens AP, Shearman MS. Related Articles, Links

Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.
J Neurochem. 2002 Aug;82(3):563-75.
PMID: 12153480 [PubMed - indexed for MEDLINE]

☐ **74:** Wirths O, Multhaup G, Czech C, Feldmann N, Blanchard V, Tremp G, Beyreuther K, Pradier L, Bayer TA. Related Articles, Links

Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice.
Brain Pathol. 2002 Jul;12(3):275-86.
PMID: 12146796 [PubMed - indexed for MEDLINE]

☐ **75:** Clamagirand C, Joulie C, Panchal M, Sekhri R, Hanquez C, Cohen P, Rholam M. Related Articles, Links

Specific cleavage of beta-amyloid peptides by a metallopeptidase from Xenopus laevis skin secretions.
Comp Biochem Physiol B Biochem Mol Biol. 2002 Aug;132(4):751-9.
PMID: 12128061 [PubMed - in process]

☐ **76:** Mohajeri MH, Wollmer MA, Nitsch RM. Related Articles, Links

Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo.
J Biol Chem. 2002 Sep 20;277(38):35460-5. Epub 2002 Jul 08.
PMID: 12105192 [PubMed - indexed for MEDLINE]

☐ **77:** Morley JE, Farr SA, Flood JF. Related Articles, Links

Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice.
Neurobiol Learn Mem. 2002 Jul;78(1):125-38.
PMID: 12071671 [PubMed - indexed for MEDLINE]

☐ **78:** Sasaki N, Takeuchi M, Chowei H, Kikuchi S, Hayashi Y, Nakano N, Ikeda H, Yamagishi S, Kitamoto T, Saito T, Makita Z. Related Articles, Links

Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.
Neurosci Lett. 2002 Jun 28;326(2):117-20.
PMID: 12057842 [PubMed - indexed for MEDLINE]

☐ **79:** Stone JR, Okonkwo DO, Singleton RH, Mutlu LK, Helm GA, Povlishock JT. Related Articles, Links

Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid Beta peptide in traumatic axonal injury.
J Neurotrauma. 2002 May;19(5):601-14.
PMID: 12042095 [PubMed - indexed for MEDLINE]

☐ **80:** DeGiorgio LA, Shimizu Y, Chun HS, Kim YS, Sugama S, Son JH. Related Articles, Links

Joh TH, Volpe BT.

Amyloid precursor protein gene disruption attenuates degeneration of substantia nigra compacta neurons following axotomy.
Brain Res. 2002 May 31;938(1-2):38-44.
PMID: 12031533 [PubMed - indexed for MEDLINE]

81: Frenkel D, Solomon B. Related Articles, Links

Filamentous phage as vector-mediated antibody delivery to the brain.
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5675-9.
PMID: 11960022 [PubMed - indexed for MEDLINE]

82: Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. Related Articles, Links

Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease.
Neuroscience. 2002;110(2):199-211.
PMID: 11958863 [PubMed - indexed for MEDLINE]

83: Mbebi C, See V, Mercken L, Pradier L, Mullier U, Loeffler JP. Related Articles, Links

Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/calmodulin protein kinase IV-dependent signaling pathway.
J Biol Chem. 2002 Jun 7;277(23):20979-90. Epub 2002 Mar 04.
PMID: 11877414 [PubMed - indexed for MEDLINE]

84: Toro VC, Tehranian R, Zetterstrom M, Eriksson G, Langel U, Bartfai T, Iverfeld K. Related Articles, Links

Increased gene expression of interleukin-1alpha and interleukin-6 in rat primary glial cells induced by beta-amyloid fragment.
J Mol Neurosci. 2001 Dec;17(3):341-50.
PMID: 11859930 [PubMed - indexed for MEDLINE]

85: Frenkel D, Solomon B. Related Articles, Links

Towards Alzheimer's beta-amyloid vaccination.
Biologicals. 2001 Sep-Dec;29(3-4):243-7.
PMID: 11851323 [PubMed - indexed for MEDLINE]

86: Thal DR, Ghebremedhin E, Haass C, Schultz C. Related Articles, Links

UV light-induced autofluorescence of full-length Abeta-protein deposits in the human brain.
Clin Neuropathol. 2002 Jan-Feb;21(1):35-40.
PMID: 11846043 [PubMed - indexed for MEDLINE]

87: Nicolau C, Greferath R, Balaban TS, Lazarte JE, Hopkins RJ. Related Articles, Links

A liposome-based therapeutic vaccine against beta -amyloid plaques on the pancreas of transgenic NORBA mice.
Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2332-7. Epub 2002 Feb 12.
PMID: 11842183 [PubMed - indexed for MEDLINE]

88: Schenk D, Games D, Seubert P. Related Articles, Links

Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.
J Mol Neurosci. 2001 Oct;17(2):259-67. Review.
PMID: 11816797 [PubMed - indexed for MEDLINE]

89: Cummings BJ, Mason AJ, Kim RC, Sheu PC, Anderson AJ. Related Articles, Links

Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging.
Neurobiol Aging. 2002 Mar-Apr;23(2):161-70.

PMID: 11804699 [PubMed - indexed for MEDLINE]

☐ **90:** Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D. Related Articles, Links

Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels.
DNA Cell Biol. 2001 Nov;20(11):731-6.
PMID: 11788051 [PubMed - indexed for MEDLINE]

☐ **91:** Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE. Related Articles, Links

Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide.
DNA Cell Biol. 2001 Nov;20(11):723-9.
PMID: 11788050 [PubMed - indexed for MEDLINE]

☐ **92:** Vehmas AK, Borchelt DR, Price DL, McCarthy D, Wills-Karp M, Peper MJ, Rudow G, Luyinbazi J, Siew LT, Troncoso JC. Related Articles, Links

beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology.
DNA Cell Biol. 2001 Nov;20(11):713-21.
PMID: 11788049 [PubMed - indexed for MEDLINE]

☐ **93:** Lemere CA, Maron R, Selkoe DJ, Weiner HL. Related Articles, Links

Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease.
DNA Cell Biol. 2001 Nov;20(11):705-11.
PMID: 11788048 [PubMed - indexed for MEDLINE]

☐ **94:** Solomon B. Related Articles, Links

Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease.
DNA Cell Biol. 2001 Nov;20(11):697-703.
PMID: 11788047 [PubMed - indexed for MEDLINE]

☐ **95:** Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El-Khoury JB. Related Articles, Links

CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils.
Am J Pathol. 2002 Jan;160(1):101-12.
PMID: 11786404 [PubMed - indexed for MEDLINE]

☐ **96:** Lambri M, Djurovic V, Kibble M, Cairns N, Al-Sarraj S. Related Articles, Links

Specificity and sensitivity of betaAPP in head injury.
Clin Neuropathol. 2001 Nov-Dec;20(6):263-71.
PMID: 11758782 [PubMed - indexed for MEDLINE]

☐ **97:** Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL. Related Articles, Links

Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.
J Neurochem. 2001 Nov;79(3):595-605.
PMID: 11701763 [PubMed - indexed for MEDLINE]

☐ **98:** Szpak GM, Lewandowska E, Lechowicz W, Bertrand E, Wierzba-Bobrowicz T, Gwiazda E, Pasennik E, Kosno-Kruszewska E, Lipczynska-Lojkowska W, Bochynska A, Fiszer U. Related Articles, Links

h cb h g e e e fcg e ch b e

Lewy body variant of Alzheimer's disease and Alzheimer's disease: a comparative immunohistochemical study.
Folia Neuropathol. 2001;39(2):63-71.
PMID: 11680637 [PubMed - indexed for MEDLINE]

99: Toupalik P, Bouska I, Chadova I. Related Articles, Links

[Differences in immunohistochemical findings in traumatic and hypoxic changes in the central nervous system]
Soud Lek. 2001 Jul;46(3):34-6. Czech.
PMID: 11669015 [PubMed - indexed for MEDLINE]

100: Nunan J, Shearman MS, Checler F, Cappai R, Evin G, Beyreuther K, Masters CL, Small DH. Related Articles, Links

The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase.
Eur J Biochem. 2001 Oct;268(20):5329-36.
PMID: 11606195 [PubMed - indexed for MEDLINE]

101: Carter DB, Dunn E, McKinley DD, Stratman NC, Boyle TP, Kuiper SL, Oostveen JA, Weaver RJ, Boller JA, Gurney ME. Related Articles, Links

Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain.
Ann Neurol. 2001 Oct;50(4):468-75.
PMID: 11601499 [PubMed - indexed for MEDLINE]

102: von Bernhardi R, Ramirez G, Matile H, Dobeli H. Related Articles, Links

Immobilized amyloid precursor protein constructs: a tool for the in vitro screening of glial cell reactivity.
Eur J Neurosci. 2001 Sep;14(6):946-56.
PMID: 11595033 [PubMed - indexed for MEDLINE]

103: Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C. Related Articles, Links

Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome.
Neurobiol Dis. 2001 Oct;8(5):792-806.
PMID: 11592849 [PubMed - indexed for MEDLINE]

104: Thatte U. Related Articles, Links

AN-1792 (Elan).
Curr Opin Investig Drugs. 2001 May;2(5):663-7. Review.
PMID: 11569944 [PubMed - indexed for MEDLINE]

105: Gotz J, Chen F, van Dorpe J, Nitsch RM. Related Articles, Links

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils.
Science. 2001 Aug 24;293(5534):1491-5.
PMID: 11520988 [PubMed - indexed for MEDLINE]

106: Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL. Related Articles, Links

Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease.
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10273-8. Epub 2001 Aug 21.
PMID: 11517335 [PubMed - indexed for MEDLINE]

107: Brayden DJ, Templeton L, McClean S, Barbour R, Huang J, Nguyen M, Ahern D, Motter R, Johnson-Wood K, Vasquez N. Related Articles, Links

Schenk D, Seubert P.

Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice.
Vaccine. 2001 Jul 20;19(30):4185-93.
PMID: 11457544 [PubMed - indexed for MEDLINE]

108: Toupalik P, Bouska I, Jezkova J. Related Articles, Links

[Effect of autolysis on histochemical examinations of the central nervous system]
Soud Lek. 2001 Apr;46(2):18-20. Czech.
PMID: 11455721 [PubMed - indexed for MEDLINE]

109: Pluta R, Misicka A, Barcikowska M, Spisacka S, Lipkowski AW, Januszewski S. Related Articles, Links

Possible reverse transport of beta-amyloid peptide across the blood-brain barrier.
Acta Neurochir Suppl. 2000;76:73-7.
PMID: 11450095 [PubMed - indexed for MEDLINE]

110: Singleton RH, Stone JR, Okonkwo DO, Pellicane AJ, Povlishock JT. Related Articles, Links

The immunophilin ligand FK506 attenuates axonal injury in an impact-acceleration model of traumatic brain injury.
J Neurotrauma. 2001 Jun;18(6):607-14.
PMID: 11437083 [PubMed - indexed for MEDLINE]

111: Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M. Related Articles, Links

Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.
Neurosci Lett. 2001 Jul 13;307(2):101-4.
PMID: 11427310 [PubMed - indexed for MEDLINE]

112: Myagkova MA, Gavrilova SI, Lermontova NN, Kalyn YB, Selezneva ND, Zharikov GA, Kolykhalov IV, Abramenko TV, Serkova TP, Bachurin SO. Related Articles, Links

Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer's disease and senile dementia of the Alzheimer type.
Bull Exp Biol Med. 2001 Feb;131(2):127-9.
PMID: 11391392 [PubMed - indexed for MEDLINE]

113: Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K, Yamaguchi T. Related Articles, Links

beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease.
Neuroscience. 2001;104(2):299-310.
PMID: 11377835 [PubMed - indexed for MEDLINE]

114: Matsumoto A, Itoh K, Seki T, Motozaki K, Matsuyama S. Related Articles, Links

Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons.
Eur J Neurosci. 2001 May;13(9):1653-7.
PMID: 11359517 [PubMed - indexed for MEDLINE]

115: Chung H, Brazil MI, Irizarry MC, Hyman BT, Maxfield FR. Related Articles, Links

Uptake of fibrillar beta-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice.
Neuroreport. 2001 May 8;12(6):1151-4.
PMID: 11338182 [PubMed - indexed for MEDLINE]

116: Chong YH, Sung JH, Shin SA, Chung JH, Suh YH. Related Articles, Links

Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1.
J Biol Chem. 2001 Jun 29;276(26):23511-7. Epub 2001 Apr 16.
PMID: 11306564 [PubMed - indexed for MEDLINE]

117: Englund P, Jacobsson SO, Fowler CJ. Related Articles, Links

Investigation into the effects of amyloid (1-42) beta-peptide upon basal and antigen-stimulated hexosaminidase and serotonin release from rat RBL-2H3 basophilic leukemia cells.
Methods Find Exp Clin Pharmacol. 2000 Nov;22(9):657-61.
PMID: 11294005 [PubMed - indexed for MEDLINE]

118: Cedazo-Minguez A, Wiehager B, Winblad B, Huttinger M, Cowburn RF. Related Articles, Links

Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts.
Neurochem Int. 2001 Jun;38(7):615-25.
PMID: 11290387 [PubMed - indexed for MEDLINE]

119: Frenkel D, Kariv N, Solomon B. Related Articles, Links

Generation of auto-antibodies towards Alzheimer's disease vaccination.
Vaccine. 2001 Mar 21;19(17-19):2615-9.
PMID: 11257400 [PubMed - indexed for MEDLINE]

120: Duker NJ, Sperling J, Soprano KJ, Druin DP, Davis A, Ashworth R. Related Articles, Links

beta-Amyloid protein induces the formation of purine dimers in cellular DNA.
J Cell Biochem. 2001;81(3):393-400.
PMID: 11255222 [PubMed - indexed for MEDLINE]

121: Gerlai R. Related Articles, Links

Alzheimer's disease: beta-amyloid hypothesis strengthened!
Trends Neurosci. 2001 Apr;24(4):199. No abstract available.
PMID: 11249992 [PubMed - indexed for MEDLINE]

122: Matsumoto A, Motozaki K, Seki T, Sasaki R, Kawabe T. Related Articles, Links

Expression of human brain carboxypeptidase B, a possible cleaving enzyme for beta-amyloid precursor protein, in peripheral fluids.
Neurosci Res. 2001 Mar;39(3):313-7.
PMID: 11248371 [PubMed - indexed for MEDLINE]

123: Husemann J, Silverstein SC. Related Articles, Links

Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain.
Am J Pathol. 2001 Mar;158(3):825-32.
PMID: 11238031 [PubMed - indexed for MEDLINE]

124: D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. Related Articles, Links

Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease.

Histopathology. 2001 Feb;38(2):120-34.
PMID: 11207825 [PubMed - indexed for MEDLINE]

☐ **125:** Russo C, Salis S, Dolcini V, Venezia V, Song XH, Teller JK, Schettini G. Related Articles, Links

Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.
Neurobiol Dis. 2001 Feb;8(1):173-80. Erratum in: Neurobiol Dis 2001 Jun;8(3):540.
PMID: 11162251 [PubMed - indexed for MEDLINE]

☐ **126:** Kumar VB, Farr SA, Flood JF, Kamlesh V, Franko M, Banks WA, Morley JE. Related Articles, Links

Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice.
Peptides. 2000 Dec;21(12):1769-75.
PMID: 11150636 [PubMed - indexed for MEDLINE]

☐ **127:** Morley JE, Kumar VB, Bernardo AE, Farr SA, Uezu K, Tumosa N, Flood JF. Related Articles, Links

Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory.
Peptides. 2000 Dec;21(12):1761-7.
PMID: 11150635 [PubMed - indexed for MEDLINE]

☐ **128:** Lin B, Ginsberg MD, Busto R. Related Articles, Links

Hyperglycemic but not normoglycemic global ischemia induces marked early intraneuronal expression of beta-amyloid precursor protein.
Brain Res. 2001 Jan 5;888(1):107-116.
PMID: 11146057 [PubMed - indexed for MEDLINE]

☐ **129:** Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E. Related Articles, Links

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.
Amyloid. 2000 Dec;7(4):245-58.
PMID: 11132093 [PubMed - indexed for MEDLINE]

☐ **130:** Sudo H, Jiang H, Yasukawa T, Hashimoto Y, Niikura T, Kawasumi M, Matsuda S, Takeuchi Y, Aiso S, Matsuoka M, Murayama Y, Nishimoto I. Related Articles, Links

Antibody-regulated neurotoxic function of cell-surface beta-amyloid precursor protein.
Mol Cell Neurosci. 2000 Dec;16(6):708-23.
PMID: 11124892 [PubMed - indexed for MEDLINE]

☐ **131:** Seiffert D, Mitchell T, Stern AM, Roach A, Zhan Y, Grzanna R. Related Articles, Links

Positive-negative epitope-tagging of beta amyloid precursor protein to identify inhibitors of A beta processing.
Brain Res Mol Brain Res. 2000 Dec 8;84(1-2):115-26.
PMID: 11113538 [PubMed - indexed for MEDLINE]

☐ **132:** Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, Kim KS, Zlokovic B, Kalra VK. Related Articles, Links

beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1.
Am J Physiol Cell Physiol. 2000 Dec;279(6):C1772-81.
PMID: 11078691 [PubMed - indexed for MEDLINE]

☐ **133:** Frenkel D, Katz O, Solomon B. Related Articles, Links

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration.
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11455-9.
PMID: 11027345 [PubMed - indexed for MEDLINE]

☐ **134:** Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford F, Mullan M. Related Articles, Links

CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.
J Neurosci. 2000 Oct 15;20(20):7587-94.
PMID: 11027218 [PubMed - indexed for MEDLINE]

☐ **135:** Rossner S, Beck M, Stahl T, Mendla K, Schliebs R, Bigl V. Related Articles, Links

Constitutive overactivation of protein kinase C in guinea pig brain increases alpha-secretory APP processing without decreasing beta-amyloid generation.
Eur J Neurosci. 2000 Sep;12(9):3191-200.
PMID: 10998103 [PubMed - indexed for MEDLINE]

☐ **136:** Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, Fujino Y, Nakajima M, Yamamoto T, Akatsu H, Mitsui S, Yamaguchi N. Related Articles, Links

Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.
Psychiatry Clin Neurosci. 2000 Aug;54(4):419-26.
PMID: 10997858 [PubMed - indexed for MEDLINE]

☐ **137:** Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Kostovic I, Winblad B, Bogdanovi Related Articles, Links

nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease.
Exp Neurol. 2000 Sep;165(1):12-26.
PMID: 10964481 [PubMed - indexed for MEDLINE]

☐ **138:** Taguchi J, Fujii A, Fujino Y, Tsujioka Y, Takahashi M, Tsuboi Y, Wada I, Yamada T. Related Articles, Links

Different expression of calreticulin and immunoglobulin binding protein in Alzheimer's disease brain.
Acta Neuropathol (Berl). 2000 Aug;100(2):153-60.
PMID: 10963362 [PubMed - indexed for MEDLINE]

☐ **139:** DeGiorgio LA, DeGiorgio N, Milner TA, Conti B, Volpe BT. Related Articles, Links

Neurotoxic APP C-terminal and beta-amyloid domains colocalize in the nuclei of substantia nigra pars reticulata neurons undergoing delayed degeneration.
Brain Res. 2000 Aug 25;874(2):137-46.
PMID: 10960598 [PubMed - indexed for MEDLINE]

☐ **140:** Tanabe Y, Ishizu H, Ishiguro K, Itoh N, Terada S, Haraguchi T, Kawai K, Kuroda S. Related Articles, Links

Tau pathology in diffuse neurofibrillary tangles with calcification (DNTC): biochemical and immunohistochemical investigation.
Neuroreport. 2000 Aug 3;11(11):2473-7.
PMID: 10943706 [PubMed - indexed for MEDLINE]

☐ **141:** Helmuth L. Related Articles, Links

Alzheimer's congress. Further progress on a beta-amyloid vaccine.

Science. 2000 Jul 21;289(5478):375. No abstract available.
PMID: 10939941 [PubMed - indexed for MEDLINE]

142: Stone JR, Singleton RH, Povlishock JT. Related Articles, Links

Antibodies to the C-terminus of the beta-amyloid precursor protein (APP): a site specific marker for the detection of traumatic axonal injury.
Brain Res. 2000 Jul 21;871(2):288-302.
PMID: 10899295 [PubMed - indexed for MEDLINE]

143: Kaneko I, Kubo T, Morimoto K. Related Articles, Links

[Neurotoxicity of beta-amyloid]
Nippon Yakurigaku Zasshi. 2000 Feb;115(2):67-77. Review. Japanese.
PMID: 10876793 [PubMed - indexed for MEDLINE]

144: Horsburgh K, Cole GM, Yang F, Savage MJ, Greenberg BD, Gentleman SM, Graham DI, Nicoll JA. Related Articles, Links

beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury.
Neuropathol Appl Neurobiol. 2000 Apr;26(2):124-32.
PMID: 10840275 [PubMed - indexed for MEDLINE]

145: Rohn TT, Ivins KJ, Bahr BA, Cotman CW, Cribbs DH. Related Articles, Links

A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis.
J Neurochem. 2000 Jun;74(6):2331-42.
PMID: 10820193 [PubMed - indexed for MEDLINE]

146: Sparks DL, Kuo YM, Roher A, Martin T, Lukas RJ. Related Articles, Links

Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations.
Ann N Y Acad Sci. 2000 Apr;903:335-44.
PMID: 10818523 [PubMed - indexed for MEDLINE]

147: Brown WR, Moody DM, Thore CR, Challa VR. Related Articles, Links

Cerebrovascular pathology in Alzheimer's disease and leukoaraiosis.
Ann N Y Acad Sci. 2000 Apr;903:39-45.
PMID: 10818487 [PubMed - indexed for MEDLINE]

148: Frenkel D, Solomon B, Benhar I. Related Articles, Links

Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody.
J Neuroimmunol. 2000 Jul 1;106(1-2):23-31.
PMID: 10814779 [PubMed - indexed for MEDLINE]

149: Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC. Related Articles, Links

Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice.
J Neurosci. 2000 May 15;20(10):3606-11.
PMID: 10804202 [PubMed - indexed for MEDLINE]

150: Marzolo MP, von Bernhardi R, Bu G, Inestrosa NC. Related Articles, Links

Expression of alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) in rat microglial cells.
J Neurosci Res. 2000 May 1;60(3):401-11.
PMID: 10797543 [PubMed - indexed for MEDLINE]

151: Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW. Related Articles, Links

Region-specific age at onset of beta-amyloid in dogs.
Neurobiol Aging. 2000 Jan-Feb;21(1):89-96.
PMID: 10794853 [PubMed - indexed for MEDLINE]

152: Azizeh BY, Head E, Ibrahim MA, Torp R, Tenner AJ, Kim RC, Lott IT, Cotman CW. Related Articles, Links

Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs.
Exp Neurol. 2000 May;163(1):111-22.
PMID: 10785449 [PubMed - indexed for MEDLINE]

153: Capell A, Steiner H, Romig H, Keck S, Baader M, Grim MG, Baumeister R, Haass C. Related Articles, Links

Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch.
Nat Cell Biol. 2000 Apr;2(4):205-11.
PMID: 10783238 [PubMed - indexed for MEDLINE]

154: Brazil MI, Chung H, Maxfield FR. Related Articles, Links

Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia.
J Biol Chem. 2000 Jun 2;275(22):16941-7.
PMID: 10747968 [PubMed - indexed for MEDLINE]

155: Salinero O, Moreno-Flores MT, Wandosell F. Related Articles, Links

Increasing neurite outgrowth capacity of beta-amyloid precursor protein proteoglycan in Alzheimer's disease.
J Neurosci Res. 2000 Apr 1;60(1):87-97.
PMID: 10723071 [PubMed - indexed for MEDLINE]

156: Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. Related Articles, Links

Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1456-60.
PMID: 10677483 [PubMed - indexed for MEDLINE]

157: Cescato R, Dumermuth E, Spiess M, Paganetti PA. Related Articles, Links

Increased generation of alternatively cleaved beta-amyloid peptides in cells expressing mutants of the amyloid precursor protein defective in endocytosis.
J Neurochem. 2000 Mar;74(3):1131-9.
PMID: 10693945 [PubMed - indexed for MEDLINE]

158: Matsumoto A. Related Articles, Links

The 68K protease has beta-secretase-like activity for lymphocyte precursor protein but not for brain substrate.
Neuroreport. 2000 Feb 7;11(2):373-7.
PMID: 10674489 [PubMed - indexed for MEDLINE]

159: Yoshiyama Y, Asahina M, Hattori T. Related Articles, Links

Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain.
Acta Neuropathol (Berl). 2000 Feb;99(2):91-5.
PMID: 10672313 [PubMed - indexed for MEDLINE]

160: Toro F, Lopera F, Ossa J, Madrigal L, Mira A, Diaz A, Parra S. Related Articles, Links

[Detection of antibodies to beta-amyloid in carriers of E280A mutation in

h cb h g e e e fcg e ch b e

the presenilin-1 gene]
Rev Neurol. 1999 Dec 16-31;29(12):1104-7. Spanish.
PMID: 10652730 [PubMed - indexed for MEDLINE]

161: Al-Abed Y, Bucala R. Related Articles, Links

Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts.
Bioconjug Chem. 2000 Jan-Feb;11(1):39-45.
PMID: 10639083 [PubMed - indexed for MEDLINE]

162: Campbell E, Pearson RC, Parkinson D. Related Articles, Links

Methods to uncover an antibody epitope in the KPI domain of Alzheimer's amyloid precursor protein for immunohistochemistry in human brain.
J Neurosci Methods. 1999 Nov 15;93(2):133-8.
PMID: 10634498 [PubMed - indexed for MEDLINE]

163: Frederikse PH, Zigler SJ Jr, Farnsworth PN, Carper DA. Related Articles, Links

Prion protein expression in mammalian lenses.
Curr Eye Res. 2000 Feb;20(2):137-43.
PMID: 10617916 [PubMed - indexed for MEDLINE]

164: Webster SD, Tenner AJ, Poulos TL, Cribbs DH. Related Articles, Links

The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation.
Neurobiol Aging. 1999 May-Jun;20(3):297-304.
PMID: 10588577 [PubMed - indexed for MEDLINE]

165: Jung SS, Gauthier S, Cashman NR. Related Articles, Links

Beta-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease.
Neurobiol Aging. 1999 May-Jun;20(3):249-57.
PMID: 10588572 [PubMed - indexed for MEDLINE]

166: Nakano S, Akiguchi I, Nakamura S, Satoi H, Kawashima S, Kimura J. Related Articles, Links

Aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis.
Neurology. 1999 Nov 10;53(8):1671-6.
PMID: 10563611 [PubMed - indexed for MEDLINE]

167: Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. Related Articles, Links

The role of cholesterol in the biosynthesis of beta-amyloid.
Neuroreport. 1999 Jun 3;10(8):1699-705.
PMID: 10501560 [PubMed - indexed for MEDLINE]

168: Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka S, Mori H. Related Articles, Links

Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease.
Arch Neurol. 1999 Sep;56(9):1111-8.
PMID: 10488812 [PubMed - indexed for MEDLINE]

169: Guenette SY, Chen J, Ferland A, Haass C, Capell A, Tanzi RE. Related Articles, Links

hFE65L influences amyloid precursor protein maturation and secretion.
J Neurochem. 1999 Sep;73(3):985-93.
PMID: 10461887 [PubMed - indexed for MEDLINE]

170: Kurt MA, Davies DC, Kidd M. Related Articles, Links

beta-Amyloid immunoreactivity in astrocytes in Alzheimer's disease brain biopsies: an electron microscope study.
Exp Neurol. 1999 Jul;158(1):221-8.
PMID: 10448435 [PubMed - indexed for MEDLINE]

171: Markaryan A, Morozova I, Lee BS, Kaplan A. Related Articles, Links

Atypical processing of amyloid precursor fusion protein by proteolytic activity in Pichia pastoris.
Biochem Biophys Res Commun. 1999 Aug 19;262(1):263-8. Erratum in: Biochem Biophys Res Commun 1999 Sep 24;263(2):596.
PMID: 10448103 [PubMed - indexed for MEDLINE]

172: Gonzalo-Ruiz A. Related Articles, Links

[Changes in neurotransmission systems after the injection of beta-amyloid protein beta (12-28) in the hypothalamus and anterior thalamus of the rat]
Rev Neurol. 1999 May 16-31;28(10):931-41. Review. Spanish.
PMID: 10416226 [PubMed - indexed for MEDLINE]

173: Schroder R, Linke RP. Related Articles, Links

Cerebrovascular involvement in systemic AA and AL amyloidosis: a clear haematogenic pattern.
Virchows Arch. 1999 Jun;434(6):551-60.
PMID: 10394892 [PubMed - indexed for MEDLINE]

174: Yuan H, Zhai P, Anderson LM, Pan J, Thimmapaya B, Koo EH, Marquez-Sterling NR. Related Articles, Links

Recombinant adenovirus is an appropriate vector for endocytotic protein trafficking studies in cultured neurons.
J Neurosci Methods. 1999 Apr 1;88(1):45-54.
PMID: 10379578 [PubMed - indexed for MEDLINE]

175: Fonseca MJ, Head E, Velazquez P, Cotman CW, Tenner AJ. Related Articles, Links

The presence of isoaspartic acid in beta-amyloid plaques indicates plaque age.
Exp Neurol. 1999 Jun;157(2):277-88.
PMID: 10364440 [PubMed - indexed for MEDLINE]

176: Yang DS, Small DH, Seydel U, Smith JD, Hallmayer J, Gandy SE, Martins RN. Related Articles, Links

Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner.
Neuroscience. 1999;90(4):1217-26.
PMID: 10338292 [PubMed - indexed for MEDLINE]

177: Ohsawa I, Takamura C, Morimoto T, Ishiguro M, Kohsaka S. Related Articles, Links

Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells.
Eur J Neurosci. 1999 Jun;11(6):1907-13.
PMID: 10336659 [PubMed - indexed for MEDLINE]

178: Oehmichen M, Theuerkauf I, Meissner C. Related Articles, Links

Is traumatic axonal injury (AI) associated with an early microglial activation? Application of a double-labeling technique for simultaneous detection of microglia and AI.
Acta Neuropathol (Berl). 1999 May;97(5):491-4.
PMID: 10334486 [PubMed - indexed for MEDLINE]

☐ **179:** Johnson G, Moore SW. Related Articles, Links

The adhesion function on acetylcholinesterase is located at the peripheral anionic site.
Biochem Biophys Res Commun. 1999 May 19;258(3):758-62.
PMID: 10329459 [PubMed - indexed for MEDLINE]

☐ **180:** Abraham CR, Marshall DC, Tibbles HE, Otto K, Long HJ, Billingslea AM, Hastey R, Johnson R, Fine RE, Smith SJ, Simons ER, Davies TA. Related Articles, Links

Platelets and DAMI megakaryocytes possess beta-secretase-like activity.
J Lab Clin Med. 1999 May;133(5):507-15.
PMID: 10235134 [PubMed - indexed for MEDLINE]

☐ **181:** Howlett DR, Perry AE, Godfrey F, Swatton JE, Jennings KH, Spitzfaden C, Wadsworth H, Wood SJ, Markwell RE. Related Articles, Links

Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans.
Biochem J. 1999 May 15;340 (Pt 1):283-9.
PMID: 10229684 [PubMed - indexed for MEDLINE]

☐ **182:** Frenkel D, Balass M, Katchalski-Katzir E, Solomon B. Related Articles, Links

High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation.
J Neuroimmunol. 1999 Mar 1;95(1-2):136-42.
PMID: 10229123 [PubMed - indexed for MEDLINE]

☐ **183:** Lin B, Schmidt-Kastner R, Busto R, Ginsberg MD. Related Articles, Links

Progressive parenchymal deposition of beta-amyloid precursor protein in rat brain following global cerebral ischemia.
Acta Neuropathol (Berl). 1999 Apr;97(4):359-68.
PMID: 10208275 [PubMed - indexed for MEDLINE]

☐ **184:** Pike CJ. Related Articles, Links

Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer's disease.
J Neurochem. 1999 Apr;72(4):1552-63.
PMID: 10098861 [PubMed - indexed for MEDLINE]

☐ **185:** Fabrizi C, Businaro R, Lauro GM, Starace G, Fumagalli L. Related Articles, Links

Activated alpha2macroglobulin increases beta-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells.
Exp Neurol. 1999 Feb;155(2):252-9.
PMID: 10072300 [PubMed - indexed for MEDLINE]

☐ **186:** Winkler K, Scharnagl H, Tisljar U, Hoschutzky H, Friedrich I, Hoffmann MM, Huttinger M, Wieland H, Marz W. Related Articles, Links

Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis.
J Lipid Res. 1999 Mar;40(3):447-55.
PMID: 10064733 [PubMed - indexed for MEDLINE]

☐ **187:** Huber G, Thompson A, Gruninger F, Mechler H, Hochstrasser R, Hauri HP, Malherbe P. Related Articles, Links

cDNA cloning and molecular characterization of human brain metalloprotease MP100: a beta-secretase candidate?
J Neurochem. 1999 Mar;72(3):1215-23.
PMID: 10037494 [PubMed - indexed for MEDLINE]

☐ **188:** Brouillet E, Trembleau A, Galanaud D, Volovitch M, Bouillot C, Valenza C, Prochiantz A, Allinquant B. Related Articles, Links

The amyloid precursor protein interacts with Go heterotrimeric protein within a cell compartment specialized in signal transduction.
J Neurosci. 1999 Mar 1;19(5):1717-27.
PMID: 10024358 [PubMed - indexed for MEDLINE]

☐ **189:** Ohara S, Tsukada M, Ikeda S. Related Articles, Links

On the occurrence of neuronal sprouting in the frontal cortex of a patient with Down's syndrome.
Acta Neuropathol (Berl). 1999 Jan;97(1):85-90.
PMID: 9930899 [PubMed - indexed for MEDLINE]

☐ **190:** Egensperger R, Weggen S, Ida N, Multhaup G, Schnabel R, Beyreuther K, Bayer TA. Related Articles, Links

Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease.
Acta Neuropathol (Berl). 1999 Feb;97(2):113-8.
PMID: 9928821 [PubMed - indexed for MEDLINE]

☐ **191:** Su GC, Arendash GW, Kalaria RN, Bjugstad KB, Mullan M. Related Articles, Links

Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage.
Brain Res. 1999 Feb 6;818(1):105-17.
PMID: 9914443 [PubMed - indexed for MEDLINE]

☐ **192:** Tuszynski MH, Smith DE, Roberts J, McKay H, Mufson E. Related Articles, Links

Targeted intraparenchymal delivery of human NGF by gene transfer to the primate basal forebrain for 3 months does not accelerate beta-amyloid plaque deposition.
Exp Neurol. 1998 Dec;154(2):573-82.
PMID: 9878192 [PubMed - indexed for MEDLINE]

☐ **193:** Leanza G. Related Articles, Links

Chronic elevation of amyloid precursor protein expression in the neocortex and hippocampus of rats with selective cholinergic lesions.
Neurosci Lett. 1998 Nov 20;257(1):53-6.
PMID: 9857964 [PubMed - indexed for MEDLINE]

☐ **194:** Jin LW, Hearn MG, Ogburn CE, Dang N, Nochlin D, Ladiges WC, Martin GM. Related Articles, Links

Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis.
Am J Pathol. 1998 Dec;153(6):1679-86.
PMID: 9846957 [PubMed - indexed for MEDLINE]

☐ **195:** Daly J 4th, Lahiri DK, Justus DE, Kotwal GJ. Related Articles, Links

Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's disease brain.
Life Sci. 1998;63(23):2121-31.
PMID: 9839536 [PubMed - indexed for MEDLINE]

☐ **196:** Ohshita T, Nakatani A, Hiroi Y. Related Articles, Links

Purification by column chromatographies of beta-amyloid precursor proteins and their association with other 95 kDa protein in rat brain.

J Chromatogr B Biomed Sci Appl. 1998 Sep 25;716(1-2):107-18.
PMID: 9824223 [PubMed - indexed for MEDLINE]

☐ **197:** Kraszpulski M, Soininen H, Riekkinen P Sr, Alafuzoff I. Related Articles, Links

Pitfalls in the quantitative estimation of beta-amyloid immunoreactivity in human brain tissue.
Histochem Cell Biol. 1998 Oct;110(4):439-45.
PMID: 9792423 [PubMed - indexed for MEDLINE]

☐ **198:** Mizuno T, Haass C, Michikawa M, Yanagisawa K. Related Articles, Links

Cholesterol-dependent generation of a unique amyloid beta-protein from apically missorted amyloid precursor protein in MDCK cells.
Biochim Biophys Acta. 1998 Aug 14;1373(1):119-30.
PMID: 9733943 [PubMed - indexed for MEDLINE]

☐ **199:** Yilmazer-Hanke DM. Related Articles, Links

Pathogenesis of Alzheimer-related neuritic plaques: AT8 immunoreactive dystrophic neurites precede argyrophilic neurites in plaques of the entorhinal region, hippocampal formation, and amygdala.
Clin Neuropathol. 1998 Jul-Aug;17(4):194-8.
PMID: 9707333 [PubMed - indexed for MEDLINE]

☐ **200:** Hock C, Golombowski S, Muller-Spahn F, Peschel O, Riederer A, Probst A, Mandelkow E, Unger J. Related Articles, Links

Histological markers in nasal mucosa of patients with Alzheimer's disease.
Eur Neurol. 1998 Jul;40(1):31-6.
PMID: 9693230 [PubMed - indexed for MEDLINE]

☐ **201:** Munch G, Cunningham AM, Riederer P, Braak E. Related Articles, Links

Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease.
Brain Res. 1998 Jun 15;796(1-2):307-10.
PMID: 9689484 [PubMed - indexed for MEDLINE]

☐ **202:** Shen Y, Sullivan T, Lee CM, Meri S, Shiosaki K, Lin CW. Related Articles, Links

Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide.
Brain Res. 1998 Jun 15;796(1-2):187-97.
PMID: 9689469 [PubMed - indexed for MEDLINE]

☐ **203:** Frenkel D, Balass M, Solomon B. Related Articles, Links

N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies.
J Neuroimmunol. 1998 Aug 1;88(1-2):85-90.
PMID: 9688328 [PubMed - indexed for MEDLINE]

☐ **204:** Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG. Related Articles, Links

Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis.
J Neurosci Res. 1998 Jun 15;52(6):691-8.
PMID: 9669318 [PubMed - indexed for MEDLINE]

☐ **205:** Hoshino S, Tamaoka A, Takahashi M, Kobayashi S, Furukawa T, Oaki Y, Mori O, Matsuno S, Shoji S, Inomata M, Teramoto A. Related Articles, Links

Emergence of immunoreactivities for phosphorylated tau and amyloid-beta protein in chronic stage of fluid percussion injury in rat brain.
Neuroreport. 1998 Jun 1;9(8):1879-83.

h cb hg e e e fcg e ch b e

PMID: 9665619 [PubMed - indexed for MEDLINE]

206: Terryberry JW, Thor G, Peter JB. Related Articles, Links

Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis.
Neurobiol Aging. 1998 May-Jun;19(3):205-16.
PMID: 9661995 [PubMed - indexed for MEDLINE]

207: McGillem GS, Guidry C, Dacheux RF. Related Articles, Links

Antigenic changes of rabbit retinal Muller cells in culture.
Invest Ophthalmol Vis Sci. 1998 Jul;39(8):1453-61.
PMID: 9660494 [PubMed - indexed for MEDLINE]

208: Miguel-Hidalgo JJ, Alvarez A, Cacabelos R. Related Articles, Links

Plasticity of Congo red staining displayed by subpopulations of neurons within the rat central nervous system.
Cell Tissue Res. 1998 Jul;293(1):75-86.
PMID: 9634599 [PubMed - indexed for MEDLINE]

209: Salinero O, Garrido JJ, Wandosell F. Related Articles, Links

Amyloid precursor protein proteoglycan is increased after brain damage.
Biochim Biophys Acta. 1998 Apr 28;1406(3):237-50.
PMID: 9630651 [PubMed - indexed for MEDLINE]

210: Nakamura Y, Yamamoto M, Kumamaru E. Related Articles, Links

A variant very low density lipoprotein receptor lacking 84 base pairs of O-linked sugar domain in the human brain myelin.
Brain Res. 1998 May 18;793(1-2):47-53.
PMID: 9630508 [PubMed - indexed for MEDLINE]

211: Spuler S, Emslie-Smith A, Engel AG. Related Articles, Links

Amyloid myopathy: an underdiagnosed entity.
Ann Neurol. 1998 Jun;43(6):719-28.
PMID: 9629841 [PubMed - indexed for MEDLINE]

212: Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM. Related Articles, Links

Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels.
J Neuropathol Exp Neurol. 1998 Apr;57(4):353-9.
PMID: 9600229 [PubMed - indexed for MEDLINE]

213: Honda S, Itoh F, Yoshimoto M, Hinoda Y, Imai K. Related Articles, Links

Changes in morphology of neuroblastoma cells treated with all-trans retinoic acid combined with transfer of the C-terminal region of the amyloid precursor protein.
J Clin Lab Anal. 1998;12(3):172-8.
PMID: 9591705 [PubMed - indexed for MEDLINE]

214: Rossner S. Related Articles, Links

Cholinergic immunolesions by 192IgG-saporin--useful tool to simulate pathogenic aspects of Alzheimer's disease.
Int J Dev Neurosci. 1997 Nov;15(7):835-50. Review.
PMID: 9568532 [PubMed - indexed for MEDLINE]

215: Varner JA, Jensen KF, Horvath W, Isaacson RL. Related Articles, Links

Chronic administration of aluminum-fluoride or sodium-fluoride to rats in drinking water: alterations in neuronal and cerebrovascular integrity.

Brain Res. 1998 Feb 16;784(1-2):284-98.
PMID: 9518651 [PubMed - indexed for MEDLINE]

216: Minn A, Schubert M, Neiss WF, Muller-Hill B. Related Articles, Links

Enhanced GFAP expression in astrocytes of transgenic mice expressing the human brain-specific trypsinogen IV.
Glia. 1998 Apr;22(4):338-47.
PMID: 9517566 [PubMed - indexed for MEDLINE]

217: Murai H, Pierce JE, Raghupathi R, Smith DH, Saatman KE, Trojanowski JQ, Lee VM, Loring JF, Eckman C, Younkin S, McIntosh TK. Related Articles, Links

Twofold overexpression of human beta-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury.
J Comp Neurol. 1998 Mar 23;392(4):428-38.
PMID: 9514508 [PubMed - indexed for MEDLINE]

218: Dwork AJ, Liu D, Kaufman MA, Prohovnik I. Related Articles, Links

Archival, formalin-fixed tissue: its use in the study of Alzheimer's type changes.
Clin Neuropathol. 1998 Jan-Feb;17(1):45-9.
PMID: 9496540 [PubMed - indexed for MEDLINE]

219: Friedman LM, Matsuda Y, Lazarovici P. Related Articles, Links

The microbial alkaloid toxin staurosporine blocks the phorbol ester-induced increase in beta-amyloid precursor protein in PC12 cells.
Nat Toxins. 1997;5(5):173-9.
PMID: 9496375 [PubMed - indexed for MEDLINE]

220: Robertson TA, Dutton NS, Martins RN, Roses AD, Kakulas BA, Papadimitriou JM. Related Articles, Links

Age-related congophilic inclusions in the brains of apolipoprotein E-deficient mice.
Neuroscience. 1998 Jan;82(1):171-80.
PMID: 9483513 [PubMed - indexed for MEDLINE]

221: Kobayashi K, Muramori F, Aoki T, Hayashi M, Miyazu K, Fukutani Y, Mukai M, Koshino F. Related Articles, Links

KP-1 is a marker for extraneuronal neurofibrillary tangles and senile plaques in Alzheimer diseased brains.
Dement Geriatr Cogn Disord. 1998 Jan-Feb;9(1):13-9.
PMID: 9469259 [PubMed - indexed for MEDLINE]

222: Dickson TC, Saunders HL, Vickers JC. Related Articles, Links

Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease.
Neuropathol Appl Neurobiol. 1997 Dec;23(6):483-91.
PMID: 9460714 [PubMed - indexed for MEDLINE]

223: Bayer TA, Paliga K, Weggen S, Wiestler OD, Beyreuther K, Multhaup G. Related Articles, Links

Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer's disease.
Acta Neuropathol (Berl). 1997 Dec;94(6):519-24.
PMID: 9444352 [PubMed - indexed for MEDLINE]

224: Jen A, Wickenden C, Rohan de Silva HA, Patel AJ. Related Articles, Links

Preparation and purification of antisera against different regions or

isoforms of beta-amyloid precursor protein.
Brain Res Brain Res Protoc. 1997 Dec 1;2(1):23-30.
PMID: 9438067 [PubMed - indexed for MEDLINE]

225: Shalit F, Sredni B, Rosenblatt-Bin H, Kazimirsky G, Brodie C, Huberman M. Related Articles, Links

Beta-amyloid peptide induces tumor necrosis factor-alpha and nitric oxide production in murine macrophage cultures.
Neuroreport. 1997 Nov 10;8(16):3577-80.
PMID: 9427329 [PubMed - indexed for MEDLINE]

226: Zambrano N, De Renzis S, Minopoli G, Faraonio R, Donini V, Scaloni A, Cimino F, Russo T. Related Articles, Links

DNA-binding protein Pur alpha and transcription factor YY1 function as transcription activators of the neuron-specific FE65 gene promoter.
Biochem J. 1997 Nov 15;328 (Pt 1):293-300.
PMID: 9359867 [PubMed - indexed for MEDLINE]

227: Pluta R, Misicka A, Januszewski S, Barcikowska M, Lipkowski AW. Related Articles, Links

Transport of human beta-amyloid peptide through the rat blood-brain barrier after global cerebral ischemia.
Acta Neurochir Suppl (Wien). 1997;70:247-9.
PMID: 9416336 [PubMed - indexed for MEDLINE]

228: Gearing M, Levey AI, Mirra SS. Related Articles, Links

Diffuse plaques in the striatum in Alzheimer disease (AD): relationship to the striatal mosaic and selected neuropeptide markers.
J Neuropathol Exp Neurol. 1997 Dec;56(12):1363-70.
PMID: 9413285 [PubMed - indexed for MEDLINE]

229: An SF, Giometto B, Groves M, Miller RF, Beckett AA, Gray F, Tavolato B, Scaravilli F. Related Articles, Links

Axonal damage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS.
J Neuropathol Exp Neurol. 1997 Nov;56(11):1262-8.
PMID: 9370237 [PubMed - indexed for MEDLINE]

230: Goodwin JL, Kehrli ME Jr, Uemura E. Related Articles, Links

Integrin Mac-1 and beta-amyloid in microglial release of nitric oxide.
Brain Res. 1997 Sep 12;768(1-2):279-86.
PMID: 9369326 [PubMed - indexed for MEDLINE]

231: Lahiri DK, Farlow MR, Sambamurti K, Nall C. Related Articles, Links

The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells.
Life Sci. 1997;61(20):1985-92.
PMID: 9366505 [PubMed - indexed for MEDLINE]

232: Matsumoto A, Minami M, Matsumoto R. Related Articles, Links

The beta-amyloid epitope masking activity in human brain is identified as albumin.
Neuroreport. 1997 Oct 20;8(15):3297-301.
PMID: 9351660 [PubMed - indexed for MEDLINE]

233: Lahiri DK, Farlow MR, Nurnberger JI Jr, Greig NH. Related Articles, Links

Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures.
Ann N Y Acad Sci. 1997 Sep 26;826:416-21.

PMID: 9329715 [PubMed - indexed for MEDLINE]

234: Sasaki S, Iwata M. Related Articles, Links

Immunocytochemical and ultrastructural study of pericapillary rosettes in amyotrophic lateral sclerosis.
Acta Neuropathol (Berl). 1997 Oct;94(4):338-44.
PMID: 9341934 [PubMed - indexed for MEDLINE]

235: Garcia-Ladona FJ, Huss Y, Frey P, Ghandour MS. Related Articles, Links

Oligodendrocytes express different isoforms of beta-amyloid precursor protein in chemically defined cell culture conditions: in situ hybridization and immunocytochemical detection.
J Neurosci Res. 1997 Oct 1;50(1):50-61.
PMID: 9379493 [PubMed - indexed for MEDLINE]

236: Shea TB, Prabhakar S, Ekinci FJ. Related Articles, Links

Beta-amyloid and ionophore A23187 evoke tau hyperphosphorylation by distinct intracellular pathways: differential involvement of the calpain/protein kinase C system.
J Neurosci Res. 1997 Sep 15;49(6):759-68.
PMID: 9335263 [PubMed - indexed for MEDLINE]

237: Miller JD, Cummings J, Maresh GA, Walker DG, Castillo GM, Ngo C, Kimata K, Kinsella MG, Wight TN, Snow AD. Related Articles, Links

Localization of perlecan (or a perlecan-related macromolecule) to isolated microglia in vitro and to microglia/macrophages following infusion of beta-amyloid protein into rodent hippocampus.
Glia. 1997 Oct;21(2):228-43.
PMID: 9336237 [PubMed - indexed for MEDLINE]

238: Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, Dobbins JR, Wyrick T, Miller JR, MacKellar W, Hepburn D, Corvalan J, McClure D, Liu X, Stephenson D, Clemens J, Johnstone EM. Related Articles, Links

Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain.
J Biol Chem. 1997 Oct 3;272(40):25135-42.
PMID: 9312124 [PubMed - indexed for MEDLINE]

239: Brewer GJ. Related Articles, Links

Effects of acidosis on the distribution of processing of the beta-amyloid precursor protein in cultured hippocampal neurons.
Mol Chem Neuropathol. 1997 Jun;31(2):171-86.
PMID: 9376023 [PubMed - indexed for MEDLINE]

240: Yamada T, Tsuboi Y, Takahashi M. Related Articles, Links

Interrelationship between beta-amyloid deposition and complement-activated oligodendroglia.
Dement Geriatr Cogn Disord. 1997 Sep-Oct;8(5):267-72.
PMID: 9298627 [PubMed - indexed for MEDLINE]

241: Dewji NN, Singer SJ. Related Articles, Links

Cell surface expression of the Alzheimer disease-related presenilin proteins.
Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9926-31.
PMID: 9275228 [PubMed - indexed for MEDLINE]

242: Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Related Articles, Links

Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.
J Neurosci. 1997 Aug 15;17(16):6142-51.
PMID: 9236226 [PubMed - indexed for MEDLINE]

243: Cutler P, Brown F, Camilleri P, Carpenter D, George A, Gray C, Haran M, Stewart B. Related Articles, Links

The recognition of haemoglobin by antibodies raised for the immunoassay of beta-amyloid.
FEBS Lett. 1997 Jul 28;412(2):341-5.
PMID: 9256248 [PubMed - indexed for MEDLINE]

244: Ohsawa I, Takamura C, Kohsaka S. Related Articles, Links

The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture.
Biochem Biophys Res Commun. 1997 Jul 9;236(1):59-65.
PMID: 9223426 [PubMed - indexed for MEDLINE]

245: Luth HJ, Arendt T. Related Articles, Links

Co-expression of APP with cNOS but not iNOS after cortical injury in rat.
Neuroreport. 1997 Jul 7;8(9-10):2321-4.
PMID: 9243633 [PubMed - indexed for MEDLINE]

246: Giometto B, An SF, Groves M, Scaravilli T, Geddes JF, Miller R, Tavolato B, Beckett AA, Scaravilli F. Related Articles, Links

Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities.
Ann Neurol. 1997 Jul;42(1):34-40.
PMID: 9225683 [PubMed - indexed for MEDLINE]

247: Haas C, Cazorla P, Miguel CD, Valdivieso F, Vazquez J. Related Articles, Links

Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein.
Biochem J. 1997 Jul 1;325 (Pt 1):169-75.
PMID: 9224643 [PubMed - indexed for MEDLINE]

248: Rohan de Silva HA, Jen A, Wickenden C, Jen LS, Wilkinson SL, Patel AJ. Related Articles, Links

Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes.
Brain Res Mol Brain Res. 1997 Jul;47(1-2):147-56.
PMID: 9221912 [PubMed - indexed for MEDLINE]

249: Yamada T, Wakabayashi K, Kakihara T, Gejyo F, Takahashi H, Itoh Y. Related Articles, Links

Further characterization of a monoclonal antibody recognizing apolipoprotein E peptides in amyloid deposits.
Ann Clin Lab Sci. 1997 Jul-Aug;27(4):276-81.
PMID: 9210972 [PubMed - indexed for MEDLINE]

250: Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T. Related Articles, Links

Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease.
Psychiatry Clin Neurosci. 1997 Jun;51(3):135-8.
PMID: 9225377 [PubMed - indexed for MEDLINE]

251: Arai Y, Suzuki A, Mizuguchi M, Takashima S. Related Articles, Links

Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains.
Brain Dev. 1997 Jun;19(4):290-4.
PMID: 9187481 [PubMed - indexed for MEDLINE]

252: Mielke JG, Murphy MP, Maritz J, Bengualid KM, Ivy GO. Related Articles, Links

Chloroquine administration in mice increases beta-amyloid immunoreactivity and attenuates kainate-induced blood-brain barrier dysfunction.
Neurosci Lett. 1997 May 23;227(3):169-72.
PMID: 9185677 [PubMed - indexed for MEDLINE]

253: Sasaki A, Iijima M, Yokoo H, Shoji M, Nakazato Y. Related Articles, Links

Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study.
Brain Res. 1997 May 2;755(2):193-201.
PMID: 9175887 [PubMed - indexed for MEDLINE]

254: Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Related Articles, Links

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4109-12.
PMID: 9108113 [PubMed - indexed for MEDLINE]

255: Xu S, Gaskin F. Related Articles, Links

Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease.
Mech Ageing Dev. 1997 Mar;94(1-3):213-22.
PMID: 9147373 [PubMed - indexed for MEDLINE]

256: Koo EH. Related Articles, Links

Phorbol esters affect multiple steps in beta-amyloid precursor protein trafficking and amyloid beta-protein production.
Mol Med. 1997 Mar;3(3):204-11.
PMID: 9100226 [PubMed - indexed for MEDLINE]

257: Robertson TA, Dutton NS, Martins RN, Roses AD, Kakulas BA, Papadimitriou JM. Related Articles, Links

Beta-amyloid protein-containing inclusions in skeletal muscle of apolipoprotein-E-deficient mice.
Am J Pathol. 1997 Feb;150(2):417-27.
PMID: 9033257 [PubMed - indexed for MEDLINE]

258: Marambaud P, Chevallier N, Barelli H, Wilk S, Checler F. Related Articles, Links

Proteasome contributes to the alpha-secretase pathway of amyloid precursor protein in human cells.
J Neurochem. 1997 Feb;68(2):698-703.
PMID: 9003058 [PubMed - indexed for MEDLINE]

259: Walter J, Capell A, Hung AY, Langen H, Schnolzer M, Thinakaran G, Sisodia SS, Selkoe DJ, Haass C. Related Articles, Links

Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations.
J Biol Chem. 1997 Jan 17;272(3):1896-903.
PMID: 8999878 [PubMed - indexed for MEDLINE]

260: McDermott JR, Gibson AM. Related Articles, Links

Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme.
Neurochem Res. 1997 Jan;22(1):49-56.
PMID: 9021762 [PubMed - indexed for MEDLINE]

261: Drache B, Diehl GE, Beyreuther K, Perlmutter LS, Konig G. Related Articles, Links

Bcl-xl-specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states.
J Neurosci Res. 1997 Jan 1;47(1):98-108.
PMID: 8981243 [PubMed - indexed for MEDLINE]

262: Matsumoto A, Enomoto T, Fujiwara Y, Baba H, Matsumoto R. Related Articles, Links

Enhanced aggregation of beta-amyloid-containing peptides by extracellular matrix and their degradation by the 68 kDa serine protease prepared from human brain.
Neurosci Lett. 1996 Dec 20;220(3):159-62.
PMID: 8994217 [PubMed - indexed for MEDLINE]

263: Sihag RK, Cataldo AM. Related Articles, Links

Brain beta-spectrin is a component of senile plaques in Alzheimer's disease.
Brain Res. 1996 Dec 16;743(1-2):249-57.
PMID: 9017252 [PubMed - indexed for MEDLINE]

264: Hirai T, Kojima S, Shimada A, Umemura T, Sakai M, Itakura C. Related Articles, Links

Age-related changes in the olfactory system of dogs.
Neuropathol Appl Neurobiol. 1996 Dec;22(6):531-9.
PMID: 9004244 [PubMed - indexed for MEDLINE]

265: Nielson KA, Cummings BJ, Cotman CW. Related Articles, Links

Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex.
Brain Res. 1996 Nov 25;741(1-2):284-93.
PMID: 9001734 [PubMed - indexed for MEDLINE]

266: Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ. Related Articles, Links

Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities.
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13170-5.
PMID: 8917563 [PubMed - indexed for MEDLINE]

267: Su JH, Cummings BJ, Cotman CW. Related Articles, Links

Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments.
Brain Res. 1996 Nov 11;739(1-2):79-87.
PMID: 8955927 [PubMed - indexed for MEDLINE]

268: Jung SS, Nalbantoglu J, Cashman NR. Related Articles, Links

Alzheimer's beta-amyloid precursor protein is expressed on the surface of immediately ex vivo brain cells: a flow cytometric study.
J Neurosci Res. 1996 Nov 1;46(3):336-48.
PMID: 8933373 [PubMed - indexed for MEDLINE]

269: Yokota M, Saido TC, Tani E, Yamaura I, Minami N. Related Articles, Links

Cytotoxic fragment of amyloid precursor protein accumulates in

hippocampus after global forebrain ischemia.
J Cereb Blood Flow Metab. 1996 Nov;16(6):1219-23.
PMID: 8898694 [PubMed - indexed for MEDLINE]

270: Dewji NN, Singer SJ. Related Articles, Links

Specific transcellular binding between membrane proteins crucial to Alzheimer disease.
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12575-80.
PMID: 8901624 [PubMed - indexed for MEDLINE]

271: Stephens DJ, Austen BM. Related Articles, Links

Metabolites of the beta-amyloid precursor protein generated by beta-secretase localise to the trans-Golgi network and late endosome in 293 cells.
J Neurosci Res. 1996 Oct 15;46(2):211-25.
PMID: 8915898 [PubMed - indexed for MEDLINE]

272: De Bleecker JL, Ertl BB, Engel AG. Related Articles, Links

Patterns of abnormal protein expression in target formations and unstructured cores.
Neuromuscul Disord. 1996 Oct;6(5):339-49.
PMID: 8938698 [PubMed - indexed for MEDLINE]

273: Mitake S, Katada E, Otsuka Y, Matsukawa N, Iwase T, Tsugu T, Fujimori O, Ojika K. Related Articles, Links

Possible implication of hippocampal cholinergic neurostimulating peptide (HCNP)-related components in Hirano body formation.
Neuropathol Appl Neurobiol. 1996 Oct;22(5):440-5.
PMID: 8930956 [PubMed - indexed for MEDLINE]

274: Kuo H, Ingram DK, Walker LC, Tian M, Hengemihle JM, Jucker M. Related Articles, Links

Similarities in the age-related hippocampal deposition of periodic acid-schiff-positive granules in the senescence-accelerated mouse P8 and C57BL/6 mouse strains.
Neuroscience. 1996 Oct;74(3):733-40.
PMID: 8884769 [PubMed - indexed for MEDLINE]

275: Vodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie QW, Smith TW, Weidner J, Mumford R, Webber R, Nathan C, Roberts AB, Lippa CF, Sporn MB. Related Articles, Links

Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease.
J Exp Med. 1996 Oct 1;184(4):1425-33.
PMID: 8879214 [PubMed - indexed for MEDLINE]

276: De La Monte SM, Carlson RI, Brown NV, Wands JR. Related Articles, Links

Profiles of neuronal thread protein expression in Alzheimer's disease.
J Neuropathol Exp Neurol. 1996 Oct;55(10):1038-50.
PMID: 8858001 [PubMed - indexed for MEDLINE]

277: Castillo GM, Cummings JA, Ngo C, Yang W, Snow AD. Related Articles, Links

Novel purification and detailed characterization of perlecan isolated from the Engelbreth-Holm-Swarm tumor for use in an animal model of fibrillar A beta amyloid persistence in brain.
J Biochem (Tokyo). 1996 Aug;120(2):433-44.
PMID: 8889831 [PubMed - indexed for MEDLINE]

278: Brewer GJ. Related Articles, Links

h cb h g e e e fcg e ch b e

Thrombin causes cell spreading and redistribution of beta-amyloid immunoreactivity in cultured hippocampal neurons.
J Neurochem. 1996 Jul;67(1):119-30.
PMID: 8666982 [PubMed - indexed for MEDLINE]

279: Nomura Y, Yamanaka Y, Kitamura Y, Arima T, Ohnuki T, Oomura Y, Sasaki K, Nagashima K, Ihara Y. Related Articles, Links

Senescence-accelerated mouse. Neurochemical studies on aging.
Ann N Y Acad Sci. 1996 Jun 15;786:410-8.
PMID: 8687038 [PubMed - indexed for MEDLINE]

280: Brown AM, Tummolo DM, Spruyt MA, Jacobsen JS, Sonnenberg-Reines J. Related Articles, Links

Evaluation of cathepsins D and G and EC 3.4.24.15 as candidate beta-secretase proteases using peptide and amyloid precursor protein substrates.
J Neurochem. 1996 Jun;66(6):2436-45.
PMID: 8632167 [PubMed - indexed for MEDLINE]

281: Fukuchi K, Ohman T, Dang N, Smith AC, Furlong CE, Martin GM. Related Articles, Links

Overexpressions of cDNAs for beta-amyloid precursor proteins 695, 751, and 770 enhance the secretion of beta-amyloid precursor protein derivatives and the survival of P19-derived neurons.
J Neurochem. 1996 May;66(5):2201-4.
PMID: 8780054 [PubMed - indexed for MEDLINE]

282: Fraser SP, Suh YH, Chong YH, Djamgoz MB. Related Articles, Links

Membrane currents induced in Xenopus oocytes by the C-terminal fragment of the beta-amyloid precursor protein.
J Neurochem. 1996 May;66(5):2034-40.
PMID: 8780033 [PubMed - indexed for MEDLINE]

283: Koo EH, Squazzo SL, Selkoe DJ, Koo CH. Related Articles, Links

Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody.
J Cell Sci. 1996 May;109 (Pt 5):991-8.
PMID: 8743946 [PubMed - indexed for MEDLINE]

284: Tamaoka A, Endoh R, Shoji S, Takahashi H, Hirokawa K, Teplow DB, Selkoe DJ, Mori H. Related Articles, Links

Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Neurobiol Aging. 1996 May-Jun;17(3):405-14.
PMID: 8725902 [PubMed - indexed for MEDLINE]

285: Nelson PT, Saper CB. Related Articles, Links

Injections of okadaic acid, but not beta-amyloid peptide, induce Alz-50 immunoreactive dystrophic neurites in the cerebral cortex of sheep.
Neurosci Lett. 1996 Apr 19;208(2):77-80.
PMID: 8859894 [PubMed - indexed for MEDLINE]

286: Johnstone EM, Babbey LE, Stephenson D, Paul DC, Santerre RF, Clemens JA, Williams DC, Little SP. Related Articles, Links

Nuclear and cytoplasmic localization of the beta-amyloid peptide (1-43) in transfected 293 cells.
Biochem Biophys Res Commun. 1996 Mar 27;220(3):710-8.
PMID: 8607830 [PubMed - indexed for MEDLINE]

287: Zhang M, Olsson Y. Related Articles, Links

Beta-amyloid precursor protein accumulates in axons around hematogenous metastases of the human brain: immunohistochemical observations.
Clin Neuropathol. 1996 Mar-Apr;15(2):74-8.
PMID: 8925600 [PubMed - indexed for MEDLINE]

288: Tekirian TL, Cole GM, Russell MJ, Yang F, Wekstein DR, Patel E, Snowdon DA, Markesbery WR, Geddes JW. Related Articles, Links

Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains.
Neurobiol Aging. 1996 Mar-Apr;17(2):249-57.
PMID: 8744406 [PubMed - indexed for MEDLINE]

289: Liberski PP, Yanagihara R, Brown P, Kordek R, Kloszewska I, Bratosiewicz J, Gajdusek DC. Related Articles, Links

Microwave treatment enhances the immunostaining of amyloid deposits in both the transmissible and non-transmissible brain amyloidoses.
Neurodegeneration. 1996 Mar;5(1):95-9.
PMID: 8731388 [PubMed - indexed for MEDLINE]

290: Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. Related Articles, Links

Localization and cell association of C1q in Alzheimer's disease brain.
Exp Neurol. 1996 Mar;138(1):22-32.
PMID: 8593893 [PubMed - indexed for MEDLINE]

291: Yasuhara O, Schwab C, Matsuo A, Kim SU, Steele JC, Akiguchi I, Kimura J, McGeer EG, McGeer PL. Related Articles, Links

Midkine-like immunoreactivity in extracellular neurofibrillary tangles in brains of patients with parkinsonism-dementia complex of Guam.
Neurosci Lett. 1996 Feb 23;205(2):107-10.
PMID: 8907328 [PubMed - indexed for MEDLINE]

292: Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK. Related Articles, Links

Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle.
Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1314-9.
PMID: 8577761 [PubMed - indexed for MEDLINE]

293: Konig G, Graham P, Bushnell A, Webster S, Wunderlich D, Perlmutter LS. Related Articles, Links

Development and characterization of a monoclonal antibody 369.2B specific for the carboxyl-terminus of the beta A4 peptide.
Ann N Y Acad Sci. 1996 Jan 17;777:344-55.
PMID: 8624111 [PubMed - indexed for MEDLINE]

294: McGeer PL, McGeer EG. Related Articles, Links

Anti-inflammatory drugs in the fight against Alzheimer's disease.
Ann N Y Acad Sci. 1996 Jan 17;777:213-20. Review.
PMID: 8624086 [PubMed - indexed for MEDLINE]

295: Solomon B, Koppel R, Hanan E, Katzav T. Related Articles, Links

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):452-5.
PMID: 8552659 [PubMed - indexed for MEDLINE]

296: Lahiri DK, Farlow MR. Related Articles, Links

Differential effect of tacrine and physostigmine on the secretion of the

beta-amyloid precursor protein in cell lines.
J Mol Neurosci. 1996 Spring;7(1):41-9.
PMID: 8835781 [PubMed - indexed for MEDLINE]

☐ **297:** Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska EB, Wischik CM. Related Articles, Links

Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease.
Acta Neuropathol (Berl). 1996;91(6):633-41.
PMID: 8781663 [PubMed - indexed for MEDLINE]

☐ **298:** Akaaboune M, Verdiere-Sahuque M, Lachkar S, Festoff BW, Hantai D. Related Articles, Links

Serine proteinase inhibitors in human skeletal muscle: expression of beta-amyloid protein precursor and alpha 1-antichymotrypsin in vivo and during myogenesis in vitro.
J Cell Physiol. 1995 Dec;165(3):503-11.
PMID: 7593229 [PubMed - indexed for MEDLINE]

☐ **299:** Saito Y, Buciak J, Yang J, Pardridge WM. Related Articles, Links

Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.
Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10227-31.
PMID: 7479757 [PubMed - indexed for MEDLINE]

☐ **300:** Link CD. Related Articles, Links

Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans.
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9368-72.
PMID: 7568134 [PubMed - indexed for MEDLINE]

☐ **301:** Matsumoto A, Matsumoto R, Baba H, Fujiwara Y. Related Articles, Links

A serine protease in Alzheimer's disease cells cleaves a 16K-peptide with flanking residues upstream to beta-amyloid-N-terminus as natural substrate.
Neurosci Lett. 1995 Aug 11;195(3):171-4.
PMID: 8584202 [PubMed - indexed for MEDLINE]

☐ **302:** Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK. Related Articles, Links

LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation.
Cell. 1995 Jul 28;82(2):331-40.
PMID: 7543026 [PubMed - indexed for MEDLINE]

☐ **303:** Banati RB, Gehrmann J, Wiessner C, Hossmann KA, Kreutzberg GW. Related Articles, Links

Glial expression of the beta-amyloid precursor protein (APP) in global ischemia.
J Cereb Blood Flow Metab. 1995 Jul;15(4):647-54.
PMID: 7790414 [PubMed - indexed for MEDLINE]

☐ **304:** Kida E, Wisniewski KE, Wisniewski HM. Related Articles, Links

Early amyloid-beta deposits show different immunoreactivity to the amino- and carboxy-terminal regions of beta-peptide in Alzheimer's disease and Down's syndrome brain.
Neurosci Lett. 1995 Jun 30;193(2):105-8.
PMID: 7478152 [PubMed - indexed for MEDLINE]

305: Griffith LS, Mathes M, Schmitz B. Related Articles, Links

Beta-amyloid precursor protein is modified with O-linked N-acetylglucosamine.
J Neurosci Res. 1995 Jun 1;41(2):270-8.
PMID: 7650762 [PubMed - indexed for MEDLINE]

306: Saito F, Tani A, Miyatake T, Yanagisawa K. Related Articles, Links

N-linked oligosaccharide of beta-amyloid precursor protein (beta APP) of C6 glioma cells: putative regulatory role in beta APP processing.
Biochem Biophys Res Commun. 1995 May 25;210(3):703-10.
PMID: 7763244 [PubMed - indexed for MEDLINE]

307: Yamada T, Kobayashi T. Related Articles, Links

The mutation in amyloid precursor protein inhibits both alpha- and beta-secretion.
Neurosci Lett. 1995 May 19;191(1-2):103-6.
PMID: 7659274 [PubMed - indexed for MEDLINE]

308: Fang Q, Kannapell CC, Fu SM, Xu S, Gaskin F. Related Articles, Links

VH and VL gene usage by anti-beta-amyloid autoantibodies in Alzheimer's disease: detection of highly mutated V regions in both heavy and light chains.
Clin Immunol Immunopathol. 1995 May;75(2):159-67.
PMID: 7704974 [PubMed - indexed for MEDLINE]

309: Greenberg SM, Kosik KS. Related Articles, Links

Secreted beta-APP stimulates MAP kinase and phosphorylation of tau in neurons.
Neurobiol Aging. 1995 May-Jun;16(3):403-7; discussion 407-8.
PMID: 7566349 [PubMed - indexed for MEDLINE]

310: Kimura T, Takamatsu J, Araki N, Goto M, Kondo A, Miyakawa T, Horiuchi S. Related Articles, Links

Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease?
Neuroreport. 1995 Apr 19;6(6):866-8.
PMID: 7612872 [PubMed - indexed for MEDLINE]

311: Oohira A, Kushima Y, Matsui F, Watanabe E. Related Articles, Links

Detection of Alzheimer's beta-amyloid precursor related proteins bearing chondroitin sulfate both in the juvenile rat brain and in the conditioned medium of primary cultured astrocytes.
Neurosci Lett. 1995 Apr 7;189(1):25-8.
PMID: 7603617 [PubMed - indexed for MEDLINE]

312: Pike CJ, Cummings BJ, Cotman CW. Related Articles, Links

Early association of reactive astrocytes with senile plaques in Alzheimer's disease.
Exp Neurol. 1995 Apr;132(2):172-9.
PMID: 7789457 [PubMed - indexed for MEDLINE]

313: Yamazaki T, Selkoe DJ, Koo EH. Related Articles, Links

Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons.
J Cell Biol. 1995 Apr;129(2):431-42.
PMID: 7721945 [PubMed - indexed for MEDLINE]

Kim CS, Han YF, Etcheberrigaray R, Nelson TJ, Olds JL.

☐ **314:** Yoshioka T, Alkon DL. Related Articles, Links

Alzheimer and beta-amyloid-treated fibroblasts demonstrate a decrease in a memory-associated GTP-binding protein, Cp20.
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3060-4.
PMID: 7708775 [PubMed - indexed for MEDLINE]

☐ **315:** Okamoto T, Takeda S, Murayama Y, Ogata E, Nishimoto I. Related Articles, Links

Ligand-dependent G protein coupling function of amyloid transmembrane precursor.
J Biol Chem. 1995 Mar 3;270(9):4205-8.
PMID: 7876177 [PubMed - indexed for MEDLINE]

☐ **316:** Qiu WQ, Ferreira A, Miller C, Koo EH, Selkoe DJ. Related Articles, Links

Cell-surface beta-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner.
J Neurosci. 1995 Mar;15(3 Pt 2):2157-67.
PMID: 7891158 [PubMed - indexed for MEDLINE]

☐ **317:** Palacios G, Mengod G, Tortosa A, Ferrer I, Palacios JM. Related Articles, Links

Increased beta-amyloid precursor protein expression in astrocytes in the gerbil hippocampus following ischaemia: association with proliferation of astrocytes.
Eur J Neurosci. 1995 Mar 1;7(3):501-10.
PMID: 7773447 [PubMed - indexed for MEDLINE]

☐ **318:** Walker DG, Kim SU, McGeer PL. Related Articles, Links

Complement and cytokine gene expression in cultured microglial derived from postmortem human brains.
J Neurosci Res. 1995 Mar 1;40(4):478-93.
PMID: 7616608 [PubMed - indexed for MEDLINE]

☐ **319:** Van Gool D, De Strooper B, Van Leuven F, Dom R. Related Articles, Links

Amyloid precursor protein accumulation in Lewy body dementia and Alzheimer's disease.
Dementia. 1995 Mar-Apr;6(2):63-8.
PMID: 7606281 [PubMed - indexed for MEDLINE]

☐ **320:** Armstrong RA, Winsper SJ, Blair JA. Related Articles, Links

Hypothesis: is Alzheimer's disease a metal-induced immune disorder?
Neurodegeneration. 1995 Mar;4(1):107-11.
PMID: 7600179 [PubMed - indexed for MEDLINE]

☐ **321:** McRae A, Gilland E, Bona E, Hagberg H. Related Articles, Links

Microglia activation after neonatal hypoxic-ischemia.
Brain Res Dev Brain Res. 1995 Feb 16;84(2):245-52.
PMID: 7743644 [PubMed - indexed for MEDLINE]

☐ **322:** Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Related Articles, Links

Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.
Neuron. 1995 Feb;14(2):457-66.
PMID: 7857653 [PubMed - indexed for MEDLINE]

☐ **323:** Sabo S, Lambert MP, Kessey K, Wade W, Krafft G, Klein WL. Related Articles, Links

Interaction of beta-amyloid peptides with integrins in a human nerve cell line.

Neurosci Lett. 1995 Jan 16;184(1):25-8.
PMID: 7739799 [PubMed - indexed for MEDLINE]

☐ 324: Cabal A, Alonso-Cortina V, Gonzalez-Vazquez LO, Naves FJ, Del Valle ME, Vega JA. Related Articles, Links

beta-Amyloid precursor protein (beta APP) in human gut with special reference to the enteric nervous system.
Brain Res Bull. 1995;38(5):417-23.
PMID: 8665264 [PubMed - indexed for MEDLINE]

☐ 325: Schwab C, Steele JC, Akiyama H, McGeer EG, McGeer PL. Related Articles, Links

Relationship of amyloid beta/A4 protein to the neurofibrillary tangles in Guamanian parkinsonism-dementia.
Acta Neuropathol (Berl). 1995;90(3):287-98.
PMID: 8525803 [PubMed - indexed for MEDLINE]

☐ 326: Mangone CA, Castano EM, Levy E, Abiusi G, Wisniewski T, Marques MR, Faccio E, Gorelick PB, Frangione B, Sica RE. Related Articles, Links

Early onset Alzheimer's disease in a South American pedigree from Argentina.
Acta Neurol Scand. 1995 Jan;91(1):6-13.
PMID: 7732777 [PubMed - indexed for MEDLINE]

☐ 327: Triarhou LC, Sola C, Mengod G, Garcia-Ladona FJ, Landwehrmeyer B, Ghetti B, Palacios JM. Related Articles, Links

Ventral mesencephalic grafts in the neostriatum of the weaver mutant mouse: structural molecule and receptor studies.
Cell Transplant. 1995 Jan-Feb;4(1):39-48.
PMID: 7728332 [PubMed - indexed for MEDLINE]

☐ 328: Mena R, Edwards P, Perez-Olvera O, Wischik CM. Related Articles, Links

Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease.
Acta Neuropathol (Berl). 1995;89(1):50-6.
PMID: 7709731 [PubMed - indexed for MEDLINE]

☐ 329: Jakes R, Harrington CR, Spillantini MG, Goedert M, Klug A. Related Articles, Links

Characterisation of an antibody relevant to the neuropathology of Alzheimer disease.
Alzheimer Dis Assoc Disord. 1995 Spring;9(1):47-51.
PMID: 7605621 [PubMed - indexed for MEDLINE]

☐ 330: Yamada T, Miyazaki K, Koshikawa N, Takahashi M, Akatsu H, Yamamoto T. Related Articles, Links

Selective localization of gelatinase A, an enzyme degrading beta-amyloid protein, in white matter microglia and in Schwann cells.
Acta Neuropathol (Berl). 1995;89(3):199-203.
PMID: 7538720 [PubMed - indexed for MEDLINE]

☐ 331: Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM. Related Articles, Links

Polyclonals to beta-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum.
Brain Res. 1994 Dec 19;667(1):138-42.
PMID: 7895077 [PubMed - indexed for MEDLINE]

☐ 332: Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA, Finch CE. Related Articles, Links

Purification and characterization of brain clusterin.
Biochem Biophys Res Commun. 1994 Nov 15;204(3):1131-6.
PMID: 7980587 [PubMed - indexed for MEDLINE]

☐ **333:** O'Brien TJ, McKelvie PA, Vrodos N. Related Articles, Links

Bilateral trigeminal amyloidoma: an unusual case of trigeminal neuropathy with a review of the literature. Case report.
J Neurosurg. 1994 Nov;81(5):780-3. Review.
PMID: 7931626 [PubMed - indexed for MEDLINE]

☐ **334:** Katsetos CD, Krishna L, Friedberg E, Reidy J, Karkavelas G, Savory J. Related Articles, Links

Lobar pilocytic astrocytomas of the cerebral hemispheres: II. Pathobiology--morphogenesis of the eosinophilic granular bodies.
Clin Neuropathol. 1994 Nov-Dec;13(6):306-14.
PMID: 7851045 [PubMed - indexed for MEDLINE]

☐ **335:** McGeer PL, Klegeris A, Walker DG, Yasuhara O, McGeer EG. Related Articles, Links

Pathological proteins in senile plaques.
Tohoku J Exp Med. 1994 Nov;174(3):269-77.
PMID: 7761992 [PubMed - indexed for MEDLINE]

☐ **336:** Yang F, Mak K, Vinters HV, Frautschy SA, Cole GM. Related Articles, Links

Monoclonal antibody to the C-terminus of beta-amyloid.
Neuroreport. 1994 Oct 27;5(16):2117-20.
PMID: 7865758 [PubMed - indexed for MEDLINE]

☐ **337:** Burke WJ, Galvin NJ, Chung HD, Stoff SA, Gillespie KN, Cataldo AM, Nixon RA. Related Articles, Links

Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease.
Brain Res. 1994 Oct 24;661(1-2):35-42.
PMID: 7834382 [PubMed - indexed for MEDLINE]

☐ **338:** Sherriff FE, Bridges LR, De Souza DS. Related Articles, Links

Non-Alzheimer neurofibrillary tangles show beta-amyloid-like immunoreactivity.
Neuroreport. 1994 Oct 3;5(15):1897-900.
PMID: 7531003 [PubMed - indexed for MEDLINE]

☐ **339:** Dreyer RN, Bausch KM, Fracasso P, Hammond LJ, Wunderlich D, Wirak DO, Davis G, Brini CM, Buckholz TM, Konig G, et al. Related Articles, Links

Processing of the pre-beta-amyloid protein by cathepsin D is enhanced by a familial Alzheimer's disease mutation.
Eur J Biochem. 1994 Sep 1;224(2):265-71.
PMID: 7523115 [PubMed - indexed for MEDLINE]

☐ **340:** van de Nes JA, Sluiter AA, Pool CW, Kamphorst W, Ravid R, Swaab DF. Related Articles, Links

The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas.
Brain Res. 1994 Aug 29;655(1-2):97-109.
PMID: 7812796 [PubMed - indexed for MEDLINE]

☐ **341:** Durham HD, Minotti S, Dooley NP, Nalbantoglu J. Related Articles, Links

Expression of the intermediate filament-associated protein related to beta-amyloid precursor protein is developmentally regulated in cultured cells.
J Neurosci Res. 1994 Aug 15;38(6):629-39.
PMID: 7807580 [PubMed - indexed for MEDLINE]

☐ **342:** Heinonen O, Soininen H, Syrjanen S, Neittaanmaki H, Paljarvi L. Related Articles, Links

Kosunen O, Syrjanen K, Riekkinen P Sr.

beta-Amyloid protein immunoreactivity in skin is not a reliable marker of Alzheimer's disease. An autopsy-controlled study.
Arch Neurol. 1994 Aug;51(8):799-804.
PMID: 8042928 [PubMed - indexed for MEDLINE]

343: Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA. Related Articles, Links

Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease.
Mol Neurobiol. 1994 Aug-Dec;9(1-3):107-13.
PMID: 7888086 [PubMed - indexed for MEDLINE]

344: Singh VK. Related Articles, Links

Studies of neuroimmune markers in Alzheimer's disease.
Mol Neurobiol. 1994 Aug-Dec;9(1-3):73-81.
PMID: 7534089 [PubMed - indexed for MEDLINE]

345: Snyder SW, Wang GT, Barrett L, Ladror US, Casuto D, Lee CM, Krafft GA, Holzman RB, Holzman TF. Related Articles, Links

Complement C1q does not bind monomeric beta-amyloid.
Exp Neurol. 1994 Jul;128(1):136-42.
PMID: 8070518 [PubMed - indexed for MEDLINE]

346: Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Related Articles, Links

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).
Neuron. 1994 Jul;13(1):45-53.
PMID: 8043280 [PubMed - indexed for MEDLINE]

347: Walker LC, Price DL, Voytko ML, Schenk DB. Related Articles, Links

Labeling of cerebral amyloid in vivo with a monoclonal antibody.
J Neuropathol Exp Neurol. 1994 Jul;53(4):377-83.
PMID: 8021711 [PubMed - indexed for MEDLINE]

348: Banati RB, Gehrmann J, Kreutzberg GW. Related Articles, Links

Glial beta-amyloid precursor protein: expression in the dentate gyrus after entorhinal cortex lesion.
Neuroreport. 1994 Jun 27;5(11):1359-61.
PMID: 7919199 [PubMed - indexed for MEDLINE]

349: Saido TC, Yokota M, Maruyama K, Yamao-Harigaya W, Tani E, Ihara Y, Kawashima S. Related Articles, Links

Spatial resolution of the primary beta-amyloidogenic process induced in postischemic hippocampus.
J Biol Chem. 1994 May 27;269(21):15253-7.
PMID: 8195161 [PubMed - indexed for MEDLINE]

350: Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P. Related Articles, Links

Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid.
Biochem Biophys Res Commun. 1994 May 16;200(3):1598-603.
PMID: 8185615 [PubMed - indexed for MEDLINE]

351: Schmidt ML, DiDario AG, Lee VM, Trojanowski JQ. Related Articles, Links

An extensive network of PHF tau-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in

Alzheimer disease.
FEBS Lett. 1994 May 9;344(1):69-73.
PMID: 8181568 [PubMed - indexed for MEDLINE]

352: Murphy GM Jr, Forno LS, Higgins L, Scardina JM, Eng LF, Cordell B. Related Articles, Links

Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders.
Am J Pathol. 1994 May;144(5):1082-8.
PMID: 8178931 [PubMed - indexed for MEDLINE]

353: Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak DR, Nelson SJ, Griffin WS. Related Articles, Links

Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease.
J Neuropathol Exp Neurol. 1994 May;53(3):231-8.
PMID: 8176406 [PubMed - indexed for MEDLINE]

354: Akaaboune M, Ma J, Festoff BW, Greenberg BD, Hantai D. Related Articles, Links

Neurotrophic regulation of mouse muscle beta-amyloid protein precursor and alpha 1-antichymotrypsin as revealed by axotomy.
J Neurobiol. 1994 May;25(5):503-14.
PMID: 8071658 [PubMed - indexed for MEDLINE]

355: Matsumoto A, Fujiwara Y. Related Articles, Links

Ca(2+)-dependent 68-kilodalton protease in familial Alzheimer's disease cells cleaves the N-terminus of beta-amyloid.
Biochemistry. 1994 Apr 5;33(13):3941-8.
PMID: 8142398 [PubMed - indexed for MEDLINE]

356: Beeson JG, Shelton ER, Chan HW, Gage FH. Related Articles, Links

Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies.
J Comp Neurol. 1994 Apr 1;342(1):78-96.
PMID: 8207129 [PubMed - indexed for MEDLINE]

357: Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI Related Articles, Links

Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease.
J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):419-25.
PMID: 8163989 [PubMed - indexed for MEDLINE]

358: Bilak M, Askanas V, Engel WK. Related Articles, Links

Alpha 1-antichymotrypsin is strongly immunolocalized at normal human and rat neuromuscular junctions.
Synapse. 1994 Apr;16(4):280-3.
PMID: 8059338 [PubMed - indexed for MEDLINE]

359: Hajimohammadreza I, Anderson VE, Cavanagh JB, Seville MP, Nolan CC, Anderton BH, Leigh PN. Related Articles, Links

beta-Amyloid precursor protein fragments and lysosomal dense bodies are found in rat brain neurons after ventricular infusion of leupeptin.
Brain Res. 1994 Mar 21;640(1-2):25-32.
PMID: 8004453 [PubMed - indexed for MEDLINE]

360: Bickel U, Lee VM, Trojanowski JQ, Pardridge WM. Related Articles, Links

Development and in vitro characterization of a cationized monoclonal

antibody against beta A4 protein: a potential probe for Alzheimer's disease.
Bioconjug Chem. 1994 Mar-Apr;5(2):119-25.
PMID: 8031874 [PubMed - indexed for MEDLINE]

361: Loffler J, Langui D, Probst A, Huber G. Related Articles, Links

Accumulation of a 50 kDa N-terminal fragment of beta-APP695 in Alzheimer's disease hippocampus and neocortex.
Neurochem Int. 1994 Mar;24(3):281-8.
PMID: 8025536 [PubMed - indexed for MEDLINE]

362: Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K. Related Articles, Links

Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain.
Am J Pathol. 1994 Feb;144(2):337-47.
PMID: 8311117 [PubMed - indexed for MEDLINE]

363: Hartig W, Hausen D, Brauer K, Arendt T, Bigl V, Bruckner G. Related Articles, Links

Digoxigenin-tagged anti-GFAP and multiple labelling of human glia, vessels and beta-amyloid.
Neuroreport. 1994 Jan 31;5(5):573-6. Erratum in: Neuroreport 1994 Apr 14;5 (8):following 1014.
PMID: 8025246 [PubMed - indexed for MEDLINE]

364: Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, Arai M, Schreier WA, Morgan DG. Related Articles, Links

An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain.
Neuron. 1994 Jan;12(1):219-34.
PMID: 8292358 [PubMed - indexed for MEDLINE]

365: Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ. Related Articles, Links

Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau.
Am J Pathol. 1994 Jan;144(1):177-87.
PMID: 8291607 [PubMed - indexed for MEDLINE]

366: Westarp ME, Foring B, Rasmussen H, Schraff S, Mertens T, Kornhuber HH. Related Articles, Links

Retroviral synthetic peptide serum antibodies in human sporadic amyotrophic lateral sclerosis.
Peptides. 1994;15(2):207-14.
PMID: 8008625 [PubMed - indexed for MEDLINE]

367: Maat-Schieman ML, Radder CM, van Duinen SG, Haan J, Roos RA. Related Articles, Links

Hereditary cerebral hemorrhage with amyloidosis (Dutch): a model for congophilic plaque formation without neurofibrillary pathology.
Acta Neuropathol (Berl). 1994;88(4):371-8.
PMID: 7839831 [PubMed - indexed for MEDLINE]

368: Zemlan FP, Vogelsang GD, McLaughlin L, Dean GE. Related Articles, Links

Alzheimer's paired helical filaments: amyloid precursor protein epitope mapping.
Brain Res Bull. 1994;33(4):387-92.
PMID: 7510209 [PubMed - indexed for MEDLINE]

☐ **369:** Cummings BJ, Su JH, Cotman CW. Related Articles, Links

Neuritic involvement within bFGF immunopositive plaques of Alzheimer's disease.
Exp Neurol. 1993 Dec;124(2):315-25.
PMID: 8287930 [PubMed - indexed for MEDLINE]

☐ **370:** Sussman MA, Bilak M, Kedes L, Engel WK, Askanas V. Related Articles, Links

Tropomodulin is highly concentrated at the postsynaptic domain of human and rat neuromuscular junctions.
Exp Cell Res. 1993 Dec;209(2):388-91.
PMID: 8262158 [PubMed - indexed for MEDLINE]

☐ **371:** Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS. Related Articles, Links

Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease.
Neurobiol Aging. 1993 Nov-Dec;14(6):589-96.
PMID: 8295661 [PubMed - indexed for MEDLINE]

☐ **372:** Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Related Articles, Links

Characterization of beta-amyloid peptide from human cerebrospinal fluid.
J Neurochem. 1993 Nov;61(5):1965-8.
PMID: 8229004 [PubMed - indexed for MEDLINE]

☐ **373:** Jucker M, Walker LC, Kibbey MC, Kleinman HK, Ingram DK. Related Articles, Links

Localization of a laminin-binding protein in brain.
Neuroscience. 1993 Oct;56(4):1009-22.
PMID: 8284032 [PubMed - indexed for MEDLINE]

☐ **374:** Higgins LS, Catalano R, Quon D, Cordell B. Related Articles, Links

Transgenic mice expressing human beta-APP751, but not mice expressing beta-APP695, display early Alzheimer's disease-like histopathology.
Ann N Y Acad Sci. 1993 Sep 24;695:224-7.
PMID: 8239286 [PubMed - indexed for MEDLINE]

☐ **375:** Askanas V, Bilak M, Engel WK, Leclerc A, Tome F. Related Articles, Links

Prion protein is strongly immunolocalized at the postsynaptic domain of human normal neuromuscular junctions.
Neurosci Lett. 1993 Sep 3;159(1-2):111-4.
PMID: 8264949 [PubMed - indexed for MEDLINE]

☐ **376:** Uchida K, Okuda R, Yamaguchi R, Tateyama S, Nakayama H, Goto N. Related Articles, Links

Double-labeling immunohistochemical studies on canine senile plaques and cerebral amyloid angiopathy.
J Vet Med Sci. 1993 Aug;55(4):637-42.
PMID: 8399746 [PubMed - indexed for MEDLINE]

☐ **377:** Holmes C, Webster MT, Procter AW, Francis PT, Bowen DM. Related Articles, Links

Relationship between beta-amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex.
Biochem Soc Trans. 1993 Aug;21 (Pt 3)(3):238S. No abstract available.
PMID: 8224394 [PubMed - indexed for MEDLINE]

☐ **378:** Miklossy J. Related Articles, Links

Alzheimer's disease--a spirochetosis?
Neuroreport. 1993 Jul;4(7):841-8.
PMID: 8369471 [PubMed - indexed for MEDLINE]

☐ **379:** Leclerc A, Tome FM, Fardeau M. Related Articles, Links

Ubiquitin and beta-amyloid-protein in inclusion body myositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: an immunocytochemical study.
Neuromuscul Disord. 1993 Jul;3(4):283-91.
PMID: 8268725 [PubMed - indexed for MEDLINE]

☐ **380:** Singhrao SK, Neal JW, Newman GR. Related Articles, Links

Corpora amylacea could be an indicator of neurodegeneration.
Neuropathol Appl Neurobiol. 1993 Jun;19(3):269-76.
PMID: 8355813 [PubMed - indexed for MEDLINE]

☐ **381:** Coria F, Moreno A, Rubio I, Garcia MA, Morato E, Mayor F Jr. Related Articles, Links

The cellular pathology associated with Alzheimer beta-amyloid deposits in non-demented aged individuals.
Neuropathol Appl Neurobiol. 1993 Jun;19(3):261-8.
PMID: 8355812 [PubMed - indexed for MEDLINE]

☐ **382:** DeWitt DA, Silver J, Canning DR, Perry G. Related Articles, Links

Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease.
Exp Neurol. 1993 Jun;121(2):149-52.
PMID: 8339766 [PubMed - indexed for MEDLINE]

☐ **383:** Fukuchi K, Sopher B, Furlong CE, Smith AC, Dang N, Martin GM. Related Articles, Links

Selective neurotoxicity of COOH-terminal fragments of the beta-amyloid precursor protein.
Neurosci Lett. 1993 May 14;154(1-2):145-8.
PMID: 8361630 [PubMed - indexed for MEDLINE]

☐ **384:** Stoll J, Balbo A, Ault B, Rapoport SI, Fine A. Related Articles, Links

Long-term transplants of mouse trisomy 16 hippocampal neurons, a model for Down's syndrome, do not develop Alzheimer's disease neuropathology.
Brain Res. 1993 May 7;610(2):295-304.
PMID: 8319091 [PubMed - indexed for MEDLINE]

☐ **385:** Scott SA, Johnson SA, Zarow C, Perlmutter LS. Related Articles, Links

Inability to detect beta-amyloid protein precursor mRNA in Alzheimer plaque-associated microglia.
Exp Neurol. 1993 May;121(1):113-8.
PMID: 8495706 [PubMed - indexed for MEDLINE]

☐ **386:** Yasuhara O, Muramatsu H, Kim SU, Muramatsu T, Maruta H, McGeer PL. Related Articles, Links

Midkine, a novel neurotrophic factor, is present in senile plaques of Alzheimer disease.
Biochem Biophys Res Commun. 1993 Apr 15;192(1):246-51.
PMID: 8476427 [PubMed - indexed for MEDLINE]

☐ **387:** Lahiri DK. Related Articles, Links

The stability of beta-amyloid precursor protein in nine different cell types.
Biochem Mol Biol Int. 1993 Apr;29(5):849-58.
PMID: 8508138 [PubMed - indexed for MEDLINE]

☐ **388:** Gaskin F, Finley J, Fang Q, Xu S, Fu SM. Related Articles, Links

Human antibodies reactive with beta-amyloid protein in Alzheimer's

disease.
J Exp Med. 1993 Apr 1;177(4):1181-6.
PMID: 8459212 [PubMed - indexed for MEDLINE]

389: Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. Related Articles, Links

Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein.
Neuron. 1993 Feb;10(2):243-54.
PMID: 8094963 [PubMed - indexed for MEDLINE]

390: Buee L, Ding W, Delacourte A, Fillit H. Related Articles, Links

Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide.
Brain Res. 1993 Jan 22;601(1-2):154-63.
PMID: 8431762 [PubMed - indexed for MEDLINE]

391: Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, Bryant K, Fritz LC, Galasko D, Thal LJ, et al. Related Articles, Links

Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide.
Nature. 1993 Jan 21;361(6409):260-3.
PMID: 7678698 [PubMed - indexed for MEDLINE]

392: Nelson PT, Marton L, Saper CB. Related Articles, Links

Alz-50 immunohistochemistry in the normal sheep striatum: a light and electron microscope study.
Brain Res. 1993 Jan 15;600(2):285-97.
PMID: 8094642 [PubMed - indexed for MEDLINE]

393: Wisniewski HM, Weigel J. Related Articles, Links

Migration of perivascular cells into the neuropil and their involvement in beta-amyloid plaque formation.
Acta Neuropathol (Berl). 1993;85(6):586-95.
PMID: 8337937 [PubMed - indexed for MEDLINE]

394: Su JH, Cummings BJ, Cotman CW. Related Articles, Links

Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease.
Neuroscience. 1992 Dec;51(4):801-13.
PMID: 1488123 [PubMed - indexed for MEDLINE]

395: Perlmutter LS, Scott SA, Barron E, Chui HC. Related Articles, Links

MHC class II-positive microglia in human brain: association with Alzheimer lesions.
J Neurosci Res. 1992 Dec;33(4):549-58. Erratum in: J Neurosci Res 1993 Jun 15;35 (3):346.
PMID: 1484388 [PubMed - indexed for MEDLINE]

396: Lahiri DK, Nall C, Farlow MR. Related Articles, Links

The cholinergic agonist carbachol reduces intracellular beta-amyloid precursor protein in PC 12 and C6 cells.
Biochem Int. 1992 Dec;28(5):853-60.
PMID: 1288495 [PubMed - indexed for MEDLINE]

397: Kammesheidt A, Boyce FM, Spanoyannis AF, Cummings BJ, Ortegon M, Cotman C, Vaught JL, Neve RL. Related Articles, Links

Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the

Alzheimer amyloid precursor in the brain.
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10857-61.
PMID: 1438289 [PubMed - indexed for MEDLINE]

☐ **398:** Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, et al. Related Articles, Links

Complement activation by beta-amyloid in Alzheimer disease.
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10016-20.
PMID: 1438191 [PubMed - indexed for MEDLINE]

☐ **399:** Brewer GJ, Ashford JW. Related Articles, Links

Human serum stimulates Alzheimer markers in cultured hippocampal neurons.
J Neurosci Res. 1992 Nov;33(3):355-69.
PMID: 1335088 [PubMed - indexed for MEDLINE]

☐ **400:** Palacios G, Palacios JM, Mengod G, Frey P. Related Articles, Links

Beta-amyloid precursor protein localization in the Golgi apparatus in neurons and oligodendrocytes. An immunocytochemical structural and ultrastructural study in normal and axotomized neurons.
Brain Res Mol Brain Res. 1992 Oct;15(3-4):195-206.
PMID: 1331676 [PubMed - indexed for MEDLINE]

☐ **401:** Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. Related Articles, Links

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.
Nature. 1992 Sep 24;359(6393):325-7.
PMID: 1406936 [PubMed - indexed for MEDLINE]

☐ **402:** Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al. Related Articles, Links

Amyloid beta-peptide is produced by cultured cells during normal metabolism.
Nature. 1992 Sep 24;359(6393):322-5.
PMID: 1383826 [PubMed - indexed for MEDLINE]

☐ **403:** Dooley NP, Gauthier S, Durham HD. Related Articles, Links

Antibody to beta-amyloid precursor protein recognizes an intermediate filament-associated protein in Alzheimer's and control fibroblasts.
J Neurosci Res. 1992 Sep;33(1):60-7.
PMID: 1453484 [PubMed - indexed for MEDLINE]

☐ **404:** Askanas V, Engel WK, Alvarez RB. Related Articles, Links

Strong immunoreactivity of beta-amyloid precursor protein, including the beta-amyloid protein sequence, at human neuromuscular junctions.
Neurosci Lett. 1992 Aug 31;143(1-2):96-100.
PMID: 1436686 [PubMed - indexed for MEDLINE]

☐ **405:** Murphy GM Jr, Greenberg BD, Ellis WG, Forno LS, Salamat SM, Gonzalez-DeWhitt PA, Lowery DE, Tinklenberg JR, Eng LF. Related Articles, Links

Alzheimer's disease. Beta-amyloid precursor protein expression in the nucleus basalis of Meynert.
Am J Pathol. 1992 Aug;141(2):357-61.
PMID: 1386714 [PubMed - indexed for MEDLINE]

☐ **406:** Lippa CF, Smith TW. Related Articles, Links

The indusium griseum in Alzheimer's disease: an immunocytochemical study.
J Neurol Sci. 1992 Aug;111(1):39-45.
PMID: 1328542 [PubMed - indexed for MEDLINE]

407: Shioi J, Anderson JP, Ripellino JA, Robakis NK. Related Articles, Links

Chondroitin sulfate proteoglycan form of the Alzheimer's beta-amyloid precursor.
J Biol Chem. 1992 Jul 15;267(20):13819-22.
PMID: 1629183 [PubMed - indexed for MEDLINE]

408: Mizuguchi M, Ikeda K, Kim SU. Related Articles, Links

Differential distribution of cellular forms of beta-amyloid precursor protein in murine glial cell cultures.
Brain Res. 1992 Jul 3;584(1-2):219-25.
PMID: 1515940 [PubMed - indexed for MEDLINE]

409: Festoff BW, Rao JS, Chen M. Related Articles, Links

Protease nexin I, thrombin- and urokinase-inhibiting serpin, concentrated in normal human cerebrospinal fluid.
Neurology. 1992 Jul;42(7):1361-6.
PMID: 1620346 [PubMed - indexed for MEDLINE]

410: Rogers J, Schultz J, Brachova L, Lue LF, Webster S, Bradt B, Cooper NR, Moss DE. Related Articles, Links

Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease.
Res Immunol. 1992 Jul-Aug;143(6):624-30. Review. No abstract available.
PMID: 1455054 [PubMed - indexed for MEDLINE]

411: Arai H, Schmidt ML, Lee VM, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ. Related Articles, Links

Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease.
Neurology. 1992 Jul;42(7):1315-22.
PMID: 1377804 [PubMed - indexed for MEDLINE]

412: Askanas V, Engel WK, Alvarez RB. Related Articles, Links

Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis.
Am J Pathol. 1992 Jul;141(1):31-6.
PMID: 1321564 [PubMed - indexed for MEDLINE]

413: Caputo CB, Sobel IR, Scott CW, Brunner WF, Barth PT, Blowers DP. Related Articles, Links

Association of the carboxy-terminus of beta-amyloid protein precursor with Alzheimer paired helical filaments.
Biochem Biophys Res Commun. 1992 Jun 30;185(3):1034-40.
PMID: 1627127 [PubMed - indexed for MEDLINE]

414: Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. Related Articles, Links

Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments.
Nature. 1992 Jun 11;357(6378):500-3.
PMID: 1608449 [PubMed - indexed for MEDLINE]

415: Cummings BJ, Su JH, Geddes JW, Van Nostrand WE, Wagner SL, Cunningham DD, Cotman CW. Related Articles, Links

Aggregation of the amyloid precursor protein within degenerating neurons

and dystrophic neurites in Alzheimer's disease.
Neuroscience. 1992 Jun;48(4):763-77.
PMID: 1378573 [PubMed - indexed for MEDLINE]

416: Mizuguchi M, Ikeda K, Kim SU. Related Articles, Links

beta-Amyloid precursor protein of Alzheimer's disease in cultured bovine oligodendrocytes.
J Neurosci Res. 1992 May;32(1):34-42.
PMID: 1629942 [PubMed - indexed for MEDLINE]

417: McGeer PL, Akiyama H, Kawamata T, Yamada T, Walker DG, Ishii T. Related Articles, Links

Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy.
J Neurosci Res. 1992 Mar;31(3):428-42.
PMID: 1640495 [PubMed - indexed for MEDLINE]

418: Askanas V, Engel WK, Alvarez RB, Glenner GG. Related Articles, Links

beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis.
Lancet. 1992 Feb 29;339(8792):560-1. No abstract available.
PMID: 1346915 [PubMed - indexed for MEDLINE]

419: Ohgami T, Kitamoto T, Tateishi J. Related Articles, Links

Alzheimer's amyloid precursor protein accumulates within axonal swellings in human brain lesions.
Neurosci Lett. 1992 Feb 17;136(1):75-8.
PMID: 1635670 [PubMed - indexed for MEDLINE]

420: Wunderlich D, Lee A, Fracasso RP, Mierz DV, Bayney RM, Ramabhadran TV. Related Articles, Links

Use of recombinant fusion proteins for generation and rapid characterization of monoclonal antibodies. Application to the Kunitz domain of human beta amyloid precursor protein.
J Immunol Methods. 1992 Feb 14;147(1):1-11.
PMID: 1371794 [PubMed - indexed for MEDLINE]

421: Delvaux A, Van der Elst L, Octave JN. Related Articles, Links

Inhibition of trypsin by the beta-amyloid protein precursor. A comparative study between transfected cells, human brain and cerebrospinal fluid.
FEBS Lett. 1992 Feb 3;297(1-2):124-6.
PMID: 1551418 [PubMed - indexed for MEDLINE]

422: Choi-Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe T, Tomita M. Related Articles, Links

SP-40,40 is a constituent of Alzheimer's amyloid.
Acta Neuropathol (Berl). 1992;83(3):260-4.
PMID: 1373021 [PubMed - indexed for MEDLINE]

423: Barcikowska M, Kujawa M, Wisniewski H. Related Articles, Links

beta-Amyloid deposits within the cerebellum of persons older than 80 years of age.
Neuropatol Pol. 1992;30(3-4):285-93.
PMID: 1340921 [PubMed - indexed for MEDLINE]

424: Frautschy SA, Baird A, Cole GM. Related Articles, Links

Effects of injected Alzheimer beta-amyloid cores in rat brain.
Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8362-6.

h cb h g e e e fcg e ch b e

PMID: 1924295 [PubMed - indexed for MEDLINE]

☐ **425:** Ito H, Hirano H, Yen SH, Kato S. Related Articles, Links

Demonstration of beta amyloid protein-containing neurofibrillary tangles in parkinsonism-dementia complex on Guam.
Neuropathol Appl Neurobiol. 1991 Oct;17(5):365-73.
PMID: 1758569 [PubMed - indexed for MEDLINE]

☐ **426:** Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. Related Articles, Links

Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein.
Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7552-6.
PMID: 1652752 [PubMed - indexed for MEDLINE]

☐ **427:** Price JL, Davis PB, Morris JC, White DL. Related Articles, Links

The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease.
Neurobiol Aging. 1991 Jul-Aug;12(4):295-312.
PMID: 1961359 [PubMed - indexed for MEDLINE]

☐ **428:** Chen M, Yankner BA. Related Articles, Links

An antibody to beta amyloid and the amyloid precursor protein inhibits cell-substratum adhesion in many mammalian cell types.
Neurosci Lett. 1991 Apr 29;125(2):223-6.
PMID: 1715534 [PubMed - indexed for MEDLINE]

☐ **429:** Knops J, Johnson-Wood K, Schenk DB, Sinha S, Lieberburg I, McConlogue L. Related Articles, Links

Isolation of baculovirus-derived secreted and full-length beta-amyloid precursor protein.
J Biol Chem. 1991 Apr 15;266(11):7285-90.
PMID: 1901866 [PubMed - indexed for MEDLINE]

☐ **430:** Fraser PE, Duffy LK, O'Malley MB, Nguyen J, Inouye H, Kirschner DA. Related Articles, Links

Morphology and antibody recognition of synthetic beta-amyloid peptides.
J Neurosci Res. 1991 Apr;28(4):474-85.
PMID: 1908024 [PubMed - indexed for MEDLINE]

☐ **431:** Matsumoto A, Fujiwara Y. Related Articles, Links

Abnormal and deficient processing of beta-amyloid precursor protein in familial Alzheimer's disease lymphoblastoid cells.
Biochem Biophys Res Commun. 1991 Mar 15;175(2):361-5.
PMID: 1902089 [PubMed - indexed for MEDLINE]

☐ **432:** Henriksson T, Barbour RM, Braa S, Ward P, Fritz LC, Johnson-Wood K, Chung HD, Burke W, Reinikainen KJ, Riekkinen P, et al. Related Articles, Links

Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay.
J Neurochem. 1991 Mar;56(3):1037-42.
PMID: 1899691 [PubMed - indexed for MEDLINE]

☐ **433:** Pendlebury WW, Iole ED, Tracy RP, Dill BA. Related Articles, Links

Intracerebral hemorrhage related to cerebral amyloid angiopathy and t-PA treatment.
Ann Neurol. 1991 Feb;29(2):210-3.

PMID: 1901466 [PubMed - indexed for MEDLINE]

434: Joachim C, Games D, Morris J, Ward P, Frenkel D, Selkoe D. Related Articles, Links

Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques.
Am J Pathol. 1991 Feb;138(2):373-84.
PMID: 1704190 [PubMed - indexed for MEDLINE]

435: Takahashi H, Hirokawa K, Ando S, Obata K. Related Articles, Links

Immunohistological study on brains of Alzheimer's disease using antibodies to fetal antigens, C-series gangliosides and microtubule-associated protein 5.
Acta Neuropathol (Berl). 1991;81(6):626-31.
PMID: 1909079 [PubMed - indexed for MEDLINE]

436: Becker L, Mito T, Takashima S, Onodera K. Related Articles, Links

Growth and development of the brain in Down syndrome.
Prog Clin Biol Res. 1991;373:133-52. Review.
PMID: 1838182 [PubMed - indexed for MEDLINE]

437: Zhao XH, Schoenheit C, Duffy LK. Related Articles, Links

A heparin-binding protein from neuroblastoma cells: immunological comparison to beta-amyloid precursor protein.
Comp Biochem Physiol A. 1991;100(3):715-8.
PMID: 1685979 [PubMed - indexed for MEDLINE]

438: Breen KC, Bruce M, Anderton BH. Related Articles, Links

Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion.
J Neurosci Res. 1991 Jan;28(1):90-100.
PMID: 1645774 [PubMed - indexed for MEDLINE]

439: Yankner BA, Caceres A, Duffy LK. Related Articles, Links

Nerve growth factor potentiates the neurotoxicity of beta amyloid.
Proc Natl Acad Sci U S A. 1990 Nov;87(22):9020-3.
PMID: 2174172 [PubMed - indexed for MEDLINE]

440: Snow AD, Mar H, Nochlin D, Sekiguchi RT, Kimata K, Koike Y, Wight TN. Related Articles, Links

Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome.
Am J Pathol. 1990 Nov;137(5):1253-70.
PMID: 2146882 [PubMed - indexed for MEDLINE]

441: Bodmer S, Podlisny MB, Selkoe DJ, Heid I, Fontana A. Related Articles, Links

Transforming growth factor-beta bound to soluble derivatives of the beta amyloid precursor protein of Alzheimer's disease.
Biochem Biophys Res Commun. 1990 Sep 14;171(2):890-7.
PMID: 2119582 [PubMed - indexed for MEDLINE]

442: Kanemaru K, Hasegawa M, Shimada H, Ihara Y. Related Articles, Links

The presence of a novel protein in calf serum that recognizes beta amyloid in the formalin-fixed section.
Am J Pathol. 1990 Sep;137(3):677-87.
PMID: 1698030 [PubMed - indexed for MEDLINE]

443: Tate-Ostroff B, Majocha RE, Walcott EC, Ventosa-Michelman M, Marotta CA. Related Articles, Links

Colocalization of amino terminal and A4 (beta-amyloid) antigens in Alzheimer plaques: evidence for coordinated processing of the amyloid precursor protein.
J Geriatr Psychiatry Neurol. 1990 Jul-Sep;3(3):139-45.
PMID: 2126439 [PubMed - indexed for MEDLINE]

444: Shelton ER, Cohn R, Fish L, Obernolte R, Tahilramani R, Nestor JJ, Chan HW Related Articles, Links

Characterization of beta-amyloid precursor proteins with or without the protease-inhibitor domain using anti-peptide antibodies.
J Neurochem. 1990 Jul;55(1):60-9.
PMID: 2113083 [PubMed - indexed for MEDLINE]

445: Wolf D, Quon D, Wang Y, Cordell B. Related Articles, Links

Identification and characterization of C-terminal fragments of the beta-amyloid precursor produced in cell culture.
EMBO J. 1990 Jul;9(7):2079-84.
PMID: 1694126 [PubMed - indexed for MEDLINE]

446: Stern RA, Trojanowski JQ, Lee VM. Related Articles, Links

Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood.
FEBS Lett. 1990 May 7;264(1):43-7.
PMID: 1692541 [PubMed - indexed for MEDLINE]

447: Spillantini MG, Goedert M, Jakes R, Klug A. Related Articles, Links

Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease.
Proc Natl Acad Sci U S A. 1990 May;87(10):3947-51.
PMID: 2111023 [PubMed - indexed for MEDLINE]

448: Singhrao S, Cole G, Henderson WJ, Newman GR. Related Articles, Links

LR White embedding allows a multi-method approach to the analysis of brain tissue from patients with Alzheimer's disease.
Histochem J. 1990 May;22(5):257-68.
PMID: 1966829 [PubMed - indexed for MEDLINE]

449: Spillantini MG, Goedert M, Jakes R, Klug A. Related Articles, Links

Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease.
Proc Natl Acad Sci U S A. 1990 May;87(10):3952-6.
PMID: 1692627 [PubMed - indexed for MEDLINE]

450: Cataldo AM, Nixon RA. Related Articles, Links

Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain.
Proc Natl Acad Sci U S A. 1990 May;87(10):3861-5.
PMID: 1692625 [PubMed - indexed for MEDLINE]

451: Arai H, Lee VM, Otvos L Jr, Greenberg BD, Lowery DE, Sharma SK, Schmidt ML, Trojanowski JQ. Related Articles, Links

Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques.
Proc Natl Acad Sci U S A. 1990 Mar;87(6):2249-53.
PMID: 1690426 [PubMed - indexed for MEDLINE]

452: Kitaguchi N, Tokushima Y, Oishi K, Takahashi Y, Shiojiri S, Nakamura S, Tanaka S, Kodaira R, Ito H. Related Articles, Links

Determination of amyloid beta protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin-antibody sandwich ELISA.
Biochem Biophys Res Commun. 1990 Feb 14;166(3):1453-9.
PMID: 2106318 [PubMed - indexed for MEDLINE]

453: Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL. Related Articles, Links

Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.
Proc Natl Acad Sci U S A. 1990 Feb;87(4):1561-5.
PMID: 1689489 [PubMed - indexed for MEDLINE]

454: Chou WG, Zain SB, Rehman S, Tate-Ostroff B, Majocha RE, Benes FM, Marotta CA. Related Articles, Links

Alzheimer cortical neurons containing abundant amyloid mRNA. Relationship to amyloid deposition and senile plaques.
J Psychiatr Res. 1990;24(1):37-50.
PMID: 2195164 [PubMed - indexed for MEDLINE]

455: Dewji NN, Shelton ER, Adler MJ, Chan HW, Seegmiller JE, Coronel C. Related Articles, Links

Processing of Alzheimer's disease-associated beta-amyloid precursor protein.
J Mol Neurosci. 1990;2(1):19-27.
PMID: 2124135 [PubMed - indexed for MEDLINE]

456: Murphy GM Jr, Eng LF, Cordell B, Wang Y, Ellis WG, Meissner L, Tinklenberg JR Related Articles, Links

Beta-amyloid precursor detected in human cerebral cortex.
Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(3):309-17.
PMID: 2113696 [PubMed - indexed for MEDLINE]

457: Takahashi H, Kurashima C, Utsuyama M, Hirokawa K. Related Articles, Links

Immunohistological study of senile brains by using a monoclonal antibody recognizing beta amyloid precursor protein: significance of granular deposits in relation with senile plaques.
Acta Neuropathol (Berl). 1990;80(3):260-5.
PMID: 1698004 [PubMed - indexed for MEDLINE]

458: Picken MM, Larrondo-Lillo M, Coria F, Gallo GR, Shelanski ML, Frangione B. Related Articles, Links

Distribution of the protease inhibitor alpha 1-antichymotrypsin in cerebral and systemic amyloid.
J Neuropathol Exp Neurol. 1990 Jan;49(1):41-8.
PMID: 1688925 [PubMed - indexed for MEDLINE]

459: Suenaga T, Hirano A, Llena JF, Ksiezak-Reding H, Yen SH, Dickson DW. Related Articles, Links

Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer's disease.
J Neuropathol Exp Neurol. 1990 Jan;49(1):31-40.
PMID: 1688924 [PubMed - indexed for MEDLINE]

460: Palmert MR, Siedlak SL, Podlisny MB, Greenberg B, Shelton ER, Chan HW, Usiak M, Selkoe DJ, Perry G, Younkin SG. Related Articles, Links

Soluble derivatives of the beta amyloid protein precursor of Alzheimer's disease are labeled by antisera to the beta amyloid protein.
Biochem Biophys Res Commun. 1989 Nov 30;165(1):182-8.
PMID: 2480122 [PubMed - indexed for MEDLINE]

☐ **461:** Behrouz N, Defossez A, Delacourte A, Hublau P, Mazzuca M. Related Articles, Links

An antiserum to the N-terminal subsequence of the Alzheimer amyloid beta protein does not react with neurofibrillary tangles.
J Gerontol. 1989 Nov;44(6):B156-9.
PMID: 2681356 [PubMed - indexed for MEDLINE]

☐ **462:** Siman R, Card JP, Nelson RB, Davis LG. Related Articles, Links

Expression of beta-amyloid precursor protein in reactive astrocytes following neuronal damage.
Neuron. 1989 Sep;3(3):275-85.
PMID: 2518369 [PubMed - indexed for MEDLINE]

☐ **463:** Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG. Related Articles, Links

The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid.
Proc Natl Acad Sci U S A. 1989 Aug;86(16):6338-42.
PMID: 2503832 [PubMed - indexed for MEDLINE]

☐ **464:** Takio K, Hasegawa M, Titani K, Ihara Y. Related Articles, Links

Identification of beta protein precursor in newborn rat brain.
Biochem Biophys Res Commun. 1989 May 15;160(3):1296-301.
PMID: 2499330 [PubMed - indexed for MEDLINE]

☐ **465:** Anderson J, Wallace W, Snyder S, Haroutunian V, Roberts JL, Lieberburg I. Related Articles, Links

Cellular forms of the rat and human beta-amyloid precursor protein (BAPP).
Brain Res. 1989 Jan 30;478(2):391-8.
PMID: 2647209 [PubMed - indexed for MEDLINE]

☐ **466:** Benes FM, Reifel JL, Majocha RE, Marotta CA. Related Articles, Links

Evidence for a diffusional model of Alzheimer amyloid A4 (beta-amyloid) deposition during neuritic plaque formation.
Neuroscience. 1989;33(3):483-8.
PMID: 2700016 [PubMed - indexed for MEDLINE]

☐ **467:** Bird TD, Lampe TH, Nemens EJ, Sumi SM, Nochlin D, Schellenberg GD, Wijsman EM. Related Articles, Links

Characteristics of familial Alzheimer's disease in nine kindreds of Volga German ancestry.
Prog Clin Biol Res. 1989;317:229-34.
PMID: 2602419 [PubMed - indexed for MEDLINE]

☐ **468:** Gentleman SM, Bruton C, Allsop D, Lewis SJ, Polak JM, Roberts GW. Related Articles, Links

A demonstration of the advantages of immunostaining in the quantification of amyloid plaque deposits.
Histochemistry. 1989;92(4):355-8.
PMID: 2478507 [PubMed - indexed for MEDLINE]

☐ **469:** Wisniewski HM, Wen GY, Kim KS. Related Articles, Links

Comparison of four staining methods on the detection of neuritic plaques.
Acta Neuropathol (Berl). 1989;78(1):22-7.
PMID: 2472039 [PubMed - indexed for MEDLINE]

☐ **470:** Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG. Related Articles, Links

Antisera to an amino-terminal peptide detect the amyloid protein

precursor of Alzheimer's disease and recognize senile plaques.
Biochem Biophys Res Commun. 1988 Oct 14;156(1):432-7.
PMID: 3140814 [PubMed - indexed for MEDLINE]

☐ **471:** Selkoe DJ, Podlisny MB, Joachim CL, Vickers EA, Lee G, Fritz LC, Oltersdorf T. Related Articles, Links

Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues.
Proc Natl Acad Sci U S A. 1988 Oct;85(19):7341-5.
PMID: 3140239 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Jul 27 2004 06:47:37

```
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:36:58 ON 31 AUG 2004

=> file BIOSCIENCE
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ADISCTI' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:37:08 ON 31 AUG 2004

FILE 'AQUALINE' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:37:08 ON 31 AUG 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 15:37:08 ON 31 AUG 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:37:08 ON 31 AUG 2004

FILE 'CAPLUS' ENTERED AT 15:37:08 ON 31 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:37:08 ON 31 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
```

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserve

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 15:37:08 ON 31 AUG 2004

FILE 'FOMAD' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:37:08 ON 31 AUG 2004

FILE 'HEALSAFE' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemis

FILE 'LIFESCI' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:37:08 ON 31 AUG 2004

FILE 'NIOSHTIC' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:37:08 ON 31 AUG 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 15:37:08 ON 31 AUG 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:37:08 ON 31 AUG 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 15:37:08 ON 31 AUG 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 15:37:08 ON 31 AUG 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 15:37:08 ON 31 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:37:08 ON 31 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 15:37:08 ON 31 AUG 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

```
FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S amyloid-beta OR beta-amyloid OR Abeta
  23 FILES SEARCHED...
  38 FILES SEARCHED...
  63 FILES SEARCHED...
L1      101603 AMYLOID-BETA OR BETA-AMYLOID OR ABETA

=> S L1 AND antibody
  25 FILES SEARCHED...
  59 FILES SEARCHED...
L2       16298 L1 AND ANTIBODY

=> DUP REM L2
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY   8% COMPLETE FOR L2
PROCESSING IS APPROXIMATELY  19% COMPLETE FOR L2
PROCESSING IS APPROXIMATELY  51% COMPLETE FOR L2
PROCESSING IS APPROXIMATELY  60% COMPLETE FOR L2
PROCESSING IS APPROXIMATELY  68% COMPLETE FOR L2
PROCESSING IS APPROXIMATELY  80% COMPLETE FOR L2
PROCESSING IS APPROXIMATELY  90% COMPLETE FOR L2
PROCESSING IS APPROXIMATELY  96% COMPLETE FOR L2
PROCESSING COMPLETED FOR L2
L3          9071 DUP REM L2 (7227 DUPLICATES REMOVED)

=> S L3 AND 1-28
  14 FILES SEARCHED...
  27 FILES SEARCHED...
  41 FILES SEARCHED...
  59 FILES SEARCHED...
  64 FILES SEARCHED...
  69 FILES SEARCHED...
L4          469 L3 AND 1-28

=> D L4 1-469

L4   ANSWER 1 OF 469  ADISINSIGHT COPYRIGHT (C) 2004  Adis Data Information BV
     on STN
ACCESSION NUMBER:       1998:6139  ADISINSIGHT
SOURCE:                 Adis R&D Insight
DOCUMENT NO:            006795
CHANGE DATE:            Jun 21, 2004
GENERIC NAME:           Celecoxib
SYNONYM:                SC 58635; YM 177; Zycel
CHEMICAL NAME:          Benzenesulfonamide, 4-(1,1,1-trifluoromethyl-
                        5-(4-methylphenyl) pyrazol-1-yl)-
TRADE NAME:             Celebra(R); Celebrex(R); Niflam(R); Onsenal(R)
MOLECULAR FORMULA:      C17 H14 F3 N3 O2 S
CAS REGISTRY NO.:       169590-42-5
STRUCTURE:


/ Structure 1 in file .gra /


RELATED CAS REG. NO.:   194044-54-7
EPHMRA ATC CODE:        A16A Other Alimentary Tract and Metabolism Products; L1
                        Antineoplastics; L1X All Other Antineoplastic; M1A3
                        Coxibs; N2B Non-Narcotics and Anti-Pyretics; N7D9 All
                        other anti-Alzheimer products
WHO ATC CODE:           A16A Other Alimentary Tract and Metabolism Products; L01
                        Antineoplastic Agents; L01X Other Antineoplastic Agents;
                        M01A-H Coxibs; M01A-H01 Celecoxib; N02B Other Analgesics
                        and Antipyretics; N07X Other Nervous System Drugs
HIGHEST DEV. PHASE:     Launched

COMPANY INFORMATION
ORIGINATOR:             Pfizer (United States)
PARENT:                 Pfizer
LICENSEE:               Roemmers; Yamanouchi
OTHER:                  Zydus-Cadila
```

OTHER SOURCES: 800973514; 800712861; 800743413; 800950955; 800839353; 800837873; 800726754; 800726737; 800755209; 800937449; 800863310; 800844220; 800818414; 800827845; 800860047; 800935615; 800837487; 800857797; 800743415; 800852321; 800837422; 800831388; 800444812; 800482402; 800772000; 800950401; 800909538; 800940410; 800479359; 800829655; 800786768; 800786769; 800756763; 800743412; 800756770; 800784217; 800739681; 800830480

WORD COUNT: 7988

L4 ANSWER 2 OF 469 BIOENG COPYRIGHT 2004 CSA on STN
AN 2004317885 BIOENG
DN 4004187
TI Monoclonal ***antibodies*** inhibit in vitro fibrillar aggregation of the Alzheimer ***beta*** - ***amyloid*** peptide
AU Solomon, B; Koppel, R; Hanan, E; Katzav, T
CS Dep. Mol. Microbiol. and Biotechnol., George S. Wise Fac. Life Sci., Tel-Aviv Univ., Ramat Aviv 69978, Israel
SO Proceedings of the National Academy of Sciences, USA [PROC. NATL. ACAD. SCI. USA], vol. 93, no. 1, pp. 452-455, 1996
ISSN: 0027-8424
DT Journal
LA English
SL English
OS CSA Neurosciences Abstracts; Medical and Pharmaceutical Biotechnology Abstracts

L4 ANSWER 3 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:2023 BIOSIS
DN PREV200400004998
TI Humoral immune response to fibrillar ***beta*** - ***amyloid*** peptide.
AU Miller, David L. [Reprint Author]; Currie, Julia R.; Mehta, Pankaj D.; Potempska, Anna; Hwang, Yu-Wen; Wegiel, Jerzy
CS New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY, 10314, USA
davidlm.interport@rcn.com
SO Biochemistry, (October 14 2003) Vol. 42, No. 40, pp. 11682-11692. print.
ISSN: 0006-2960 (ISSN print).
DT Article
LA English
ED Entered STN: 17 Dec 2003
Last Updated on STN: 17 Dec 2003

L4 ANSWER 4 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:577634 BIOSIS
DN PREV200100577634
TI ***Antibody*** -mediated attenuation of Ab-toxicity.
AU Chauhan, N. B. [Reprint author]; Siegel, G. J. [Reprint author]; Lichtor, T.
CS Neurology, Hines VA, Hines, IL, USA
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 854. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 12 Dec 2001
Last Updated on STN: 25 Feb 2002

L4 ANSWER 5 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:180840 BIOSIS
DN PREV199900180840
TI Competition of ***Abeta*** amyloid peptide and apolipoprotein E for receptor-mediated endocytosis.
AU Winkler, Karl [Reprint author]; Scharnagl, Hubert; Tisljar, Ursula; Hoschuetzky, Heinz; Friedrich, Isolde; Hoffmann, Michael M.; Huettinger, Manfred; Wieland, Heinrich; Maerz, Winfried
CS Department of Clinical Chemistry, Albert Ludwigs-University, Freiburg, Germany
SO Journal of Lipid Research, (March, 1999) Vol. 40, No. 3, pp. 447-455.

CODEN: JLPRAW. ISSN: 0022-2275.
DT Article
LA English
ED Entered STN: 5 May 1999
Last Updated on STN: 5 May 1999

L4 ANSWER 6 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1997:433580 BIOSIS
DN PREV199799732783
TI ***Beta*** - ***Amyloid*** -induced neurotoxicity of a hybrid septal cell line associated with increased tau phosphorylation and expression of ***beta*** - ***amyloid*** precursor protein.
AU Le, Weidong; Xie, Wen Jie; Kong, Rong; Appel, Stanley H. [Reprint author]
CS Dep. Neurol., Baylor Coll. Med., 6501 Fannin NB302, Houston, TX 77030, USA
SO Journal of Neurochemistry, (1997) Vol. 69, No. 3, pp. 978-985.
CODEN: JONRA9. ISSN: 0022-3042.
DT Article
LA English
ED Entered STN: 8 Oct 1997
Last Updated on STN: 8 Oct 1997

L4 ANSWER 7 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1997:309787 BIOSIS
DN PREV199799617590
TI Development and aging changes in the expression of amyloid precursor protein in Down syndrome brains.
AU Arai, Yasuhiro [Reprint author]; Suzuki, Arata; Mizuguchi, Masashi; Takashima, Sachio
CS Dep. Mental Retardation Birth Defect Res., Natl. Inst. Neurosci., Natl. Cent. Neurol. Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187, Japan
SO Brain and Development, (1997) Vol. 19, No. 4, pp. 290-294.
ISSN: 0387-7604.
DT Article
LA English
ED Entered STN: 26 Jul 1997
Last Updated on STN: 26 Jul 1997

L4 ANSWER 8 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1997:274581 BIOSIS
DN PREV199799566299
TI Increased incidence of anti- ***beta*** - ***amyloid*** autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease.
AU Xu, Shihua; Gaskin, Felicia [Reprint author]
CS Dep. Psychiatric Med., Univ. Virginia, Sch. Med., Health Sci. Cent. No. 203, Charlottesville, VA 22908, USA
SO Mechanisms of Ageing and Development, (1997) Vol. 94, No. 1-3, pp. 213-222.
CODEN: MAGDA3. ISSN: 0047-6374.
DT Article
LA English
ED Entered STN: 24 Jun 1997
Last Updated on STN: 24 Jun 1997

L4 ANSWER 9 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1997:221477 BIOSIS
DN PREV199799513193
TI Disaggregation of Alzheimer ***beta*** - ***amyloid*** by site-directed mAb.
AU Solomon, Beka [Reprint author]; Koppel, Rela; Frankel, Dan; Hanan-Aharon, Eilat
CS Dep. Molecular Microbiol. Biotechnol., Tel Aviv Univ., Ramat Aviv 69978, Israel
SO Proceedings of the National Academy of Sciences of the United States of America, (1997) Vol. 94, No. 8, pp. 4109-4112.
CODEN: PNASA6. ISSN: 0027-8424.
DT Article
LA English
ED Entered STN: 22 May 1997
Last Updated on STN: 22 May 1997

STN
AN 1996:425067 BIOSIS
DN PREV199699156123
TI Diffuse plaques contain C-terminal A-beta-42 and not A-beta-40: Evidence from cats and dogs.
AU Cummings, Brian J. [Reprint author]; Satou, Takao; Head, Elizabeth; Milgram, Norton W.; Cole, Greg M.; Savage, Mary J.; Podlisny, Marcia B.; Selkoe, Dennis J.; Siman, Robert; Greenberg, Barry D.; Cotman, Carl W.
CS Lab. Molecular Neurosciences, Mailman Res. Cent., McLean Hosp., 115 Mill Street, Belmont, MA 02178, USA
SO Neurobiology of Aging, (1996) Vol. 17, No. 4, pp. 653-659.
CODEN: NEAGDO. ISSN: 0197-4580.
DT Article
LA English
ED Entered STN: 26 Sep 1996
Last Updated on STN: 26 Sep 1996

L4 ANSWER 11 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1996:336064 BIOSIS
DN PREV199699058420
TI ***Antibodies*** to ***amyloid*** ***beta*** protein (A-beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
AU Tamaoka, Akira; Endoh, Riuko; Shoji, Shin'ichi; Takahashi, Hiroshi; Hirokawa, Katsuiku; Teplow, David B.; Selkoe, Dennis J.; Mori, Hiroshi [Reprint author]
CS Dep. Molecular Biol., Tokyo Inst. Psychiatry, 2-1-8 Kamikitazawa, Setagayaku, Tokyo 156, Japan
SO Neurobiology of Aging, (1996) Vol. 17, No. 3, pp. 405-414.
CODEN: NEAGDO. ISSN: 0197-4580.
DT Article
LA English
ED Entered STN: 26 Jul 1996
Last Updated on STN: 26 Sep 1996

L4 ANSWER 12 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1995:537375 BIOSIS
DN PREV199598551675
TI Surface phosphorylation by ecto-protein kinase C in brain neurons: A target for Alzheimer's ***beta*** - ***amyloid*** peptides.
AU Hogan, Michael V.; Pawlowska, Zofia; Yang, Hui-Ai; Kornecki, Elizabeth; Ehrlich, Yigal H. [Reprint author]
CS Program Neurosci., CSI/CUNY, Building 6S, Room 320, 2800 Victory Blvd., Staten Island, NY 10314, USA
SO Journal of Neurochemistry, (1995) Vol. 65, No. 5, pp. 2022-2030.
CODEN: JONRA9. ISSN: 0022-3042.
DT Article
LA English
ED Entered STN: 14 Dec 1995
Last Updated on STN: 27 Jan 1996

L4 ANSWER 13 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1995:365811 BIOSIS
DN PREV199598380111
TI Differential binding of vascular cell-derived proteoglycans (Perlecan, Biglycan, Decorin, and Versican) to the ***beta*** - ***amyloid*** protein of Alzheimer's disease.
AU Snow, Alan D. [Reprint author]; Kinsella, Michael G.; Parks, Esther; Sekiguchi, Raymond T.; Miller, John D.; Kimata, Koji; Wight, Thomas N.
CS Dep. Pathology, Box 356480, Univ. Washington, Seattle, WA 98195-6480, USA
SO Archives of Biochemistry and Biophysics, (1995) Vol. 320, No. 1, pp. 84-95.
CODEN: ABBIA4. ISSN: 0003-9861.
DT Article
LA English
ED Entered STN: 30 Aug 1995
Last Updated on STN: 30 Aug 1995

L4 ANSWER 14 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1995:342263 BIOSIS
DN PREV199598356563
TI Intracellular A-beta-1-42 Aggregates Stimulate the Accumulation of Stable,

Transfected Cells.
AU Yang, Austin J.; Knauer, Mary; Burdick, Debra A.; Glabe, Charles [Reprint author]
CS Dep. Mol. Biol., Univ. California, Irvine, CA 92717, USA
SO Journal of Biological Chemistry, (1995) Vol. 270, No. 24, pp. 14786-14792. CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 10 Aug 1995
Last Updated on STN: 13 Sep 1995

L4 ANSWER 15 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1993:368684 BIOSIS
DN PREV199396054359
TI Alpha-1-Antichymotrypsin binding to Alzheimer A-beta peptides is sequence specific and induces fibril disaggregation in vitro.
AU Fraser, Paul E. [Reprint author]; Nguyen, Jack T.; McLachlan, Donald R.; Abraham, Carmela R.; Kirschner, Daniel A.
CS Centre Research Neurodegenerative Diseases, Tanz Neurosci. Building, Univ. Toronto, 6 Queen's Park Crescent West, Toronto, ON M5S 1A8, Canada
SO Journal of Neurochemistry, (1993) Vol. 61, No. 1, pp. 298-305. CODEN: JONRA9. ISSN: 0022-3042.
DT Article
LA English
ED Entered STN: 6 Aug 1993
Last Updated on STN: 8 Aug 1993

L4 ANSWER 16 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1993:255079 BIOSIS
DN PREV199395134254
TI Monoclonal ***antibody*** to beta peptide, recognizing amyloid deposits, neuronal cells and lipofuscin pigments in systemic organs.
AU Takahashi, Hiroshi; Utsuyama, Masanori; Kurashima, Chieri; Mori, Hiroshi; Hirokawa, Katsuiku [Reprint author]
CS Brain Res. Inst., University Tokyo, Japan
SO Acta Neuropathologica, (1993) Vol. 85, No. 2, pp. 159-166. CODEN: ANPTAL. ISSN: 0001-6322.
DT Article
LA English
ED Entered STN: 21 May 1993
Last Updated on STN: 22 May 1993

L4 ANSWER 17 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1993:252221 BIOSIS
DN PREV199395131396
TI Human ***antibodies*** reactive with ***beta*** - ***amyloid*** protein in Alzheimer's disease.
AU Gaskin, Felicia [Reprint author]; Finley, James; Fang, Qiang; Xu, Shihua; Fu, Shu Man
CS Dep. Psychiatry, Box 203, Univ. Virginia Health Sci. Cent., Charlottesville, VA 22908, USA
SO Journal of Experimental Medicine, (1993) Vol. 177, No. 4, pp. 1181-1186. CODEN: JEMEAV. ISSN: 0022-1007.
DT Article
LA English
ED Entered STN: 21 May 1993
Last Updated on STN: 13 Jul 1993

L4 ANSWER 18 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1991:274918 BIOSIS
DN PREV199192007533; BA92:7533
TI MORPHOLOGY AND ***ANTIBODY*** RECOGNITION OF SYNTHETIC ***BETA*** ***AMYLOID*** PEPTIDES.
AU FRASER P E [Reprint author]; DUFFY L K; O'MALLEY M B; NGUYEN J; INOUYE H; KIRSCHNER D A
CS NEUROL RES, CHILDREN'S HOSPITAL, ENDERS 2, 320 LONGWOOD AVE, BOSTON, MASS 02115, USA
SO Journal of Neuroscience Research, (1991) Vol. 28, No. 4, pp. 474-485. CODEN: JNREDK. ISSN: 0360-4012.
DT Article
FS BA

ED Entered STN: 13 Jun 1991
Last Updated on STN: 13 Jun 1991

L4 ANSWER 19 OF 469 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1991:51666 BIOSIS
DN PREV199191029947; BA91:29947
TI DEVELOPMENTAL AND AGING CHANGES IN THE EXPRESSION PATTERNS OF ***BETA*** ***AMYLOID*** IN THE BRAINS OF NORMAL AND DOWN SYNDROME CASES.
AU TAKASHIMA S [Reprint author]; KURUTA H; MITO T; NISHIZAWA M; KUNISHITA T; TABIRA T
CS DEP MENTAL RETARDATION BIRTH DEFECT RES, NATL INST NEUROSCI, NCNP, 4-1-1 OGAWAHIGASHIMACHI, KODAIRA, TOKYO 187, JPN
SO Brain and Development, (1990) Vol. 12, No. 4, pp. 367-371.
ISSN: 0387-7604.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 10 Jan 1991
Last Updated on STN: 10 Jan 1991

L4 ANSWER 20 OF 469 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 2004-01358 BIOTECHDS
TI Treating, preventing and/or diagnosing a condition related to ***Abeta*** expression, such as anxiety or mood disorders, including Alzheimer's disease, depression, and schizophrenia, by administering an anti- ***Abeta*** ***antibody*** to the subject;
involving vector-mediated gene transfer and expression in host cell for use in gene therapy
AU GERLAI R T
PA LILLY and CO ELI
PI WO 2003090772 6 Nov 2003
AI WO 2003-US10473 17 Apr 2003
PRAI US 2002-375462 25 Apr 2002; US 2002-375462 25 Apr 2002
DT Patent
LA English
OS WPI: 2003-865528 [80]

L4 ANSWER 21 OF 469 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 2003-13421 BIOTECHDS
TI Novel analog of amyloid precursor protein or ***beta*** ***amyloid*** for treating Alzheimer's disease, has amyloid precursor protein/ ***beta*** ***amyloid*** incorporating B-cell epitope of amyloid protein and foreign T-helper epitope;
vector-mediated gene transfer and expression in host cell for recombinant vaccine and Alzheimer disease therapy
AU RASMUSSEN P B; JENSEN M R; NIELSEN K G; KOEFOED P; DEGAN F D
PA PHARMEXA AS
PI WO 2003015812 27 Feb 2003
AI WO 2002-DK547 20 Aug 2002
PRAI US 2002-373027 16 Apr 2002; DK 2001-1231 20 Aug 2001
DT Patent
LA English
OS WPI: 2003-312718 [30]

L4 ANSWER 22 OF 469 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 1994-12231 BIOTECHDS
TI Monoclonal ***antibody*** specific for ***beta*** - ***amyloid*** or a derivative;
prepared by hybridoma construction and useful for Alzheimer disease diagnosis and therapy
PA Takeda-Chem.
PI WO 9417197 4 Aug 1994
AI WO 1994-JP89 24 Jan 1994
PRAI JP 1993-334773 28 Dec 1993; JP 1993-10132 25 Jan 1993
DT Patent
LA Japanese
OS WPI: 1994-264110 [32]

L4 ANSWER 23 OF 469 CANCERLIT on STN
AN 97189236 CANCERLIT
DN 97189236 PubMed ID: 9037507
TI Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, A beta 1-42, in differentiated PC12 cells.

CS Department of Molecular Biology, University of California, Irvine 92697, USA.
NC AG00538 (NIA)
GM07311 (NIGMS)
NS31230 (NINDS)
SO BRAIN RESEARCH, (1997 Jan 23) 746 (1-2) 275-84.
Journal code: 0045503. ISSN: 0006-8993.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 97189236
EM 199704
ED Entered STN: 19970618
Last Updated on STN: 19970618

L4 ANSWER 24 OF 469 CANCERLIT on STN
AN 96352571 CANCERLIT
DN 96352571 PubMed ID: 8717367
TI The helix-loop-helix transcription factor USF interacts with the basal promoter of human amyloid precursor protein.
AU Bourbonniere M; Nalbantoglu J
CS Department of Neurology and Neurosurgery, McGill University, Montreal, Que, Canada.
SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1996 Jan) 35 (1-2) 304-8.
Journal code: 8908640. ISSN: 0169-328X.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 96352571
EM 199610
ED Entered STN: 19961106
Last Updated on STN: 19970509

L4 ANSWER 25 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:610650 CAPLUS
TI The SAMP8 mouse as a model for Alzheimer disease: Studies from Saint Louis University
AU Morley, J. E.; Banks, W. A.; Kumar, V. B.; Farr, S. A.
CS GRECC St. Louis VAMC, Saint Louis University, St. Louis, MO, USA
SO International Congress Series (2004), 1260(Senescence-Accelerated Mouse (SAM)), 23-28
CODEN: EXMDA4; ISSN: 0531-5131
PB Elsevier Science B.V.
DT Journal
LA English

L4 ANSWER 26 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:946065 CAPLUS
DN 138:38056
TI Mutant forms of cholera holotoxin as an adjuvant
IN Green, Bruce A.; Holmes, Randall K.; Jobling, Michael G.; Zhu, Duzhang
PA American Cyanamid Company, USA; Government of the United States of America as Represented by the Uniformed Services University of the Health Sciences
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002098369	A2	20021212	WO 2002-US21008	20020605
	WO 2002098369	A3	20030220		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1404279	A2	20040407	EP 2002-756368	20020605

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI US 2001-296531P P 20010607
WO 2002-US21008 W 20020605

L4 ANSWER 27 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:927177 CAPLUS
DN 138:23639
TI ***Amyloid*** . ***beta*** . peptide fragment linked to helper T cell epitope for prevention and treatment of Alzheimer's disease
IN Wang, Chang Yi
PA United Biomedical, Inc., USA
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002096350	A2	20021205	WO 2002-US10293	20020402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003068325	A1	20030410	US 2001-865294	20010525
PRAI US 2001-865294	A	20010525		

L4 ANSWER 28 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:152212 CAPLUS
DN 135:134171
TI Sandwich-type enzyme immunoassay for amyloid A4 protein in cerebrospinal fluid from patients with head trauma
AU Pirim, Ibrahim
CS Department of Biochemistry, Ataturk University, Erzurum, 25240, Turk.
SO Turkish Journal of Medical Sciences (2001), 31(1), 47-50
CODEN: TJMEEA; ISSN: 1300-0144
PB Scientific and Technical Research Council of Turkey
DT Journal
LA English
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:511887 CAPLUS
DN 125:192578
TI Apolipoprotein E uptake is increased by ***beta*** - ***amyloid*** peptides and reduced by blockade of the LDL receptor
AU Beffert, Uwe; Aumont, Nicole; Dea, Doris; Davignon, Jean; Poirier, Judes
CS Douglas Hosp. Res. Cent., McGill Univ., Montreal, QC, H4H 1R3, Can.
SO Neurodegenerative Diseases: Molecular and Cellular Mechanisms and Therapeutic Advances, [Proceedings of the Washington International Spring Symposium], 15th, Washington, D. C., May 15-17, 1995 (1996), Meeting Date 1995, 103-108. Editor(s): Fiskum, Gary. Publisher: Plenum, New York, N. Y.
CODEN: 63GLAO
DT Conference
LA English

L4 ANSWER 30 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:489436 CAPLUS
DN 125:139684
TI Inhibitory effect of monoclonal ***antibodies*** on Alzheimer's . ***beta*** .- ***amyloid*** peptide aggregation
AU Hanan, Eilat; Solomon, Beka
CS Faculty Life Sciences, Tel-Aviv University, Ramat Aviv, 69978, Israel
SO Amyloid (1996), 3(2), 130-133
CODEN: AIJIET; ISSN: 1350-6129
PB Parthenon Publishing
DT Journal
LA English

L4 ANSWER 31 OF 469 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:577060 CAPLUS
DN 121:177060
TI The monoclonal ***antibody*** Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas
AU van de Nes, J. A. P.; Sluiter, A. A.; Pool, C. W.; Kamphorst, W.; Ravid, R.; Swaab, D. F.
CS Netherlands Institute for Brain Research, Amsterdam, Neth.
SO Brain Research (1994), 655(1-2), 97-109
CODEN: BRREAP; ISSN: 0006-8993
DT Journal
LA English

L4 ANSWER 32 OF 469 CIN COPYRIGHT 2004 ACS on STN
AN 25(10):10502V CIN
TI A Mab to prevent Alzheimer's disease and a connection to an apoptosis gene
SO Biotechnol. News, 9 Feb 1996 (960209), 16(4), p. 4. ISSN: 0273-3226;
CODEN: BINWEY.
LA English

L4 ANSWER 33 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAE35672 peptide DGENE
TI Novel peptide immunogen comprising a helper T cell epitope, an N-terminal fragment of ***amyloid*** ***beta*** peptide linked to the epitope, and optionally a spacer, useful for preventing or treating Alzheimer's disease -
IN Wang C Y
PA (UNBI-N) UNITED BIOMEDICAL INC.
PI WO 2002096350 A2 20021205 77p
AI WO 2002-US10293 20020402
PRAI US 2001-865294 20010525
DT Patent
LA English
OS 2003-201258 [19]
DESC Human ***beta*** ***amyloid*** peptide (residues ***1*** - ***28***).

L4 ANSWER 34 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABP72693 Protein DGENE
TI Novel analog of amyloid precursor protein or ***beta*** ***amyloid*** for treating Alzheimer's disease, has amyloid precursor protein/ ***beta*** ***amyloid*** incorporating B-cell epitope of amyloid protein and foreign T-helper epitope -
IN Rasmussen P B; Jensen M R; Nielsen K G; Koefoed P; Degan F D
PA (PHAR-N) PHARMEXA AS.
PI WO 2003015812 A2 20030227 122p
AI WO 2002-DK547 20020820
PRAI DK 2001-1231 20010820
US 2001-337543P 20011022
DK 2002-558 20020416
US 2002-373027P 20020416
DT Patent
LA English
OS 2003-312718 [30]
CR N-PSDB: ABZ81991
DESC Human amyloid precursor protein.

L4 ANSWER 35 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82664 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

AN AAB82663 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 37 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82662 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 38 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82661 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 39 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82660 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 40 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82659 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.

AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 41 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82658 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 42 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82657 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 43 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82656 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 44 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82655 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 45 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82654 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 46 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82653 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 47 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82652 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 48 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82651 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 49 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82650 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F

PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 50 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82649 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 51 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82648 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 52 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82647 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 53 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82646 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]

L4 ANSWER 54 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82645 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 55 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82644 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 56 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82643 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 57 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82642 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 58 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82641 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -

PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 59 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82640 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 60 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82639 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 61 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82638 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 62 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82637 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English

DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 63 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82636 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 64 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82635 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 65 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82634 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 66 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82633 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 67 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82632 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent

IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 68 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82631 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 69 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82630 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 70 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82629 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 71 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82628 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent

OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 72 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82627 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 73 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82626 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 74 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82625 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 75 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82624 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 76 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82623 Peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as

fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC All-D peptide used in Alzheimer's disease vaccine.

L4 ANSWER 77 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB82622 peptide DGENE
TI Preventing/treating amyloid-related disease, especially Alzheimer's disease, comprises administering antigenic all-D peptide, e.g. as vaccine, which elicits production of ***antibodies*** to prevent fibrillogenesis and associated cellular toxicity -
IN Chalifour R; Hebert L; Kong X; Gervais F
PA (NEUR-N) NEUROCHEM INC.
PI WO 2001039796 A2 20010607 31p
AI WO 2000-CA1413 20001129
PRAI US 1999-168594 19991129
US 2000-724842 20001128
DT Patent
LA English
OS 2001-441458 [47]
DESC ***Amyloid*** - ***beta*** peptide.

L4 ANSWER 78 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR60371 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (1-16).

L4 ANSWER 79 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR60370 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (35-43).

L4 ANSWER 80 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR60369 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125

JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (25-35).

L4 ANSWER 81 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR60368 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (***1*** - ***28***).

L4 ANSWER 82 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR60367 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (1-43).

L4 ANSWER 83 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR60366 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (1-42).

L4 ANSWER 84 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR60365 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent

OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (1-41).

L4 ANSWER 85 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR60364 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (1-40).

L4 ANSWER 86 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR60363 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (1-39).

L4 ANSWER 87 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR60362 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (1-38).

L4 ANSWER 88 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAR60373 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (18-28).

AN AAR60372 peptide DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC ***Beta*** - ***amyloid*** (17-28).

L4 ANSWER 90 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAQ70434 DNA DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC Human amyloid precursor protein anti-sense oligonucleotide.

L4 ANSWER 91 OF 469 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAQ70433 DNA DGENE
TI ***Antibodies*** recognising specific parts of ***beta*** - ***amyloid*** - can be used for diagnosis of diseases implicating ***beta*** - ***amyloid*** , such as Alzheimer's disease
IN Kitada C; Odaka A; Suzuki N
PA (TAKE) TAKEDA CHEM IND LTD.
PI WO 9417197 A1 19940804 116p
AI WO 1994-JP89 19940124
PRAI JP 1993-10132 19930125
JP 1993-19035 19930205
JP 1993-286985 19931116
JP 1993-334773 19931228
DT Patent
LA Japanese
OS 1994-264110 [32]
DESC Human amyloid precursor protein sense oligonucleotide.

L4 ANSWER 92 OF 469 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 97344335 EMBASE
DN 1997344335
TI Neuroimaging of vessel amyloid in Alzheimer's disease.
AU Friedland R.P.; Kalaria R.; Berridge M.; Miraldi F.; Hedera P.; Reno J.; Lyle L.; Marotta C.A.
CS R.P. Friedland, Department of Neurology, Case Western Reserve, University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, United States. rpf2@po.cwru.edu
SO Annals of the New York Academy of Sciences, (1997) 826/- (242-247).
Refs: 30
ISSN: 0077-8923 CODEN: ANYAA
CY United States
DT Journal; Conference Article
FS 008 Neurology and Neurosurgery
023 Nuclear Medicine
037 Drug Literature Index
LA English
SL English

L4 ANSWER 93 OF 469 IFIPAT COPYRIGHT 2004 IFI on STN

TI SOLUBLE CYCLIC ANALOGUES OF ***BETA*** ***AMYLOID*** PEPTIDE
IN Bernhagen Jurgen (DE); Brunner Herwig (DE); Kapurniotu Afroditi (DE)
PA Unassigned Or Assigned To Individual (68000)
PI US 2004116337 A1 20040617
AI US 2001-250581 20011221
WO 2001-EP15181 20011221
20011221 PCT 371 date
20011221 PCT 102(e) date
PRAI DE 2001-101014309 20010113
FI US 2004116337 20040617
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 25
GI 2 Figure(s).
FIGS. 1 and 2 show electron micrographs of the fibril-forming behavior of c beta-AP128 (1A), beta-AP (***1*** - ***28***) (1B), (Lys17, Asp21) beta-AP (***1*** - ***28***) (linear control peptide) (1C) and betaAP (***1*** - ***28***) (2A) and a 1:1 mixtures of beta-AP (***1*** - ***28***) and c beta -AP128 (2B).
FIG. 3 shows schematically the structure of a peptide having an intramolecular bridge according to the invention and of the linear control peptide.

L4 ANSWER 94 OF 469 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10323911 IFIPAT;IFIUDB;IFICDB
TI IMMUNOGENIC PEPTIDE COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE; A PEPTIDE IMMUNOGEN OF ABOUT 20 TO 100 AMINO ACIDS LONG COMPRISING: A HELPER T CELL (TH) EPITOPE, AN N-TERMINAL FRAGMENT OF A BETA 1-42 PEPTIDE, CONSISTING FROM 10-28 AMINO ACID RESIDUES
IN Wang Chang Yi
PA Unassigned Or Assigned To Individual (68000)
PI US 2003068325 A1 20030410
AI US 2001-865294 20010525
FI US 2003068325 20030410
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 80
GI 2 Figure(s).
FIGS. 1a, 1b, 1c, 1d, 1e and If are photographs showing Immunoperoxidase staining of serial sections from 2 AD brains, using Avidin-Biotinylated ***Antibody*** Complex (ABC) method with immune and preimmune sera at 1:100 dilution under 10 x magnification. FIGS. 1a, and 1d show significant binding of ***antibodies*** to both senile plaques and A beta plaques (both labelled as "P") on thioflavine S positive blood vessels (labelled as "BV"). The ***antibodies*** were generated in guinea pigs using A beta ***1*** - ***28*** -epsilon K-MVF Th1-16 (SEQ ID NO:74) prepared in ISA51 water-in-oil emulsion. FIGS. 1b and 1e show the cross reactivity of ***antibodies*** raised against the same peptide immunogen in CFA/ICFA. FIGS. 1c and 1f show brain sections using preimmune sera.
FIGS. 2a, 2b, 2c, 2d, and 2e are photographs showing Immunoperoxidase staining of serial sections of AD brain with immune and preimmune sera at 1:100 dilution and under 40 x magnification. FIGS. 2a and 2d showed that the ***antibodies*** in guinea pigs immunized with A beta ***1*** - ***28*** -epsilon K-MVF Th-1-16 (SEQ ID NO:74) prepared in ISA51 water-in-oil emulsion strongly stained the plaques (P) forming a pattern of cores. FIG. 2b is a photograph of the staining pattern of AD pig brain sections using the same immunogen in CFA/ICFA formulation. The anti-sera reacted predominantly with plaques on the blood vessels (BV). FIG. 2c is a photograph of a guinea pig brain section with preimmune serum and showed no staining. FIG. 2e shows the brain section with hyperimmune sera generated by immunization with A beta ***1*** - ***28*** peptide alone in CFA/ICFA showing a surprisingly weak staining pattern despite the strong reactivity with A beta ***1*** - ***28*** by ELISA.

L4 ANSWER 95 OF 469 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10016325 IFIPAT;IFIUDB;IFICDB
TI IDENTIFICATION OF AGENTS THAT PROTECT AGAINST INFLAMMATORY INJURY TO NEURONS; PREVENTION COMPLEXING
IN GIULIAN DANA
PA Unassigned Or Assigned To Individual (68000)
PPA Baylor College of Medicine (Probable)
PI US 2001016327 A1 20010823

RLI US 1996-717551 19960920 DIVISION 6071493
FI US 2001016327 20010823
US 6071493
US 6475742 20021105
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 99
GI 29 Figure(s).

FIG. 1 displays the chemical structure of NTox, a neurotoxin released by microglia and macrophages after exposure to senile plaques in vitro or in vivo. Chemical and enzymatic modifications of the isolated toxin have identified within NTox a phenolic hydroxyl group sensitive to tyrosinase, a ring structure sensitive to reduction by rhodium, and a terminal amine sensitive to fluorescamine (fluram) or plasma amine oxidase (PAO).

FIGS. 2A and B display steps in the isolation of NTox from frozen Alzheimer brain gray matter that involved extractions into ethyl acetate, acid hydrolysis and sequential gradient reverse phase high performance liquid chromatography (RP-HPLC). FIG. 2A shows the final step of purification by RP-HPLC, using a C18 column and an acetonitrile gradient, shows a peak with elution at about 14% acetonitrile. Importantly, this peak is found in Alzheimer but not in control brain and corresponds to activity which is highly toxic to ciliary neurons. FIG. 2B displays the degree of purification of neurotoxin from Alzheimer brain tissue. Dose response curves show that the ED50= 10 mu M in the ultrafiltrate compared with 100 pM for highly purified toxin following acid hydrolysis and C18 RP-HPLC. From such preparations, estimations of greater-than 100,000 fold purification of toxin from human brain. The phenolic content is estimated by UVmax at 265 nm with a similar result obtained when values are normalized to amine content measured by fluorescamine.

FIG. 3 shows the correlation between microglial clusters found in Alzheimer brain and levels of extracted neurotoxins. NTox was isolated from tissue blocks by aqueous extraction and 2step ion exchange chromatography (DOWEX and SP-SEPHADEX) while neighboring portions of adjacent tissue stained for HLA-DR(+) microglial clusters (scored as mean number of clusters per mm2 in 50 random field. Spearman rank correlation was highly significant (n=71 tissue regions from 6 brains; rs less-than 0. 0005) suggesting that significant amounts of NTox are found in Alzheimer brain within brain structures laden with reactive microglia.

FIGS. 4A and B sets forth the results of neurotoxin infused directly into rat brain kills neurons in vivo. Niss1 stained rat hippocampus (CA3 region) 5 days after stereotaxic injection of neurotoxin. Dead and dying, pyknotic neurons are readily apparent as darkly stained, shrunken profiles in the side injected with a neurotoxin recovered from Alzheimer brain (FIG. 4B; Bar=40 micron), compared to the contralateral hippocampus injected with an identical non-toxic fraction from age matched normal brain (FIG. 4A). The inventor estimates about 100 pmoles of purified neurotoxin were contained in the 1.0 mu 1 fluid volume injected into the hippocampus.

FIG. 5 shows the specificity of A beta 1-42 to macrophages is seen by comparison with incubating either macrophages or kidney cells with microspheres coupled to A beta 1-42 for 4 hours at 37 degrees C. in the presence of increasing amounts of A beta 10-16 mixed with the culture media. As shown, competition occurs with the macrophages in a dose dependent manner while no changes in binding are seen for kidney cells. These and similar data indicate a specificity for A beta binding to in microglia, macrophages, and other classes of microglia-like cells.

FIGS. 6A and B shows twenty four hour exposure of human embryonic kidney (HEK) cells to 1 nM of NTox resulted in significant cell death as measured by trypan blue staining but only in those cells expressing heteromeric NMDA receptors. FIG. 6A) Photomicrograph of trypan blue(+) control HEK cells exposed to NTox. Few blue, dead cells are noted. FIG. 6B shows HEK cells expressing NMDA1b/2A were also exposed to NTox for 24 hours. As seen, far larger number of dying cells appear. This NTox killing effect was found in heteromeric expression (R1/R2) and could be blocked by MK-801.

FIGS. 7A, B, and C show SpheresA beta 1-42 in vivo. Weeks after implantation of large microspheres (250 micron diameter) remain embedded within brain neocortex (FIG. 7A). FIG. 7B shows an implanted SphereBSA with very few scavenger receptor(+) microglia abutting the control microsphere. In contrast, SpheresA beta 1-42 chronically stimulate the presence of reactive cells (FIG. 7C). Microglia were visualized by uptake of fluorescent labeled acetylated LDL, DiI-ac-LDL Bar=40 mu m, FIG. 7A; 25 mu m FIGS. 7B and C.

FIGS. 8A and B shows scavenger receptor II mRNA in tissue surrounding

there is a 5-fold increase in receptor mRNA surrounding the SphereA beta 1-42 when compared to undamaged control tissue or SphereBSA. FIG. 8B, in contrast, reveals that all sites had similar levels of the marker mRNA G3PDH. Data support histological changes.

FIGS. 9A, B, and C shows infusion of A beta 1-42 into the neocortex of adult rat produces an inflammatory response 5 days later at the site of injection as seen by the presence of reactive microglia and macrophages labeled with DiI-ac-LDL (0.5 nmoles injected. FIG. 9B reveals that co-infusion of 0.5 nmoles of A beta 1-42 plus 1.0 nmole of A beta 13-16 blocks the interaction of A beta 1-42 with microglia in vivo and reduces the local brain inflammatory response while co-infusion with 1. 0 nmole A beta 1-5 did not alter inflammation (FIG. 9C, Bar= 30 microns).

FIG. 10 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of immuno-suppressive drugs (0.1 to 10 mu M) showed that only chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs with therapeutic potential for Alzheimer Disease.

FIG. 11 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of signal transduction inhibitors (0.01 to 100 mu M) showed that only compounds that block the tyrosine kinases (damacanthal and genistein) chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs which serve as lead compounds for development of therapeutics for Alzheimer Disease.

FIG. 12 shows a comparison of NTox with other brain-derived compounds which contain a phenolic and terminal amine group. Tyramine appears to significant structural similarity with NTox. Tyramine, however, has no known neurotoxic or neuroprotective properties.

FIG. 13 reveals neuroprotective effects of NTox-like compounds. Test conditions include microglia stimulated with A beta 1-42, isolated NTox applied to neurons directly, or neurons mixed with 100 mu M of the toxin quinolinic acid (QUIN). As shown, only tyramine prevented neuronal injury. Importantly, this protective effect did not occur with quinolinic acid which points to existence of families of molecules which could prevent microglia-mediated neuron injury.

FIGS. 14A-D displays neurotoxic microglia activated by betaamyloid peptide. FIG. 14A shows a fluorescence photomicrograph of neurons immuno-stained with anti-neurofilament and anti-MAP 2 ***antibodies*** found in control hippocampal cultures (1,200 cells per mm2) that were supplemented with microglia (500 per mm2). FIG. 14B shows a culture identical to FIG. 13A exposed to synthetic human A beta 1-42 (1 mu mole/1) for 72 hours resulting in a dramatic loss of neurons (Bar= 20 microns). FIG. 14C shows testing of various A beta peptides in a neurotoxicity assay using rat hippocampal cultures supplemented with microglia resulting in 70-80% killing of neurons after exposure for 72 hours to human A beta 1-40, A beta 1-42, or A beta 1-42 coupled to microspheres (Spheres A beta 1-42) while elimination of microglia from the cultures prevented neuron death. The pattern of neuron killing by synthetic peptides was similar to that elicited by either isolated AD plaques or native A beta purified from plaques. Interestingly, rodent A beta 1-40 (Arg5, Phe10, and Arg13) did not activate microglia. The A beta peptides containing either the N-terminus of the peptide (A beta 1-11, A beta 1-16, and A beta ***1*** - ***28***) or C-terminus (A beta 17-43) alone also were inactive. FIG. 14D shows the capacity of A beta 1-42 (1 mu mole/1) to activate microglia examined after modification of the N-terminal region by chemical or enzymatic methods. Altering residues in the 13 to 16 domain blocked the A beta 1-42 induction of neurotoxic microglia. Cyclohexanedione (CHD)-modification of Arg5; tetranitromethane (TNM)modification of Tyr10; diethylpyrocarbonate (DEPC)modification of His6, His13, His14 with hydroxylamine used to reverse the DEPC effect; transglutaminase (TNG) modification of Gln15; ethyl acetimidate (EAM)-modification of Lys16.

FIGS. 15A-D depicts inhibition of A beta binding to microglia. FIG. 15A shows A beta 1-42 coupled to fluorescent microspheres and the Spheres A beta 1-42 monitored for binding to microglia after 4 hours at 37 degrees C. in the presence of peptides (all at 10 mu moles/1). Only peptides containing residues 13-16 were able to competitively block sphere binding. FIG. 15B shows that enzymatic treatments of microglia altered A beta binding to cells. Spheresmal-BsA (which bind to scavenger receptors) or Spheres A beta 1-42 were incubated with microglia for 4 hours following pre-treatment of cells with trypsin (5000 units/ml at 37 degrees C. for 60 min followed by inactivation with soybean trypsin inhibitor), with heparinase (heparin lyase EC 4.2.2.7; two consecutive

(chondroitin ABC lyase EC 4.3.3.4; two consecutive treatments each of 0.02 units/ml for 60 min). Binding by either Spheres A beta 1-42 or Spheresmal-BSA to microglia were reduced by trypsin. Heparinase, however, only decreased SpheresA beta 1-42 while chondroitinase affected neither A beta or scavenger ligand binding sites. FIG. 15C shows that competition with ligands again suggest the involvement of a heparin sulfate-containing site on microglia with reduction of binding in the presence of heparin sulfate (50 mu g/ml) or A beta 1-16 (10 mu mole/l). In contrast, scavenger receptor binding of Spheresmal-BSA was blocked by known scavenger receptor ligands such as dextran sulfate (500 mu g/ml) or acetylated LDL (ac-LDL, 200 mu g/ml). FIG. 15D shows that plaque induction of neurotoxicity in microglia involves heparin sulfate-containing site. Microglia mixed with hippocampal neurons were treated with combinations of beta-Dxyloside (1 mm), heparinase (0.02 units/ml), or chondroitinase (0.04 units/ml) and then exposed to plaques. Enzyme treatments alone, particularly that of heparinase brought on some reduction in neurotoxic activity; however, a combination of both enzymatic degradation of heparin sulfate plus competitive blockade of glycosylation by beta-D-xyloside completely eliminated plaque activation.

FIGS. 16A-C displays neurotoxic microglia blocked by A beta peptides. FIG. 16A shows both A beta 1-42 (1 mu moles/1) in solution and or SpheresA beta 1-42 (250,000 per well) added to hippocampal cultures supplemented with microglia in the presence of various synthetic A beta peptides (all at 10 mu moles/1). Peptides containing residues 13 to 16 prevented A beta induction of neurotoxic microglia. FIG. 16B shows that dose curves show a greater blocking capacity for those peptides containing residues within the 1-16 hydrophilic portion of A beta . Addition of more hydrophobic segments (beyond residue 16) diminish the ability of peptide to block A beta 1-42 interactions with microglia. FIG. 16C sets forth comparisons of various peptides confirm that the HHQK domain of A beta blocks plaque activation of neurotoxic microglia.

FIG. 17 sets forth a table of the effects of ***beta*** - ***Amyloid*** peptides upon microglia. All peptides which contain the unmodified region encompassing residues 13-16 (shaded) block A beta 1-42 to bind to SpheresA beta 1-42, the ability of A beta 1-42 to induce microglial neurotoxicity, and the ability of AD plaques to induce microglial neurotoxicity. NA= not applied in this neurotoxicity test, since the free peptide induces microglial toxicity.

FIGS. 18A-G show selective elimination of microglia from mixed hippocampal cultures. Control cultures (FIGS. 18A, 18C, 18E) show complex neuronal networks revealed by MAP-2/neurofilament immunostaining (FIG. 18A), the presence of DiI-ac-LDL(+) microglia (FIG. 18B), and near confluent feeder layer of GFAP(+) astrocytes (FIG. 18C). After treatment of cultures with saporin coupled to acetylated LDL (FIGS. 18B, 18D, 18F), there was an elimination of microglia (FIG. 18D) without effect on survival of either neurons (FIG. 18B) or astroglia (FIG. 18F). Bar= 25 mu m. FIG. 18G shows counts of specific cell populations with and without Sap-ac-LDL treatment confirm the specific depletion of microglia. Data are expressed as mean values +/-standard error obtained from 9 randomly selected fields from at least 5 independent cultures viewed at 200 x magnification.

FIGS. 19A-D displays constituents of solubilized native senile plaques elicit neuron killing. FIG. 19A shows neuritic/core or diffuse plaques were isolated from cortical gray matter, solubilized in formic acid, and dialyzed against a betaine buffer. Equal amounts of plaque protein (normalized to total amine content at 400 mu moles/1) were added to neuronal cultures in the presence (100,000 cells per culture) or absence of rat microglia. As shown, solubilized neuritic/core plaque proteins (Neuritic/Core Plaque) lead to significant killing of neurons, but only in the presence of microglia. Neither solubilized diffuse plaque proteins (Diffuse Plaque) nor the betaine buffer (Buffer Control) elicited neurotoxic activity. FIG. 19B shows size-exclusion chromatography of neuritic/core plaque proteins using two Superose 12 columns in tandem (300 mm x 10 mm x 2; beads 10 mu m diameter). The chromatogram was developed with 80% glass distilled formic acid at a flow rate of 0.3 ml per minute and monitored at 280 nm. The approximate molecular masses of the fractions were: S1, 200 kDa; S2, 45 kDa; S3, 15 kDa; S4, 10 kDa; and S5, 5 kDa. FIG. 19C shows a histogram in which exposure to peaks S3, S4, and S5 all elicited significant increases in the percent of reactive microglia as defined by morphologic criteria, whereas peaks S1 and S2 do not. FIG. 19D shows fractions of solubilized neuritic/ core plaques applied to hippocampal cultures in the presence or absence of microglia. No neuron killing was detected in cultures free of microglia. Neuron loss appeared, however, in microglia containing cultures exposed to peaks S3, S4, and S5, all which contain A beta .

FIGS. 20A-E displays soluble fractions of native plaques induce microglial

exposed to peak S1 (FIG. 20A) or peak S5 (FIG. 20B) and immuno-stained for the presence of A beta . As shown, aggregates of A beta are found throughout the cultures incubated with peak S5 (Bar= 25 microns). Phase photomicrographs show cultured microglia as process bearing cells with spinous surfaces typical of non-reactive cells despite exposure to peak S4 (FIG. 20C). In contrast, microglia exposed to peak S5 retract processes and take on a reactive cell morphology similar to that found in AD brain (FIG. 20D; Bar= 5 microns).

FIGS. 21A-D displays toxic actions of synthetic A beta peptides upon neurons. FIG. 21A and 21B shows high concentrations of most A beta peptides placed in hippocampal cultures containing neurons and astroglia (but depleted of microglia) show little effect. There is, however, a generalized cytotoxic action by A beta 25-35 at greater-than 30 mu moles/1 on both neurons (FIG. 21A) and astroglia (FIG. 21B). In the absence of microglia, none of the A beta peptides (at 1 mu mole/1) produce destruction of neurons. When rat microglia are added to neuronal cultures, however, only A beta 1-40 and A beta 1-42 elicit neuron killing (FIG. 21C). As shown in FIG. 21D, addition of increasing numbers of microglia show a saturated neuron killing response at a density of 150 microglia per mm2 when incubated with 1 mu mole/liter A beta 1-42; microglia found within the E18 culture at the time of plating (endogenous microglia) also showed an efficient killing capacity in the presence of A beta . These observations point to the need to deplete neuron cultures of microglia when assessing mechanisms of A beta toxicity. Dose response curves reveal A beta 1-42 to be the most potent microglial stimulus with an estimated ED50 of 10 nmoles/1 compared to 80 nmoles/1 for A beta 1-40 (500 microglia per mm2; FIG. 21E).

FIGS. 22A-F depicts cellular responses upon exposure to synthetic A beta peptides. Phase microscopy shows that cultured rat microglia undergo morphological changes with retraction of processes when exposed to 1 mu mole/1 A beta 1-42 (FIG. 22E); in contrast, 1 mu mole/1 A beta 17-43 (FIG. 22C) does not alter microglial morphology which appear identical to untreated cells grown under control conditions (FIG. 22A). Fluorescence microscopy of neuron plus microglia cultures showed robust NF(+) MAP2(+) hippocampal neurons (FIG. 22B) that are undamaged after addition of conditioned media (10% vol/vol) from microglia incubated with 1 mu mole/1 A beta 17-43 (FIG. 22D). Significant neuron loss occurred, however, if hippocampal cultures were exposed to conditioned media from microglia incubated with 1 mu mole/1 A beta 1-42 (FIG. 22F). Bar= 25 microns.

FIGS. 23A-E displays A beta activation of microglia after coupling to microspheres. Fluorescently labeled microspheres were covalently coupled to A beta 1-42 and placed in hippocampal cultures containing rat microglia (500 cells per mm2) After 72 hours, A beta 1-42-spheres (FIG. 23A) were localized specifically within DiI-ac-LDL(+) microglia (FIG. 23B, co-localization noted by arrows). In contrast, A beta 17-43microspheres (FIG. 23C) showed no consistent association with microglia (FIG. 23D; Bar= 20 micron). FIG. 23E) Comparison of capacity of A beta in solution or coupled to microspheres (beadbound) to elicit neurotoxic microglia (250,000 microspheres per culture; 100,000 microglia per culture; 72 hour incubation). Neuronal loss was similar if A beta peptides were in solution or bound to beads, indicating that fibril formation, or other changes in tertiary structure, were not necessary to stimulate neurotoxic microglia.

FIGS. 24A-H depicts fluorescent photomicrographs of hippocampal cultures after exposure to A beta 1-42. FIG. 24A shows control cultures show complex networks of NF(+), MAP-2(+) neurons. FIG. 24B shows exposure of cultures to 100 mu moles/liter A beta 142 in the absence of microglia has no effect on neuron number, while (FIG. 24C) addition of 100 nmoles/liter A beta 1-42 in the presence of rat microglia (500 cells per mm2) destroyed nearly all neurons. FIGS. 24D-G shows immunostaining for neuronspecific enolase (NSE) is not specific to neurons in CNS cultures as shown by immunofluorescent visualization of glia in cultures of neuron-free optic nerve, including galactocerebroside(+) oligodenroglia (FIG. 24D) and GFAP(+) astrocytes (FIG. 24F) which are both NSE(+) (FIG. 24E and 24G, respectively). Bar= 10 mu m. In FIG. 24H, ciliary neuron cultures showed that A beta 1-42 is not toxic to neurons in the absence of brain glia (A beta 1-42 only) after 48 hour exposure. Conditioned media from A beta 1-42-stimulated microglia (Microglia+ A beta 1-42) did, however, kill neurons, indicating that astrocytes are not necessary to the microglial neurotoxicity.

FIGS. 25A-E displays human microglia and neuron killing. FIG. 25A shows only A beta-containing fractions from solubilized neuritic/core plaques (peaks S3 (54 nmole/1), S4 (220 mu mole/1) , and S5 (250 mu mole/1)) elicit human microglia to engage in neurotoxic behaviors. FIG. 25B shows that when tested at 1 mu mole/liter concentrations, synthetic A beta 1-40

microglia, while smaller AP fragments had no effect. Despite neuron killing, there is no evidence of increased production of nitrate or nitrite by human cells stimulated with either native (FIG. 25C) or synthetic (FIG. 25D) AD. FIG. 25E shows that neuron killing could be induced by human or rat microglia exposed to 1 mu mole/liter of the human forms of either A beta 1-42 or A beta 1-40. The rodent form of A beta 1-40, however, was inactive, as were fragments of human A beta, including 128, 12-28, and 17-43.

FIGS. 26A-C displays drug blockade of A beta induced neuron killing by rat and human microglia. To investigate mechanisms of cell killing, rat microglia were stimulated with 1 mu mole/l A beta 1-42 (Rat/A beta 1-42) and human cells with fraction S5 (containing 250 mu mole/l of native A beta 1-42) from solubilized neuritic/core plaques (Human/S5 Peak). FIG. 26A shows agents that act as free radical scavengers (vitamin E, 100 mu M; catalase, 25 units/ml; glutathione, 100 mu M) did not block microglial killing of neurons. No protective effects were observed with the nitric oxide synthetase inhibitors L-N-5-(1imin-oethyl)ornithine hydrochloride (L-NIO, 10 mu M) or diphenyl iodonium (DPI, 300 nM), although the NMDA antagonist AP5 prevented neuron death. FIG. 26B shows other NMDA antagonists acting at the receptor site (A beta 7), at the polyamine regulatory site (ifenprodil), or at the ion channel (MK801) all blocked neuron death, while the non-NMDA glutamate antagonists (GAMS, BNQX) did not. All drugs were applied at 10 mu M. FIG. 26C shows isolation of neurotoxin from culture media conditioned by A beta-stimulated rat microglia (A beta 1-42/ Microglia) or from frozen AD gray matter (AD Brain) involved extractions in ethyl acetate (pH 10.5), acid hydrolysis, and sequential gradient RP-HPLC (C18 column using a 0 to 20% acetonitrile gradient in dH2O with 0.1% trifluoroacetic acid). Neurotoxin activities from microglial conditioned media copurifies with that from AD brain tissue with a co-elution using RP-HPLC at about 14% acetonitrile. Neurotoxicity was not found within control brain extracts or from unstimulated microglial culture media.

FIG. 27 depicts A beta domains and interactions with microglia. FIG. 10A shows a phase photomicrograph of rat microglial cell adhering to Sepharose bead coupled to human A beta 1-42 peptides. FIG. 27B shows a fluorescence photomicrograph of the same bead showing adherent cell labeled by the fluorescent microglial marker DiI-ac-LDL; Bar= 20 microns. FIG. 27C shows rat microglial adherence to Sepharose-coupled beads after six hours. Plaque proteins derived from neuritic/core plaques provided an anchoring site for microglia, as did A beta 1-42. Importantly, A beta ***1*** - ***28*** also promoted bead binding, while A beta 17-43 d: not. Controls included beads coupled to glycine (Control glycine) and to bovine serum albumin (Control-BSA). Data shown are expressed as the numbers of adhering cells per 100 randomly selected beads +/-standard error after 6 hour incubation at 37 degrees C.

FIGS. 28A-G displays that the A beta cell binding domain is required for activation of neurotoxic microglia. Fluorescent photomicrographs showing microsphere binding to enriched cultures of rat microglia (500/mm2) after 4 hour incubation at 37 degrees C. Coupling of A beta peptides to fluorescent microspheres showed that A beta 1-42 (FIG. 28A), A beta 12-28 (FIG. 28D), and A beta 10-16 (FIG. 28E) readily bind, while peptides A beta 17-43 (FIG. 28B), A beta 1-11 (FIG. 28C), and A beta 1-5 (FIG. 28F) did not. Quantitations of binding pattern (FIG. 28G) indicated that regions of the N-terminus-containing amino acid residues 10-16 were necessary for A beta binding to microglia. Data are expressed as mean values +/-standard error when viewed at 200 x magnification.

FIG. 29 displays the comparison of A beta effects upon microglia. FIG. 29A shows dose response curves in which although A beta 10-16 is able to bind to microglia, it did not elicit neurotoxic microglia. The addition of this microglial binding domain to A beta 17-42 (which neither binds to microglia nor elicits toxicity) created a peptide, A beta 10-42, which both bound to microglia and stimulated microglia to kill neurons. FIG. 29B shows a diagram comparing the structures and functions of synthetic peptides. The shaded area illustrates the Nterminal portion of A beta that differs between human and rat forms and which appears necessary for microglial adherence. !

L4 ANSWER 96 OF 469 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10016324 IFIPAT;IFIUDB;IFICDB
TI IDENTIFICATION OF AGENTS THAT PROTECT AGAINST INFLAMMATORY INJURY TO NEURONS; PREVENTION COMPLEXING
IN GIULIAN DANA
PA Unassigned Or Assigned To Individual (68000)
PPA Baylor College of Medicine (Probable)
PI US 2001016326 A1 20010823

RLI US 1996-717551 19960920 DIVISION 6071493
FI US 2001016326 20010823
US 6071493
US 6451544 20020917
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 99
GI 29 Figure(s).

FIG. 1 displays the chemical structure of NTox, a neurotoxin released by microglia and macrophages after exposure to senile plaques in vitro or in vivo. Chemical and enzymatic modifications of the isolated toxin have identified within NTox a phenolic hydroxyl group sensitive to tyrosinase, a ring structure sensitive to reduction by rhodium, and a terminal amine sensitive to fluorescamine (fluram) or plasma amine oxidase (PAO).

FIGS. 2A and B display steps in the isolation of NTox from frozen Alzheimer brain gray matter that involved extractions into ethyl acetate, acid hydrolysis and sequential gradient reverse phase high performance liquid chromatography (RP-HPLC). FIG. 2A shows the final step of purification by RP-HPLC, using a C18 column and an acetonitrile gradient, shows a peak with elution at about 14% acetonitrile. Importantly, this peak is found in Alzheimer but not in control brain and corresponds to activity which is highly toxic to ciliary neurons. FIG. 2B displays the degree of purification of neurotoxin from Alzheimer brain tissue. Dose response curves show that the ED50=10 mu M in the ultrafiltrate compared with 100 pM for highly purified toxin following acid hydrolysis and C18 RP-HPLC. From such preparations, estimations of greater-than 100,000 fold purification of toxin from human brain. The phenolic content is estimated by UVmax at 265 nm with a similar result obtained when values are normalized to amine content measured by fluorescamine.

FIG. 3 shows the correlation between microglial clusters found in Alzheimer brain and levels of extracted neurotoxins. NTox was isolated from tissue blocks by aqueous extraction and 2step ion exchange chromatography (DOWEX and SP-SEPHADEX) while neighboring portions of adjacent tissue stained for HLA-DR(+) microglial clusters (scored as mean number of clusters per mm2 in 50 random field. Spearman rank correlation was highly significant (n=71 tissue regions from 6 brains; rs less-than 0. 0005) suggesting that significant amounts of NTox are found in Alzheimer brain within brain structures laden with reactive microglia.

FIGS. 4A and B sets forth the results of neurotoxin infused directly into rat brain kills neurons in vivo. Niss1 stained rat hippocampus (CA3 region) 5 days after stereotaxic injection of neurotoxin. Dead and dying, pyknotic neurons are readily apparent as darkly stained, shrunken profiles in the side injected with a neurotoxin recovered from Alzheimer brain (FIG. 4B; Bar=40 micron), compared to the contralateral hippocampus injected with an identical non-toxic fraction from age matched normal brain (FIG. 4A). The inventor estimates about 100 pmoles of purified neurotoxin were contained in the 1.0 mu l fluid volume injected into the hippocampus.

FIG. 5 shows the specificity of A beta 1-42 to macrophages is seen by comparison with incubating either macrophages or kidney cells with microspheres coupled to A beta 1-42 for 4 hours at 37 degrees C. in the presence of increasing amounts of A beta 10-16 mixed with the culture media. As shown, competition occurs with the macrophages in a dose dependent manner while no changes in binding are seen for kidney cells. These and similar data indicate a specificity for A beta binding to in microglia, macrophages, and other classes of microglia-like cells.

FIGS. 6A and B shows twenty four hour exposure of human embryonic kidney (HEK) cells to 1 nM of NTox resulted in significant cell death as measured by trypan blue staining but only in those cells expressing heteromeric NMDA receptors. FIG. 6A) Photomicrograph of trypan blue(+) control HEK cells exposed to NTox. Few blue, dead cells are noted. FIG. 6B shows HEK cells expressing NMDA1b/2A were also exposed to NTox for 24 hours. As seen, far larger number of dying cells appear. This NTox killing effect was found in heteromeric expression (R1/R2) and could be blocked by MK-801.

FIGS. 7A, B, and C show SpheresA beta 1-42 in vivo. Weeks after implantation of large microspheres (250 micron diameter) remain embedded within brain neocortex (FIG. 7A). FIG. 7B shows an implanted SphereBSA with very few scavenger receptor(+) microglia abutting the control microsphere. In contrast, SpheresA beta 1-42 chronically stimulate the presence of reactive cells (FIG. 7C). Microglia were visualized by uptake of fluorescent labeled acetylated LDL, Dil-ac-LDL Bar=40 mu m, FIG. 7A; 25 mu m FIGS. 7B and C.

FIGS. 8A and B shows scavenger receptor II mRNA in tissue surrounding

there is a 5-fold increase in receptor mRNA surrounding the SphereA beta 1-42 when compared to undamaged control tissue or SphereBSA. FIG. 8B, in contrast, reveals that all sites had similar levels of the marker mRNA G3PDH. Data support histological changes.

FIGS. 9A, B, and C shows infusion of A beta 1-42 into the neocortex of adult rat produces an inflammatory response 5 days later at the site of injection as seen by the presence of reactive microglia and macrophages labeled with Dil-ac-LDL (0.5 nmoles injected. FIG. 9B reveals that co-infusion of 0.5 nmoles of A beta 1-42 plus 1.0 nmole of A beta 13-16 blocks the interaction of A beta 1-42 with microglia in vivo and reduces the local brain inflammatory response while co-infusion with 1. 0 nmole A beta 1-5 did not alter inflammation (FIG. 9C, Bar=30 microns).

FIG. 10 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of immuno-suppressive drugs (0.1 to 10 mu M) showed that only chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs with therapeutic potential for Alzheimer Disease.

FIG. 11 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of signal transduction inhibitors (0.01 to 100 mu M) showed that only compounds that block the tyrosine kinases (damacanthal and genistein) chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs which serve as lead compounds for development of therapeutics for Alzheimer Disease.

FIG. 12 shows a comparison of NTox with other brain-derived compounds which contain a phenolic and terminal amine group. Tyramine appears to significant structural similarity with NTox. Tyramine, however, has no known neurotoxic or neuroprotective properties.

FIG. 13 reveals neuroprotective effects of NTox-like compounds. Test conditions include microglia stimulated with A beta 1-42, isolated NTox applied to neurons directly, or neurons mixed with 100 mu M of the toxin quinolinic acid (QUIN). As shown, only tyramine prevented neuronal injury. Importantly, this protective effect did not occur with quinolinic acid which points to existence of families of molecules which could prevent microglia-mediated neuron injury.

FIGS. 14A-D displays neurotoxic microglia activated by betaamyloid peptide. FIG. 14A shows a fluorescence photomicrograph of neurons immuno-stained with anti-neurofilament and anti-MA beta 2 ***antibodies*** found in control hippocampal cultures (1,200 cells pe mm2) that were supplemented with microglia (500 per mm2). FIG. 14B shows a culture identical to FIG. 13A exposed to synthetic human A beta 1-42 (1 mu mole/l) for 72 hours resulting in a dramatic loss of neurons (Bar=20 microns). FIG. 14C shows testing of various A beta peptides in a neurotoxicity assay using rat hippocampal cultures supplemented with microglia resulting in 70-80% killing of neurons after exposure for 72 hours to human A beta 1-40, A beta 1-42, or A beta 1-42 coupled to microspheres (Spheres A beta 1-42) while elimination of microglia from the cultures prevented neuron death. The pattern of neuron killing by synthetic peptides was similar to that elicited by either isolated AD plaques or native A beta purified from plaques. Interestingly, rodent A beta 1-40 (Arg5, Phe10, and Arg13) did not activate microglia. The A beta peptides containing either the N-terminus of the peptide (A beta 1-11, A beta 1-16, and A beta ***1*** - ***28***) or C-terminus (A beta 17-43) alone also were inactive. FIG. 14D shows the capacity of A beta 1-42 (1 mu mole/l) to activate microglia examined after modification of the N-terminal region by chemical or enzymatic methods. Altering residues in the 13 to 16 domain blocked the A beta 1-42 induction of neurotoxic microglia. Cyclohexanedione (CHD)-modification of Arg5; tetranitromethane (TNM)modification of Tyr10; diethylpyrocarbonate (DEPC)-modification of His6, His13, His14 with hydroxylamine used to reverse the DEPC effect; transglutaminase (TNG) modification of Gln15; ethyl acetimidate (EAM)-modification of Lys16.

FIGS. 15A-D depicts inhibition of A beta binding to microglia. FIG. 15A shows A beta 1-42 coupled to fluorescent microspheres and the Spheres A beta 1-42 monitored for binding to microglia after 4 hours at 37 degrees C. in the presence of peptides (all at 10 mu moles/l). Only peptides containing residues 13-16 were able to competitively block sphere binding. FIG. 15B shows that enzymatic treatments of microglia altered A beta binding to cells. Spheresmal-BSA (which bind to scavenger receptors) or SpheresA beta 1-42 were incubated with microglia for 4 hours following pre-treatment of cells with trypsin (5000 units/ml at 37 degrees C. for 60 min followed by inactivation with soybean trypsin inhibitor), with heparinase (heparin lyase EC 4.2.2.7; two consecutive treatments each of

lyase EC 4.3.3.4; two consecutive treatments each of 0.02 units/ml for 60 min). Binding by either SpheresA beta 1-42 or Spheresmal-BSA to microglia were reduced by trypsin. Heparinase, however, only decreased SpheresA beta 1-42 while chondroitinase affected neither A beta or scavenger ligand binding sites. FIG. 15C shows that competition with ligands again suggest the involvement of a heparin sulfate-containing site on microglia with reduction of binding in the presence of heparin sulfate (50 mu g/ml) or A beta 1-16 (10 mu mole/l). In contrast, scavenger receptor binding of Spheresmal-BSA was blocked by known scavenger receptor ligands such as dextran sulfate (500 mu g/ml) or acetylated LDL (ac-LDL, 200 mu g/ml). FIG. 15D shows that plaque induction of neurotoxicity in microglia involves heparin sulfate-containing site. Microglia mixed with hippocampal neurons were treated with combinations of beta-Dxyloside (1 mm), heparinase (0.02 units/ml), or chondroitinase (0.04 units/ml) and then exposed to plaques. Enzyme treatments alone, particularly that of heparinase brought on some reduction in neurotoxic activity; however, a combination of both enzymatic degradation of heparin sulfate plus competitive blockade of glycosylation by beta-D-xyloside completely eliminated plaque activation.

FIGS. 16A-C displays neurotoxic microglia blocked by A beta peptides. FIG. 16A shows both A beta 1-42 (1 mu moles/l) in solution and or SpheresA beta 1-42 (250,000 per well) added to hippocampal cultures supplemented with microglia in the presence of various synthetic A beta peptides (all at 10 mu moles/l). Peptides containing residues 13 to 16 prevented A beta induction of neurotoxic microglia. FIG. 16B shows that dose curves show a greater blocking capacity for those peptides containing residues within the 1-16 hydrophilic portion of A beta . Addition of more hydrophobic segments (beyond residue 16) diminish the ability of peptide to block A beta 1-42 interactions with microglia. FIG. 16C sets forth comparisons of various peptides confirm that the HHQK domain of A beta blocks plaque activation of neurotoxic microglia.

FIG. 17 sets forth a table of the effects of ***beta*** - ***Amyloid*** peptides upon microglia. All peptides which contain the unmodified region encompassing residues 13-16 (shaded) block A beta 1-42 to bind to SpheresA beta 1-42, the ability of A beta 1-42 to induce microglial neurotoxicity, and the ability of AD plaques to induce microglial neurotoxicity. NA=not applied in this neurotoxicity test, since the free peptide induces microglial toxicity.

FIGS. 18A-G show selective elimination of microglia from mixed hippocampal cultures. Control cultures (FIGS. 18A, 18C, 18E) show complex neuronal networks revealed by MAP-2/neurofilament immunostaining (FIG. 18A), the presence of DiI-ac-LDL(+) microglia (FIG. 18B), and near confluent feeder layer of GFAP(+) astrocytes (FIG. 18C). After treatment of cultures with saporin coupled to acetylated LDL (FIG. 18B, 18D, 18F), there was an elimination of microglia (FIG. 18D) without effect on survival of either neurons (FIG. 18B) or astroglia (FIG. 18F). Bar=25 mu m. FIG. 18G shows counts of specific cell populations with and without Sap-ac-LDL treatment confirm the specific depletion of microglia. Data are expressed as mean values +/standard error obtained from 9 randomly selected fields from at least 5 independent cultures viewed at 200 x magnification.

FIGS. 19A-D displays constituents of solubilized native senile plaques elicit neuron killing. FIG. 19A shows neuritic/core or diffuse plaques were isolated from cortical gray matter, solubilized in formic acid, and dialyzed against a betaine buffer. Equal amounts of plaque protein (normalized to total amine content at 400 mu moles/l) were added to neuronal cultures in the presence (100,000 cells per culture) or absence of rat microglia. As shown, solubilized neuritic/core plaque proteins (Neuritic/Core Plaque) lead to significant killing of neurons, but only in the presence of microglia. Neither solubilized diffuse plaque proteins (Diffuse Plaque) nor the betaine buffer (Buffer Control) elicited neurotoxic activity. FIG. 19B shows size-exclusion chromatography of neuritic/core plaque proteins using two Superose 12 columns in tandem (300 mm x 10 mm x 2; beads 10 mu m diameter). The chromatogram was developed with 80% glass distilled formic acid at a flow rate of 0.3 ml per minute and monitored at 280 nm. The approximate molecular masses of the fractions were: S1, 200 kDa; S2, 45 kDa; S3, 15 kDa; S4, 10 kDa; and S5, 5 kDa. FIG. 19C shows a histogram in which exposure to peaks S3, S4, and S5 all elicited significant increases in the percent of reactive microglia as defined by morphologic criteria, whereas peaks S1 and S2 do not. FIG. 19D shows fractions of solubilized neuritic/ core plaques applied to hippocampal cultures in the presence or absence of microglia. No neuron killing was detected in cultures free of microglia. Neuron loss appeared, however, in microglia containing cultures exposed to peaks S3, S4, and S5, all which contain A beta .

FIGS. 20A-E displays soluble fractions of native plaques induce microglial

exposed to peak S1 (FIG. 20A) or peak S5 (FIG. 20B) and immuno-stained for the presence of A beta . As shown, aggregates of A beta are found throughout the cultures incubated with peak S5 (Bar =25 microns). Phase photomicrographs show cultured microglia as process bearing cells with spinous surfaces typical of non-reactive cells despite exposure to peak S4 (FIG. 20C). In contrast, microglia exposed to peak S5 retract processes and take on a reactive cell morphology similar to that found in AD brain (FIG. 20D; Bar=5 microns).

FIGS. 21A-D displays toxic actions of synthetic A beta peptides upon neurons. FIG. 21A and 21B shows high concentrations of most A beta peptides placed in hippocampal cultures containing neurons and astroglia (but depleted of microglia) show little effect. There is, however, a generalized cytotoxic action by A beta 25-35 at greater-than 30 mu moles/l on both neurons (FIG. 21A) and astroglia (FIG. 21B). In the absence of microglia, none of the A beta peptides (at 1 mu mole/l) produce destruction of neurons. When rat microglia are added to neuronal cultures, however, only A beta 1-40 and A beta 1-42 elicit neuron killing (FIG. 21C). As shown in FIG. 21D, addition of increasing numbers of microglia show a saturated neuron killing response at a density of 150 microglia per mm2 when incubated with 1 mu mole/liter A beta 1-42; microglia found within the E18 culture at the time of plating (endogenous microglia) also showed an efficient killing capacity in the presence of A beta . These observations point to the need to deplete neuron cultures of microglia when assessing mechanisms of A beta toxicity. Dose response curves reveal A beta 1-42 to be the most potent microglial stimulus with an estimated ED50 of 10 nmoles/l compared to 80 nmoles/l for A beta 1-40 (500 microglia per mm2; FIG. 21E).

FIGS. 22A-F depicts cellular responses upon exposure to synthetic A beta peptides. Phase microscopy shows that cultured rat microglia undergo morphological changes with retraction of processes when exposed to 1 mu mole/l A beta 1-42 (FIG. 22E); in contrast, 1 mu mole/l A beta 17-43 (FIG. 22C) does not alter microglial morphology which appear identical to untreated cells grown under control conditions (FIG. 22A). Fluorescence microscopy of neuron plus microglia cultures showed robust NF(+) MAP2(+) hippocampal neurons (FIG. 22B) that are undamaged after addition of conditioned media (10% vol/vol) from microglia incubated with 1 mu mole/l A beta 17-43 (FIG. 22D). Significant neuron loss occurred, however, if hippocampal cultures were exposed to conditioned media from microglia incubated with 1 mu mole/l A beta 1-42 (FIG. 22F). Bar =25 microns.

FIGS. 23A-E displays A beta activation of microglia after coupling to microspheres. Fluorescently labeled microspheres were covalently coupled to A beta 1-42 and placed in hippocampal cultures containing rat microglia (500 cells per mm2). After 72 hours, A beta 1-42-spheres (FIG. 23A) were localized specifically within DiI-ac-LDL(+) microglia (FIG. 23B, co-localization noted by arrows). In contrast, A beta 17-43microspheres (FIG. 23C) showed no consistent association with microglia (FIG. 23D; Bar=20 micron). FIG. 23E) Comparison of capacity of A beta in solution or coupled to microspheres (beadbound) to elicit neurotoxic microglia (250,000 microspheres per culture; 100,000 microglia per culture; 72 hour incubation). Neuronal loss was similar if A beta peptides were in solution or bound to beads, indicating that fibril formation, or other changes in tertiary structure, were not necessary to stimulate neurotoxic microglia.

FIGS. 24A-H depicts fluorescent photomicrographs of hippocampal cultures after exposure to A beta 1-42. FIG. 24A shows control cultures show complex networks of NF(+), MAP-2(+) neurons. FIG. 24B shows exposure of cultures to 100 mu moles/liter A beta 142 in the absence of microglia has no effect on neuron number, while (FIG. 24C) addition of 100 nmoles/liter A beta 1-42 in the presence of rat microglia (500 cells per mm2) destroyed nearly all neurons. FIGS. 24D-G shows immunostaining for neuronspecific enolase (NSE) is not specific to neurons in CNS cultures as shown by immunofluorescent visualization of glia in cultures of neuron-free optic nerve, including galactocerebroside(+) oligodenroglia (FIG. 24D) and GFAP(+) astrocytes (FIG. 24F) which are both NSE(+) (FIGS. 24E and 24G, respectively). Bar=10 mu m. In FIG. 24H, ciliary neuron cultures showed that A beta 1-42 is not toxic to neurons in the absence of brain glia (A beta 1-42 only) after 48 hour exposure. Conditioned media from A beta 1-42-stimulated microglia (Microglia+A beta 1-42) did, however, kill neurons, indicating that astrocytes are not necessary to the microglial neurotoxicity.

FIGS. 25A-E displays human microglia and neuron killing. FIG. 25A shows only A beta-containing fractions from solubilized neuritic/core plaques (peaks S3 (54 nmole/l), S4 (220 nmole/l), and S5 (250 nmole/l)) elicit human microglia to engage in neurotoxic behaviors. FIG. 25B shows that when tested at 1 mu mole/liter concentrations, synthetic A beta 1-40 and

while smaller A beta fragments had no effect. Despite neuron killing, there is no evidence of increased production of nitrate or nitrite by human cells stimulated with either native (FIG. 25C) or synthetic (FIG. 25D) AD. FIG. 25E shows that neuron killing could be induced by human or rat microglia exposed to 1 mu mole/liter of the human forms of either A beta 1-42 or A beta 1-40. The rodent form of A beta 1-40, however, was inactive, as were fragments of human A beta, including 128, 12-28, and 17-43.

FIGS. 26A-C displays drug blockade of A beta induced neuron killing by rat and human microglia. To investigate mechanisms of cell killing, rat microglia were stimulated with 1 mu mole/l A beta 1-42 (Rat/A beta 1-42) and human cells with fraction S5 (containing 250 nmole/l of native A beta 1-42) from solubilized neuritic/core plaques (Human/S5 Peak). FIG. 26A shows agents that acct as free radical scavengers (vitamin E, 100 mu M; catalase, 25 units/ml; glutathione, 100 mu M) did not block microglial killing of neurons. No protective effects were observed with the nitric oxide synthetase inhibitors L-N-5-(1imin-oethyl)ornithine hydrochloride (L-NIO, 10 mu M) or diphenyl iodonium (DPI, 300 nM), although the NMDA antagonist AP5 prevented neuron death. FIG. 26B shows other NMDA antagonists acting at the receptor site (AP7), at the polyamine regulatory site (ifenprodil), or at the ion channel (MK801) all blocked neuron death, while the non-NMDA glutamate antagonists (GAMS, BNQX) did not. All drugs were applied at 10 mu M. FIG. 26C shows isolation of neurotoxin from culture media conditioned by A beta-stimulated rat microglia (A beta 1-42/ Microglia) or from frozen AD gray matter (AD Brain) involved extractions in ethyl acetate (pH 10.5), acid hydrolysis, and sequential gradient RP-HPLC (C18 column using a 0 to 20% acetonitrile gradient in dH2O with 0.1% trifluoroacetic acid). Neurotoxin activities from microglial conditioned media copurifies with that from AD brain tissue with a co-elution using RP-HPLC at about 14% acetonitrile. Neurotoxicity was not found within control brain extracts or from unstimulated microglial culture media.

FIG. 27 depicts A beta domains and interactions with microglia. FIG. 10A shows a phase photomicrograph of rat microglial cell adhering to Sepharose bead coupled to human A beta 1-42 peptides. FIG. 27B shows a fluorescence photomicrograph of the same bead showing adherent cell labeled by the fluorescent microglial marker Dil-ac-LDL; Bar=20 microns. FIG. 27C shows rat microglial adherence to Sepharose-coupled beads after six hours. Plaque proteins derived from neuritic/core plaques provided an anchoring site for microglia, as did A beta 1-42. Importantly, A beta ***1*** - ***28*** also promoted bead binding, while A beta 17-43 d: not. Controls included beads coupled to glycine (Control glycine) and to bovine serum albumin (Control-BSA). Data shown are expressed as the numbers of adhering cells per 100 randomly selected beads +/-standard error after 6 hour incubation at 37 degrees C.

FIGS. 28A-G displays that the A beta cell binding domain is required for activation of neurotoximicroglia. Fluorescent photomicrographs showing microsphere binding to enriched cultures of rat microglia (500/mm2) after 4 hour incubation at 37 C. Coupling of A beta peptides to fluorescent microspheres showed that A beta 1-42 (FIG. 28A), A beta 12-28 (FIG. 28D), and A beta 10-16 (FIG. 28E) readily bind, while peptides A beta 17-43 (FIG. 28B), A beta 1-11 (FIG. 28C), and A beta 1-5 (FIG. 28F) did not. Quantitations of binding pattern (FIG. 28G) indicated that regions of the N-terminus-containing amino acid residues 10-16 were necessary for A beta binding to microglia. Data are expressed as mean values +/-standard error when viewed at 200 x magnification.

FIG. 29 displays the comparison of A beta effects upon microglia. FIG. 29A shows dose response curves in which although A beta 10-16 is able to bind to microglia, it did not elicit neurotoxic microglia. The addition of this microglial binding domain to A beta 17-42 (which neither binds to microglia nor elicits toxicity) created a peptide, A beta 10-42, which both bound to microglia and stimulated microglia to kill neurons. FIG. 29B shows a diagram comparing the structures and functions of synthetic peptides. The shaded area illustrates the Nterminal portion of A beta that differs between human and rat forms and which appears necessary for microglial adherence. !

L4 ANSWER 97 OF 469 IFIPAT COPYRIGHT 2004 IFI on STN
AN 04045610 IFIPAT;IFIUDB;IFICDB
TI DISCORDANT HELIX STABILIZATION FOR PREVENTION OF AMYLOID FORMATION
IN Johansson Jan (SE)
PI US 6716589 B2 20040406
US 2002143105 A1 20021003
AI US 2001-988842 20011119
PRAI US 2000-251662P 20001206 (Provisional)

PI US 6716589 20040406
US 2002143105 20021003
DT Utility; Granted Patent - Utility, with Pre-Grant Publication
FS CHEMICAL
GRANTED
MRN 012778 MFN: 0340
CLMN 26
GI 14 Drawing Sheet(s), 20 Figure(s).

FIG. 1 is a bar graph that depicts the occurrence of alphahelical segments with high beta-strand propensities. The number of protein segments are plotted versus the lengths of the segments for which experimentally determined alpha-helices coincide with beta-strands predicted with a PHD reliability index greater-double-equals 5 for all residues. The PBD codes are given for the proteins from which the helices with greaterdouble-equals 7 residues emanate. Codes in bold identify proteins that form amyloid fibrils in vivo, and italics denote proteins shown to form fibrils. The outcome of predictions for prion proteins from human (hPrP) and mouse (mPrP) are indicated. The PDB codes represent, in alphabetical order: 1aa0=fibritin deletion mutant (Bacteriophage T4), 1 aura=carboxylesterase (Pseudomonas fluorescens), 1b10(sPrP)=prion protein (Syrian hamster), 1b2va=heme-binding protein A (Serratia marcescens), 1b5ea=dCMP hydroxymethylase (Bacteriophage T4), 1b8oa=purine nucleoside phosphorylase (Bos taurus), 1ba6= ***beta*** ***amyloid*** protein (Homo sapiens), 1bct=bacteriorhodopsin (Halobacterium halobium), 1b11=parathyroid hormone receptor (Homo sapiens), 1 cpo=chloroperoxidase (Leptoxyphium fumago), 1cv8=staphopain (Staphylococcus aureus), 1 ecra=replication terminator protein (Escherichia coli), 1ggtb=coagulation factor XIII (Homo sapiens) , 1h2as-hydrogenase (Desulfovibrio vulgaris), 1iab=astacin (Astacus astacus), 1jkmb=brefeldin A esterase (Bacillus subtilis), 1kpta=killer toxin (Ustilago maydis), 11ml=leishmanolysin (Leishmania major), 1mhdb=smad MH1 doman (Homo sapiens), 1mnma=transcription factor MVM1 (Saccharomyces cerevisiae), 1mtyd=methane monooxygenase (Methylococcus capsulatus), 1nom=DNA polymerase beta (Rattus norvegicus), 1noza=DNA polymerase (Bacteriophage T4), 1pbv-sec7 domain of exchange factor ARNO (Homo sapiens), 1quta=lytic transglycosylase Slt35 (Escherichia coli) 1smd=salivary amylase (Homo sapiens), 1spf (SP-C)=surfactant-associated protein C (Sus scrofa), 1sra=osteonectin (Homo sapiens), 1taha=lipase (Burkholdia glumae), 1tca=lipase B (Candida antarctica), 1vns=chloroperoxidase (Curvularia inaequalis), 1wer=Ras-GTPaseactivating domain of p120GAP (Homo sapiens), 2erl=pheromone Er1 (Eurplotes raikovi), 2ifo=inovirus (Xanthomonas oryzae), 2occk=cytochrome C oxidase (Bos taurus), 2sqca=squalene-hopene cyclase (Alicyclobacillus acidocaldarius), 3aig=adamalysin II (Crotalus adamanteus), 3pte=transpeptidase (Xstreptomyces R61).

FIGS. 2A-2B are a set of diagrams that depict the characteristics of long discordant helix segments. Amino acid sequences, together with determined and predicted secondary structure elements for sequences having greater-double-equals 9=residue discordant segments are shown. Also shown are those discordant segments of A beta, mouse PrP, and human PrP. The proteins are grouped by the length of their discordant stretch. The experimentally determined helical segments are drawn as blue cylinders in the bottom row of each case in which the amino acid sequences and residue positions in the PDB entries of the corresponding proteins are given (Top to bottom in each set: Set 16 contains SEQ ID NOs:4-6; Set 15 contains SEQ ID NOs:7 and 8; Set 8 contains SEQ ID NO;9; Set 13 contains SEQ ID NOs:10 and 11; Set 12 contains SEQ ID NOs:12 and 13; Set 10 contains SEQ ID NOs:14 and 15; Set 11 contains SEQ ID NOs:1618; Set 9 contains SEQ ID NOs: 19-20 (top row left to right) and 21-23 (bottom row left to right). The locations of the beta -strands predicted by PHD are visualized by yellow strands in the middle row of each case, wherein the reliability index for each residue is shown. The Chou-Fasman-based predictions averaged for 6-residue segments are plotted above residue 3 in each segment and given in the top row of each case. E and e denote extended structures (i.e., beta-strands) predicted with high and low probability, respectively, as in Chou and Fasman (1978, Adv. Enzymol. 47:45-148), and H and h represent predicted helical structures in an analogous manner.

FIG. 3 is a diagram that depicts the amino acid sequence (bottom row; SEQ ID NO:24) and predicted secondary structure by PHD and according to Chou-Fasman analysis for a polyleucine analogue of SP-C (lung surfactant protein C). The PHD predictions including reliability indices are given in the middle row and the ChouFasman data in the top row, but in this case an alpha-helix is predicted by both methods, symbolized by a blue cylinder for the PHD prediction.

FIG. 4 is a graph that depicts data from an experiment in which the relative amounts of SP-C(squares) and SP-C(Leu) (triangles) remaining in

time points after solubilization were measured.
FIG. 5 is a set of diagrams that depict the experimentally determined and predicted secondary structures of positions ***1*** - ***28*** of A beta (SEQ ID NO:25; top) and a valiant of A beta (***1*** - ***28***) in which three residues have been changed to alanine (K16A, L17A, F20A) (SEQ ID NO:26; bottom). Symbols are as described for FIGS. 2 and 4.
FIGS. 6A-6C are graphs depicting the effects various tripeptides on fibril formation by A beta (14-23) (FIG. 6A). A beta (12-24) (FIG. 6B), and A beta (1-40) (FIG. 6C). Unless otherwise indicated, the tripeptides have free N- and C-termini. The results are representative for two to three independent experiments.
FIG. 7 is a graph depicting the effects of various tripeptides and tetrapeptides on fibril formation by A beta (14-23).
FIG. 8 is a graph depicting the effects of the peptides KAD, AAA, and KFFE (SEQ ID NO:1) on A beta (1-40) aggregation. Samples were analyzed in duplicate.
FIGS. 9A-9E depict the fibrillar structures of A beta (1-40) formed in the absence of tripeptide (9A), in the presence of KAD (9B), acetyl-KAD-amide (9C), AAA (9D), or acetyl-AAA-amide (9E).
FIG. 10 depicts the KAD peptide in an energy-minimized conformation (top structure), the KAD peptide in an extended conformation (middle structure), and the KFFE (SEQ ID NO:1) peptide in an extended conformation (bottom structure). The amino and carboxyl groups of the charged side-chains are on the same side of the polypeptide backbone in KAD and the distances between them are then shown. In KFFE, the charged side-chains are on opposite sides of the polypeptide backbone.
FIG. 11A depicts the charge separation of A beta (15-23) in alpha-helical and beta-strand conformations. The figure shows the A beta (15-23) region in helical conformation, symbolized by the cylinder. The charged side-chains Lys16, Glu22 and Asp23 are shown.
FIG. 11B depicts the charge separation of A beta (15-23) in alpha-helical and beta-strand conformations. The A beta (1523) region is modeled in beta-strand/extended conformation, indicated by the wavy strand. The charged side-chains are shown. For the helical conformation, the distances between the epsilon-amino group of Lys16 and the gamma-carboxyl group of Glu22 and the beta-carboxyl group of Asp23 are shown, and for the extended conformation the Lys16-Glu22 distance is indicated.
FIG. 12 is a model of A beta fibril formation and the associated effects of helix-stabilizing agents. The upper row depicts the transformations that helical A beta peptides are thought to undergo to form beta-sheet fibrils. Monomeric A beta in aqueous solution is structurally disordered (i.e. it interconverts between different structures including alphahelical and beta-strand conformations) and A beta in extended conformation will be able to polymerize via the formation of intermolecular contacts in beta-sheets. Compounds that can interact preferentially with helical A beta (here represented by the doubly charged ligand) will shift the equilibrium from the extended conformation and thereby reduce formation of fibrils. The cylinder represents the helix centered around residues 16-23 of A beta and the + and -signs represent Lys16 and Glu22/Asp23, respectively.

L4 ANSWER 98 OF 469 JICST-EPlus COPYRIGHT 2004 JST on STN
AN 920642317 JICST-EPlus
TI Immunohistochemical Studies on Canine Cerebral Amyloid Angiopathy and Senile Plaques.
AU UCHIDA K; TANI Y; UETSUKA K; NAKAYAMA H; GOTO N
CS Univ. Tokyo, Tokyo, JPN
SO J Vet Med Sci, (1992) vol. 54, no. 4, pp. 659-667. Journal Code: F0905A (Fig. 14, Tbl. 2, Ref. 35)
ISSN: 0916-7250
CY Japan
DT Journal; Article
LA English
STA New

L4 ANSWER 99 OF 469 MEDLINE on STN
AN 2004243118 MEDLINE
DN PubMed ID: 14985339
TI Copper depletion down-regulates expression of the Alzheimer's disease ***amyloid*** - ***beta*** precursor protein gene.
AU Bellingham Shayne A; Lahiri Debomoy K; Maloney Bryan; La Fontaine Sharon; Multhaup Gerd; Camakaris James
CS Department of Genetics, The University of Melbourne, Parkville, Victoria 3010, Australia.
NC AG 18739 (NIA)

SO Journal of biological chemistry, (2004 May 7) 279 (19) 20378-86.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200406
ED Entered STN: 20040515
Last Updated on STN: 20040616
Entered Medline: 20040615

L4 ANSWER 100 OF 469 MEDLINE on STN
AN 96067122 MEDLINE
DN PubMed ID: 7588622
TI Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence.
AU De Strooper B; Simons M; Multhaup G; Van Leuven F; Beyreuther K; Dotti C G
CS Cell Biology Program, European Molecular Biology Laboratory, Heidelberg, Germany.
SO EMBO journal, (1995 Oct 16) 14 (20) 4932-8.
Journal code: 8208664. ISSN: 0261-4189.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199512
ED Entered STN: 19960124
Last Updated on STN: 19980206
Entered Medline: 19951221

L4 ANSWER 101 OF 469 MEDLINE on STN
AN 90099541 MEDLINE
DN PubMed ID: 2513586
TI A study of beta protein precursor using antiserum against a synthetic peptide (***1*** - ***28***).
AU Harigaya Y; Shoji M; Yamaguchi H; Hirai S; Takatama M
CS Department of Neurology, Gunma University School of Medicine, Japan.
SO Progress in clinical and biological research, (1989) 317 945-52.
Journal code: 7605701. ISSN: 0361-7742.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199001
ED Entered STN: 19900328
Last Updated on STN: 19980206
Entered Medline: 19900131

L4 ANSWER 102 OF 469 MEDLINE on STN
AN 88138281 MEDLINE
DN PubMed ID: 3277908
TI Immunohistochemical study of cerebral amyloid angiopathy: use of an antiserum to a synthetic 28-amino-acid peptide fragment of the Alzheimer's disease amyloid precursor.
AU Vinters H V; Pardridge W M; Yang J
CS Department of Pathology, UCLA Medical Center 90024.
SO Human pathology, (1988 Feb) 19 (2) 214-22.
Journal code: 9421547. ISSN: 0046-8177.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198803
ED Entered STN: 19900308
Last Updated on STN: 19980206
Entered Medline: 19880328

L4 ANSWER 103 OF 469 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 96:700116 SCISEARCH
GA The Genuine Article (R) Number: VH858
TI SPECIFIC DOMAINS OF ***BETA*** - ***AMYLOID*** FROM ALZHEIMER PLAQUE ELICIT NEURON KILLING IN HUMAN MICROGLIA
AU GIULIAN D (Reprint); HAVERKAMP L J; YU J H; KARSHIN W; TOM D; LI J;

CS BAYLOR COLL MED, DEPT NEUROL, ALZHEIMERS DIS RES CTR, HOUSTON, TX, 77030 (Reprint); BAYLOR COLL MED, DEPT PATHOL, ALZHEIMERS DIS RES CTR, HOUSTON, TX, 77030; SUN HLTH RES INST, HALDERMAN LAB ALZHEIMERS DIS RES, SUN CITY, AZ, 85351
CYA USA
SO JOURNAL OF NEUROSCIENCE, (01 OCT 1996) Vol. 16, No. 19, pp. 6021-6037. ISSN: 0270-6474.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 73
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 104 OF 469 USPATFULL on STN
AN 2004:215966 USPATFULL
TI Inhibitors of Memapsin 2 and use thereof
IN Tang, Jordan J. N., Edmond, OK, UNITED STATES
Ghosh, Arun K., River Forest, IL, UNITED STATES
PA Oklahoma Medical Research Foundation, Oklahoma City, OK, UNITED STATES (U.S. corporation)
The Board of Trustees of the University of Illinois, Urbana, IL, UNITED STATES (U.S. corporation)
PI US 2004167075 A1 20040826
AI US 2004-820953 A1 20040408 (10)
RLI Continuation of Ser. No. US 2000-603713, filed on 27 Jun 2000, PENDING
PRAI US 1999-141363P 19990628 (60)
US 1999-168060P 19991130 (60)
US 2000-177836P 20000125 (60)
US 2000-178368P 20000127 (60)
US 2000-210292P 20000608 (60)
DT Utility
FS APPLICATION
LN.CNT 2388
INCL INCLM: 514/014.000
INCLS: 530/326.000
NCL NCLM: 514/014.000
NCLS: 530/326.000
IC [7]
ICM: A61K038-10
ICS: C07K007-08

L4 ANSWER 105 OF 469 USPATFULL on STN
AN 2004:211476 USPATFULL
TI Polynucleotide encoding neuromedin U receptor
IN Harland, Lee, Kent, UNITED KINGDOM
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6780611 B1 20040824
AI US 2000-684725 20001006 (9)
PRAI GB 1999-23888 19991008
DT Utility
FS GRANTED
LN.CNT 3220
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 435/252.300; 435/254.110; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 435/252.300; 435/254.110; 536/023.500
IC [7]
ICM: C12N015-00
ICS: C12N015-63; C12N015-85; C12N001-21; C07H021-04
EXF 536/23.5; 536/23.1; 536/24.3; 435/320.1; 435/325; 435/252.3; 435/254.11; 435/254.2; 435/69.1; 435/254.1; 435/455

L4 ANSWER 106 OF 469 USPATFULL on STN
AN 2004:203958 USPATFULL
TI Novel heterocyclic derivatives
IN Kakihana, Mitsuru, Hyogo, JAPAN
Kato, Kaneyoshi, Hyogo, JAPAN
Mori, Masaaki, Ibaraki, JAPAN
Yamashita, Toshiro, Ibaraki, JAPAN
PI US 2004157850 A1 20040812
AI US 2003-474963 A1 20031016 (10)
WO 2002-JP4148 20020425
PRAI JP 2001-128677 20010426
JP 2002-43523 20020220
DT Utility

LN.CNT 5569
INCL INCLM: 514/249.000
INCLS: 514/314.000; 544/349.000; 546/167.000
NCL NCLM: 514/249.000
NCLS: 514/314.000; 544/349.000; 546/167.000
IC [7]
ICM: C07D043-04
ICS: C07D041-04; A61K031-498; A61K031-4709
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 107 OF 469 USPATFULL on STN
AN 2004:197463 USPATFULL
TI Modified carbamate-containing prodrugs and methods of synthesizing same
IN Ekwuribe, Nnochiri Nkem, Cary, NC, UNITED STATES
Riggs-Sauthier, Jennifer, Raleigh, NC, UNITED STATES
Dyakonov, Tatyana A., Durham, NC, UNITED STATES
PI US 2004152769 A1 20040805
AI US 2003-703647 A1 20031107 (10)
PRAI US 2002-424796P 20021109 (60)
US 2003-483676P 20030630 (60)
DT Utility
FS APPLICATION
LN.CNT 2938
INCL INCLM: 514/478.000
INCLS: 514/615.000; 514/114.000
NCL NCLM: 514/478.000
NCLS: 514/615.000; 514/114.000
IC [7]
ICM: A61K031-66
ICS: A61K031-325; A61K031-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 108 OF 469 USPATFULL on STN
AN 2004:190681 USPATFULL
TI Aspartyl protease inhibitors
IN Yang, Wenjin, Foster City, CA, UNITED STATES
PI US 2004147454 A1 20040729
AI US 2003-731922 A1 20031210 (10)
RLI Continuation-in-part of Ser. No. US 2003-462127, filed on 16 Jun 2003, PENDING
PRAI WO 2003-US18858 20030616
US 2002-430693P 20021203 (60)
US 2002-389194P 20020617 (60)
DT Utility
FS APPLICATION
LN.CNT 4176
INCL INCLM: 514/019.000
INCLS: 514/357.000; 514/408.000; 546/335.000; 546/336.000; 548/567.000
NCL NCLM: 514/019.000
NCLS: 514/357.000; 514/408.000; 546/335.000; 546/336.000; 548/567.000
IC [7]
ICM: A61K038-04
ICS: C07D213-56; A61K031-44; A61K031-40; C07D207-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 109 OF 469 USPATFULL on STN
AN 2004:190160 USPATFULL
TI 94 human secreted proteins
IN Ruben, Steven M., Brookeville, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Young, Paul, Gaithersburg, MD, UNITED STATES
Florence, Kimberly, Rockville, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Mucenski, Michael, Cincinnati, OH, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Moore, Paul A., North Bethesda, MD, UNITED STATES
Komatsoulis, George, Silver Spring, MD, UNITED STATES

PI US 2004146930 A1 20040729
AI US 2004-800834 A1 20040316 (10)
RLI Division of Ser. No. US 2002-115123, filed on 4 Apr 2002, PENDING
Division of Ser. No. US 1999-461325, filed on 14 Dec 1999, GRANTED, Pat. No. US 6475753 Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999, PENDING
PRAI US 1998-89507P 19980616 (60)
US 1998-89508P 19980616 (60)
US 1998-89509P 19980616 (60)
US 1998-89510P 19980616 (60)
US 1998-90112P 19980622 (60)
US 1998-90113P 19980622 (60)
DT Utility
FS APPLICATION
LN.CNT 18341
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500; 530/388.100
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500; 530/388.100
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 110 OF 469 USPATFULL on STN
AN 2004:184612 USPATFULL
TI Methods for analysis of spectral data and their applications: atherosclerosis/coronary heart disease
IN Nicholson, Jeremy Kirk, London, UNITED KINGDOM
Holmes, Elaine, London, UNITED KINGDOM
Lindon, John Christopher, London, UNITED KINGDOM
Brindle, Joanne Tracey, London, UNITED KINGDOM
Grainger, David John, Cambridge, UNITED KINGDOM
PI US 2004142496 A1 20040722
AI US 2003-475573 A1 20031022 (10)
WO 2002-GB1854 20020423
PRAI GB 2001-9930 20010423
GB 2001-17428 20010717
DT Utility
FS APPLICATION
LN.CNT 5700
INCL INCLM: 436/536.000
INCLS: 600/410.000
NCL NCLM: 436/536.000
NCLS: 600/410.000
IC [7]
ICM: A61B005-05
ICS: G01N033-536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 111 OF 469 USPATFULL on STN
AN 2004:184452 USPATFULL
TI Method for determining skin stress or skin ageing in vitro
IN Petersohn, Dirk, Koeln, GERMANY, FEDERAL REPUBLIC OF
Conradt, Marcus, Pretoria, SOUTH AFRICA
Hofmann, Kay, Koeln, GERMANY, FEDERAL REPUBLIC OF
PI US 2004142335 A1 20040722
AI US 2003-450797 A1 20030917 (10)
WO 2001-EP15178 20011220
PRAI DE 2001-100121 20010103
DT Utility
FS APPLICATION
LN.CNT 11268
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 112 OF 469 USPATFULL on STN
AN 2004:184069 USPATFULL
TI Death domain containing receptor 5
IN Ni, Jian, Rockville, MD, UNITED STATES

Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2004141952 A1 20040722
AI US 2004-774622 A1 20040210 (10)
RLI Continuation of Ser. No. US 2001-874138, filed on 6 Jun 2001, GRANTED, Pat. No. US 6743625 Continuation of Ser. No. US 2000-565009, filed on 4 May 2000, PENDING Continuation-in-part of Ser. No. US 1998-42583, filed on 17 Mar 1998, PENDING
PRAI US 1999-148939P 19990813 (60)
US 1999-133238P 19990507 (60)
US 1999-132498P 19990504 (60)
US 1997-54021P 19970729 (60)
US 1997-40846P 19970317 (60)
DT Utility
FS APPLICATION
LN.CNT 8875
INCL INCLM: 424/085.100
INCLS: 424/131.100; 514/012.000; 514/192.000; 514/210.090; 514/200.000
NCL NCLM: 424/085.100
NCLS: 424/131.100; 514/012.000; 514/192.000; 514/210.090; 514/200.000
IC [7]
ICM: A61K038-19
ICS: A61K038-17; A61K039-395; A61K031-496; A61K031-704; A61K031-545; A61K031-397; A61K031-407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 113 OF 469 USPATFULL on STN
AN 2004:179126 USPATFULL
TI Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease
IN Robertson, David W., Glenview, IL, UNITED STATES
Krafft, Grant A., Glenview, IL, UNITED STATES LR
PA Pharmacia Corporation (U.S. corporation)
PI US 2004138296 A1 20040715
AI US 2003-627357 A1 20030725 (10)
PRAI US 2002-402760P 20020812 (60)
US 2002-402778P 20020812 (60)
US 2002-402674P 20020812 (60)
US 2002-402655P 20020812 (60)
US 2002-402773P 20020812 (60)
US 2002-402675P 20020812 (60)
US 2002-402676P 20020812 (60)
DT Utility
FS APPLICATION
LN.CNT 2898
INCL INCLM: 514/461.000
INCLS: 514/467.000; 514/314.000; 514/568.000
NCL NCLM: 514/461.000
NCLS: 514/467.000; 514/314.000; 514/568.000
IC [7]
ICM: A61K031-4709
ICS: A61K031-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 114 OF 469 USPATFULL on STN
AN 2004:177787 USPATFULL
TI Death domain containing receptor 5
IN Ni, Jian, Germantown, MD, UNITED STATES
Gentz, Reiner L., Belo Horizonte, BRAZIL
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2004136951 A1 20040715
AI US 2003-648825 A1 20030827 (10)
RLI Continuation-in-part of Ser. No. US 2000-565009, filed on 4 May 2000, PENDING Continuation-in-part of Ser. No. US 1998-42583, filed on 17 Mar 1998, PENDING
PRAI US 2002-413747P 20020927 (60)
US 2002-406307P 20020828 (60)
US 1999-148939P 19990813 (60)
US 1999-133238P 19990507 (60)
US 1999-132498P 19990504 (60)
US 1997-54021P 19970729 (60)
US 1997-40846P 19970317 (60)

FS APPLICATION
LN.CNT 12832
INCL INCLM: 424/085.100
INCLS: 424/131.100
NCL NCLM: 424/085.100
NCLS: 424/131.100
IC [7]
ICM: A61K038-19
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 115 OF 469 USPATFULL on STN
AN 2004:172618 USPATFULL
TI Aspartyl protease inhibitors
IN Yang, Wenjin, Foster City, CA, UNITED STATES
Cary, Douglas R., San Francisco, CA, UNITED STATES
Jacobs, Jeffrey W., San Mateo, CA, UNITED STATES
Lu, Wanli, Burlingame, CA, UNITED STATES
Lu, Yafan, South San Francisco, CA, UNITED STATES
Sun, Jian, San Mateo, CA, UNITED STATES
Zhong, Min, Foster City, CA, UNITED STATES
PI US 2004132782 A1 20040708
AI US 2003-462127 A1 20030616 (10)
PRAI US 2002-430693P 20021203 (60)
US 2002-389194P 20020617 (60)
DT Utility
FS APPLICATION
LN.CNT 6959
INCL INCLM: 514/357.000
INCLS: 514/408.000; 514/534.000; 514/599.000; 514/634.000; 514/620.000; 514/603.000; 546/329.000; 548/571.000; 560/041.000; 564/086.000; 564/163.000; 564/237.000
NCL NCLM: 514/357.000
NCLS: 514/408.000; 514/534.000; 514/599.000; 514/634.000; 514/620.000; 514/603.000; 546/329.000; 548/571.000; 560/041.000; 564/086.000; 564/163.000; 564/237.000
IC [7]
ICM: A61K031-44
ICS: A61K031-40; A61K031-165; A61K031-155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 116 OF 469 USPATFULL on STN
AN 2004:171998 USPATFULL
TI Novel beta-secretase and modulation of beta-secretase activity
IN Zhong, Ziyang, Union City, CA, UNITED STATES
Cordell, Barbara, Palo Alto, CA, UNITED STATES
Quon, Diana Hom, Redwood City, CA, UNITED STATES
Liu, Yu-Wang, Santa Clara, CA, UNITED STATES
Xu, Qiang, Cupertino, CA, UNITED STATES
Schimmoller, Frauke, Menlo Park, CA, UNITED STATES
Hyslop, Paul Andrew, Indianapolis, IN, UNITED STATES
Johnstone, Edward Marion, Indianapolis, IN, UNITED STATES
Little, Sheila Parks, Indianapolis, IN, UNITED STATES
Queener, Stephen Wyatt, Indianapolis, IN, UNITED STATES
Yin, Tinggui, Indianapolis, IN, UNITED STATES
PI US 2004132159 A1 20040708
AI US 2003-740865 A1 20031218 (10)
RLI Division of Ser. No. US 2000-566746, filed on 9 May 2000, ABANDONED
PRAI US 1999-134074P 19990513 (60)
DT Utility
FS APPLICATION
LN.CNT 1628
INCL INCLM: 435/226.000
INCLS: 514/001.000
NCL NCLM: 435/226.000
NCLS: 514/001.000
IC [7]
ICM: C12N009-64
ICS: A61K031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 117 OF 469 USPATFULL on STN
AN 2004:166084 USPATFULL
TI Aminoethanol derivatives
IN Kori, Masakuni, Hyogo, JAPAN

Fuse, Hiromitsu, Ibaraki, JAPAN
Yamamoto, Toshihiro, Osaka, JAPAN
PI US 2004127574 A1 20040701
AI US 2003-470351 A1 20030725 (10)
WO 2002-JP532 20020125
PRAI JP 2001-19280 20010126
DT Utility
FS APPLICATION
LN.CNT 25402
INCL INCLM: 514/651.000
INCLS: 564/355.000
NCL NCLM: 514/651.000
NCLS: 564/355.000
IC [7]
ICM: A61K031-137
ICS: C07C215-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 118 OF 469 USPATFULL on STN
AN 2004:166065 USPATFULL
TI Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and parkinson's disease
IN Snow, Alan D., Lynnwood, WA, UNITED STATES
Nguyen, Beth P., Bothell, WA, UNITED STATES
Castillo, Gerardo M., Seattle, WA, UNITED STATES
Sanders, Virginia J., Seattle, WA, UNITED STATES
Lake, Thomas P., Snohomish, WA, UNITED STATES
Larsen, Lesley, Dunedin, NEW ZEALAND
Weavers, Rex T., Dunedin, NEW ZEALAND
Lorimer, Stephen D., Dunedin, NEW ZEALAND
Larsen, David S., Dunedin, NEW ZEALAND
Coffen, David L., San Diego, CA, UNITED STATES
Coffen, Charlotte, Belcamp, MD, UNITED STATES LR
PI US 2004127555 A1 20040701
AI US 2003-452851 A1 20030530 (10)
PRAI US 2002-385144P 20020531 (60)
US 2002-409100P 20020909 (60)
US 2002-412272P 20020920 (60)
US 2002-435880P 20021220 (60)
US 2003-463104P 20030414 (60)
DT Utility
FS APPLICATION
LN.CNT 3898
INCL INCLM: 514/464.000
INCLS: 514/646.000; 514/649.000; 514/706.000; 514/721.000; 514/734.000; 514/689.000; 549/435.000; 564/336.000; 568/047.000; 568/337.000
NCL NCLM: 514/464.000
NCLS: 514/646.000; 514/649.000; 514/706.000; 514/721.000; 514/734.000; 514/689.000; 549/435.000; 564/336.000; 568/047.000; 568/337.000
IC [7]
ICM: A61K031-34
ICS: A61K031-137; C07C049-786; A61K031-075; A61K031-12; A61K031-095
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 119 OF 469 USPATFULL on STN
AN 2004:166004 USPATFULL
TI Alpha-(N-sulfonamido)acetamide derivatives as ***beta*** - ***amyloid*** inhibitors
IN Parker, Michael F., Higganum, CT, UNITED STATES
McElhone, Katharine E., Cromwell, CT, UNITED STATES
Mate, Robert A., Waterbury, CT, UNITED STATES
Bronson, Joanne J., Durham, CT, UNITED STATES
Gai, Yonghua, Killingworth, CT, UNITED STATES
Bergstrom, Carl P., Madison, CT, UNITED STATES
Marcin, Lawrence R., Bethany, CT, UNITED STATES
Macor, John E., Guilford, CT, UNITED STATES
PI US 2004127494 A1 20040701
AI US 2002-326365 A1 20021220 (10)
PRAI US 2001-344322P 20011220 (60)
DT Utility
FS APPLICATION
LN.CNT 6526
INCL INCLM: 514/227.500
INCLS: 514/237.800; 514/255.020; 514/357.000; 514/408.000; 514/317.000;

514/211.030; 540/544.000; 544/059.000; 544/060.000; 544/167.000;
544/383.000; 546/159.000; 546/229.000; 546/331.000; 548/470.000;
548/503.000; 548/950.000; 564/086.000
NCL NCLM: 514/227.500
NCLS: 514/237.800; 514/255.020; 514/357.000; 514/408.000; 514/317.000;
514/416.000; 514/419.000; 514/602.000; 514/313.000; 514/210.200;
514/211.030; 540/544.000; 544/059.000; 544/060.000; 544/167.000;
544/383.000; 546/159.000; 546/229.000; 546/331.000; 548/470.000;
548/503.000; 548/950.000; 564/086.000
IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-495; A61K031-496; A61K031-4709; A61K031-454;
A61K031-405; A61K031-4035; A61K031-397
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 120 OF 469 USPATFULL on STN
AN 2004:159212 USPATFULL
TI Compositions useful as inhibitors of rock and other protein kinases
IN Cao, Jingrong, Newton, MA, UNITED STATES
Gao, Huai, Natick, MA, UNITED STATES
Green, Jeremy, Burlington, MA, UNITED STATES
Marhefka, Craig, Belmont, MA, UNITED STATES
PI US 2004122016 A1 20040624
AI US 2003-696862 A1 20031030 (10)
PRAI US 2002-422441P 20021030 (60)
US 2003-476433P 20030606 (60)
US 2003-476691P 20030606 (60)
US 2003-479903P 20030619 (60)
DT Utility
FS APPLICATION
LN.CNT 4366
INCL INCLM: 514/252.050
INCLS: 514/255.050; 514/256.000; 514/342.000; 544/238.000; 544/331.000;
544/333.000; 544/405.000; 514/089.000
NCL NCLM: 514/252.050
NCLS: 514/255.050; 514/256.000; 514/342.000; 544/238.000; 544/331.000;
544/333.000; 544/405.000; 514/089.000
IC [7]
ICM: A61K031-506
ICS: A61K031-501; A61K031-497; A61K031-675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 121 OF 469 USPATFULL on STN
AN 2004:159143 USPATFULL
TI Compounds which inhibit beta-secretase activity and methods of use thereof
IN Ghosh, Arun K., River Forest, IL, UNITED STATES
Tang, Jordan J. N., Edmond, OK, UNITED STATES
Bilcer, Geoffrey, Oklahoma City, OK, UNITED STATES
Chang, Wanpin, Edmond, OK, UNITED STATES
Hong, Lin, Oklahoma City, OK, UNITED STATES
Koelsch, Gerald E., Oklahoma City, OK, UNITED STATES
Loy, Jeffrey A., Norman, OK, UNITED STATES
Turner, Robert T., III, Oklahoma City, OK, UNITED STATES
Devasumadram, Thippeswamy, Edmond, OK, UNITED STATES
PA Oklahoma Medical Research Foundation, Oklahoma City, OK, UNITED STATES (U.S. corporation)
The Board of Trustees of the University of Illinois, Urbana, IL, UNITED STATES (U.S. corporation)
PI US 2004121947 A1 20040624
AI US 2002-281092 A1 20021023 (10)
RLI Continuation-in-part of Ser. No. US 2001-32818, filed on 28 Dec 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US50826, filed on 28 Dec 2001, PENDING
PRAI US 2001-275756P 20010314 (60)
US 2000-258705P 20001228 (60)
US 2001-335952P 20011023 (60)
US 2001-333545P 20011127 (60)
US 2002-348464P 20020114 (60)
US 2002-348615P 20020114 (60)
US 2002-390804P 20020620 (60)
US 2002-397557P 20020719 (60)
US 2002-397619P 20020719 (60)
DT Utility
FS APPLICATION

INCL INCLM: 514/012.000
INCLS: 514/007.000; 530/350.000
NCL NCLM: 514/012.000
NCLS: 514/007.000; 530/350.000
IC [7]
ICM: A61K038-16
ICS: C07K014-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 122 OF 469 USPATFULL on STN
AN 2004:151477 USPATFULL
TI Interleukin 17 receptor-like protein
IN Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2004115698 A1 20040617
AI US 2003-645702 A1 20030822 (10)
RLI Division of Ser. No. US 2001-796844, filed on 2 Mar 2001, PENDING Continuation-in-part of Ser. No. WO 2000-US5759, filed on 6 Mar 2000, PENDING Continuation-in-part of Ser. No. WO 1999-US21048, filed on 15 Sep 1999, PENDING Continuation-in-part of Ser. No. US 1999-268311, filed on 16 Mar 1999, GRANTED, Pat. No. US 6482923 Continuation-in-part of Ser. No. US 1998-154219, filed on 16 Sep 1998, GRANTED, Pat. No. US 6635443 Continuation-in-part of Ser. No. US 1999-268311, filed on 16 Mar 1999, GRANTED, Pat. No. US 6482923 Continuation-in-part of Ser. No. US 1999-268311, filed on 16 Mar 1999, GRANTED, Pat. No. US 6482923 Continuation-in-part of Ser. No. US 1998-154219, filed on 16 Sep 1998, GRANTED, Pat. No. US 6635443 Continuation-in-part of Ser. No. US 1998-154219, filed on 16 Sep 1998, GRANTED, Pat. No. US 6635443
PRAI WO 1998-US19121 19980916
US 2000-187015P 20000306 (60)
US 1997-59133P 19970917 (60)
DT Utility
FS APPLICATION
LN.CNT 11515
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 123 OF 469 USPATFULL on STN
AN 2004:146966 USPATFULL
TI Aromatic sulfone hydroxamic acid metalloprotease inhibitor
IN Barta, Thomas E, Evanston, IL, United States
Becker, Daniel P, Glenview, IL, United States
Bedell, Louis J, Mt. Prospect, IL, United States
Boehm, Terri L, Ballwin, MO, United States
Carroll, Jeffrey N, Collinsville, IL, United States
DeCrescenzo, Gary A, St. Charles, MO, United States
Fobian, Yvette M, Wildwood, MO, United States
Freskos, John N, Clayton, MO, United States
Getman, Daniel P, Chesterfield, MO, United States
McDonald, Joseph J, Ballwin, MO, United States
Li, Madeleine H, Vernon Hills, IL, United States
Hockerman, Susan L, Lincolnwood, IL, United States
Howard, Susan C, Fenton, MO, United States
Kolodziej, Steve A, Ballwin, MO, United States
Mischke, Deborah A, Defiance, MO, United States
Rico, Joseph G, Ballwin, MO, United States
Stehle, Nathan W, Ballwin, MO, United States
Tollefson, Michael B, Hainesville, IL, United States
Vernier, William F, St. Louis, MO, United States
Villamil, Clara I, Glenview, IL, United States
PA Pharmacia Corporation, St. Louis, MO, United States (U.S. corporation)
PI US 6750228 B1 20040615
AI US 2000-570731 20000512 (9)
RLI Continuation-in-part of Ser. No. US 1999-311837, filed on 14 May 1999 Continuation-in-part of Ser. No. US 1999-256948, filed on 24 Feb 1999, now abandoned
PRAI US 1998-101080P 19980918 (60)
US 1998-95501 19980806 (90)

US 1997-66007P 19971114 (60)
DT Utility
FS GRANTED
LN.CNT 9861
INCL INCLM: 514/316.000
INCLS: 514/318.000; 514/328.000; 514/330.000; 546/189.000; 546/193.000; 546/220.000; 546/225.000
NCL NCLM: 514/316.000
NCLS: 514/318.000; 514/328.000; 514/330.000; 546/189.000; 546/193.000; 546/220.000; 546/225.000
IC [7]
ICM: A61K031-445
ICS: C07D211-06
EXF 514/316; 514/328; 514/318; 514/330; 546/189; 546/193; 546/220; 546/225
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 124 OF 469 USPATFULL on STN
AN 2004:145132 USPATFULL
TI Aromatic sulfone hydroxamic acids and their use as protease inhibitors
IN Freskos, John N., Clayton, MO, UNITED STATES
Fobian, Yvette M., Wildwood, MO, UNITED STATES
Barta, Thomas E., Evanston, IL, UNITED STATES
Becker, Daniel P., Glenview, IL, UNITED STATES
Bedell, Louis J., Mt. Prospect, IL, UNITED STATES
Boehm, Terri L., Ballwin, MO, UNITED STATES
Carroll, Jeffery N., Columbia, IL, UNITED STATES
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES
Hockerman, Susan L., Chicago, IL, UNITED STATES
Kassab, Darren J., Wildwood, MO, UNITED STATES
Kolodziej, Steve A., Ballwin, MO, UNITED STATES
McDonald, Joseph, Wildwood, MO, UNITED STATES
Mischke, Deborah A., Defiance, MO, UNITED STATES
Norton, Monica B., St. Louis, MO, UNITED STATES
Rico, Joseph G., Ballwin, MO, UNITED STATES
Talley, John J., Cambridge, MA, UNITED STATES
Villamil, Clara I., Glenview, IL, UNITED STATES
Wang, Lijuan Jane, Wildwood, MO, UNITED STATES
PI US 2004110805 A1 20040610
AI US 2003-657034 A1 20030905 (10)
RLI Division of Ser. No. US 2002-142737, filed on 10 May 2002, PENDING
PRAI US 2001-290375P 20010511 (60)
DT Utility
FS APPLICATION
LN.CNT 15248
INCL INCLM: 514/357.000
INCLS: 514/575.000; 514/408.000; 546/336.000; 548/577.000; 562/621.000; 514/534.000
NCL NCLM: 514/357.000
NCLS: 514/575.000; 514/408.000; 546/336.000; 548/577.000; 562/621.000; 514/534.000
IC [7]
ICM: A61K031-44
ICS: A61K031-40; A61K031-19; A61K031-24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 125 OF 469 USPATFULL on STN
AN 2004:141189 USPATFULL
TI Isoxazoline derivative and a process for the preparation thereof
IN Kim, Eunice Eun-Kyeong, Daejeon, KOREA, REPUBLIC OF
Park, Mi-Jeong, Daejeon, KOREA, REPUBLIC OF
Lee, Tae-Hee, Daejeon, KOREA, REPUBLIC OF
Chang, Hye-Kyung, Daejeon, KOREA, REPUBLIC OF
Park, Tae-Kyo, Daejeon, KOREA, REPUBLIC OF
Kang, Chang-Yuil, Seoul, KOREA, REPUBLIC OF
Kim, Young-Myeong, Chunchon, KOREA, REPUBLIC OF
Moon, Kwang-Yul, Daejeon, KOREA, REPUBLIC OF
Oh, Young-Leem, Daejeon, KOREA, REPUBLIC OF
Min, Chang-Hee, Daejeon, KOREA, REPUBLIC OF
Chung, Hyun-Ho, Daejeon, KOREA, REPUBLIC OF
PA LG Chem Investment Ltd., Seoul, KOREA, REPUBLIC OF (non-U.S. corporation)
PI US 6747050 B1 20040608
WO 2001021600 20010329
AI US 2002-88288 20020315 (10)
WO 2000-KR1047 20000918

KR 1999-48608 19991104
DT Utility
FS GRANTED
LN.CNT 3777
INCL INCLM: 514/378.000
INCLS: 548/240.000; 546/146.000; 546/169.000; 514/307.000; 514/314.000
NCL NCLM: 514/378.000
NCLS: 514/307.000; 514/314.000; 546/146.000; 546/169.000; 548/240.000
IC [7]
ICM: A61K031-42
ICS: A61K031-422; C07D261-04
EXF 548/240; 514/378
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 126 OF 469 USPATFULL on STN
AN 2004:139439 USPATFULL
TI Protein kinase inhibitors and uses thereof
IN Cochran, John, Marshfield, MA, UNITED STATES
Green, Jeremy, Burlington, MA, UNITED STATES
Hale, Michael R., Bedford, MA, UNITED STATES
Ledford, Brian, Attleboro, MA, UNITED STATES
Maltais, Francois, Tewksbury, MA, UNITED STATES
Nanthakumar, Suganthini, Newton, MA, UNITED STATES
PI US 2004106615 A1 20040603
AI US 2003-639784 A1 20030812 (10)
PRAI US 2002-403256P 20020814 (60)
US 2002-416802P 20021008 (60)
DT Utility
FS APPLICATION
LN.CNT 5486
INCL INCLM: 514/242.000
INCLS: 514/247.000; 514/252.030; 514/275.000; 544/238.000; 544/183.000; 544/331.000
NCL NCLM: 514/242.000
NCLS: 514/247.000; 514/252.030; 514/275.000; 544/238.000; 544/183.000; 544/331.000
IC [7]
ICM: A61K031-53
ICS: A61K031-501; A61K031-506; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 127 OF 469 USPATFULL on STN
AN 2004:139422 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***Beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Thompson, Richard C., Frankfort, IN, UNITED STATES
Wilkie, Stephen, Indianapolis, IN, UNITED STATES
Stack, Douglas R., Fishers, IN, UNITED STATES
Vanmeter, Eldon E., Greenwood, IN, UNITED STATES
Shi, Qing, Carmel, IN, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Martinsville, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2004106598 A1 20040603
AI US 2003-392332 A1 20030320 (10)
RLI Division of Ser. No. US 1999-338191, filed on 22 Jun 1999, GRANTED, Pat. No. US 6569851
PRAI US 1998-160067P 19980622 (60)
DT Utility
FS APPLICATION
LN.CNT 12955
INCL INCLM: 514/212.030
INCLS: 514/424.000; 514/327.000; 514/580.000; 514/588.000
NCL NCLM: 514/212.030
NCLS: 514/424.000; 514/327.000; 514/580.000; 514/588.000
IC [7]

ICS: A61K031-445; A61K031-4015; A61K031-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 128 OF 469 USPATFULL on STN
AN 2004:127588 USPATFULL
TI Antiamyloid phenylsulfonamides: N-alkanol derivatives
IN Smith, David W., Madison, CT, UNITED STATES
Parker, Michael F., Higganum, CT, UNITED STATES
PI US 2004097572 A1 20040520
AI US 2003-626299 A1 20030724 (10)
PRAI US 2002-400241P 20020801 (60)
DT Utility
FS APPLICATION
LN.CNT 937
INCL INCLM: 514/400.000
INCLS: 514/534.000; 514/562.000; 514/602.000; 548/338.100; 560/012.000; 562/430.000; 564/084.000
NCL NCLM: 514/400.000
NCLS: 514/534.000; 514/562.000; 514/602.000; 548/338.100; 560/012.000; 562/430.000; 564/084.000
IC [7]
ICM: A61K031-4172
ICS: A61K031-195; A61K031-24; A61K031-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 129 OF 469 USPATFULL on STN
AN 2004:127511 USPATFULL
TI Method for treating fibrotic diseases or other indications IIIC
IN Wagle, Dilip, New York, NY, UNITED STATES
Gall, Martin, Morristown, NJ, UNITED STATES
Bell, Stanley C., Narberth, PA, UNITED STATES
LaVoie, Edmond J., Princeton Junction, NJ, UNITED STATES
PI US 2004097495 A1 20040520
AI US 2003-691839 A1 20031023 (10)
RLI Continuation of Ser. No. US 2001-36857, filed on 31 Dec 2001, PENDING
PRAI US 2000-259294P 20001229 (60)
US 2001-259238P 20010102 (60)
US 2001-296246P 20010606 (60)
DT Utility
FS APPLICATION
LN.CNT 3287
INCL INCLM: 514/227.500
INCLS: 514/383.000; 514/396.000; 514/406.000; 514/231.200; 514/252.100; 514/315.000; 514/365.000; 514/374.000; 514/242.000; 514/252.010; 514/255.050; 514/256.000; 514/336.000
NCL NCLM: 514/227.500
NCLS: 514/383.000; 514/396.000; 514/406.000; 514/231.200; 514/252.100; 514/315.000; 514/365.000; 514/374.000; 514/242.000; 514/252.010; 514/255.050; 514/256.000; 514/336.000
IC [7]
ICM: A61K031-54
ICS: A61K031-535; A61K031-497; A61K031-445; A61K031-425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 130 OF 469 USPATFULL on STN
AN 2004:126956 USPATFULL
TI ***ANTIBODIES*** AGAINST INTERLEUKIN-17 RECEPTOR LIKE PROTEIN
IN Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2004096935 A1 20040520
AI US 2001-796844 A1 20010302 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US5759, filed on 6 Mar 2000, UNKNOWN
PRAI WO 1998-US19121 19980916
US 2000-187015P 20000306 (60)
DT Utility
FS APPLICATION
LN.CNT 11562
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C07K014-705; C07H021-04; C07K014-715

L4 ANSWER 131 OF 469 USPATFULL on STN
AN 2004:116758 USPATFULL
TI Method of reducing aluminum levels in the central nervous system
IN Croom, Jr., Warren J., Cary, NC, United States
Berg, Brian M., Sanford, NC, United States
Taylor, Ian L., Kiawah Island, SC, United States
PA North Carolina State University, Raleigh, NC, United States (U.S. corporation)
MUSC Foundation for Research Development, Charleston, SC, United States (U.S. corporation)
PI US 6734166 B1 20040511
AI US 2000-499980 20000208 (9)
DT Utility
FS GRANTED
LN.CNT 1603
INCL INCLM: 514/012.000
INCLS: 514/002.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000
NCL NCLM: 514/012.000
NCLS: 514/002.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000
IC [7]
ICM: A61K038-16
ICS: A61K038-10; A61K038-05
EXF 514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 514/2; 530/324-329; 530/309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 132 OF 469 USPATFULL on STN
AN 2004:114812 USPATFULL
TI Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
IN Moebius, Hans-Joerg, Frankfurt Am Main, GERMANY, FEDERAL REPUBLIC OF
PI US 2004087658 A1 20040506
AI US 2003-691895 A1 20031023 (10)
PRAI US 2002-420918P 20021024 (60)
DT Utility
FS APPLICATION
LN.CNT 3764
INCL INCLM: 514/579.000
NCL NCLM: 514/579.000
IC [7]
ICM: A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 133 OF 469 USPATFULL on STN
AN 2004:114174 USPATFULL
TI Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
IN Holmes, Todd, Belmont, MA, UNITED STATES
Zhang, Shuguang, Lexington, MA, UNITED STATES
Rich, Alexander, Cambridge, MA, UNITED STATES
DiPersio, C. Michael, Norton, MA, UNITED STATES
Lockshin, Curtis, Lexington, MA, UNITED STATES
PI US 2004087013 A1 20040506
AI US 2003-390472 A1 20030317 (10)
RLI Continuation of Ser. No. US 1997-824515, filed on 26 Mar 1997, GRANTED, Pat. No. US 5987623 Continuation of Ser. No. US 1994-293284, filed on 22 Aug 1994, GRANTED, Pat. No. US 5955343 Continuation-in-part of Ser. No. US 1992-973326, filed on 28 Dec 1992, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2512
INCL INCLM: 435/325.000
INCLS: 530/329.000
NCL NCLM: 435/325.000
NCLS: 530/329.000
IC [7]
ICM: C12N005-02
ICS: C07K007-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:114036 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Agee, Michele L., Wallingford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Berghs, Constance, New Haven, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Chant, John S., Branford, CT, UNITED STATES
Chaudhuri, Amitabha, Madison, CT, UNITED STATES
DiPippo, Vincent A., East Haven, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Eisen, Andrew, Rockville, MD, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Khramtsov, Nikolai V., Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Mezes, Peter S., Old Lyme, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Ooi, Chean Eng., Branford, CT, UNITED STATES
Ort, Tatiana, Milford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Rothenberg, Mark E., Clinton, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Zhong, Mei, Branford, CT, UNITED STATES
PI US 2004086875 A1 20040506
AI US 2002-287226 A1 20021104 (10)
PRAI US 2001-334421P 20011130 (60)
US 2002-354392P 20020204 (60)
US 2002-360148P 20020227 (60)
US 2002-364000P 20020313 (60)
US 2002-404821P 20020820 (60)
US 2001-334526P 20011130 (60)
US 2002-354409P 20020204 (60)
US 2002-364227P 20020313 (60)
US 2001-334027P 20011128 (60)
US 2001-331641P 20011120 (60)
US 2001-335610P 20011115 (60)
US 2001-333461P 20011127 (60)
US 2002-403619P 20020815 (60)
US 2001-336664P 20011204 (60)
US 2002-361925P 20020305 (60)
US 2002-405631P 20020823 (60)
US 2001-333072P 20011106 (60)
US 2001-338314P 20011207 (60)
US 2002-354393P 20020204 (60)
US 2002-361790P 20020305 (60)
US 2002-364182P 20020313 (60)
US 2002-353288P 20020201 (60)
US 2002-362230P 20020305 (60)
US 2002-364181P 20020313 (60)
US 2001-338390P 20011207 (60)
US 2002-361833P 20020305 (60)
US 2002-405368P 20020823 (60)
US 2001-339008P 20011210 (60)
US 2002-362625P 20020305 (60)
US 2002-364197P 20020313 (60)
US 2002-401594P 20020807 (60)
US 2002-405402P 20020823 (60)
US 2001-339006P 20011210 (60)
US 2002-353280P 20020201 (60)

US 2002-405496P 20020823 (60)
US 2001-333072P 20011106 (60)
US 2001-338626P 20011105 (60)
US 2001-348283P 20011109 (60)
US 2001-335610P 20011115 (60)
US 2001-331641P 20011120 (60)
US 2001-331630P 20011120 (60)
US 2001-332152P 20011121 (60)
US 2001-334300P 20011129 (60)
US 2002-401787P 20020807 (60)
US 2002-396703P 20020717 (60)
US 2002-401552P 20020806 (60)
US 2001-336576P 20011204 (60)
US 2001-335610P 20011115 (60)
US 2002-381621P 20020517 (60)
US 2002-383675P 20020528 (60)
US 2002-406125P 20020826 (60)
US 2001-338543P 20011116 (60)
US 2001-339286P 20011211 (60)
US 2001-336576P 20011204 (60)
US 2001-333912P 20011128 (60)
DT Utility
FS APPLICATION
LN.CNT 37497
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 514/012.000; 530/350.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 514/012.000; 530/350.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 135 OF 469 USPATFULL on STN
AN 2004:108140 USPATFULL
TI Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
IN Mjalli, Adnan M.M., Jamestown, NC, UNITED STATES
Andrews, Robert C., Jamestown, NC, UNITED STATES
Gopalaswamy, Ramesh, Jamestown, NC, UNITED STATES
Hari, Anitha, High Point, NC, UNITED STATES
Avor, Kwasi S., High Point, NC, UNITED STATES
Qabaja, Ghassan, High Point, NC, UNITED STATES
Guo, Xiao-Chuan, High Point, NC, UNITED STATES
Gupta, Suparna, Greensboro, NC, UNITED STATES
Jones, David R., Asheboro, NC, UNITED STATES
Chen, Xin, High Point, NC, UNITED STATES
PI US 2004082542 A1 20040429
AI US 2003-382203 A1 20030305 (10)
PRAI US 2002-361983P 20020305 (60)
DT Utility
FS APPLICATION
LN.CNT 15091
INCL INCLM: 514/063.000
INCLS: 514/310.000; 514/314.000; 514/365.000; 514/374.000; 514/400.000; 514/266.200; 514/266.230; 544/284.000; 546/148.000; 548/110.000; 548/190.000; 548/222.000; 548/326.500; 514/264.100; 544/279.000
NCL NCLM: 514/063.000
NCLS: 514/310.000; 514/314.000; 514/365.000; 514/374.000; 514/400.000; 514/266.200; 514/266.230; 544/284.000; 546/148.000; 548/110.000; 548/190.000; 548/222.000; 548/326.500; 514/264.100; 544/279.000
IC [7]
ICM: A61K031-695
ICS: A61K031-4709; A61K031-517; A61K031-519; A61K031-426; A61K031-422; A61K031-4162
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 136 OF 469 USPATFULL on STN
AN 2004:103677 USPATFULL
TI Single nucleotide polymorphisms in genes
IN Lander, Eric S., Cambridge, MA, United States
Cargill, Michele, Gaithersburg, MD, United States

Bolk, Stacey, West Roxbury, MA, United States
Daley, George Q., Weston, MA, United States
McCarthy, Jeanette J., San Diego, CA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Whitehead Institute for Biomedical Research, Cambridge, MA, United States (U.S. corporation)
PI US 6727063 B1 20040427
AI US 2000-657472 20000907 (9)
PRAI US 2000-220947P 20000726 (60)
US 2000-225724P 20000816 (60)
US 1999-153357P 19990910 (60)
DT Utility
FS GRANTED
LN.CNT 14015
INCL INCLM: 435/006.000
INCLS: 435/091.100; 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/091.100; 435/091.200
IC [7]
ICM: C12Q001-68
ICS: C12P019-34
EXF 435/6; 435/91.1; 435/91.2; 536/23.1; 536/24.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 137 OF 469 USPATFULL on STN
AN 2004:101757 USPATFULL
TI Lactam compound
IN Koenig, Thomas Mitchell, Camby, IN, UNITED STATES
Mitchell, David, Indianapolis, IN, UNITED STATES
Nissen, Jeffrey Scott, Indianapolis, IN, UNITED STATES
PI US 2004077627 A1 20040422
AI US 2003-415057 A1 20030903 (10)
WO 2001-US27796 20011102
DT Utility
FS APPLICATION
LN.CNT 1843
INCL INCLM: 514/212.070
INCLS: 540/523.000
NCL NCLM: 514/212.070
NCLS: 540/523.000
IC [7]
ICM: A61K031-55
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 138 OF 469 USPATFULL on STN
AN 2004:101158 USPATFULL
TI Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis
IN Mannick, Elizabeth E., 1234 Joseph Street, New Orleans, LA, UNITED STATES 70115
Liu, Zhiyun, 8100 Cambridge Street, #143, Houston, TX, UNITED STATES 77054
Serrano, Maria-Stella, 3721 Lilac Lane, Metairie, LA, UNITED STATES 70001
PI US 2004077020 A1 20040422
AI US 2003-432785 A1 20031120 (10)
WO 2001-US45096 20011130
DT Utility
FS APPLICATION
LN.CNT 2607
INCL INCLM: 435/007.100
NCL NCLM: 435/007.100
IC [7]
ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 139 OF 469 USPATFULL on STN
AN 2004:94708 USPATFULL
TI Molecular toxicology modeling
IN Mendrick, Donna, Gaithersburg, MD, UNITED STATES
Porter, Mark, Gaithersburg, MD, UNITED STATES
Johnson, Kory, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES

PI US 2004072160 A1 20040415
AI US 2002-152319 A1 20020522 (10)
PRAI US 2001-292335P 20010522 (60)
US 2001-297523P 20010613 (60)
US 2001-298925P 20010619 (60)
US 2001-303810P 20010710 (60)
US 2001-303807P 20010710 (60)
US 2001-303808P 20010710 (60)
US 2001-315047P 20010828 (60)
US 2001-324928P 20010927 (60)
US 2001-330867P 20011101 (60)
US 2001-330462P 20011022 (60)
US 2001-331805P 20011121 (60)
US 2001-336144P 20011206 (60)
US 2001-340873P 20011219 (60)
US 2002-357843P 20020221 (60)
US 2002-357842P 20020221 (60)
US 2002-357844P 20020221 (60)
US 2002-364134P 20020315 (60)
US 2002-370206P 20020408 (60)
US 2002-370247P 20020408 (60)
US 2002-370144P 20020408 (60)
US 2002-371679P 20020412 (60)
US 2002-372794P 20020417 (60)
DT Utility
FS APPLICATION
LN.CNT 27909
INCL INCLM: 435/006.000
INCLS: 435/091.200; 436/084.000
NCL NCLM: 435/006.000
NCLS: 435/091.200; 436/084.000
IC [7]
ICM: C12Q001-68
ICS: C12P019-34; G01N033-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 140 OF 469 USPATFULL on STN
AN 2004:89118 USPATFULL
TI Novel human proteins, polynucleotides encoding them and methods of using the same
IN Shimkets, Richard A., Guilford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Mezes, Peter S., Old Lyme, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Spytek, Kimberly Ann, New Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Edinger, Shlomit, New Haven, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Szekeres, Edward S., JR., Branford, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
PI US 2004068095 A1 20040408
AI US 2002-96625 A1 20020313 (10)
RLI Continuation-in-part of Ser. No. US 2001-972211, filed on 5 Oct 2001, PENDING
PRAI US 2001-275892P 20010314 (60)
US 2001-296860P 20010608 (60)
DT Utility
FS APPLICATION
LN.CNT 14761
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K001-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 141 OF 469 USPATFULL on STN
AN 2004:88568 USPATFULL
TI Prevention and treatment of amyloid-associated disorders
IN Hyslop, Paul Andrew, Indianapolis, IN, UNITED STATES
Miller, Foy Dean, Camby, IN, UNITED STATES
Higgins, Linda S., Palo Alto, CA, UNITED STATES
Catalano, Rosanne, Hayward, CA, UNITED STATES
Cordell, Barbara, Palo Alto, CA, UNITED STATES
Puchacz, Elzbieta, Pleasanton, CA, UNITED STATES
PI US 2004067538 A1 20040408
AI US 2003-624950 A1 20030721 (10)
RLI Division of Ser. No. US 2000-608640, filed on 30 Jun 2000, GRANTED, Pat. No. US 6596474
PRAI US 1999-142175P 19990701 (60)
DT Utility
FS APPLICATION
LN.CNT 1260
INCL INCLM: 435/007.200
NCL NCLM: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 142 OF 469 USPATFULL on STN
AN 2004:85245 USPATFULL
TI Methods for inhibiting diabetic complications
IN Khalifah, Raja, Overland Park, KS, United States
Hudson, Billy G., Lenexa, KS, United States
PA Kansas University Medical Center, Kansas City, KS, United States (U.S. corporation)
PI US 6716858 B1 20040406
AI US 1999-416915 19991013 (9)
RLI Continuation-in-part of Ser. No. US 1997-971285, filed on 17 Nov 1997, now patented, Pat. No. US 6228858 Continuation-in-part of Ser. No. US 1996-711555, filed on 10 Sep 1996, now patented, Pat. No. US 5985857
PRAI US 1995-3268P 19950828 (60)
US 1998-104276P 19981014 (60)
DT Utility
FS GRANTED
LN.CNT 3293
INCL INCLM: 514/345.000
INCLS: 514/349.000; 514/350.000; 514/354.000; 514/356.000
NCL NCLM: 514/345.000
NCLS: 514/349.000; 514/350.000; 514/354.000; 514/356.000
IC [7]
ICM: A61K031-44
EXF 514/345; 514/349; 514/350; 514/354; 514/356
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 143 OF 469 USPATFULL on STN
AN 2004:85238 USPATFULL
TI Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
IN Li, Jia-He, Cockeysville, MD, United States
Zhang, Jie, Ellicott City, MD, United States
PA Guilford Pharmaceuticals, Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6716828 B1 20040406
AI US 2001-781195 20010213 (9)
RLI Division of Ser. No. US 1999-387767, filed on 1 Sep 1999
DT Utility
FS GRANTED
LN.CNT 3327
INCL INCLM: 514/080.000
INCLS: 544/232.000; 544/233.000; 514/081.000; 514/248.000
NCL NCLM: 514/080.000
NCLS: 514/081.000; 514/248.000; 544/232.000; 544/233.000
IC [7]
ICM: C07D491-04
ICS: C07D498-04; C07F009-141; A61K031-47; A61K031-50
EXF 544/233; 544/232; 514/248; 514/80; 514/81
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 144 OF 469 USPATFULL on STN
AN 2004:83519 USPATFULL
TI Benzofuran derivatives
IN Boddupalli, Sekhar, San Jose, CA, UNITED STATES
Walkinshaw, Gail, San Jose, CA, UNITED STATES
Wang, Bing, Cupertino, CA, UNITED STATES
PI US 2004063975 A1 20040401
AI US 2003-667280 A1 20030917 (10)
RLI Continuation-in-part of Ser. No. US 2003-361141, filed on 6 Feb 2003, GRANTED, Pat. No. US 6653346
PRAI US 2002-355331P 20020207 (60)
US 2002-429584P 20021127 (60)
DT Utility
FS APPLICATION
LN.CNT 3181
INCL INCLM: 549/462.000
INCLS: 514/469.000
NCL NCLM: 549/462.000
NCLS: 514/469.000
IC [7]
ICM: C07D307-93
ICS: A61K031-343
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 145 OF 469 USPATFULL on STN
AN 2004:78840 USPATFULL
TI Death domain containing receptors
IN Yu, Guo-Liang, Berkeley, CA, United States
Ni, Jian, Rockville, MD, United States
Dixit, Vishva M., Los Altos Hills, CA, United States
Gentz, Reiner L., Rockville, MD, United States
Dillon, Patrick J., Carlsbad, CA, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6713061 B1 20040330
AI US 2000-557908 20000421 (9)
RLI Continuation-in-part of Ser. No. US 1997-815469, filed on 11 Mar 1997, now patented, Pat. No. US 6153402
PRAI US 1999-136741P 19990528 (60)
US 1999-130488P 19990422 (60)
US 1997-37341P 19970206 (60)
US 1996-28711P 19961017 (60)
US 1996-13285P 19960312 (60)
DT Utility
FS GRANTED
LN.CNT 8849
INCL INCLM: 424/185.100
INCLS: 424/192.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 424/185.100
NCLS: 424/192.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: A61K039-00
ICS: C07K014-705
EXF 530/350; 536/23.5; 435/69.1; 424/185.1; 424/192.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 146 OF 469 USPATFULL on STN
AN 2004:77121 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, R. Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Fancisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James A., Indianpolis, IN, UNITED STATES

Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
Mcdaniel, Stacey L., Indianapolis, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2004058900 A1 20040325
AI US 2003-336767 A1 20030106 (10)
RLI Division of Ser. No. US 2001-915342, filed on 27 Jul 2001, PENDING
Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25655
INCL INCLM: 514/183.000
INCLS: 514/212.020; 514/317.000; 514/284.000; 514/212.070; 514/221.000; 514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000
NCL NCLM: 514/183.000
NCLS: 514/212.020; 514/317.000; 514/284.000; 514/212.070; 514/221.000; 514/220.000; 514/211.050; 514/457.000; 514/471.000; 514/732.000
IC [7]
ICM: A61K031-553
ICS: A61K031-55; A61K031-554; A61K031-551; A61K031-5513; A61K031-473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 147 OF 469 USPATFULL on STN
AN 2004:70714 USPATFULL
TI Fused pyrazole derivatives bieng protein kinase inhibitors
IN Alberti, Michael John, Research Triangle Park, NC, UNITED STATES
Baldwin, Ian, Stevenage, UNITED KINGDOM
Cheung, Mui, Research Triangle Park, NC, UNITED STATES
Cockerill, Stuart, Stevenage, UNITED KINGDOM
Harris, Philip, Stevenage, UNITED KINGDOM
Jung, David, Research Triangle Park, NC, UNITED STATES
Peckham, Gregory, Research Triangle Park, NC, UNITED STATES
Peel, Michael, Research Triangle Park, NC, UNITED STATES
Badiang, Jennifer, Research Triangle Park, NC, UNITED STATES
Stevens, Kirk, Research Triangle Park, NC, UNITED STATES
Veal, James, Research Triangle Park, NC, UNITED STATES
PI US 2004053942 A1 20040318
AI US 2003-362146 A1 20030707 (10)
WO 2001-GB3783 20010822
PRAI GB 2000-20556 20000822
GB 2000-20576 20000822
DT Utility
FS APPLICATION
LN.CNT 4935
INCL INCLM: 514/256.000
INCLS: 514/303.000; 544/333.000; 546/113.000
NCL NCLM: 514/256.000
NCLS: 514/303.000; 544/333.000; 546/113.000
IC [7]
ICM: A61K031-506
ICS: C07D471-02; A61K031-4745
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 148 OF 469 USPATFULL on STN
AN 2004:69595 USPATFULL
TI Dihydropyrazolopyridine compounds and pharmaceutical use thereof
IN Kohara, Toshiyuki, Tokyo, JAPAN
Fukunaga, Kenji, Tokyo, JAPAN
Fujimura, Masatake, Tokyo, JAPAN
Hanano, Tokushi, Tokyo, JAPAN
Okabe, Hirotaka, Tokyo, JAPAN
PI US 2004052822 A1 20040318
AI US 2003-631847 A1 20030801 (10)
RLI Continuation-in-part of Ser. No. WO 2002-JP829, filed on 1 Feb 2002, UNKNOWN
PRAI JP 2001-26379 20010202
JP 2001-81238 20010321
JP 2001-304707 20010928
JP 2002-230581 20020807

FS APPLICATION
LN.CNT 10081
INCL INCLM: 424/280.100
NCL NCLM: 424/280.100
IC [7]
ICM: A61K045-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 149 OF 469 USPATFULL on STN
AN 2004:64333 USPATFULL
TI Aromatic sulfone hydroxamic acid metalloprotease inhibitor
IN Barta, Thomas E., Evanston, IL, UNITED STATES
Becker, Daniel P., Glenview, IL, UNITED STATES
Boehm, Terri L., Ballwin, MO, UNITED STATES
DeCrezcenzo, Gary A., St. Charles, MO, UNITED STATES
Freskos, John N., Clayton, MO, UNITED STATES
Getman, Daniel P., Chesterfield, MO, UNITED STATES
McDonald, Joseph J., Wildwood, MO, UNITED STATES
Villamil, Clara I., Glenview, IL, UNITED STATES
Bedell, Louis John, Mt. Prospect, IL, UNITED STATES
Carroll, Jeffery N., Columbia, IL, UNITED STATES
Fletcher, Theresa R., Kirkwood, MO, UNITED STATES
Hockerman, Susan Landis, Lincolnwood, IL, UNITED STATES
Kolodziej, Stephen A., Ballwin, MO, UNITED STATES
Li, Madeleine H., Vernon Hills, IL, UNITED STATES
Mischke, Deborah A., Defiance, MO, UNITED STATES
Mullins, Patrick B., St. Louis, MO, UNITED STATES
Howard, Carol Pearcy, Fenton, MO, UNITED STATES
Rico, Joseph Gerace, Ballwin, MO, UNITED STATES
Stehle, Nathan W., Grafton, WI, UNITED STATES
PI US 2004048852 A1 20040311
AI US 2003-337942 A1 20030107 (10)
RLI Division of Ser. No. US 2000-554082, filed on 31 Jul 2000, GRANTED, Pat. No. US 6541489 A 371 of International Ser. No. WO 1998-US23242, filed on 12 Nov 1998, PENDING
PRAI WO 1997-WO9925687 19971114
US 1997-66007P 19971114 (60)
DT Utility
FS APPLICATION
LN.CNT 16505
INCL INCLM: 514/217.120
INCLS: 514/227.500; 514/237.800; 514/252.120; 514/317.000; 514/357.000; 514/365.000; 514/374.000; 514/400.000; 514/408.000; 514/575.000
NCL NCLM: 514/217.120
NCLS: 514/227.500; 514/237.800; 514/252.120; 514/317.000; 514/357.000; 514/365.000; 514/374.000; 514/400.000; 514/408.000; 514/575.000
IC [7]
ICM: A61K031-55
ICS: A61K031-54; A61K031-537; A61K031-445; A61K031-497; A61K031-495; A61K031-44; A61K031-19; A61K031-421; A61K031-426; A61K031-4172
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 150 OF 469 USPATFULL on STN
AN 2004:64329 USPATFULL
TI Novel gamma secretase inhibitors
IN Pissarnitski, Dmitri A., Scotch Plains, NJ, UNITED STATES
Josien, Hubert B., Hoboken, NJ, UNITED STATES
Smith, Elizabeth M., Verona, NJ, UNITED STATES
Clader, John W., Cranford, NJ, UNITED STATES
Asberom, Theodros, West Orange, NJ, UNITED STATES
Guo, Tao, Dayton, NJ, UNITED STATES
Hobbs, Douglas W., Yardley, PA, UNITED STATES
PA Schering-Plough Corporation and Pharmacopeia, Inc. (U.S. corporation)
PI US 2004048848 A1 20040311
AI US 2003-358898 A1 20030205 (10)
PRAI US 2002-355618P 20020206 (60)
DT Utility
FS APPLICATION
LN.CNT 3259
INCL INCLM: 514/217.050
INCLS: 514/217.040; 514/217.080; 514/235.500; 514/253.120; 514/316.000; 514/326.000; 540/597.000; 540/598.000; 544/129.000; 544/360.000; 546/186.000; 546/208.000
NCL NCLM: 514/217.050
NCLS: 514/217.040; 514/217.080; 514/235.500; 514/253.120; 514/316.000;

546/186.000; 546/208.000
IC [7]
ICM: A61K031-55
ICS: A61K031-5377; A61K031-496; A61K031-4545; A61K031-454; C07D413-02; C07D043-02; C07D041-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 151 OF 469 USPATFULL on STN
AN 2004:63809 USPATFULL
TI Aza-peptide epoxides
IN Powers, James C., Atlanta, GA, UNITED STATES
Asgian, Juliana L., Fullerton, CA, UNITED STATES
James, Karen E., Cumming, GA, UNITED STATES
Li, Zhao-Zhao, Norcross, GA, UNITED STATES
PI US 2004048327 A1 20040311
AI US 2003-603054 A1 20030624 (10)
PRAI US 2002-394221P 20020705 (60)
US 2002-394023P 20020705 (60)
US 2002-394024P 20020705 (60)
DT Utility
FS APPLICATION
LN.CNT 4866
INCL INCLM: 435/023.000
INCLS: 530/330.000; 530/331.000; 549/551.000; 544/147.000
NCL NCLM: 435/023.000
NCLS: 530/330.000; 530/331.000; 549/551.000; 544/147.000
IC [7]
ICM: C12Q001-37
ICS: C07K007-06; C07K005-06; C07K005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 152 OF 469 USPATFULL on STN
AN 2004:58251 USPATFULL
TI Substituted phenylalkanoic acid derivatives and use thereof
IN Shoda, Motoshi, Shizuoka, JAPAN
Kuriyama, Hiroshi, Shizuoka, JAPAN
PI US 2004044258 A1 20040304
AI US 2003-368435 A1 20030220 (10)
PRAI JP 2002-45293 20020221
JP 2002-301543 20021016
US 2002-358337P 20020222 (60)
US 2002-419098P 20021018 (60)
DT Utility
FS APPLICATION
LN.CNT 15610
INCL INCLM: 568/959.000
NCL NCLM: 568/959.000
IC [7]
ICM: C07C027-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 153 OF 469 USPATFULL on STN
AN 2004:58065 USPATFULL
TI Substituted hydroxyethylamines
IN TenBrink, Ruth, Kalamazoo, MI, UNITED STATES
Maillard, Michel, Redwood Shores, CA, UNITED STATES
Warpehoski, Martha, Portage, MI, UNITED STATES
PI US 2004044072 A1 20040304
AI US 2002-313849 A1 20021206 (10)
PRAI US 2001-338452P 20011206 (60)
DT Utility
FS APPLICATION
LN.CNT 7547
INCL INCLM: 514/489.000
INCLS: 560/159.000; 560/115.000; 514/521.000; 558/410.000
NCL NCLM: 514/489.000
NCLS: 560/159.000; 560/115.000; 514/521.000; 558/410.000
IC [7]
ICM: A61K031-325
ICS: A61K031-277; C07C271-52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 154 OF 469 USPATFULL on STN
AN 2004:57970 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical

amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2004043977 A1 20040304
AI US 2003-336687 A1 20030106 (10)
RLI Division of Ser. No. US 2001-915362, filed on 27 Jul 2001, GRANTED, Pat. No. US 6541466 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25738
INCL INCLM: 514/183.000
INCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000; 514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000; 540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000; 546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000; 514/662.000; 564/454.000
NCL NCLM: 514/183.000
NCLS: 514/212.030; 514/212.070; 514/312.000; 514/220.000; 514/221.000; 514/288.000; 514/327.000; 514/460.000; 540/451.000; 540/496.000; 540/504.000; 540/523.000; 540/484.000; 546/153.000; 546/158.000; 546/076.000; 546/216.000; 549/273.000; 549/283.000; 514/659.000; 514/662.000; 564/454.000
IC [7]
ICM: A61K031-5513
ICS: A61K031-551; A61K031-55; A61K031-4706; A61K031-473; A61K031-445; A61K031-366; A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 155 OF 469 USPATFULL on STN
AN 2004:57923 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Anderson, David W., Plantsville, CT, UNITED STATES
Bento, Patricia, Wolcott, CT, UNITED STATES
Boldog, Ferenc, North Haven, CT, UNITED STATES
Burgess, Catherine, Wethersfield, CT, UNITED STATES
Casman, Stacie, North Haven, CT, UNITED STATES
Furtak, Katarzyna, Ansonia, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Gould-Rothberg, Bonnie, Guilford, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Heyes, Melvyn, New Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Spytek, Kimberly, Ellington, CT, UNITED STATES
Stone, David, Guilford, CT, UNITED STATES
Zhong, Mei, Branford, CT, UNITED STATES
Malyankar, Uriel, Branford, CT, UNITED STATES
Edinger, Shlomit, New Haven, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Rothenberg, Mark, Clinton, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
PI US 2004043930 A1 20040304
AI US 2003-403161 A1 20030331 (10)
RLI Continuation-in-part of Ser. No. US 2001-779679, filed on 8 Feb 2001,

PRAI US 2002-370349P 20020405 (60)
US 2002-384543P 20020530 (60)
US 2002-370969P 20020408 (60)
US 2002-403748P 20020815 (60)
US 2002-372019P 20020412 (60)
US 2002-374379P 20020422 (60)
US 2000-181045P 20000208 (60)
DT Utility
FS APPLICATION
LN.CNT 27161
INCL INCLM: 514/012.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 514/012.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: A61K038-17
ICS: C07K014-47; C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 156 OF 469 USPATFULL on STN
AN 2004:51633 USPATFULL
TI Amine 1,2- and 1,3-diol compounds
IN Romero, Arthur G., Kalamazoo, MI, UNITED STATES
Schostarez, Heinrich J., Portage, MI, UNITED STATES
Roels, Christina M., Battle Creek, MI, UNITED STATES
PI US 2004039064 A1 20040226
AI US 2002-299739 A1 20021119 (10)
PRAI US 2001-333081P 20011119 (60)
US 2001-334000P 20011128 (60)
US 2002-362752P 20020308 (60)
DT Utility
FS APPLICATION
LN.CNT 10130
INCL INCLM: 514/651.000
INCLS: 564/355.000
NCL NCLM: 514/651.000
NCLS: 564/355.000
IC [7]
ICM: A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 157 OF 469 USPATFULL on STN
AN 2004:51576 USPATFULL
TI Compositions useful as inhibitors of GSK-3
IN Forster, Cornelia J., Pelham, NH, UNITED STATES
Park, Larry C., Waltham, MA, UNITED STATES
Wannamaker, Marion W., Stow, MA, UNITED STATES
Yao, Yung-Mae M., Newton, MA, UNITED STATES
PI US 2004039007 A1 20040226
AI US 2003-632340 A1 20030801 (10)
PRAI US 2002-400967P 20020802 (60)
DT Utility
FS APPLICATION
LN.CNT 2000
INCL INCLM: 514/275.000
INCLS: 514/228.500; 514/234.500; 514/252.180; 544/060.000; 544/122.000;
544/295.000; 544/328.000
NCL NCLM: 514/275.000
NCLS: 514/228.500; 514/234.500; 514/252.180; 544/060.000; 544/122.000;
544/295.000; 544/328.000
IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-506; C07D417-14; C07D413-14; C07D043-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 158 OF 469 USPATFULL on STN
AN 2004:50862 USPATFULL
TI Wound healing biomarkers
IN Burslem, Martyn Frank, Sandwich, UNITED KINGDOM
Johnson, Claire Michelle, Sandwich, UNITED KINGDOM
Cooper, Lisa, London, UNITED KINGDOM
Martin, Paul, London, UNITED KINGDOM
PI US 2004038292 A1 20040226
AI US 2002-175184 A1 20020618 (10)
PRAI GB 2001-14869 20010618

DT Utility
FS APPLICATION
LN.CNT 67123
INCL INCLM: 435/007.100
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/007.100
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: G01N033-53
ICS: C07H021-04; C12P021-02; C12N005-06; C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 159 OF 469 USPATFULL on STN
AN 2004:50778 USPATFULL
TI Gene expression in bladder tumors
IN Orntoft, Torben F., Aabyhoj, DENMARK
PI US 2004038207 A1 20040226
AI US 2001-951968 A1 20010914 (9)
RLI Division of Ser. No. US 2000-510643, filed on 22 Feb 2000, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 28561
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 160 OF 469 USPATFULL on STN
AN 2004:45056 USPATFULL
TI Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells
IN Okawa, Shigenori, Osaka, JAPAN
Miyamoto, Masaomi, Hyogo, JAPAN
Okura, Masahiro, Osaka, JAPAN
PI US 2004034049 A1 20040219
AI US 2003-398278 A1 20030401 (10)
WO 2001-JP8739 20011004
DT Utility
FS APPLICATION
LN.CNT 5795
INCL INCLM: 514/278.000
INCLS: 514/409.000
NCL NCLM: 514/278.000
NCLS: 514/409.000
IC [7]
ICM: A61K031-4747
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 161 OF 469 USPATFULL on STN
AN 2004:44501 USPATFULL
TI Proteins and nucleic acids encoding same
IN Tchernev, Velizar T., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., West Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Miller, Charles E., Hill Drive, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Gusev, Vladimir Y., UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Wolenc, Adam Ryan, New Haven, CT, UNITED STATES
Pena, Carol E. A., Guilford, CT, UNITED STATES
Furtak, Katarzyna, Anosia, CT, UNITED STATES
Grosse, William M., Bransford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES

AI US 2002-72012 A1 20020131 (10)
PRAI US 2001-267459P 20010208 (60)
US 2001-266975P 20010207 (60)
US 2001-267057P 20010207 (60)
US 2001-266767P 20010205 (60)
US 2001-266406P 20010202 (60)
US 2001-265395P 20010131 (60)
US 2001-265412P 20010131 (60)
US 2001-265517P 20010131 (60)
US 2001-265514P 20010131 (60)
US 2001-267823P 20010209 (60)
US 2001-268974P 20010215 (60)
US 2001-271855P 20010227 (60)
US 2001-271839P 20010227 (60)
US 2001-273046P 20010302 (60)
US 2001-272788P 20010302 (60)
US 2001-275989P 20010314 (60)
US 2001-275925P 20010314 (60)
US 2001-275947P 20010314 (60)
US 2001-275950P 20010314 (60)
US 2001-276450P 20010315 (60)
US 2001-276448P 20010315 (60)
US 2001-276397P 20010316 (60)
US 2001-276768P 20010316 (60)
US 2001-278652P 20010320 (60)
US 2001-278775P 20010326 (60)
US 2001-278778P 20010326 (60)
US 2001-279882P 20010329 (60)
US 2001-279884P 20010329 (60)
US 2001-280147P 20010330 (60)
US 2001-283083P 20010411 (60)
US 2001-282992P 20010411 (60)
US 2001-285133P 20010420 (60)
US 2001-285749P 20010423 (60)
US 2001-288327P 20010503 (60)
US 2001-288504P 20010503 (60)
US 2001-294047P 20010529 (60)
US 2001-294473P 20010530 (60)
US 2001-296964P 20010608 (60)
US 2001-298959P 20010618 (60)
US 2001-299324P 20010619 (60)
US 2001-312020P 20010813 (60)
US 2001-312908P 20010816 (60)
US 2001-312889P 20010816 (60)
US 2001-313930P 20010821 (60)
US 2001-315470P 20010828 (60)
US 2001-316447P 20010831 (60)
US 2001-318115P 20010907 (60)
US 2001-318118P 20010907 (60)
US 2001-318740P 20010912 (60)
US 2001-323379P 20010919 (60)
US 2001-330308P 20011018 (60)
US 2001-330245P 20011018 (60)
US 2001-332701P 20011114 (60)
US 2001-271664P 20010226 (60)
DT Utility
FS APPLICATION
LN.CNT 59681
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 435/183.000; 424/155.100
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 435/183.000; 424/155.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; A61K039-395; C12N009-00; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 162 OF 469 USPATFULL on STN
AN 2004:39568 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Kekuda, Ramesh, Danbury, CT, UNITED STATES

Malyankar, Uriel M., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Pena, Carol E. A., New Haven, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Leite, Mario W., Milford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Rothenberg, Mark E., Clinton, CT, UNITED STATES
Mazur, Ann, Bloomfield, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES

PI US 2004030110 A1 20040212
AI US 2002-114270 A1 20020402 (10)
PRAI US 2001-281086P 20010403 (60)
US 2001-281136P 20010403 (60)
US 2001-281863P 20010405 (60)
US 2001-281906P 20010405 (60)
US 2001-282020P 20010406 (60)
US 2001-282930P 20010410 (60)
US 2001-282934P 20010410 (60)
US 2001-283512P 20010412 (60)
US 2001-283710P 20010413 (60)
US 2001-284234P 20010417 (60)
US 2001-285325P 20010419 (60)
US 2001-285381P 20010420 (60)
US 2001-285609P 20010420 (60)
US 2001-285748P 20010423 (60)
US 2001-285890P 20010423 (60)
US 2001-286068P 20010424 (60)
US 2001-286292P 20010425 (60)
US 2001-287213P 20010427 (60)
US 2001-288257P 20010502 (60)
US 2001-294164P 20010529 (60)
US 2001-294484P 20010530 (60)
US 2001-298952P 20010618 (60)
US 2001-299237P 20010619 (60)
US 2001-299276P 20010619 (60)
US 2001-318750P 20010912 (60)
US 2001-324800P 20010925 (60)
US 2001-324802P 20010925 (60)
US 2001-325684P 20010927 (60)
US 2001-330143P 20011017 (60)
US 2001-332115P 20011121 (60)
US 2001-332131P 20011114 (60)
US 2001-332240P 20011114 (60)
US 2001-332779P 20011114 (60)
US 2001-337621P 20011204 (60)
US 2002-345783P 20020103 (60)
US 2002-350251P 20020116 (60)
DT Utility
FS APPLICATION
LN.CNT 35659
INCL INCLM: 536/023.100
NCL NCLM: 536/023.100
IC [7]

ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 163 OF 469 USPATFULL on STN
AN 2004:38683 USPATFULL
TI Proteins and nucleic acids encoding same
IN Edinger, Shlomit R., New Haven, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Rieger, Danier K., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Boldog, Ference L., North Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Mishra, Vishnu, Gainesville, FL, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Grosse, Michael, UNITED STATES LR
PI US 2004029222 A1 20040212
AI US 2002-218779 A1 20020814 (10)
RLI Continuation of Ser. No. US 2001-995514, filed on 28 Nov 2001, ABANDONED
PRAI US 2000-253834P 20001129 (60)
US 2000-250926P 20001130 (60)
US 2001-264180P 20010125 (60)
US 2001-313656P 20010820 (60)
US 2001-327456P 20011005 (60)
DT Utility
FS APPLICATION
LN.CNT 15385
INCL INCLM: 435/069.100
INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 530/388.100; 435/007.230; 435/006.000
NCL NCLM: 435/069.100
NCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 530/388.100; 435/007.230; 435/006.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47; C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 164 OF 469 USPATFULL on STN
AN 2004:38577 USPATFULL
TI Proteins and nucleic acids encoding same
IN Edinger, Shlomit R., New Haven, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES

Mishra, Vishnu, Gainesville, FL, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Guo, Xiaojia, Branford, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
PI US 2004029116 A1 20040212
AI US 2002-87684 A1 20020301 (10)
PRAI US 2001-313656P 20010820 (60)
US 2001-274194P 20010308 (60)
US 2001-327456P 20011005 (60)
DT Utility
FS APPLICATION
LN.CNT 15489
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 165 OF 469 USPATFULL on STN
AN 2004:32039 USPATFULL
TI Novel human proteins, polynucleotides encoding them and methods of using the same
IN Gangolli, Esha A., Madison, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Gilbert, Jennifer, Madison, CT, UNITED STATES
Casman, Stacie, North Haven, CT, UNITED STATES
Blalock, Angela, Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Vernet, Corine, Branford, CT, UNITED STATES
Shenoy, Suresh, Branford, CT, UNITED STATES
Mishra, Vishnu S., Gainesville, FL, UNITED STATES
Furtak, Katarzyna, Ansonia, CT, UNITED STATES
Gerlach, Valerie L., Branford, CT, UNITED STATES
Edinger, Shlomit, New Haven, CT, UNITED STATES
Malyanker, Uriel, Branford, CT, UNITED STATES
Stone, David, Guilford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
PI US 2004024181 A1 20040205
AI US 2001-55569 A1 20011026 (10)
PRAI US 2000-243642P 20001026 (60)
US 2000-243320P 20001026 (60)
US 2000-243592P 20001026 (60)
US 2000-243681P 20001027 (60)
US 2000-243863P 20001027 (60)
US 2000-244443P 20001031 (60)
US 2000-245029P 20001101 (60)
US 2000-244995P 20001101 (60)
US 2000-245293P 20001102 (60)
US 2000-245315P 20001102 (60)
US 2000-245316P 20001102 (60)
US 2001-262994P 20010119 (60)
US 2001-269056P 20010215 (60)
US 2001-272923P 20010302 (60)
US 2001-276565P 20010315 (60)
US 2001-318119P 20010907 (60)
DT Utility
FS APPLICATION

INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: C07K014-705
ICS: C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 166 OF 469 USPATFULL on STN
AN 2004:31882 USPATFULL
TI Aromatic sulfone hydroxamates and their use as protease inhibitors
IN Freskos, John N., Clayton, MO, UNITED STATES
Fobian, Y vette M., Wildwood, MO, UNITED STATES
Awasthi, Alok K., Skokie, IL, UNITED STATES
Barta, Thomas E., Evanston, IL, UNITED STATES
Becker, Daniel P., Glenview, IL, UNITED STATES
Bedell, Louis J., Mt. Prospect, IL, UNITED STATES
Boehm, Terri L., Ballwin, MO, UNITED STATES
Carroll, Jeffery N., Columbia, IL, UNITED STATES
Chandrakumar, Nizal S., Vernon Hills, IL, UNITED STATES
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES
Desai, Bipin N., Vernon Hills, IL, UNITED STATES
Heron, Marcia I., Wester Springs, IL, UNITED STATES
Hockerman, Susan L., Lincolnwood, IL, UNITED STATES
Jull, Sara M., Villa Park, IL, UNITED STATES
Kassab, Darren J., O' Fallon, MO, UNITED STATES
Kolodziej, Steve A., Ballwin, MO, UNITED STATES
McDonald, Joseph, Wildwood, MO, UNITED STATES
Mischke, Deborah A., Defiance, MO, UNITED STATES
Mullins, Patrick B., St Louis, MO, UNITED STATES
Norton, Monica B., St. Louis, MO, UNITED STATES
Rico, Joseph G., Ballwin, MO, UNITED STATES
Talley, John J., Cambridge, MA, UNITED STATES
Trivedi, Mahima, Skokie, IL, UNITED STATES
Villamil, Clara I., Glenview, IL, UNITED STATES
Wang, Lijuan Jane, Wildwood, MO, UNITED STATES
PI US 2004024024 A1 20040205
AI US 2002-291983 A1 20021112 (10)
RLI Continuation-in-part of Ser. No. US 2002-142737, filed on 10 May 2002, PENDING
PRAI US 2001-290375P 20010511 (60)
DT Utility
FS APPLICATION
LN.CNT 11028
INCL INCLM: 514/326.000
INCLS: 514/513.000; 514/357.000; 514/408.000; 514/575.000; 514/382.000; 514/459.000; 546/210.000; 546/207.000; 548/252.000; 549/416.000
NCL NCLM: 514/326.000
NCLS: 514/513.000; 514/357.000; 514/408.000; 514/575.000; 514/382.000; 514/459.000; 546/210.000; 546/207.000; 548/252.000; 549/416.000
IC [7]
ICM: C07D045-02
ICS: C07D043-02; A61K031-451; A61K031-454; A61K031-415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 167 OF 469 USPATFULL on STN
AN 2004:31831 USPATFULL
TI 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof
IN Nagato, Satoshi, Chiba, JAPAN
Ueno, Kohshi, Ibaraki, JAPAN
Kawano, Koki, Ibaraki, JAPAN
Norimine, Yoshihiko, Ibaraki, JAPAN
Ito, Koichi, Chiba, JAPAN
Hanada, Takahisa, Ibaraki, JAPAN
Ueno, Masataka, Ibaraki, JAPAN
Amino, Hiroyuki, Ibaraki, JAPAN
Ogo, Makoto, Ibaraki, JAPAN
Hatakeyama, Shinji, Ibaraki, JAPAN
Urawa, Yoshio, Ibaraki, JAPAN
Naka, Hiroyuki, Ibaraki, JAPAN
Groom, Anthony John, Wiltshire, UNITED KINGDOM
Rivers, Leanne, Kent, UNITED KINGDOM
PI US 2004023973 A1 20040205

WO 2001-JP4857 20010608
PRAI JP 2000-175966 20000612
GB 2000-22483 20000913
DT Utility
FS APPLICATION
LN.CNT 9028
INCL INCLM: 514/252.030
INCLS: 514/256.000; 514/332.000; 514/333.000; 544/238.000; 544/333.000; 546/256.000
NCL NCLM: 514/252.030
NCLS: 514/256.000; 514/332.000; 514/333.000; 544/238.000; 544/333.000; 546/256.000
IC [7]
ICM: A61K031-506
ICS: A61K031-501; A61K031-444; C07D043-02; C07D041-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 168 OF 469 USPATFULL on STN
AN 2004:31145 USPATFULL
TI 90 human secreted proteins
IN Ruben, Steven M., Brookeville, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie, St. Paul, MN, UNITED STATES
Janat, Fouad, Westerly, RI, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2004023283 A1 20040205
AI US 2003-621363 A1 20030718 (10)
RLI Continuation of Ser. No. US 2001-969730, filed on 4 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-774639, filed on 1 Feb 2001, PENDING Continuation of Ser. No. US 1999-244112, filed on 4 Feb 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US16235, filed on 4 Aug 1998, PENDING
PRAI US 2000-238291P 20001006 (60)
US 1997-55386P 19970805 (60)
US 1997-54807P 19970805 (60)
US 1997-55312P 19970805 (60)
US 1997-55309P 19970805 (60)
US 1997-54798P 19970805 (60)
US 1997-55310P 19970805 (60)
US 1997-54806P 19970805 (60)
US 1997-54809P 19970805 (60)
US 1997-54804P 19970805 (60)
US 1997-54803P 19970805 (60)
US 1997-54808P 19970805 (60)
US 1997-55311P 19970805 (60)
US 1997-55986P 19970818 (60)
US 1997-55970P 19970818 (60)
US 1997-56563P 19970819 (60)
US 1997-56557P 19970819 (60)
US 1997-56731P 19970819 (60)
US 1997-56365P 19970819 (60)
US 1997-56367P 19970819 (60)
US 1997-56370P 19970819 (60)
US 1997-56364P 19970819 (60)
US 1997-56366P 19970819 (60)
US 1997-56732P 19970819 (60)
US 1997-56371P 19970819 (60)
DT Utility
FS APPLICATION
LN.CNT 26395
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;

IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 169 OF 469 USPATFULL on STN
AN 2004:31067 USPATFULL
TI Method of recovering a nucleic acid encoding a proteinaceous binding domain which binds a target material
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2004023205 A1 20040205
AI US 2002-126544 A1 20020422 (10)
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, ABANDONED Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED, Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409 Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 15868
INCL INCLM: 435/005.000
INCLS: 435/006.000; 536/023.100; 536/023.720
NCL NCLM: 435/005.000
NCLS: 435/006.000; 536/023.100; 536/023.720
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 170 OF 469 USPATFULL on STN
AN 2004:30644 USPATFULL
TI Proteins and nucleic acids encoding same
IN Spytek, Kimberly A., New Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Wolenc, Adam R., New Haven, CT, UNITED STATES
Vernet, Corine, North Branford, CT, UNITED STATES
Eisen, Andrew J., Rockville, MD, UNITED STATES
Liu, Xiaohong, Lexington, MA, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Tchernev, Velizar, Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
PI US 2004022781 A1 20040205
AI US 2001-38854 A1 20011231 (10)
PRAI US 2000-258928P 20001229 (60)
US 2001-259415P 20010102 (60)
US 2001-259785P 20010104 (60)
US 2001-269814P 20010220 (60)
US 2001-279832P 20010329 (60)

US 2001-279863P 20010329 (60)
US 2001-283889P 20010413 (60)
US 2001-284447P 20010418 (60)
US 2001-286683P 20010425 (60)
US 2001-294080P 20010529 (60)
US 2001-312915P 20010816 (60)
US 2001-313325P 20010817 (60)
US 2001-322699P 20010917 (60)
US 2001-333350P 20011126 (60)
DT Utility
FS APPLICATION
LN.CNT 19237
INCL INCLM: 424/130.100
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/007.200; 530/350.000; 536/023.100; 530/388.250
NCL NCLM: 424/130.100
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/007.200; 530/350.000; 536/023.100; 530/388.250
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C07H021-04; A61K039-395; C12P021-02; C12N005-06; C07K014-47; C07K016-22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 171 OF 469 USPATFULL on STN
AN 2004:24674 USPATFULL
TI Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling
IN Downing, James R., Cordova, TN, UNITED STATES
Yeoh, Eng-Juh, Singapore, SINGAPORE
Wilkins, Dawn E., Oxford, MS, UNITED STATES
Wong, Limsoon, Singapore, SINGAPORE
PI US 2004018513 A1 20040129
AI US 2003-391271 A1 20030318 (10)
PRAI US 2002-367144P 20020322 (60)
DT Utility
FS APPLICATION
LN.CNT 9169
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 172 OF 469 USPATFULL on STN
AN 2004:23553 USPATFULL
TI Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
IN Soltero, Richard, Holly Springs, NC, UNITED STATES
Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES
Opawale, Foyeke, Raleigh, NC, UNITED STATES
Rehlaender, Bruce, Chapel Hill, NC, UNITED STATES
Hickey, Anthony, Chapel Hill, NC, UNITED STATES
Bovet, Li Li, Chapel Hill, NC, UNITED STATES
PI US 2004017387 A1 20040129
AI US 2003-382069 A1 20030305 (10)
RLI Continuation-in-part of Ser. No. US 2002-235281, filed on 5 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2002-235284, filed on 5 Sep 2002, PENDING
PRAI US 2001-318193P 20010907 (60)
US 2002-377865P 20020503 (60)
DT Utility
FS APPLICATION
LN.CNT 3722
INCL INCLM: 345/700.000
NCL NCLM: 345/700.000
IC [7]
ICM: G09G005-00

L4 ANSWER 173 OF 469 USPATFULL on STN
AN 2004:21609 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use
IN Wu, Jing, San Mateo, CA, United States

Thorsett, Eugene D., Moss Beach, CA, United States
Pleiss, Michael A., Sunnyvale, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Neitz, R. Jeffrey, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Freedman, Stephen, Walnut Creek, CA, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James A., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Henry, Steven S., New Palastine, IN, United States
McDaniel, Stacey L., Indianapolis, IN, United States
Scott, William Leonard, Indianapolis, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6683075 B1 20040127
AI US 2003-336806 20030106 (10)
RLI Division of Ser. No. US 2001-915564, filed on 27 Jul 2001 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS GRANTED
LN.CNT 19986
INCL INCLM: 514/220.000
INCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/517.000; 540/518.000
NCL NCLM: 514/220.000
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/517.000; 540/518.000
IC [7]
ICM: A61K031-55
ICS: C07D487-04; C07D243-12; C07D243-24; C07D487-00
EXF 540/496; 540/497; 540/498; 540/499; 540/504; 540/517; 540/518; 514/220; 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 174 OF 469 USPATFULL on STN
AN 2004:20717 USPATFULL
TI Rice promoters for regulation of plant expression
IN Budworth, Paul, San Diego, CA, UNITED STATES
Moughamer, Todd, San Diego, CA, UNITED STATES
Briggs, Steven P., Del Mar, CA, UNITED STATES
Cooper, Bret, La Jolla, CA, UNITED STATES
Glazebrook, Jane, San Diego, CA, UNITED STATES
Goff, Stephen Arthur, Encinitas, CA, UNITED STATES
Katagiri, Fumiaki, San Diego, CA, UNITED STATES
Kreps, Joel, Carlsbad, CA, UNITED STATES
Provart, Nicholas, Toronto, CANADA
Ricke, Darrell, San Diego, CA, UNITED STATES
Zhu, Tong, San Diego, CA, UNITED STATES
PI US 2004016025 A1 20040122
AI US 2002-260238 A1 20020926 (10)
PRAI US 2001-325448P 20010926 (60)
US 2001-325277P 20010926 (60)
US 2002-370620P 20020404 (60)
DT Utility
FS APPLICATION
LN.CNT 18818
INCL INCLM: 800/287.000
INCLS: 800/312.000; 800/320.000; 800/320.100; 800/320.200; 800/320.300; 435/419.000; 435/320.100
NCL NCLM: 800/287.000
NCLS: 800/312.000; 800/320.000; 800/320.100; 800/320.200; 800/320.300; 435/419.000; 435/320.100
IC [7]
ICM: A01H005-00
ICS: C12N015-82; C12N005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 175 OF 469 USPATFULL on STN
AN 2004:18798 USPATFULL
TI In vivo production of cyclic peptides for inhibiting protein-protein interaction
IN Lorenz, James B., Bones, NORWAY
Kinsella, Todd M., Redwood City, CA, UNITED STATES
Pray, Todd, San Francisco, CA, UNITED STATES
Bennett, Mark K., Moraga, CA, UNITED STATES
PI US 2004014100 A1 20040122
AI US 2003-422536 A1 20030423 (10)
RLI Continuation of Ser. No. US 2002-232758, filed on 30 Aug 2002, PENDING
Continuation-in-part of Ser. No. US 2001-800770, filed on 6 Mar 2001, PENDING
PRAI US 2000-187130P 20000306 (60)
DT Utility
FS APPLICATION
LN.CNT 4089
INCL INCLM: 435/006.000
INCLS: 435/007.200
NCL NCLM: 435/006.000
NCLS: 435/007.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 176 OF 469 USPATFULL on STN
AN 2004:18738 USPATFULL
TI Cardiotoxin molecular toxicology modeling
IN Mendrick, Donna, Gaithersburg, MD, UNITED STATES
Porter, Mark, Gaithersburg, MD, UNITED STATES
Johnson, Kory, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES
Elashoff, Michael, Gaithersburg, MD, UNITED STATES
PI US 2004014040 A1 20040122
AI US 2002-191803 A1 20020710 (10)
PRAI US 2001-303819P 20010710 (60)
US 2001-305623P 20010717 (60)
US 2002-369351P 20020403 (60)
US 2002-377611P 20020506 (60)
DT Utility
FS APPLICATION
LN.CNT 15812
INCL INCLM: 435/006.000
INCLS: 702/020.000
NCL NCLM: 435/006.000
NCLS: 702/020.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 177 OF 469 USPATFULL on STN
AN 2004:13596 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Guo, Xiaojia, Branford, CT, UNITED STATES
Fernandes, Elma, Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Kekuda, Ramesh, Stamford, CT, UNITED STATES
Liu, Yi, New Haven, CT, UNITED STATES
Leite, Mario, Milford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Boldog, Ference L., North Haven, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Vernet, Corine A. M., Branford, CT, UNITED STATES
Ballinger, Robert A., Newington, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Blalock, Angela D., Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Mezes, Peter D., Old Lyme, CT, UNITED STATES

Heyes, Melvyn, New Haven, CT, UNITED STATES
Herrmann, John L., Guilford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Ioime, Noelle, Hamden, CT, UNITED STATES
Pena, Carol E. A., New Haven, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Gorman, Linda, East Haven, CT, UNITED STATES
PI US 2004010119 A1 20040115
AI US 2002-74978 A1 20020212 (10)
PRAI US 2001-268221P 20010212 (60)
US 2001-268496P 20010213 (60)
US 2001-268665P 20010214 (60)
US 2001-268646P 20010214 (60)
US 2001-269136P 20010215 (60)
US 2001-269310P 20010216 (60)
US 2001-269530P 20010216 (60)
US 2001-276405P 20010315 (60)
US 2001-276703P 20010316 (60)
US 2001-276399P 20010316 (60)
US 2001-278199P 20010323 (60)
US 2001-279274P 20010328 (60)
US 2001-280238P 20010330 (60)
US 2001-280899P 20010402 (60)
US 2001-310797P 20010808 (60)
US 2001-312284P 20010814 (60)
US 2001-322294P 20010914 (60)
US 2001-322295P 20010914 (60)
US 2001-330293P 20011018 (60)
US 2001-335104P 20011031 (60)
US 2001-335109P 20011031 (60)
US 2001-332127P 20011121 (60)
US 2001-331772P 20011121 (60)
DT Utility
FS APPLICATION
LN.CNT 23189
INCL INCLM: 530/350.000
INCLS: 514/012.000; 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 530/350.000
NCLS: 514/012.000; 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; A61K038-17; C07K014-435; C07K014-47; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 178 OF 469 USPATFULL on STN
AN 2004:13496 USPATFULL
TI Aromatic sulfone hydroxamates and their use as protease inhibitors
IN Freskos, John N., Clayton, MO, UNITED STATES
Fobian, Yvette M., Wildwood, MO, UNITED STATES
Barta, Thomas E., Evanston, IL, UNITED STATES
Becker, Daniel P., Glenview, IL, UNITED STATES
Bedell, Louis J., Mt. Prospect, IL, UNITED STATES
Boehm, Terri L., Ballwin, MO, UNITED STATES
Carroll, Jeffery N., Columbia, IL, UNITED STATES
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES
Hockerman, Susan L., Chicago, IL, UNITED STATES
Kassab, Darren J., Wildwood, MO, UNITED STATES
Kolodziej, Steve A., Ballwin, MO, UNITED STATES
McDonald, Joseph, Wildwood, MO, UNITED STATES
Mischke, Deborah A., Defiance, MO, UNITED STATES
Norton, Monica B., St. Louis, MO, UNITED STATES
Rico, Joseph G., Ballwin, MO, UNITED STATES
Talley, John J., Cambridge, MA, UNITED STATES
Villamil, Clara I., Glenview, IL, UNITED STATES
Wang, Lijuan Jane, Wildwood, MO, UNITED STATES
PI US 2004010019 A1 20040115
US 6689794 B2 20040210
AI US 2002-142737 A1 20020510 (10)
PRAI US 2001-290375P 20010511 (60)
DT Utility

LN.CNT 15379
INCL INCLM: 514/346.000
INCLS: 514/424.000; 514/534.000; 514/507.000; 514/575.000; 546/297.000; 548/550.000; 560/041.000; 560/312.000; 562/621.000
NCL NCLM: 514/318.000
NCLS: 514/317.000; 514/321.000; 514/326.000; 514/336.000; 514/364.000; 514/365.000; 514/374.000; 514/376.000; 514/382.000; 514/389.000; 514/392.000; 514/422.000; 514/444.000; 546/187.000; 546/194.000; 546/197.000; 546/207.000; 546/209.000; 546/210.000; 546/211.000; 546/213.000; 546/281.700; 546/282.100; 548/131.000; 548/143.000; 548/204.000; 548/229.000; 548/236.000; 548/253.000; 548/311.100; 548/517.000; 549/060.000
IC [7]
ICM: C07D213-72
ICS: A61K031-215; C07D207-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 179 OF 469 USPATFULL on STN
AN 2004:13385 USPATFULL
TI Proteins and nucleic acids encoding same
IN Alsobrook, John P., II, Madison, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Ballinger, Robert A., Newington, CT, UNITED STATES
Boldog, Ference L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Gilbert, Jennifer A., Madison, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
A. Pena, Carol E., New Haven, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
PI US 2004009907 A1 20040115
AI US 2002-85198 A1 20020225 (10)
PRAI US 2001-271646P 20010226 (60)
US 2001-276401P 20010316 (60)
US 2001-311981P 20010813 (60)
US 2001-312858P 20010816 (60)
US 2001-271840P 20010227 (60)
US 2001-277324P 20010320 (60)
US 2001-286096P 20010424 (60)
US 2001-299695P 20010620 (60)
US 2001-315614P 20010829 (60)
US 2001-272405P 20010228 (60)
US 2001-272410P 20010228 (60)
US 2001-272414P 20010228 (60)
US 2001-278660P 20010320 (60)
US 2001-280234P 20010330 (60)
US 2001-272404P 20010228 (60)
US 2001-280039P 20010330 (60)
US 2001-313280P 20010817 (60)
US 2001-322818P 20010917 (60)
US 2001-273300P 20010302 (60)
US 2001-280818P 20010402 (60)

US 2001-294834P 20010531 (60)
US 2001-299845P 20010621 (60)
US 2001-272922P 20010302 (60)
US 2001-272787P 20010302 (60)
US 2001-285754P 20010423 (60)
US 2001-303242P 20010705 (60)
US 2001-273048P 20010302 (60)
US 2001-283443P 20010412 (60)
US 2001-291703P 20010517 (60)
DT Utility
FS APPLICATION
LN.CNT 46330
INCL INCLM: 514/012.000
INCLS: 530/350.000; 536/023.100; 514/044.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 536/023.100; 514/044.000
IC [7]
ICM: A61K038-16
ICS: A61K031-711; C07K014-435; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 180 OF 469 USPATFULL on STN
AN 2004:13003 USPATFULL
TI Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
IN Shaughnessy, John D., Little Rock, AR, UNITED STATES
Zhan, Fenghuang, Little Rock, AR, UNITED STATES
Barlogie, Bart, Little Rock, AR, UNITED STATES
PI US 2004009523 A1 20040115
AI US 2003-454263 A1 20030604 (10)
RLI Continuation-in-part of Ser. No. US 2003-409004, filed on 8 Apr 2003, PENDING Continuation-in-part of Ser. No. US 2002-289746, filed on 7 Nov 2002, PENDING
PRAI US 2002-403075P 20020813 (60)
US 2001-348238P 20011107 (60)
US 2002-355386P 20020208 (60)
DT Utility
FS APPLICATION
LN.CNT 4510
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 181 OF 469 USPATFULL on STN
AN 2004:12969 USPATFULL
TI Classification of lung carcinomas using gene expression analysis
IN Golub, Todd R., Newton, MA, UNITED STATES
Meyerson, Matthew, Concord, MA, UNITED STATES
Bhattacharjee, Arindam, Andover, MA, UNITED STATES
Staunton, Jane, Cambridge, MA, UNITED STATES
PI US 2004009489 A1 20040115
AI US 2002-259233 A1 20020927 (10)
PRAI US 2001-325962P 20010928 (60)
DT Utility
FS APPLICATION
LN.CNT 4627
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 182 OF 469 USPATFULL on STN
AN 2004:7810 USPATFULL
TI Substituted phenylsulfonamide inhibitors of ***beta*** ***amyloid*** production
IN Kreft, Anthony Frank, Langhorne, PA, UNITED STATES
Cole, Derek Cecil, New City, NY, UNITED STATES
Woller, Kevin Roger, Ayer, MA, UNITED STATES
Stock, Joseph Raymond, Monroe, NY, UNITED STATES
Kutterer, Kristina Martha, Westwood, NJ, UNITED STATES
Kubrak, Dennis Martin, Philadelphia, PA, UNITED STATES
Mann, Charles William, North Wales, PA, UNITED STATES

Casebier, David Scott, Carlisle, MA, UNITED STATES
PA Wyeth, Madison, NJ, UNITED STATES (U.S. corporation)
ArQule Inc., Woburn, MA, UNITED STATES (U.S. corporation)
PI US 2004006050 A1 20040108
AI US 2003-457641 A1 20030609 (10)
PRAI US 2002-387690P 20020611 (60)
DT Utility
FS APPLICATION
LN.CNT 3798
INCL INCLM: 514/150.000
INCLS: 514/602.000; 514/603.000; 514/467.000; 514/364.000; 534/844.000; 548/144.000; 549/430.000; 564/087.000
NCL NCLM: 514/150.000
NCLS: 514/602.000; 514/603.000; 514/467.000; 514/364.000; 534/844.000; 548/144.000; 549/430.000; 564/087.000
IC [7]
ICM: A61K031-655
ICS: A61K031-335; A61K031-18; A61K031-4245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 183 OF 469 USPATFULL on STN
AN 2004:7422 USPATFULL
TI Novel GPCR-like proteins and nucleic acids encoding same
IN Kekuda, Ramesh, Stamford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Ballinger, Robert A., Newington, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Wolenc, Adam R., East Haven, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Smithson, Glennda, Guildford, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
PI US 2004005656 A1 20040108
AI US 2001-981566 A1 20011016 (9)
PRAI US 2000-240704P 20001016 (60)
US 2001-262159P 20010117 (60)
US 2001-263340P 20010122 (60)
US 2001-264118P 20010125 (60)
US 2001-308203P 20010727 (60)
US 2000-243497P 20001026 (60)
US 2000-244542P 20001031 (60)
US 2001-269031P 20010215 (60)
US 2000-245484P 20001103 (60)
US 2000-255017P 20001212 (60)
US 2001-263216P 20010122 (60)
US 2001-268225P 20010212 (60)
DT Utility
FS APPLICATION
LN.CNT 14022
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 184 OF 469 USPATFULL on STN
AN 2004:7342 USPATFULL

IN Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Vernet, Corine A., North Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Edinger, Schlomit, New Haven, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Eisen, Andrew, Rockville, MD, UNITED STATES
Liu, Xiaohong, Lexington, MA, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
PI US 2004005576 A1 20040108
AI US 2002-231913 A1 20020830 (10)
RLI Continuation of Ser. No. US 2001-10680, filed on 6 Dec 2001, PENDING
PRAI US 2000-251660P 20001206 (60)
US 2001-260326P 20010108 (60)
US 2001-318712P 20010912 (60)
US 2000-255029P 20001212 (60)
US 2001-263800P 20010124 (60)
US 2001-286183P 20010424 (60)
US 2001-269942P 20010220 (60)
US 2001-313627P 20010820 (60)
DT Utility
FS APPLICATION
LN.CNT 17887
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 185 OF 469 USPATFULL on STN
AN 2004:7329 USPATFULL
TI Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
IN Mack, David H., Menlo Park, CA, UNITED STATES
Gish, Kurt C., San Francisco, CA, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)
PI US 2004005563 A1 20040108
AI US 2002-173999 A1 20020617 (10)
PRAI US 2002-372246P 20020412 (60)
US 2001-350666P 20011113 (60)
US 2001-315287P 20010827 (60)
US 2001-299234P 20010618 (60)
DT Utility
FS APPLICATION
LN.CNT 32540
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/366.000; 435/183.000; 435/320.100; 435/069.100; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/366.000; 435/183.000; 435/320.100; 435/069.100; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 186 OF 469 USPATFULL on STN
AN 2004:7306 USPATFULL

fusion proteins
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2004005539 A1 20040108
AI US 2002-127028 A1 20020422 (10)
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, ABANDONED Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED, Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409 Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 16057
INCL INCLM: 435/005.000
INCLS: 435/006.000; 435/007.100; 435/069.700; 435/456.000; 435/252.300; 435/320.100; 536/023.720
NCL NCLM: 435/005.000
NCLS: 435/006.000; 435/007.100; 435/069.700; 435/456.000; 435/252.300; 435/320.100; 536/023.720
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; G01N033-53; C07H021-04; C12P021-02; C12N001-21; C12N015-86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 187 OF 469 USPATFULL on STN
AN 2004:2561 USPATFULL
TI Proteins, polynucleotides encoding them and methods of using the same
IN Pena, Carol E. A., New Haven, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Furtak, Katarzyna, Ansonia, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Baumgartner, Jason C., New Haven, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
PI US 2004002584 A1 20040101
AI US 2002-80334 A1 20020221 (10)
PRAI US 2001-270523P 20010221 (60)
US 2001-322712P 20010917 (60)
US 2001-311980P 20010813 (60)
US 2001-330307P 20011018 (60)
US 2001-278796P 20010326 (60)
US 2001-281521P 20010404 (60)
US 2001-276677P 20010316 (60)
US 2001-311595P 20010810 (60)
US 2001-270220P 20010221 (60)
US 2001-274295P 20010308 (60)
US 2001-318526P 20010910 (60)
US 2001-286548P 20010425 (60)
US 2001-291765P 20010517 (60)
US 2001-270797P 20010223 (60)
US 2001-276400P 20010316 (60)

DT Utility
FS APPLICATION
LN.CNT 20544
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K001-00
ICS: C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 188 OF 469 USPATFULL on STN
AN 2004:2113 USPATFULL
TI Novel nucleic acid sequences encoding human KIAA0768 protein-like and human protein PRO228-like polypeptides
IN Shimkets, Richard A., Guilford, CT, UNITED STATES
Fernandes, Elma R., Branford, CT, UNITED STATES
Herrman, John L., Guilford, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
PA CuraGen Corporation, New Haven, CT, 06511 (U.S. corporation)
PI US 2004002134 A1 20040101
AI US 2001-977819 A1 20011015 (9)
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
PRAI US 2000-201388P 20000503 (60)
US 2000-193086P 20000330 (60)
US 2000-191158P 20000322 (60)
US 2000-189810P 20000316 (60)
US 1999-137322P 19990603 (60)
DT Utility
FS APPLICATION
LN.CNT 7136
INCL INCLM: 435/069.100
INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/069.100
NCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: C07H021-04
ICS: C12N009-00; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 189 OF 469 USPATFULL on STN
AN 2003:337233 USPATFULL
TI Mutant genes in Familial British Dementia and Familial Danish Dementia
IN Ghiso, Jorge, Elmhurst, NY, United States
Vidal, Ruben, Great Neck, NY, United States
Frangione, Blas, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 6670195 B1 20031230
AI US 2000-579012 20000526 (9)
PRAI US 1999-136238P 19990526 (60)
DT Utility
FS GRANTED
LN.CNT 2973
INCL INCLM: 436/513.000
INCLS: 530/387.100; 530/387.900; 530/388.100
NCL NCLM: 436/513.000
NCLS: 530/387.100; 530/387.900; 530/388.100
IC [7]
ICM: C07K016-00
ICS: C12P021-08; G01N033-563
EXF 530/387.1; 530/388.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 190 OF 469 USPATFULL on STN
AN 2003:335511 USPATFULL
TI Proteins, polynucleotides encoding them and methods of using the same
IN Shimkets, Richard A., Guilford, CT, UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Ballinger, Robert A., Newington, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES

Casman, Stacie J., North Haven, CT, UNITED STATES
Boldog, Ferenc, North Haven, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
PI US 2003236389 A1 20031225
AI US 2001-23634 A1 20011214 (10)
PRAI US 2000-256025P 20001215 (60)
US 2001-265163P 20010130 (60)
US 2001-272929P 20010302 (60)
US 2001-274864P 20010309 (60)
US 2001-276688P 20010316 (60)
US 2001-277880P 20010322 (60)
US 2001-286409P 20010425 (60)
US 2001-309246P 20010731 (60)
US 2001-315600P 20010829 (60)
DT Utility
FS APPLICATION
LN.CNT 11197
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K001-00
ICS: C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 191 OF 469 USPATFULL on STN
AN 2003:332380 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Pleiss, Michael A., Sunnyvale, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Neitz, R. Jeffrey, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Freedman, Stephen, Walnut Creek, CA, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James A., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Henry, Steven S., New Palestine, IN, United States
McDaniel, Stacey L., Indianapolis, IN, United States
Scott, William Leonard, Indianapolis, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6667305 B1 20031223
AI US 2003-336745 20030106 (10)
RLI Division of Ser. No. US 2002-915379, filed on 27 Jul 2002, now patented, Pat. No. US 6579867 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS GRANTED
LN.CNT 19309
INCL INCLM: 514/220.000
INCLS: 514/221.000
NCL NCLM: 514/220.000
NCLS: 514/221.000

ICM: A61P025-28
EXF 514/220; 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 192 OF 469 USPATFULL on STN
AN 2003:330769 USPATFULL
TI Succinoylamino heterocycles as inhibitors of a beta protein production
IN Thompson, Lorin A., Wilmington, DE, UNITED STATES
Kasireddy, Padmaja, Kennett Square, PA, UNITED STATES
PI US 2003232985 A1 20031218
AI US 2003-409960 A1 20030409 (10)
RLI Continuation of Ser. No. US 2001-823820, filed on 31 Mar 2001, ABANDONED
PRAI US 2000-193490P 20000331 (60)
DT Utility
FS APPLICATION
LN.CNT 3927
INCL INCLM: 544/059.000
INCLS: 544/162.000; 544/399.000; 546/226.000; 548/146.000; 548/215.000; 548/530.000
NCL NCLM: 544/059.000
NCLS: 544/162.000; 544/399.000; 546/226.000; 548/146.000; 548/215.000; 548/530.000
IC [7]
ICM: C07D279-12
ICS: C07D277-08; C07D265-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 193 OF 469 USPATFULL on STN
AN 2003:330153 USPATFULL
TI Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
IN Shaughnessy, John D., Little Rock, AR, UNITED STATES
Barlogie, Bart, Little Rock, AR, UNITED STATES
Zhan, Fenghuang, Little Rock, AR, UNITED STATES
PI US 2003232364 A1 20031218
AI US 2003-409004 A1 20030408 (10)
RLI Continuation-in-part of Ser. No. US 2002-289746, filed on 7 Nov 2002, PENDING
PRAI US 2002-403075P 20020813 (60)
US 2001-348238P 20011107 (60)
US 2002-355386P 20020208 (60)
DT Utility
FS APPLICATION
LN.CNT 4100
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 194 OF 469 USPATFULL on STN
AN 2003:330121 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Padigaru, Muralidhara, Branford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Ballinger, Robert A., Newington, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Sciore, Paul, North Haven, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES

Wolenc, Adam R., New Haven, CT, UNITED STATES
PI US 2003232332 A1 20031218
AI US 2001-24212 A1 20011218 (10)
PRAI US 2000-256635P 20001218 (60)
US 2001-259743P 20010104 (60)
US 2001-299327P 20010619 (60)
US 2001-261498P 20010112 (60)
US 2001-263689P 20010124 (60)
US 2001-267464P 20010208 (60)
US 2001-271021P 20010222 (60)
US 2001-275946P 20010314 (60)
US 2001-278150P 20010323 (60)
US 2001-285718P 20010423 (60)
US 2001-312902P 20010816 (60)
US 2000-257876P 20001221 (60)
US 2001-260718P 20010110 (60)
US 2001-284591P 20010418 (60)
DT Utility
FS APPLICATION
LN.CNT 24320
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 195 OF 469 USPATFULL on STN
AN 2003:327023 USPATFULL
TI Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
IN Ferreira, Sergio Teixeira, Rio de Janeiro, BRAZIL
De Felice, Fernanda Guarino, Rio de Janeiro, BRAZIL
Louzada, Jr., Paulo Roberto Ferreira, Rio de Janeiro, BRAZIL
PA Universidade Federal do Rio de Janeiro, BRAZIL (non-U.S. corporation)
PI US 6664297 B1 20031216
AI US 2000-692743 20001018 (9)
DT Utility
FS GRANTED
LN.CNT 723
INCL INCLM: 514/728.000
INCLS: 514/724.000; 514/727.000; 514/731.000; 514/742.000
NCL NCLM: 514/728.000
NCLS: 514/724.000; 514/727.000; 514/731.000; 514/742.000
IC [7]
ICM: A61K031-045
ICS: A61K031-04; A01N033-18; A01N033-24; A01N031-08
EXF 514/728; 514/724; 514/727; 514/731; 514/742
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 196 OF 469 USPATFULL on STN
AN 2003:325922 USPATFULL
TI Transgenic non-human mammals with progressive neurologic disease
IN Hsiao, Karen, North Oaks, MN, UNITED STATES
Borchelt, David R., Baltimore, MD, UNITED STATES
Sisodia, Sangram S., Baltimore, MD, UNITED STATES
PA John Hopkins University, a Maryland corporation (U.S. corporation)
Regents of the University of Minnesota, a Minnesota corporation (U.S. corporation)
PI US 2003229907 A1 20031211
AI US 2002-271314 A1 20021015 (10)
RLI Continuation of Ser. No. US 1999-260897, filed on 2 Mar 1999, GRANTED, Pat. No. US 6509515 Continuation of Ser. No. US 1996-664872, filed on 17 Jun 1996, GRANTED, Pat. No. US 5877399 Continuation-in-part of Ser. No. US 1996-644691, filed on 10 May 1996, ABANDONED Continuation of Ser. No. US 1994-189064, filed on 27 Jan 1994, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2716
INCL INCLM: 800/012.000
INCLS: 800/018.000
NCL NCLM: 800/012.000
NCLS: 800/018.000

ICM: A01K067-027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 197 OF 469 USPATFULL on STN
AN 2003:325042 USPATFULL
TI Methods and compounds for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis
IN Audia, James E., Indianapolis, IN, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Folmer, Beverly K., Newark, DE, UNITED STATES
Huffman, George W., Carmel, IN, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Wu, Jing, San Mateo, CA, UNITED STATES
Eid, Clark Norman, Cheshire, CT, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
PI US 2003229024 A1 20031211
AI US 2002-309569 A1 20021203 (10)
RLI Continuation of Ser. No. US 2001-789487, filed on 20 Feb 2001, PENDING
Continuation of Ser. No. US 1997-976289, filed on 21 Nov 1997, GRANTED, Pat. No. US 6191166
PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-108161P 19970228 (60)
US 1997-98558P 19970228 (60)
DT Utility
FS APPLICATION
LN.CNT 14968
INCL INCLM: 514/017.000
INCLS: 514/018.000; 514/019.000; 530/328.000; 530/329.000; 530/330.000; 530/331.000
NCL NCLM: 514/017.000
NCLS: 514/018.000; 514/019.000; 530/328.000; 530/329.000; 530/330.000; 530/331.000
IC [7]
ICM: A61K038-08
ICS: A61K038-06; A61K038-05; C07K007-08; C07K007-06; C07K005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 198 OF 469 USPATFULL on STN
AN 2003:324595 USPATFULL
TI Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
IN Yat Wah Tom, Edward, Sacramento, CA, UNITED STATES
Zlotnik, Albert, Palo Alto, CA, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)
PI US 2003228570 A1 20031211
AI US 2003-366435 A1 20030212 (10)
RLI Continuation of Ser. No. US 2002-206473, filed on 24 Jul 2002, ABANDONED
PRAI US 2002-366782P 20020321 (60)
US 2001-308188P 20010726 (60)
DT Utility
FS APPLICATION
LN.CNT 22742
INCL INCLM: 435/005.000
INCLS: 435/006.000; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 530/388.300; 536/023.720
NCL NCLM: 435/005.000
NCLS: 435/006.000; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 530/388.300; 536/023.720
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; C07H021-04; C07K014-02; C07K016-08; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 199 OF 469 USPATFULL on STN
AN 2003:324327 USPATFULL

the same
N Li, Li, Branford, CT, UNITED STATES
Furtak, Katarzyna, Ansonia, CT, UNITED STATES
Perna, Amanda, Hamden, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Guo, Xiaojia Sasha, Branford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Vernet, Corine A., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Agee, Michele, Wallingford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Edinger, Schlomit R., New Haven, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
I US 2003228301 A1 20031211
I US 2001-4378 A1 20011024 (10)
RAI US 2000-242882P 20001024 (60)
US 2000-242765P 20001024 (60)
US 2001-300206P 20010622 (60)
US 2000-242789P 20001024 (60)
US 2000-242768P 20001024 (60)
US 2000-242767P 20001024 (60)
US 2000-243622P 20001026 (60)
US 2001-273047P 20010302 (60)
US 2000-243591P 20001026 (60)
US 2000-243950P 20001027 (60)
US 2001-316509P 20010831 (60)
US 2000-243593P 20001026 (60)
US 2000-243502P 20001026 (60)
T Utility
S APPLICATION
N.CNT 10092
NCL INCLM: 424/130.100
INCLS: 435/006.000; 435/183.000; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200
CL NCLM: 424/130.100
NCLS: 435/006.000; 435/183.000; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.200
C [7]
ICM: C12Q001-68
ICS: C07H021-04; A61K039-395; C12P021-02; C12N005-06; C07K014-47; C07K016-40
AS INDEXING IS AVAILABLE FOR THIS PATENT.

4 ANSWER 200 OF 469 USPATFULL on STN
N 2003:324302 USPATFULL
I Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
N Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES
Price, Christopher H., Chapel Hill, NC, UNITED STATES
Ansari, Aslam M., Rockville, MD, UNITED STATES
Odenbaugh, Amy L., Morrisville, NC, UNITED STATES
PI US 2003228275 A1 20031211
AI US 2001-873797 A1 20010604 (9)
PT Utility
S APPLICATION
LN.CNT 6027
NCL INCLM: 424/078.380
CL NCLM: 424/078.380
C [7]
ICM: A61K038-00
ICS: A61K031-765

L4 ANSWER 201 OF 469 USPATFULL on STN
AN 2003:319260 USPATFULL
TI 28 human secreted proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Zeng, ZhiZhen, Landsdale, PA, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES
Li, Haodong, Gaithersburg, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Hastings, Gregg A., Westlake Village, CA, UNITED STATES
PI US 2003225009 A1 20031204
AI US 2002-58993 A1 20020130 (10)
RLI Continuation-in-part of Ser. No. US 2001-852659, filed on 11 May 2001, PENDING Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998, GRANTED, Pat. No. US 6448230 Continuation-in-part of Ser. No. US 2001-852797, filed on 11 May 2001, PENDING Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998, GRANTED, Pat. No. US 6448230 Continuation-in-part of Ser. No. US 2001-853161, filed on 11 May 2001, PENDING Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998, GRANTED, Pat. No. US 6448230 Continuation-in-part of Ser. No. WO 1998-US4858, filed on 12 Mar 1998, PENDING
PRAI US 2001-265583P 20010202 (60)
US 2001-265583P 20010202 (60)
US 2001-265583P 20010202 (60)
US 2001-265583P 20010202 (60)
US 1997-40762P 19970314 (60)
US 1997-40710P 19970314 (60)
US 1997-50934P 19970530 (60)
US 1997-48100P 19970530 (60)
US 1997-48357P 19970530 (60)
US 1997-48189P 19970530 (60)
US 1997-57765P 19970905 (60)
US 1997-48970P 19970606 (60)
US 1997-68368P 19971219 (60)
DT Utility
FS APPLICATION
LN.CNT 29452
INCL INCLM: 514/044.000
INCLS: 435/069.100; 435/183.000; 435/455.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 514/044.000
NCLS: 435/069.100; 435/183.000; 435/455.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: A61K048-00
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 202 OF 469 USPATFULL on STN
AN 2003:319258 USPATFULL
TI Sulfonamide derivatives of 3-substituted imidazol[1,2-d]-1,2,4-thiadiazoles and 3-substituted-[1,2,4] thiadiazolo[4,5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases
IN Tam, Tim Fat, Woodbridge, CANADA
Karimian, Khashayar, Toronto, CANADA
Leung-Toung, Regis C.S.H., Mississauga, CANADA
Zhao, Yanqing, Toronto, CANADA
Wodzinska, Jolanta Maria, Brampton, CANADA
Li, Wanren, Toronto, CANADA
Lowrie, Jayme Nicole, North York, CANADA
PA Apotex Inc. (non-U.S. corporation)
PI US 2003225007 A1 20031204
AI US 2003-397314 A1 20030327 (10)
PRAI CA 2002-2379375 20020328
DT Utility
FS APPLICATION

INCL INCLM: 514/042.000
INCLS: 514/254.030; 514/364.000; 536/018.700; 544/368.000; 548/126.000
NCL NCLM: 514/042.000
NCLS: 514/254.030; 514/364.000; 536/018.700; 544/368.000; 548/126.000
IC [7]
ICM: A61K031-7052
ICS: A61K031-496; A61K031-433; C07D498-02; C07H005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 203 OF 469 USPATFULL on STN
AN 2003:312777 USPATFULL
TI Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
IN Barta, Nancy Sue, Brighton, MI, UNITED STATES
Bigge, Christopher Franklin, Ann Arbor, MI, UNITED STATES
PI US 2003220382 A1 20031127
AI US 2002-275351 A1 20021104 (10)
WO 2001-US13254 20010425
DT Utility
FS APPLICATION
LN.CNT 1171
INCL INCLM: 514/381.000
INCLS: 514/524.000; 514/657.000; 548/254.000; 558/418.000; 564/428.000; 514/567.000; 562/435.000
NCL NCLM: 514/381.000
NCLS: 514/524.000; 514/657.000; 548/254.000; 558/418.000; 564/428.000; 514/567.000; 562/435.000
IC [7]
ICM: A61K031-41
ICS: A61K031-277; A61K031-195; A61K031-135; C07D257-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 204 OF 469 USPATFULL on STN
AN 2003:312289 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2003219886 A1 20031127
AI US 2001-896095 A1 20010629 (9)
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED, Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409 Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 15529
INCL INCLM: 435/184.000
INCLS: 435/007.100
NCL NCLM: 435/184.000
NCLS: 435/007.100
IC [7]
ICM: C12N009-99
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 205 OF 469 USPATFULL on STN
AN 2003:312125 USPATFULL
TI Fusion proteins, modified filamentous bacteriophage, and populations or libraries of same
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2003219722 A1 20031127
AI US 2002-126685 A1 20020422 (10)

Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, GRANTED, Pat. No. US 5837500 Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, GRANTED, Pat. No. US 5403484 Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, GRANTED, Pat. No. US 5223409 Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 16459
INCL INCLM: 435/005.000
INCLS: 435/069.700; 435/320.100; 435/252.300; 530/350.000; 536/023.720
NCL NCLM: 435/005.000
NCLS: 435/069.700; 435/320.100; 435/252.300; 530/350.000; 536/023.720
IC [7]
ICM: C07K014-01
ICS: C12Q001-70; C07H021-04; C12P021-04; C12N001-21; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 206 OF 469 USPATFULL on STN
AN 2003:309076 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Pleiss, Michael A., Sunnyvale, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Neitz, R. Jeffrey, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Freedman, Stephen, Walnut Creek, CA, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James A., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Henry, Steven S., New Palestine, IN, United States
McDaniel, Stacey L., Indianapolis, IN, United States
Scott, William Leonard, Indianapolis, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6653303 B1 20031125
AI US 2003-336824 20030106 (10)
RLI Division of Ser. No. US 2001-915480, filed on 27 Jul 2001, now patented, Pat. No. US 6544978 Division of Ser. No. US 1997-996422, filed on 22 Dec 1997
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS GRANTED
LN.CNT 19893
INCL INCLM: 514/220.000
INCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/513.000; 540/518.000
NCL NCLM: 514/220.000
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/513.000; 540/518.000
IC [7]
ICM: A61K031-55
ICS: C07D487-00; C07D491-00; C07D487-04; C07D243-12
EXF 514/220; 514/221; 540/496; 540/497; 540/498; 540/499; 540/504; 540/513; 540/518
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 207 OF 469 USPATFULL on STN
AN 2003:306962 USPATFULL
TI Soluble ***beta*** ***amyloid*** precursor protein secretion

IN Kakihana, Mitsuru, Kobe-shi, JAPAN
Kato, Kaneyoshi, Kawanishi-shi, JAPAN
Mori, Masaaki, Tsukuba-shi, JAPAN
Yamashita, Toshiro, Tsukuba-shi, JAPAN
PI US 2003216398 A1 20031120
AI US 2002-240996 A1 20021004 (10)
WO 2001-JP2961 20010405
DT Utility
FS APPLICATION
LN.CNT 4140
INCL INCLM: 514/249.000
INCLS: 514/312.000; 514/313.000
NCL NCLM: 514/249.000
NCLS: 514/312.000; 514/313.000
IC [7]
ICM: A61K031-47
ICS: A61K031-498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 208 OF 469 USPATFULL on STN
AN 2003:305989 USPATFULL
TI Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
IN McDonald, John R., Baie D'Urfe, CANADA
Coggins, Philip J., Pointe Claire, CANADA
PI US 2003215421 A1 20031120
AI US 2003-375209 A1 20030224 (10)
RLI Continuation of Ser. No. US 2001-792793, filed on 22 Feb 2001, PENDING
Continuation of Ser. No. US 1999-453851, filed on 2 Dec 1999, PENDING
Continuation of Ser. No. US 1999-360242, filed on 22 Jul 1999, PENDING
Continuation-in-part of Ser. No. WO 1999-CA659, filed on 21 Jul 1999, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 8058
INCL INCLM: 424/085.100
INCLS: 424/143.100; 530/351.000; 530/388.220; 435/069.500; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 424/085.100
NCLS: 424/143.100; 530/351.000; 530/388.220; 435/069.500; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: A61K038-19
ICS: C07H021-04; C12P021-02; A61K039-395; C12N005-06; C07K014-52; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 209 OF 469 USPATFULL on STN
AN 2003:294415 USPATFULL
TI Human enzyme molecules
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Lu, Dyung Aina M., San Jose, CA, UNITED STATES
Bandman, Olga, Mountain View, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Azimzai, Yalda, Castro Valley, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Lal, Preeti, Santa Clara, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
PI US 2003207430 A1 20031106
AI US 2002-220381 A1 20020828 (10)
WO 2001-US6806 20010301
DT Utility
FS APPLICATION
LN.CNT 8111
INCL INCLM: 435/183.000
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 530/388.260; 536/023.200; 800/008.000
NCL NCLM: 435/183.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 530/388.260; 536/023.200; 800/008.000
IC [7]
ICM: C12Q001-68
ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 210 OF 469 USPATFULL on STN
AN 2003:285158 USPATFULL
TI Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
IN Bush, Ashley I., Somerville, MA, United States
Huang, Xudong, Andover, MA, United States
Atwood, Craig S., Brecksville, OH, United States
Tanzi, Rudolph E., Hull, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 6638711 B1 20031028
AI US 2000-560883 20000428 (9)
RLI Continuation-in-part of Ser. No. US 380704
PRAI US 1999-131579P 19990429 (60)
DT Utility
FS GRANTED
LN.CNT 2783
INCL INCLM: 435/004.000
INCLS: 436/080.000; 436/084.000; 436/127.000; 530/350.000
NCL NCLM: 435/004.000
NCLS: 436/080.000; 436/084.000; 436/127.000; 530/350.000
IC [7]
ICM: C12Q001-00
ICS: G01N033-48; G01N033-20; C07K002-00
EXF 435/7.1; 435/7.7; 435/7.8; 435/7.9; 435/27; 435/4; 435/7.92; 436/501; 436/504; 436/904; 436/63; 436/80; 436/84; 514/2; 530/300; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 211 OF 469 USPATFULL on STN
AN 2003:282760 USPATFULL
TI Novel amino acid sequences for human epidermal growth factor-like polypeptides
IN Shimkets, Richard A., West Haven, CT, UNITED STATES
Fernandes, Elma, Branford, CT, UNITED STATES
Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
PA CuraGen Corporation, New Haven, CT, UNITED STATES, 06511 (U.S. corporation)
PI US 2003199103 A1 20031023
AI US 2001-977639 A1 20011015 (9)
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
PRAI US 2000-201388P 20000503 (60)
US 2000-193086P 20000330 (60)
US 2000-191158P 20000322 (60)
US 2000-189810P 20000316 (60)
US 1999-137322P 19990603 (60)
DT Utility
FS APPLICATION
LN.CNT 10459
INCL INCLM: 436/518.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 436/518.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-485
ICS: C07H021-04; C12P021-02; C12N005-06; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 212 OF 469 USPATFULL on STN
AN 2003:282627 USPATFULL
TI Genostics
IN Roberts, Gareth Wyn, Cambs, UNITED KINGDOM
PA GENOSTIC PHARMA LIMITED (non-U.S. corporation)
PI US 2003198970 A1 20031023
AI US 2002-206568 A1 20020729 (10)
RLI Continuation of Ser. No. US 1999-325123, filed on 3 Jun 1999, ABANDONED
PRAI GB 1998-12098 19980606
GB 1998-28289 19981223
DT Utility
FS APPLICATION
LN.CNT 4299
INCL INCLM: 435/006.000
INCLS: 536/024.300
NCL NCLM: 435/006.000

IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 213 OF 469 USPATFULL on STN
AN 2003:282611 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003198954 A1 20031023
AI US 2001-1142 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25681
INCL INCLM: 435/006.000
INCLS: 536/023.200
NCL NCLM: 435/006.000
NCLS: 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 214 OF 469 USPATFULL on STN
AN 2003:279188 USPATFULL
TI PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
IN Jackson, Paul F., Bel Air, MD, United States
Li, Jia-He, Cockeysville, MD, United States
Maclin, Keith M., Baltimore, MD, United States
Zhang, Jie, Ellicott City, MD, United States
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6635642 B1 20031021
AI US 1998-145176 19980901 (9)
RLI Continuation-in-part of Ser. No. US 1998-79512, filed on 15 May 1998, now abandoned Continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997, now abandoned Continuation-in-part of Ser. No. US 1997-922548, filed on 3 Sep 1997, now patented, Pat. No. US 6174893, issued on 16 Jan 2001
DT Utility
FS GRANTED
LN.CNT 2769
INCL INCLM: 514/248.000
INCLS: 514/247.000; 544/224.000; 544/233.000; 544/235.000
NCL NCLM: 514/248.000
NCLS: 514/247.000; 544/224.000; 544/233.000; 544/235.000
IC [7]
ICM: A61K031-50
ICS: C07D237-26
EXF 514/247; 514/248; 514/261; 514/439; 514/464; 514/465; 514/617; 514/379; 544/224; 544/264; 544/233; 544/235; 549/441; 564/63; 564/164; 564/166; 564/183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 215 OF 469 USPATFULL on STN
AN 2003:279186 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Pleiss, Michael A., Sunnyvale, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Neitz, R. Jeffrey, San Francisco, CA, United States

John, Varghese, San Francisco, CA, United States
Freedman, Stephen, Walnut Creek, CA, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James A., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Henry, Steven S., New Palestine, IN, United States
McDaniel, Stacey L., Indianapolis, IN, United States
Scott, William Leonard, Indianapolis, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6635632 B1 20031021
AI US 1997-996422 19971222 (8)
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS GRANTED
LN.CNT 22179
INCL INCLM: 514/212.030
INCLS: 514/212.040; 514/212.070; 514/212.080
NCL NCLM: 514/212.030
NCLS: 514/212.040; 514/212.070; 514/212.080
IC [7]
ICM: A61K031-55
ICS: A61P025-28
EXF 514/212.03; 514/212.04; 514/212.07; 514/212.08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 216 OF 469 USPATFULL on STN
AN 2003:279120 USPATFULL
TI Compound and methods of inhibiting or stimulating presenilin 1 and related pharmaceuticals and diagnostic agents
IN Telerman, Adam, Paris, FRANCE
Amson, Robert, Paris, FRANCE
PA Societe Molecular Engines Laboratories, Paris, FRANCE (non-U.S. corporation)
PI US 6635483 B1 20031021
AI US 1999-382396 19990825 (9)
RLI Continuation of Ser. No. WO 1998-FR1387, filed on 29 Jun 1998
PRAI FR 1997-11450 19970915
DT Utility
FS GRANTED
LN.CNT 1190
INCL INCLM: 435/458.000
INCLS: 435/006.000; 435/091.100; 435/455.000; 435/458.000; 536/023.100; 536/024.500
NCL NCLM: 435/458.000
NCLS: 435/006.000; 435/091.100; 435/455.000; 536/023.100; 536/024.500
IC [7]
ICM: C12N015-88
ICS: C12Q001-68; C12P019-34; C07H021-02; C07H021-04
EXF 435/6; 435/91.1; 435/455; 435/375; 536/23.1; 536/24.3; 536/24.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 217 OF 469 USPATFULL on STN
AN 2003:277229 USPATFULL
TI Inhibitors of nitric oxide synthase
IN Singh, Inderjit, Mount Pleasant, SC, UNITED STATES
PA MUSC Foundation for Research Development (U.S. corporation)
PI US 2003195256 A1 20031016
AI US 2002-273557 A1 20021018 (10)
RLI Division of Ser. No. US 2000-579791, filed on 25 May 2000, GRANTED, Pat. No. US 6511800 Continuation of Ser. No. WO 1998-US25360, filed on 25 Nov 1998, PENDING
PRAI US 1997-66839P 19971125 (60)
DT Utility
FS APPLICATION
LN.CNT 7728
INCL INCLM: 514/570.000
NCL NCLM: 514/570.000

ICM: A61K031-192
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 218 OF 469 USPATFULL on STN
AN 2003:257841 USPATFULL
TI Interleukin-20
IN Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Murphy, Marianne, London, UNITED KINGDOM
Ruben, Steven M., Brookeville, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Duan, D. Roxanne, Bethesda, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2003180892 A1 20030925
AI US 2002-277726 A1 20021023 (10)
RLI Division of Ser. No. US 1999-231788, filed on 15 Jan 1999, GRANTED, Pat. No. US 6486301 Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998, PENDING
PRAI US 1997-60140P 19970926 (60)
US 1997-55952P 19970818 (60)
US 1997-52870P 19970716 (60)
US 1997-60140P 19970926 (60)
US 1997-55952P 19970818 (60)
US 1997-52870P 19970716 (60)
DT Utility
FS APPLICATION
LN.CNT 5982
INCL INCLM: 435/069.520
INCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500
NCL NCLM: 435/069.520
NCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500
IC [7]
ICM: C07K014-54
ICS: C07H021-04; C12P021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 219 OF 469 USPATFULL on STN
AN 2003:251659 USPATFULL
TI Mitochondria protecting agents for treating mitochondria associated diseases
IN Ghosh, Soumitra S., San Diego, CA, UNITED STATES
Miller, Scott W., San Marcos, CA, UNITED STATES
Davis, Robert E., San Diego, CA, UNITED STATES
Moos, Walter H., Oakland, CA, UNITED STATES
PA MitoKor, San Diego, CA, UNITED STATES, 92121 (U.S. corporation)
PI US 2003176448 A1 20030918
AI US 2002-233051 A1 20020830 (10)
RLI Division of Ser. No. US 2000-733271, filed on 7 Dec 2000, GRANTED, Pat. No. US 6498191 Continuation of Ser. No. US 1999-237999, filed on 26 Jan 1999, ABANDONED
PRAI US 1998-72484P 19980126 (60)
US 1998-72487P 19980126 (60)
US 1998-72483P 19980126 (60)
US 1998-72482P 19980126 (60)
DT Utility
FS APPLICATION
LN.CNT 1700
INCL INCLM: 514/256.000
INCLS: 514/396.000; 514/397.000; 514/456.000; 514/533.000; 514/534.000; 514/544.000; 514/634.000; 514/406.000; 514/161.000
NCL NCLM: 514/256.000
NCLS: 514/396.000; 514/397.000; 514/456.000; 514/533.000; 514/534.000; 514/544.000; 514/634.000; 514/406.000; 514/161.000
IC [7]
ICM: A61K031-505
ICS: A61K031-4178; A61K031-4172; A61K031-416; A61K031-415; A61K031-35; A61K031-353; A61K031-192; A61K031-155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 220 OF 469 USPATFULL on STN
AN 2003:250985 USPATFULL
TI Human Transcriptomes

Vogelstein, Bert, Baltimore, MD, UNITED STATES
Kinzler, Kenneth W., BelAir, MD, UNITED STATES
PA The Johns Hopkins University, Baltimore, MD (U.S. corporation)
PI US 2003175771 A1 20030918
AI US 2002-330627 A1 20021230 (10)
RLI Continuation of Ser. No. US 1999-448480, filed on 24 Nov 1999, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 8656
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 221 OF 469 USPATFULL on STN
AN 2003:250967 USPATFULL
TI Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
IN Shaughnessy, John D., Little Rock, AR, UNITED STATES
Barlogie, Bart, Little Rock, AR, UNITED STATES
Zhan, Fenghaung, Little Rock, AR, UNITED STATES
PI US 2003175753 A1 20030918
AI US 2002-289746 A1 20021107 (10)
PRAI US 2002-403075P 20020813 (60)
US 2002-355386P 20020208 (60)
US 2001-348238P 20011107 (60)
DT Utility
FS APPLICATION
LN.CNT 3686
INCL INCLM: 435/006.000
INCLS: 702/020.000
NCL NCLM: 435/006.000
NCLS: 702/020.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 222 OF 469 USPATFULL on STN
AN 2003:244905 USPATFULL
TI Human chemokine beta-10 mutant polypeptides
IN Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Li, Haodong, Gaithersburg, MD, UNITED STATES
Adams, Mark D., Rockville, MD, UNITED STATES
Gentz, Solange H.L., Belo Horizonte, BRAZIL
Alderson, Ralph, Gaithersburg, MD, UNITED STATES
Li, Yuling, Germantown, MD, UNITED STATES
Parmelee, David, Rockville, MD, UNITED STATES
White, John R., Coatesville, PA, UNITED STATES
Appelbaum, Edward R., Blue Bell, PA, UNITED STATES
Salcedo, Theodora, East Syracuse, NY, UNITED STATES
PI US 2003171319 A1 20030911
AI US 2002-263139 A1 20021003 (10)
RLI Continuation-in-part of Ser. No. US 2002-125451, filed on 19 Apr 2002, PENDING Continuation-in-part of Ser. No. WO 2001-US18046, filed on 5 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-261201, filed on 3 Mar 1999, GRANTED, Pat. No. US 6458349 Continuation-in-part of Ser. No. US 1996-613822, filed on 23 Feb 1996, GRANTED, Pat. No. US 6174995 Continuation-in-part of Ser. No. US 1995-458355, filed on 2 Jun 1995, GRANTED, Pat. No. US 5981230 Continuation-in-part of Ser. No. WO 1994-US9484, filed on 23 Aug 1994, PENDING Continuation-in-part of Ser. No. WO 1994-US9484, filed on 23 Aug 1994, PENDING
PRAI US 2000-209578P 20000606 (60)
US 1999-115439P 19990108 (60)
DT Utility
FS APPLICATION
LN.CNT 13207
INCL INCLM: 514/044.000
INCLS: 424/085.100; 435/069.500; 435/320.100; 435/325.000; 530/351.000; 536/023.500; 435/006.000; 435/007.100
NCL NCLM: 514/044.000
NCLS: 424/085.100; 435/069.500; 435/320.100; 435/325.000; 530/351.000; 536/023.500; 435/006.000; 435/007.100
IC [7]

ICS: A61K038-19; C12Q001-68; G01N033-53; C07H021-04; C12P021-02; C12N005-06; C07K014-52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 223 OF 469 USPATFULL on STN
AN 2003:244221 USPATFULL
TI Proteins and nucleic acids encoding same
IN Alsobrook, John P., II, Madison, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Liu, Xiaohong, Canton, MA, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Szekeres, Edward S., JR., Branford, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Boldog, Ference L., North Haven, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Fernandes, Elma R., Branford, CT, UNITED STATES
Rieger, Danier K., Branford, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Sciore, Paul, North Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
PI US 2003170630 A1 20030911
AI US 2001-32189 A1 20011221 (10)
PRAI US 2000-257495P 20001221 (60)
US 2000-258171P 20001222 (60)
US 2001-269940P 20010220 (60)
US 2001-274192P 20010308 (60)
US 2001-277826P 20010322 (60)
US 2001-279840P 20010329 (60)
US 2001-282981P 20010411 (60)
US 2001-283656P 20010413 (60)
US 2001-309247P 20010731 (60)
US 2001-311754P 20010810 (60)
US 2001-313331P 20010817 (60)
DT Utility
FS APPLICATION
LN.CNT 16767
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 224 OF 469 USPATFULL on STN
AN 2003:244219 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003170628 A1 20030911
AI US 2001-999570 A1 20011114 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25549

INCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 225 OF 469 USPATFULL on STN
AN 2003:243794 USPATFULL
TI Death domain containing receptors
IN Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Gentz, Reiner L., Belo Horizonte, BRAZIL
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2003170203 A1 20030911
AI US 2002-189189 A1 20020705 (10)
RLI Continuation-in-part of Ser. No. US 2000-557908, filed on 21 Apr 2000, PENDING Continuation-in-part of Ser. No. US 1997-815469, filed on 11 Mar 1997, GRANTED, Pat. No. US 6153402
PRAI US 2001-314314P 20010824 (60)
US 2001-303155P 20010706 (60)
US 1999-136741P 19990528 (60)
US 1999-130488P 19990422 (60)
US 1997-37341P 19970206 (60)
US 1996-28711P 19961017 (60)
US 1996-13285P 19960312 (60)
DT Utility
FS APPLICATION
LN.CNT 9858
INCL INCLM: 424/085.100
INCLS: 424/145.100; 514/210.090; 514/011.000
NCL NCLM: 424/085.100
NCLS: 424/145.100; 514/210.090; 514/011.000
IC [7]
ICM: A61K039-395
ICS: A61K031-407; A61K038-19; A61K038-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 226 OF 469 USPATFULL on STN
AN 2003:240440 USPATFULL
TI Cysteinyl protease inhibitors
IN Munoz, Benito, 10741 Frank Daniels Rd., San Diego, CA, United States 92131
Srinivasan, Kuman, 7693 Palmilla Dr., Apt. #2116, San Diego, CA, United States 92122
Wang, Bowei, 7825 Roan Rd., San Diego, CA, United States 92129
PI US 6617426 B1 20030909
AI US 1999-338409 19990622 (9)
DT Utility
FS GRANTED
LN.CNT 2060
INCL INCLM: 530/331.000
INCLS: 514/018.000; 514/019.000
NCL NCLM: 530/331.000
IC [7]
ICM: C07K005-08
EXF 530/331; 514/18; 514/19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 227 OF 469 USPATFULL on STN
AN 2003:238482 USPATFULL
TI Reverse-turn mimetics and methods relating thereto
IN Urban, Jan, Kirkland, WA, UNITED STATES
Nakanishi, Hiroshi, Newcastle, WA, UNITED STATES
Lee, Min S., Sammamish, WA, UNITED STATES
PA Molecumetics, Ltd., Bellevue, WA (U.S. corporation)
PI US 2003166640 A1 20030904
AI US 2002-150481 A1 20020516 (10)
PRAI US 2001-291663P 20010516 (60)
DT Utility
FS APPLICATION

INCL INCLM: 514/224.200
INCLS: 514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000; 544/095.000; 544/014.000; 544/350.000; 544/345.000
NCL NCLM: 514/224.200
NCLS: 514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000; 544/095.000; 544/014.000; 544/350.000; 544/345.000
IC [7]
ICM: G01N033-53
ICS: C07D498-04; C07D487-04; A61K031-542; A61K031-5383; A61K031-498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 228 OF 469 USPATFULL on STN
AN 2003:238478 USPATFULL
TI Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production
IN Olson, Richard E., Wilmington, DE, UNITED STATES
Liu, Hong, Glen Mills, PA, UNITED STATES
Thompson, Lorin A., Wilmington, DE, UNITED STATES
PI US 2003166636 A1 20030904
AI US 2002-287117 A1 20021104 (10)
RLI Division of Ser. No. US 2001-805645, filed on 14 Mar 2001, GRANTED, Pat. No. US 6503902 Continuation-in-part of Ser. No. US 2000-661008, filed on 13 Sep 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 6969
INCL INCLM: 514/212.080
INCLS: 514/183.000; 514/326.000; 514/327.000; 514/227.800; 514/235.500; 514/253.120; 540/524.000; 544/060.000; 544/360.000; 544/130.000; 546/207.000
NCL NCLM: 514/212.080
NCLS: 514/183.000; 514/326.000; 514/327.000; 514/227.800; 514/235.500; 514/253.120; 540/524.000; 544/060.000; 544/360.000; 544/130.000; 546/207.000
IC [7]
ICM: A61K031-55
ICS: A61K031-541; A61K031-5377; A61K031-496; A61K031-4545; A61K031-454; C07D417-02; C07D413-02; C07D043-02; C07D041-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 229 OF 469 USPATFULL on STN
AN 2003:238432 USPATFULL
TI Microsomal triglyceride transfer protein
IN Wetterau, John R., II, Langhorne, PA, UNITED STATES
Sharp, Daru Young, Perrineville, NJ, UNITED STATES
Gregg, Richard E., Pennington, NJ, UNITED STATES
Biller, Scott A., Ewing, NJ, UNITED STATES
Dickson, John K., Mount Holly, NJ, UNITED STATES
Lawrence, R. Michael, Yardley, PA, UNITED STATES
Lawson, John E., Wallingford, CT, UNITED STATES
Holava, Henry M., Meriden, CT, UNITED STATES
Partyka, Richard A., Neshanic, NJ, UNITED STATES
PI US 2003166590 A1 20030904
AI US 2001-933593 A1 20010821 (9)
RLI Division of Ser. No. US 1995-486929, filed on 7 Jun 1995, PENDING Division of Ser. No. US 1993-117362, filed on 3 Sep 1993, GRANTED, Pat. No. US 5595872 Continuation-in-part of Ser. No. US 1993-15449, filed on 22 Feb 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-847503, filed on 6 Mar 1992, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4843
INCL INCLM: 514/044.000
INCLS: 536/023.200
NCL NCLM: 514/044.000
NCLS: 536/023.200
IC [7]
ICM: A61K048-00
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 230 OF 469 USPATFULL on STN
AN 2003:237862 USPATFULL
TI Monoclonal ***antibody***
IN Wiltfang, Jens, Eddigehausen, GERMANY, FEDERAL REPUBLIC OF

Monning, Ursula, Berlin, GERMANY, FEDERAL REPUBLIC OF
PI US 2003166019 A1 20030904
AI US 2002-170272 A1 20020611 (10)
PRAI EP 2001-114192 20010612
DT Utility
FS APPLICATION
LN.CNT 3683
INCL INCLM: 435/007.210
INCLS: 530/388.260
NCL NCLM: 435/007.210
NCLS: 530/388.260
IC [7]
ICM: G01N033-567
ICS: C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 231 OF 469 USPATFULL on STN
AN 2003:237706 USPATFULL
TI NARC10 and NARC16, programmed cell death-associated molecules and uses thereof
IN Chiang, Lillian Wei-Ming, Edison, NJ, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003165863 A1 20030904
AI US 2002-47855 A1 20020115 (10)
PRAI US 2001-262306P 20010116 (60)
DT Utility
FS APPLICATION
LN.CNT 4471
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 232 OF 469 USPATFULL on STN
AN 2003:237324 USPATFULL
TI Amyloid peptide inactivating enzyme to treat Alzheimer's disease
IN Hersh, Louis B., Lexington, KY, UNITED STATES
PI US 2003165481 A1 20030904
AI US 2002-159279 A1 20020603 (10)
RLI Division of Ser. No. US 2001-792079, filed on 26 Feb 2001, PENDING
PRAI US 2000-184826P 20000224 (60)
DT Utility
FS APPLICATION
LN.CNT 1712
INCL INCLM: 424/093.210
INCLS: 435/455.000; 435/368.000
NCL NCLM: 424/093.210
NCLS: 435/455.000; 435/368.000
IC [7]
ICM: A61K048-00
ICS: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 233 OF 469 USPATFULL on STN
AN 2003:232567 USPATFULL
TI Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Shi, Qing, Carmel, IN, UNITED STATES
PI US 2003162768 A1 20030828
US 6696438 B2 20040224
AI US 2002-317081 A1 20021212 (10)
RLI Division of Ser. No. US 1999-338180, filed on 22 Jun 1999, GRANTED, Pat. No. US 6528505
PRAI US 1998-160067P 19980622 (60)
US 1998-155238P 19980930 (60)
DT Utility
FS APPLICATION
LN.CNT 7196

INCLS: 514/212.050; 514/212.070; 514/220.000; 514/221.000; 540/490.000;
540/496.000; 540/500.000; 540/504.000
NCL NCLM: 514/220.000
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000;
540/504.000; 540/517.000; 540/518.000
IC [7]
ICM: A61K031-554
ICS: A61K031-553; A61K031-55; A61K031-5513; A61K031-551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 234 OF 469 USPATFULL on STN
AN 2003:231986 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003162186 A1 20030828
AI US 2002-154678 A1 20020522 (10)
PRAI US 2001-293574P 20010525 (60)
US 2001-298698P 20010615 (60)
US 2001-302277P 20010629 (60)
US 2001-305456P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 25533
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 235 OF 469 USPATFULL on STN
AN 2003:225673 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003157485 A1 20030821
AI US 2001-992095 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25484
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000;
536/023.200; 530/388.260; 435/007.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000;
536/023.200; 530/388.260; 435/007.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; A01K067-00; C07H021-04; C12N009-64;
C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 236 OF 469 USPATFULL on STN
AN 2003:220740 USPATFULL
TI Methods and compositions for diagnosing and treating rheumatoid
arthritis
IN Pittman, Debra D., Windham, NH, UNITED STATES
Feldman, Jeffrey L., Arlington, MA, UNITED STATES
Shields, Kathleen M., Harvard, MA, UNITED STATES
Trepicchio, William L., Andover, MA, UNITED STATES
PI US 2003154032 A1 20030814
AI US 2001-23451 A1 20011217 (10)
PRAI US 2000-255861P 20001215 (60)
DT Utility

LN.CNT 25385
INCL INCLM: 702/020.000
NCL NCLM: 702/020.000
IC [7]
ICM: G06F019-00
ICS: G01N033-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 237 OF 469 USPATFULL on STN
AN 2003:220259 USPATFULL
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, UNITED STATES
Thompson, Richard C., Frankfort, IN, UNITED STATES
Wilkie, Stephen C., Indianapolis, IN, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Huffman, George W., Carmel, IN, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
PI US 2003153550 A1 20030814
US 6774125 B2 20040810
AI US 2002-267017 A1 20021007 (10)
RLI Division of Ser. No. US 1999-337484, filed on 21 Jun 1999, GRANTED, Pat. No. US 6509331
PRAI US 1998-155265P 19980622 (60)
DT Utility
FS APPLICATION
LN.CNT 6533
INCL INCLM: 514/211.050
INCLS: 514/221.000; 514/220.000; 514/212.040; 514/212.050; 514/151.000; 540/490.000; 540/496.000; 540/500.000; 540/522.000; 540/523.000; 540/520.000
NCL NCLM: 514/220.000
NCLS: 514/221.000; 540/496.000; 540/497.000; 540/498.000; 540/499.000; 540/504.000; 540/517.000; 540/518.000
IC [7]
ICM: A61K031-655
ICS: A61K031-55; A61K031-553; A61K031-5513; A61K031-551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 238 OF 469 USPATFULL on STN
AN 2003:219631 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2003152921 A1 20030814
AI US 2001-876997 A1 20010608 (9)
RLI Continuation-in-part of Ser. No. US 2000-731872, filed on 7 Dec 2000, PENDING
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)
DT Utility
FS APPLICATION
LN.CNT 27600
INCL INCLM: 435/006.000
INCLS: 435/183.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/183.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C12N009-00; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 239 OF 469 USPATFULL on STN
AN 2003:214379 USPATFULL
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Thompson, Richard C., Frankfort, IN, UNITED STATES
Wilkie, Stephen C., Indianapolis, IN, UNITED STATES
Stack, Douglas R., Fishers, IN, UNITED STATES

PI US 2003149022 A1 20030807
AI US 2002-326081 A1 20021223 (10)
RLI Division of Ser. No. US 1999-338121, filed on 22 Jun 1999, PENDING
PRAI US 1998-160067P 19980622 (60)
US 1998-150704P 19980930 (60)
DT Utility
FS APPLICATION
LN.CNT 7927
INCL INCLM: 514/211.040
INCLS: 514/212.040; 514/220.000; 514/212.050; 514/221.000
NCL NCLM: 514/211.040
NCLS: 514/212.040; 514/220.000; 514/212.050; 514/221.000
IC [7]
ICM: A61K031-55
ICS: A61K031-553; A61K031-554; A61K031-5513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 240 OF 469 USPATFULL on STN
AN 2003:197032 USPATFULL
TI Prevention and treatment of amyloid-associated disorders
IN Hyslop, Paul Andrew, Indianapolis, IN, United States
Miller, Foy Dean, Camby, IN, United States
Higgins, Linda S., Palo Alto, CA, United States
Catalano, Rosanne, Hayward, CA, United States
Cordell, Barbara, Palo Alto, CA, United States
Puchacz, Elizbieta, Pleasanton, CA, United States
PA Scios Inc., Sunnyvale, CA, United States (U.S. corporation)
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6596474 B1 20030722
AI US 2000-608640 20000630 (9)
PRAI US 1999-142175P 19990701 (60)
DT Utility
FS GRANTED
LN.CNT 1226
INCL INCLM: 435/004.000
INCLS: 435/070.300; 435/347.000; 435/374.000; 424/562.000
NCL NCLM: 435/004.000
NCLS: 424/562.000; 435/070.300; 435/347.000; 435/374.000
IC [7]
ICM: C12Q001-00
ICS: C12P021-04; C12N005-06; C12N005-00; A61K035-55
EXF 424/562; 435/4; 435/70.3; 435/373; 435/347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 241 OF 469 USPATFULL on STN
AN 2003:194619 USPATFULL
TI Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides
IN Shimkets, Richard A., West Haven, CT, UNITED STATES
Fernandes, Elma, Branford, CT, UNITED STATES
Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
PA CuraGen Corporation, New Haven, CT (U.S. corporation)
PI US 2003134430 A1 20030717
AI US 2001-977751 A1 20011015 (9)
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
PRAI US 2000-201388P 20000503 (60)
US 2000-193086P 20000330 (60)
US 2000-191158P 20000322 (60)
US 2000-189810P 20000316 (60)
US 1999-137322P 19990603 (60)
DT Utility
FS APPLICATION
LN.CNT 10285
INCL INCLM: 436/518.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 436/518.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C07K014-435; G01N033-543; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 242 OF 469 USPATFULL on STN

TI Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Droste, James, Indianapolis, IN, UNITED STATES
PI US 2003130188 A1 20030710
AI US 2002-246558 A1 20020919 (10)
RLI Division of Ser. No. US 1998-32019, filed on 27 Feb 1998, PENDING
DT Utility
FS APPLICATION
LN.CNT 11320
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 514/019.000; 514/400.000; 514/419.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 514/019.000; 514/400.000; 514/419.000
IC [7]
ICM: A61K038-10
ICS: A61K038-08; A61K038-06; A61K038-05; A61K031-4172; A61K031-405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 243 OF 469 USPATFULL on STN
AN 2003:188372 USPATFULL
TI Method for treating neurodegenerative disorders
IN Reitz, Allen B., Lansdale, PA, UNITED STATES
Demeter, David A., Fishers, IN, UNITED STATES
Lee, Daniel H.S., Northhampton, PA, UNITED STATES
Wang, Hoau-Yan, Philadelphia, PA, UNITED STATES
Chen, Robert H., Belle Mead, NJ, UNITED STATES
Ross, Tina Morgan, Audubon, PA, UNITED STATES
Scott, Malcolm K., Lansdale, PA, UNITED STATES
Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES
PI US 2003130165 A1 20030710
AI US 2002-162821 A1 20020605 (10)
RLI Division of Ser. No. US 1999-320885, filed on 27 May 1999, GRANTED, Pat. No. US 6441049
PRAI US 1998-87577P 19980601 (60)
DT Utility
FS APPLICATION
LN.CNT 1505
INCL INCLM: 514/001.000
NCL NCLM: 514/001.000
IC [7]
ICM: A61K031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 244 OF 469 USPATFULL on STN
AN 2003:181716 USPATFULL
TI 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
IN Blume, Thorsten, Schildow, GERMANY, FEDERAL REPUBLIC OF
Halfbrodt, Wolfgang, Berlin, GERMANY, FEDERAL REPUBLIC OF
Kuhnke, Joachim, Porsdam, GERMANY, FEDERAL REPUBLIC OF
Monning, Ursula, Woltersdorf, GERMANY, FEDERAL REPUBLIC OF
Schneider, Herbert, Berlin, GERMANY, FEDERAL REPUBLIC OF
PI US 2003125550 A1 20030703
AI US 2002-190620 A1 20020709 (10)
PRAI DE 2001-135050 20010709
US 2001-304124P 20010711 (60)
DT Utility
FS APPLICATION
LN.CNT 2365
INCL INCLM: 544/060.000
INCLS: 544/139.000; 544/370.000; 546/199.000; 548/181.000; 548/215.000; 548/304.700; 548/306.100
NCL NCLM: 544/060.000
NCLS: 544/139.000; 544/370.000; 546/199.000; 548/181.000; 548/215.000; 548/304.700; 548/306.100
IC [7]

ICS: C07D413-02; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 245 OF 469 USPATFULL on STN
AN 2003:180701 USPATFULL
TI Sequence-directed DNA-binding molecules compositons and methods
IN Edwards, Cynthia A., Menlo Park, CA, UNITED STATES
Cantor, Charles R., Del Mar, CA, UNITED STATES
Andrews, Beth M., Maynard, MA, UNITED STATES
Turin, Lisa M., Redwood City, CA, UNITED STATES
Fry, Kirk E., Palo Alto, CA, UNITED STATES
PA Genelabs Technologies, Inc. (U.S. corporation)
PI US 2003124530 A1 20030703
AI US 2001-993346 A1 20011113 (9)
RLI Division of Ser. No. US 1999-354947, filed on 15 Jul 1999, GRANTED, Pat. No. US 6384208 Continuation of Ser. No. US 1995-482080, filed on 7 Jun 1995, GRANTED, Pat. No. US 6010849 Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, GRANTED, Pat. No. US 5578444 Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, GRANTED, Pat. No. US 5726014 Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, GRANTED, Pat. No. US 5693463 Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 10851
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 246 OF 469 USPATFULL on STN
AN 2003:180279 USPATFULL
TI Human oxidoreductase proteins
IN Yue, Henry, Sunnyvale, CA, UNITED STATES
Lal, Preeti, Santa Clara, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Hillman, Jennifer L., Mountain View, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Azimzai, Yalda, Castro Valley, CA, UNITED STATES
Lu, Dyung Aina M., San Jose, CA, UNITED STATES
PI US 2003124106 A1 20030703
AI US 2002-168274 A1 20020613 (10)
WO 2000-US33158 20001207
PRAI US 1999-60172367 19991216
DT Utility
FS APPLICATION
LN.CNT 6886
INCL INCLM: 424/094.400
INCLS: 435/069.100; 435/189.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 424/094.400
NCLS: 435/069.100; 435/189.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: A61K038-44
ICS: C12N009-02; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 247 OF 469 USPATFULL on STN
AN 2003:173967 USPATFULL
TI Lactams substituted by cyclic succinates as inhibitors of A-beta protein production
IN Olson, Richard E., Wilmington, DE, UNITED STATES
PI US 2003119815 A1 20030626
AI US 2002-287099 A1 20021104 (10)
RLI Division of Ser. No. US 2001-871840, filed on 1 Jun 2001, GRANTED, Pat. No. US 6509333
PRAI US 2000-208536P 20000601 (60)
DT Utility
FS APPLICATION
LN.CNT 6497
INCL INCLM: 514/212.030
INCLS: 514/212.080; 514/183.000; 514/327.000; 514/326.000; 540/451.000; 540/524.000; 540/527.000; 546/207.000; 546/216.000
NCL NCLM: 514/212.030
NCLS: 514/212.080; 514/183.000; 514/327.000; 514/326.000; 540/451.000;

IC [7]
ICM: A61K031-55
ICS: A61K031-454; C07D043-02; C07D041-02; C07D223-12; C07D211-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 248 OF 469 USPATFULL on STN
AN 2003:165862 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2003113717 A1 20030619
AI US 2001-893878 A1 20010629 (9)
RLI Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED
Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED
Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 15933
INCL INCLM: 435/006.000
INCLS: 435/007.200; 435/455.000; 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/007.200; 435/455.000; 435/091.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C12P019-34; C12N015-87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 249 OF 469 USPATFULL on STN
AN 2003:158903 USPATFULL
TI Death domain containing receptor 4
IN Ni, Jian, Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Pan, James G., Belmont, CA, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
Dixit, Vishva M., Los Altos Hills, CA, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2003108516 A1 20030612
AI US 2002-175902 A1 20020621 (10)
RLI Division of Ser. No. US 2000-565918, filed on 5 May 2000, GRANTED, Pat. No. US 6433147 Division of Ser. No. US 1998-13895, filed on 27 Jan 1998, GRANTED, Pat. No. US 6342363
PRAI US 1999-132922P 19990506 (60)
US 1997-37829P 19970205 (60)
US 1997-35722P 19970128 (60)
DT Utility
FS APPLICATION
LN.CNT 9230
INCL INCLM: 424/085.100
INCLS: 424/155.100; 514/012.000
NCL NCLM: 424/085.100
NCLS: 424/155.100; 514/012.000
IC [7]
ICM: A61K039-395
ICS: A61K038-19; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 250 OF 469 USPATFULL on STN
AN 2003:153434 USPATFULL
TI Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity
IN Li, Jia-He, Cockeysville, MD, UNITED STATES
Tays, Kevin Leonard, Elkridge, MD, UNITED STATES
Zhang, Jie, Ellicott City, MD, UNITED STATES
PA Guilford Pharmaceuticals Inc. (U.S. corporation)
PI US 2003105102 A1 20030605
AI US 2002-109730 A1 20020401 (10)

Continuation-in-part of Ser. No. US 1998-79509, filed on 15 May 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997, ABANDONED
DT Utility
TS APPLICATION
LN.CNT 3754
INCL INCLM: 514/248.000
INCLS: 514/252.170; 514/252.160; 514/266.200; 514/266.220; 514/266.300; 514/253.050; 514/309.000; 544/284.000; 544/363.000; 546/141.000; 544/235.000
NCL NCLM: 514/248.000
NCLS: 514/252.170; 514/252.160; 514/266.200; 514/266.220; 514/266.300; 514/253.050; 514/309.000; 544/284.000; 544/363.000; 546/141.000; 544/235.000
IC [7]
ICM: A61K031-502
ICS: A61K031-517; A61K031-519; A61K031-496; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 251 OF 469 USPATFULL on STN
AN 2003:146761 USPATFULL
TI Carbohydrate epitope mimic compounds and uses thereof
IN Simon, Maryline, Baar, SWITZERLAND
Schachner, Melitta, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Neuberger, Timothy J., Dobbs Ferry, NY, UNITED STATES
Herzberg, Uri, Yorktown Heights, NY, UNITED STATES
PI US 2003100508 A1 20030529
AI US 2002-186867 A1 20020701 (10)
RLI Continuation of Ser. No. US 2000-511956, filed on 23 Feb 2000, ABANDONED
PRAI US 1999-121327P 19990224 (60)
US 1999-155492P 19990923 (60)
DT Utility
TS APPLICATION
LN.CNT 5586
INCL INCLM: 514/014.000
INCLS: 530/326.000
NCL NCLM: 514/014.000
NCLS: 530/326.000
IC [7]
ICM: A61K038-10
ICS: C07K007-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 252 OF 469 USPATFULL on STN
AN 2003:143058 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Thompson, Richard C., Frankfort, IN, United States
Wilkie, Stephen, Indianapolis, IN, United States
Stack, Douglas R., Fishers, IN, United States
VanMeter, Eldon E., Greenwood, IN, United States
Shi, Qing, Carmel, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Dressman, Bruce A., Indianapolis, IN, United States
Cwi, Cynthia L., Indianapolis, IN, United States
Henry, Steven S., New Palestine, IN, United States
McDaniel, Stacey L., Martinsville, IN, United States
Stucky, Russell D., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
PA Elan Pharmaceutials, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6569851 B1 20030527
AI US 1999-338191 19990622 (9)
PRAI US 1998-160067P 19980622 (60)
DT Utility
TS GRANTED
LN.CNT 12808
INCL INCLM: 514/219.000
INCLS: 514/220.000; 514/221.000; 540/509.000; 540/517.000; 540/518.000;

NCL NCLM: 514/219.000
NCLS: 514/220.000; 514/221.000; 540/509.000; 540/517.000; 540/518.000; 540/558.000; 540/559.000; 540/560.000; 540/561.000
IC [7]
ICM: C07D243-24
ICS: C07D223-18; C07D223-16; C07D243-14; A61K031-55
EXF 540/509; 540/558; 540/559; 540/560; 540/561; 540/517; 540/518; 514/221; 514/219; 514/220
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 253 OF 469 USPATFULL on STN
AN 2003:141017 USPATFULL
TI Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
IN Schubert, David R., La Jolla, CA, UNITED STATES
Liu, Yuanbin, San Diego, CA, UNITED STATES
PA The Salk Institute for Biological Studies (U.S. corporation)
PI US 2003096859 A1 20030522
AI US 2002-269477 A1 20021011 (10)
RLI Division of Ser. No. US 2000-617147, filed on 17 Jul 2000, GRANTED, Pat. No. US 6472436
DT Utility
FS APPLICATION
LN.CNT 1189
INCL INCLM: 514/456.000
NCL NCLM: 514/456.000
IC [7]
ICM: A61K031-353
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 254 OF 469 USPATFULL on STN
AN 2003:140406 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003096247 A1 20030522
AI US 2001-986 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25656
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
IC [7]
ICM: C12Q001-68
ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 255 OF 469 USPATFULL on STN
AN 2003:135731 USPATFULL
TI Transgenic animals for producing specific isotypes of human ***antibodies*** via non-cognate switch regions
IN Green, Larry L., San Francisco, CA, UNITED STATES
Ivanov, Vladimir E., Fremont, CA, UNITED STATES
Davis, C. Geoffrey, Burlingame, CA, UNITED STATES
PI US 2003093820 A1 20030515
AI US 2001-999321 A1 20011130 (9)
PRAI WO 2000-US15782 20000608
DT Utility
FS APPLICATION
LN.CNT 3765
INCL INCLM: 800/008.000
INCLS: 435/069.100; 435/326.000; 435/320.100; 536/023.530
NCL NCLM: 800/008.000
NCLS: 435/069.100; 435/326.000; 435/320.100; 536/023.530

ICM: A01K067-00
ICS: C07H021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 256 OF 469 USPATFULL on STN
AN 2003:134541 USPATFULL
TI Inhibitors of memapsin 2 and use thereof
IN Tang, Jordan J. N., Edmond, OK, UNITED STATES
Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
Ghosh, Arun K., River Forest, IL, UNITED STATES
PA Oklahoma Medical Research Foundation, Oklahoma City, OK (U.S. corporation)
PI US 2003092629 A1 20030515
AI US 2001-32818 A1 20011228 (10)
PRAI US 2001-275756P 20010314 (60)
US 2000-258705P 20001228 (60)
DT Utility
FS APPLICATION
LN.CNT 2203
INCL INCLM: 514/013.000
INCLS: 530/326.000
NCL NCLM: 514/013.000
NCLS: 530/326.000
IC [7]
ICM: A61K038-10
ICS: C07K007-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 257 OF 469 USPATFULL on STN
AN 2003:133926 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003092011 A1 20030515
AI US 2001-489 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25607
INCL INCLM: 435/006.000
INCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-542; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 258 OF 469 USPATFULL on STN
AN 2003:127742 USPATFULL
TI Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
IN Kelleher, Judith A., Fremont, CA, UNITED STATES
Maples, Kirk R., San Jose, CA, UNITED STATES
Dykman, Alina, San Francisco, CA, UNITED STATES
Zhang, Yong-Kang, Santa Clara, CA, UNITED STATES
Wilcox, Allan L., Mountain View, CA, UNITED STATES
Levell, Julian, Collegeville, PA, UNITED STATES
PI US 2003087957 A1 20030508
AI US 2002-74595 A1 20020211 (10)
RLI Continuation of Ser. No. US 2000-500650, filed on 9 Feb 2000, ABANDONED
Continuation of Ser. No. US 1998-172763, filed on 15 Oct 1998, GRANTED, Pat. No. US 6046232
PRAI US 1997-62324P 19971017 (60)
US 1997-63736P 19971029 (60)
US 1998-90475P 19980624 (60)

FS APPLICATION
LN.CNT 2874
INCL INCLM: 514/466.000
INCLS: 514/640.000; 564/253.000; 549/440.000
NCL NCLM: 514/466.000
NCLS: 514/640.000; 564/253.000; 549/440.000
IC [7]
ICM: A61K031-36
ICS: A61K031-15; C07C251-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 259 OF 469 USPATFULL on STN
AN 2003:127047 USPATFULL
TI Methods and compositions for regulating bone and cartilage formation
IN Clancy, Brian M., Ashland, MA, UNITED STATES
Pittman, Debra D., Windham, NH, UNITED STATES
PI US 2003087259 A1 20030508
AI US 2002-125691 A1 20020418 (10)
PRAI US 2001-284786P 20010418 (60)
DT Utility
FS APPLICATION
LN.CNT 12451
INCL INCLM: 435/006.000
INCLS: 702/020.000
NCL NCLM: 435/006.000
NCLS: 702/020.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 260 OF 469 USPATFULL on STN
AN 2003:120793 USPATFULL
TI Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
IN Hersh, Louis B., Lexington, KY, UNITED STATES
PI US 2003083277 A1 20030501
AI US 2001-792079 A1 20010226 (9)
PRAI US 2000-184826P 20000224 (60)
DT Utility
FS APPLICATION
LN.CNT 1117
INCL INCLM: 514/044.000
INCLS: 424/094.630; 424/093.210
NCL NCLM: 514/044.000
NCLS: 424/094.630; 424/093.210
IC [7]
ICM: A61K048-00
ICS: A61K038-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 261 OF 469 USPATFULL on STN
AN 2003:120071 USPATFULL
TI Novel nucleic acid sequences encoding human cell adhesion molecule protein-like polypeptides
IN Shimkets, Richard A., West Haven, CT, UNITED STATES
Fernandes, Elma, Branford, CT, UNITED STATES
Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
PA CuraGen Corporation, New Haven, CT, 06511
PI US 2003082554 A1 20030501
AI US 2001-977033 A1 20011015 (9)
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
PRAI US 2000-201388P 20000503 (60)
US 2000-193086P 20000330 (60)
US 2000-191158P 20000322 (60)
US 2000-189810P 20000316 (60)
US 1999-137322P 19990603 (60)
DT Utility
FS APPLICATION
LN.CNT 7063
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.500

ICM: C07K014-435
ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 262 OF 469 USPATFULL on STN
AN 2003:113554 USPATFULL
TI Method for treating multiple sclerosis
IN Shankar, L. Sai Latha, New York, NY, UNITED STATES
Tatton, William G., Purchase, NY, UNITED STATES
Tatton, Nadine A., Purchase, NY, UNITED STATES
PI US 2003078295 A1 20030424
AI US 2002-205747 A1 20020726 (10)
RLI Continuation of Ser. No. US 1999-416010, filed on 8 Oct 1999, PENDING
PRAI US 1998-103742P 19981009 (60)
DT Utility
FS APPLICATION
LN.CNT 4863
INCL INCLM: 514/478.000
INCLS: 514/617.000; 514/649.000; 514/651.000
NCL NCLM: 514/478.000
NCLS: 514/617.000; 514/649.000; 514/651.000
IC [7]
ICM: A61K031-325
ICS: A61K031-165; A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 263 OF 469 USPATFULL on STN
AN 2003:109100 USPATFULL
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Thompson, Richard C., Frankfort, IN, United States
Wilkie, Stephen C., Indianapolis, IN, United States
Stack, Douglas R., Fishers, IN, United States
Shi, Qing, Carmel, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6552013 B1 20030422
AI US 1999-338121 19990622 (9)
PRAI US 1998-160067P 19980622 (60)
US 1998-150704P 19980930 (60)
DT Utility
FS GRANTED
LN.CNT 7962
INCL INCLM: 514/212.040
INCLS: 514/212.070; 540/522.000; 540/523.000
NCL NCLM: 514/212.040
NCLS: 514/212.070; 540/522.000; 540/523.000
IC [7]
ICM: C07D243-24
ICS: C07D223-18; C07D223-16; C07D409-12; A61K031-55
EXF 514/212.04; 514/212.07; 540/522; 540/523
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 264 OF 469 USPATFULL on STN
AN 2003:106809 USPATFULL
TI Peptide beta-strand mimics based on 1,2-dihydro-3(6H)-pyridinone
IN Bartlett, Paul A., Oakland, CA, UNITED STATES
Rezac, Miroslav, Chicago, IL, UNITED STATES
Olson, Steven, Metuchen, NJ, UNITED STATES
Phillips, Scott, Berkeley, CA, UNITED STATES
PA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, Oakland, CA, UNITED STATES (U.S. corporation)
PI US 2003073721 A1 20030417
AI US 2002-157759 A1 20020528 (10)
PRAI US 2001-296167P 20010605 (60)
DT Utility
FS APPLICATION
LN.CNT 1727
INCL INCLM: 514/333.000
INCLS: 514/335.000; 514/350.000; 514/341.000; 514/339.000; 546/256.000;

NCL NCLM: 514/333.000
NCLS: 514/335.000; 514/350.000; 514/341.000; 514/339.000; 546/256.000; 546/261.000; 546/272.700; 546/277.400; 546/276.400; 546/298.000
IC [7]
ICM: C07D041-14
ICS: C07D041-02; A61K031-444; A61K031-4439; A61K031-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 265 OF 469 USPATFULL on STN
AN 2003:106789 USPATFULL
TI Succinoylamino heterocycles as inhibitors of a beta protein production
IN Thompson, Lorin A., Wilmington, DE, UNITED STATES
Kasireddy, Padmaja, Kennett Square, PA, UNITED STATES
PI US 2003073701 A1 20030417
AI US 2001-823820 A1 20010331 (9)
DT Utility
FS APPLICATION
LN.CNT 3957
INCL INCLM: 514/255.010
INCLS: 514/253.010; 514/252.140; 514/256.000; 514/330.000; 514/318.000; 514/343.000; 514/423.000; 544/295.000; 544/360.000; 544/386.000; 544/333.000; 546/208.000
NCL NCLM: 514/255.010
NCLS: 514/253.010; 514/252.140; 514/256.000; 514/330.000; 514/318.000; 514/343.000; 514/423.000; 544/295.000; 544/360.000; 544/386.000; 544/333.000; 546/208.000
IC [7]
ICM: A61K031-496
ICS: A61K031-506; A61K031-4545
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 266 OF 469 USPATFULL on STN
AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
US 2001-305484P 20010712 (60)
US 2001-265305P 20010130 (60)
US 2001-267568P 20010209 (60)
US 2001-313999P 20010820 (60)
US 2001-291631P 20010516 (60)
US 2001-287112P 20010428 (60)
US 2001-278651P 20010321 (60)
US 2001-265682P 20010131 (60)
DT Utility
FS APPLICATION
LN.CNT 14253
INCL INCLM: 435/007.230
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200
NCL NCLM: 435/007.230
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200
IC [7]
ICM: G01N033-574
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 267 OF 469 USPATFULL on STN
AN 2003:106163 USPATFULL
TI DIAGNOSTIC ASSAY FOR ALZHEIMER'S DISEASE: ASSESSMENT OF AB ABNORMALITIES
IN TANZI, RUDOLPH E., CANTON, MA, UNITED STATES
BUSH, ASHLEY I., SOMERVILLE, MA, UNITED STATES
MOIR, ROBERT D., BOSTON, MA, UNITED STATES
PI US 2003073074 A1 20030417
AI US 1999-425956 A1 19991025 (9)
RLI Continuation of Ser. No. US 1997-817423, filed on 4 Aug 1997, GRANTED, Pat. No. US 5972634 A 371 of International Ser. No. WO 1994-US11895,

DT Utility
FS APPLICATION
LN.CNT 2343
INCL INCLM: 435/006.000
INCLS: 435/287.200; 435/007.900
NCL NCLM: 435/006.000
NCLS: 435/287.200; 435/007.900
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-542; G01N033-537; G01N033-543; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 268 OF 469 USPATFULL on STN
AN 2003:102440 USPATFULL
TI Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
IN Zhang, Shuguang, Cambridge, MA, United States
Lockshin, Curtis, Lexington, MA, United States
Rich, Alexander, Cambridge, MA, United States
Holmes, Todd, Cambridge, MA, United States
PA Massachusettes Insitute of Technology, Cambridge, MA, United States (U.S. corporation)
PI US 6548630 B1 20030415
AI US 1997-898300 19970722 (8)
RLI Continuation of Ser. No. US 1994-346849, filed on 30 Nov 1994, now patented, Pat. No. US 5670483 Continuation of Ser. No. US 1992-973326, filed on 28 Dec 1992, now abandoned
DT Utility
FS GRANTED
LN.CNT 2187
INCL INCLM: 530/300.000
INCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000; 514/012.000; 514/013.000; 514/014.000
NCL NCLM: 530/300.000
NCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000
IC [7]
ICM: C07K007-00
ICS: C07K016-00; A61K038-00
EXF 514/12; 514/13; 514/14; 530/300; 530/324; 530/325; 530/326; 530/327; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 269 OF 469 USPATFULL on STN
AN 2003:100295 USPATFULL
TI 87 human secreted proteins
IN Young, Paul, Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Duan, Roxanne, Gaithersburg, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Florence, Kimberly, Rockville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Lafleur, David W., Washington, DC, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2003069406 A1 20030410
AI US 2002-143090 A1 20020513 (10)
RLI Continuation of Ser. No. US 1998-154707, filed on 17 Sep 1998, PENDING Continuation-in-part of Ser. No. WO 1998-US5311, filed on 19 Mar 1998, UNKNOWN
PRAI US 1997-41277P 19970321 (60)
US 1997-42344P 19970321 (60)
US 1997-41276P 19970321 (60)
US 1997-41281P 19970321 (60)
US 1997-48094P 19970530 (60)
US 1997-48350P 19970530 (60)
US 1997-48188P 19970530 (60)
US 1997-48135P 19970530 (60)

```
       US 1997-48187P      19970530 (60)
       US 1997-48099P      19970530 (60)
       US 1997-48352P      19970530 (60)
       US 1997-48186P      19970530 (60)
       US 1997-48069P      19970530 (60)
       US 1997-48095P      19970530 (60)
       US 1997-48131P      19970530 (60)
       US 1997-48096P      19970530 (60)
       US 1997-48355P      19970530 (60)
       US 1997-48160P      19970530 (60)
       US 1997-48351P      19970530 (60)
       US 1997-48154P      19970530 (60)
       US 1997-54804P      19970805 (60)
       US 1997-56370P      19970819 (60)
       US 1997-60862P      19971002 (60)
DT     Utility
FS     APPLICATION
LN.CNT 15137
INCL   INCLM: 536/023.200
       INCLS: 435/006.000; 435/183.000; 435/069.100; 435/325.000; 435/320.100;
              530/350.000
NCL    NCLM:  536/023.200
       NCLS:  435/006.000; 435/183.000; 435/069.100; 435/325.000; 435/320.100;
              530/350.000
IC     [7]
       ICM: C12Q001-68
       ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 270 OF 469  USPATFULL on STN
AN     2003:100060  USPATFULL
TI     Pharmaceutical compositions of drug-oligomer conjugates and methods of
       treating diseases therewith
IN     Soltero, Richard, Holly Springs, NC, UNITED STATES
       Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES
       Opawale, Foyeke, Raleigh, NC, UNITED STATES
       Rehlander, Bruce, Chapel Hill, NC, UNITED STATES
       Hickey, Anthony, Chapel Hill, NC, UNITED STATES
       Li Li, Bovet, Chapel Hill, NC, UNITED STATES
PI     US 2003069170       A1   20030410
       US 6770625          B2   20040803
AI     US 2002-235284      A1   20020905 (10)
PRAI   US 2001-318193P      20010907 (60)
       US 2002-377865P      20020503 (60)
DT     Utility
FS     APPLICATION
LN.CNT 3615
INCL   INCLM: 514/002.000
       INCLS: 514/012.000; 514/171.000; 514/560.000
NCL    NCLM:  514/012.000
       NCLS:  514/003.000; 514/021.000; 514/784.000; 514/808.000
IC     [7]
       ICM: A61K038-23
       ICS: A61K031-56; A61K031-202; A61K038-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 271 OF 469  USPATFULL on STN
AN     2003:96167  USPATFULL
TI     Catalytically active recombinant memapsin and methods of use thereof
IN     Tang, Jordan J. N., Edmond, OK, United States
       Lin, Xinli, Edmond, OK, United States
       Koelsch, Gerald, Oklahoma City, OK, United States
       Hong, Lin, Oklahoma City, OK, United States
PA     Oklahoma Medical Research Foundation, Oklahoma City, OK, United States
       (U.S. corporation)
PI     US 6545127          B1   20030408
AI     US 2000-604608           20000627 (9)
PRAI   US 1999-141363P      19990628 (60)
       US 1999-168060P      19991130 (60)
       US 2000-177836P      20000125 (60)
       US 2000-178368P      20000127 (60)
       US 2000-210292P      20000608 (60)
DT     Utility
FS     GRANTED
LN.CNT 2563
```

INCLS: 702/019.000; 530/300.000; 536/023.100
NCL NCLM: 530/350.000
NCLS: 530/300.000; 536/023.100; 702/019.000
IC [7]
ICM: G01N033-48
ICS: G01N031-00; G06F019-00; A16K038-00; C07K001-00; C07K014-00; C07K017-00; C07M021-02; C07M021-04
EXF 435/212; 435/183; 435/7.1; 435/226; 435/15; 530/300; 536/350; 536/23.1; 702/19; 702/27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 272 OF 469 USPATFULL on STN
AN 2003:94733 USPATFULL
TI Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
IN Monte, Suzanne De La, East Greenwich, RI, UNITED STATES
Wands, Jack R., Waban, MA, UNITED STATES
PI US 2003066097 A1 20030403
AI US 2001-964678 A1 20010928 (9)
RLI Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371 of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN
PRAI US 1997-38908P 19970226 (60)
DT Utility
FS APPLICATION
LN.CNT 2091
INCL INCLM: 800/012.000
INCLS: 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 800/012.000
NCLS: 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: A01K067-027
ICS: C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 273 OF 469 USPATFULL on STN
AN 2003:93790 USPATFULL
TI Secreted protein HCEJQ69
IN Ruben, Steven M., Olney, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Young, Paul, Gaithersburg, MD, UNITED STATES
Florence, Kimberly, Rockville, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Mucenski, Michael, Cincinnati, OH, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Komatsoulis, George, Silver Spring, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2003065151 A1 20030403
US 6774216 B2 20040810
AI US 2002-115123 A1 20020404 (10)
RLI Division of Ser. No. US 1999-461325, filed on 14 Dec 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999, UNKNOWN
PRAI US 1998-89507P 19980616 (60)
US 1998-89508P 19980616 (60)
US 1998-89509P 19980616 (60)
US 1998-89510P 19980616 (60)
US 1998-90112P 19980622 (60)
US 1998-90113P 19980622 (60)
DT Utility
FS APPLICATION
LN.CNT 18779
INCL INCLM: 530/388.260
NCL NCLM: 530/387.900
NCLS: 530/387.100; 530/387.700; 530/388.100; 530/388.150; 430/069.100; 430/320.000; 536/023.500

ICM: C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 274 OF 469 USPATFULL on STN
AN 2003:89394 USPATFULL
TI Aromatic sulfone hydroxamic acid metalloprotease inhibitor
IN Barta, Thomas E., Evanston, IL, United States
Becker, Daniel P., Glenview, IL, United States
Boehm, Terri L., Ballwin, MO, United States
De Crescenzo, Gary A., St. Charles, MO, United States
Villamil, Clara I., Glenview, IL, United States
McDonald, Joseph J., Ballwin, MO, United States
Freskos, John N., Clayton, MO, United States
Getman, Daniel P., Chesterfield, MO, United States
PA G. D. Searle & Company, St.Louis, MO, United States (U.S. corporation)
PI US 6541489 B1 20030401
WO 9925687 19990527
AI US 2000-554082 20000731 (9)
WO 1998-US23242 19981112
20000731 PCT 371 date
PRAI US 1997-66007P 19971114 (60)
DT Utility
FS GRANTED
LN.CNT 13579
INCL INCLM: 514/330.000
INCLS: 546/192.000; 546/225.000
NCL NCLM: 514/330.000
NCLS: 546/192.000; 546/225.000
IC [7]
ICM: A61K031-445
ICS: C07D211-06
EXF 546/192; 546/225; 514/330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 275 OF 469 USPATFULL on STN
AN 2003:87011 USPATFULL
TI Secreted protein HFEAF41
IN Young, Paul, Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Tewksbury, MA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Duan, Roxanne, Bethesda, MD, UNITED STATES
Hu, Jing-Shan, Sunnyvale, CA, UNITED STATES
Florence, Kimberly, Rockville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Lafleur, David W., Washington, DC, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
PI US 2003060619 A1 20030327
AI US 2001-983966 A1 20011026 (9)
RLI Division of Ser. No. US 1998-154707, filed on 17 Sep 1998, PENDING
Continuation-in-part of Ser. No. WO 1998-US5311, filed on 19 Mar 1998, UNKNOWN
PRAI US 1997-41277P 19970321 (60)
US 1997-42344P 19970321 (60)
US 1997-41276P 19970321 (60)
US 1997-41281P 19970321 (60)
US 1997-48094P 19970530 (60)
US 1997-48350P 19970530 (60)
US 1997-48188P 19970530 (60)
US 1997-48135P 19970530 (60)
US 1997-50937P 19970530 (60)
US 1997-48187P 19970530 (60)
US 1997-48099P 19970530 (60)
US 1997-48352P 19970530 (60)
US 1997-48186P 19970530 (60)
US 1997-48069P 19970530 (60)
US 1997-48095P 19970530 (60)
US 1997-48131P 19970530 (60)
US 1997-48096P 19970530 (60)
US 1997-48355P 19970530 (60)

US 1997-48351P 19970530 (60)
US 1997-48154P 19970530 (60)
US 1997-54804P 19970805 (60)
US 1997-56370P 19970819 (60)
US 1997-60862P 19971002 (60)
DT Utility
FS APPLICATION
LN.CNT 15264
INCL INCLM: 536/023.530
INCLS: 530/388.150; 530/391.100
NCL NCLM: 536/023.530
NCLS: 530/388.150; 530/391.100
IC [7]
ICM: C07H021-04
ICS: C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 276 OF 469 USPATFULL on STN
AN 2003:78523 USPATFULL
TI 90 human secreted proteins
IN Ruben, Steven M., Olney, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Janat, Fouad, Westerly, RI, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
PI US 2003054443 A1 20030320
AI US 2001-969730 A1 20011004 (9)
RLI Continuation-in-part of Ser. No. US 2001-774639, filed on 1 Feb 2001, PENDING Continuation of Ser. No. US 1999-244112, filed on 4 Feb 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US16235, filed on 4 Aug 1998, UNKNOWN
PRAI US 2000-238291P 20001006 (60)
US 1997-55386P 19970805 (60)
US 1997-54807P 19970805 (60)
US 1997-55312P 19970805 (60)
US 1997-55309P 19970805 (60)
US 1997-54798P 19970805 (60)
US 1997-55310P 19970805 (60)
US 1997-54806P 19970805 (60)
US 1997-54809P 19970805 (60)
US 1997-54804P 19970805 (60)
US 1997-54803P 19970805 (60)
US 1997-54808P 19970805 (60)
US 1997-55311P 19970805 (60)
US 1997-55986P 19970818 (60)
US 1997-55970P 19970818 (60)
US 1997-56563P 19970819 (60)
US 1997-56557P 19970819 (60)
US 1997-56731P 19970819 (60)
US 1997-56365P 19970819 (60)
US 1997-56367P 19970819 (60)
US 1997-56370P 19970819 (60)
US 1997-56364P 19970819 (60)
US 1997-56366P 19970819 (60)
US 1997-56732P 19970819 (60)
US 1997-56371P 19970819 (60)
DT Utility
FS APPLICATION
LN.CNT 26693
INCL INCLM: 435/069.100
INCLS: 435/006.000; 435/007.100; 435/325.000; 435/320.100; 435/183.000; 536/023.100; 530/350.000
NCL NCLM: 435/069.100
NCLS: 435/006.000; 435/007.100; 435/325.000; 435/320.100; 435/183.000; 536/023.100; 530/350.000
IC [7]
ICM: C12P021-02

C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 277 OF 469 USPATFULL on STN
AN 2003:72174 USPATFULL
TI Secreted protein HFEAF41
IN Young, Paul, Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Tewksbury, MA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Duan, Roxanne, Bethesda, MD, UNITED STATES
Hu, Jing-Shan, Sunnyvale, CA, UNITED STATES
Florence, Kimberly, Rockville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Lauie A., St. Paul, MN, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Lafleur, David W., Washington, DC, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
PI US 2003050461 A1 20030313
AI US 2001-966262 A1 20011001 (9)
RLI Continuation of Ser. No. US 1998-154707, filed on 17 Sep 1998, PENDING
Continuation-in-part of Ser. No. WO 1998-US5311, filed on 19 Mar 1998, UNKNOWN
PRAI US 1997-41277P 19970321 (60)
US 1997-42344P 19970321 (60)
US 1997-41276P 19970321 (60)
US 1997-41281P 19970321 (60)
US 1997-48094P 19970530 (60)
US 1997-48350P 19970530 (60)
US 1997-48188P 19970530 (60)
US 1997-48135P 19970530 (60)
US 1997-50937P 19970530 (60)
US 1997-48187P 19970530 (60)
US 1997-48099P 19970530 (60)
US 1997-48352P 19970530 (60)
US 1997-48186P 19970530 (60)
US 1997-48069P 19970530 (60)
US 1997-48095P 19970530 (60)
US 1997-48131P 19970530 (60)
US 1997-48096P 19970530 (60)
US 1997-48355P 19970530 (60)
US 1997-48160P 19970530 (60)
US 1997-48351P 19970530 (60)
US 1997-48154P 19970530 (60)
US 1997-54804P 19970805 (60)
US 1997-56370P 19970819 (60)
US 1997-60862P 19971002 (60)
DT Utility
FS APPLICATION
LN.CNT 15105
INCL INCLM: 536/023.200
INCLS: 435/006.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 424/094.100
NCL NCLM: 536/023.200
NCLS: 435/006.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 424/094.100
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; A61K038-43; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 278 OF 469 USPATFULL on STN
AN 2003:65430 USPATFULL
TI Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof
IN Sankaranarayanan, Alangudi, Ahmedabad, INDIA
PA TORRENT PHARMACEUTICALS LTD. (non-U.S. corporation)
PI US 2003045554 A1 20030306
AI US 2002-116135 A1 20020405 (10)
PRAI US 2001-281380P 20010405 (60)
DT Utility

LN.CNT 4729
INCL INCLM: 514/340.000
INCLS: 546/275.400; 546/276.400
NCL NCLM: 514/340.000
NCLS: 546/275.400; 546/276.400
IC [7]
ICM: A61K031-4439
ICS: C07D041-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 279 OF 469 USPATFULL on STN
AN 2003:64730 USPATFULL
TI Secreted protein HCEJQ69
IN Ruben, Steven M., Olney, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Mucenski, Michael, Cincinnati, OH, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Komatsoulis, George A., Silver Spring, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
PI US 2003044851 A1 20030306
US 6627741 B2 20030930
AI US 2001-12542 A1 20011212 (10)
RLI Division of Ser. No. US 1999-461325, filed on 14 Dec 1999, PENDING
Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999, UNKNOWN
PRAI US 1998-89507P 19980616 (60)
US 1998-89508P 19980616 (60)
US 1998-89509P 19980616 (60)
US 1998-89510P 19980616 (60)
US 1998-90112P 19980622 (60)
US 1998-90113P 19980622 (60)
DT Utility
FS APPLICATION
LN.CNT 18831
INCL INCLM: 435/007.200
INCLS: 530/387.100; 435/326.000
NCL NCLM: 530/389.200
NCLS: 530/387.100; 530/387.300; 530/387.700; 530/387.900; 530/388.100; 530/388.150; 530/389.100
IC [7]
ICM: G01N033-53
ICS: C07K016-00; C12N005-16; C12N005-06; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 280 OF 469 USPATFULL on STN
AN 2003:64662 USPATFULL
TI Human genes and gene expression products
IN Williams, Lewis T., Mill Valley, CA, UNITED STATES
Escobedo, Jaime, Alamo, CA, UNITED STATES
Innis, Michael A., UNITED STATES
Garcia, Pablo Dominguez, San Francisco, CA, UNITED STATES
Sudduth-Klinger, Julie, Kensington, CA, UNITED STATES
Reinhard, Christoph, Alameda, CA, UNITED STATES
Randazzo, Filippo, Oakland, CA, UNITED STATES
Kennedy, Giulia C., San Francisco, CA, UNITED STATES
Pot, David, Arlington, VA, UNITED STATES
Kassam, Altaf, Oakland, CA, UNITED STATES
Lamson, George, Moraga, CA, UNITED STATES
Drmanac, Radjoe, Palo Alto, CA, UNITED STATES
Dickson, Mark, Hollister, CA, UNITED STATES
Labat, Ivan, Mountain View, CA, UNITED STATES
Jones, Lee William, Sunnyvale, CA, UNITED STATES

PI US 2003044783 A1 20030306
AI US 2001-803719 A1 20010309 (9)
PRAI US 2000-188609P 20000309 (60)
DT Utility
FS APPLICATION
LN.CNT 23459
INCL INCLM: 435/006.000
  INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 530/388.100
NCL NCLM: 435/006.000
  NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 530/388.100
IC [7]
  ICM: C12Q001-68
  ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-435; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 281 OF 469 USPATFULL on STN
AN 2003:60218 USPATFULL
TI Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
  Dressman, Bruce A., Indianapolis, IN, United States
  Shi, Qing, Carmel, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
  Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6528505 B1 20030304
AI US 1999-338180 19990622 (9)
PRAI US 1998-160067P 19980622 (60)
  US 1998-155238P 19980930 (60)
DT Utility
FS GRANTED
LN.CNT 7113
INCL INCLM: 514/212.040
  INCLS: 514/212.070; 540/522.000; 540/523.000
NCL NCLM: 514/212.040
  NCLS: 514/212.070; 540/522.000; 540/523.000
IC [7]
  ICM: C07D223-14
  ICS: C07D243-06; C07D243-10; C07D243-12; A61K031-55
EXF 540/522; 540/523; 514/212.04; 514/212.07
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 282 OF 469 USPATFULL on STN
AN 2003:46308 USPATFULL
TI Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
IN De La Monte, Suzanne, East Greenwich, RI, UNITED STATES
  Wands, Jack R., Waban, MA, UNITED STATES
PI US 2003033621 A1 20030213
AI US 2001-964667 A1 20010928 (9)
RLI Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371 of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN
PRAI US 1997-38908P 19970226 (60)
DT Utility
FS APPLICATION
LN.CNT 2088
INCL INCLM: 800/012.000
  INCLS: 800/014.000; 435/325.000; 435/456.000; 536/023.200; 435/320.100
NCL NCLM: 800/012.000
  NCLS: 800/014.000; 435/325.000; 435/456.000; 536/023.200; 435/320.100
IC [7]
  ICM: A01K067-027
  ICS: C07H021-04; C12N005-06; C12N015-86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 283 OF 469 USPATFULL on STN
AN 2003:37603 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
  Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

AI US 2001-924340 A1 20010806 (9)
PRAI US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25650
INCL INCLM: 435/069.100
INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 435/006.000
NCL NCLM: 435/069.100
NCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 435/006.000
IC [7]
ICM: C12P021-02
ICS: C12Q001-68; C07H021-04; C12N009-00; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 284 OF 469 USPATFULL on STN
AN 2003:37516 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027161 A1 20030206
AI US 2001-992600 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25529
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
IC [7]
ICM: C12Q001-68
ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 285 OF 469 USPATFULL on STN
AN 2003:37513 USPATFULL
TI Novel nucleic acid sequences encoding human breast tumor-associated protein 47-like polypeptides
IN Shimkets, Richard A., West Haven, CT, UNITED STATES
Fernandes, Elma, Branford, CT, UNITED STATES
Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
PA CuraGen Corporation, New Haven, CT, UNITED STATES, 06511 (U.S. corporation)
PI US 2003027158 A1 20030206
AI US 2001-977418 A1 20011015 (9)
RLI Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
PRAI US 2000-201388P 20000503 (60)
US 2000-193086P 20000330 (60)
US 2000-191158P 20000322 (60)
US 2000-189810P 20000316 (60)
US 1999-137322P 19990603 (60)
DT Utility
FS APPLICATION
LN.CNT 7101
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.100; 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12P021-02; C12N005-06

L4 ANSWER 286 OF 469 USPATFULL on STN
AN 2003:37187 USPATFULL
TI Anionic liposomes for delivery of bioactive agents
IN Lakkaraju, Aparna, Minneapolis, MN, UNITED STATES
Dubinsky, Janet M., St. Paul, MN, UNITED STATES
Low, Walter, Shorewood, MN, UNITED STATES
Rahman, Yueh-Erh, LaJolla, CA, UNITED STATES
PI US 2003026831 A1 20030206
AI US 2002-131786 A1 20020422 (10)
PRAI US 2001-285337P 20010420 (60)
DT Utility
FS APPLICATION
LN.CNT 3617
INCL INCLM: 424/450.000
NCL NCLM: 424/450.000
IC [7]
ICM: A61K009-127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 287 OF 469 USPATFULL on STN
AN 2003:33487 USPATFULL
TI Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
IN Li, Jia-He, Cockeysville, MD, United States
Zhang, Jie, Ellicott City, MD, United States
Jackson, Paul F., Bel Air, MD, United States
Maclin, Keith M., Baltimore, MD, United States
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6514983 B1 20030204
AI US 1998-145181 19980901 (9)
RLI Continuation-in-part of Ser. No. US 1998-47502, filed on 25 Mar 1998, now patented, Pat. No. US 6306889 Continuation-in-part of Ser. No. US 1997-922548, filed on 3 Sep 1997, now patented, Pat. No. US 6346536
DT Utility
FS GRANTED
LN.CNT 3587
INCL INCLM: 514/285.000
INCLS: 514/183.000; 514/410.000; 546/061.000; 546/062.000; 546/066.000; 548/421.000
NCL NCLM: 514/285.000
NCLS: 514/183.000; 514/410.000; 546/061.000; 546/062.000; 546/066.000; 548/421.000
IC [7]
ICM: A61K031-47
ICS: C07D217-22; C07D217-18; C07D401-04
EXF 546/61; 546/62; 546/66; 514/183; 514/288; 514/298; 514/285; 514/410; 548/421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 288 OF 469 USPATFULL on STN
AN 2003:30934 USPATFULL
TI Compounds and their use
IN Ferraris, Dana V., Eldersburg, MD, UNITED STATES
Li, Jia-He, Cockeysville, MD, UNITED STATES
Kalish, Vincent J., Annapolis, MD, UNITED STATES
Zhang, Jie, Ellicott City, MD, UNITED STATES
PI US 2003022883 A1 20030130
AI US 2001-996776 A1 20011130 (9)
PRAI US 2000-250132P 20001201 (60)
US 2001-310274P 20010807 (60)
DT Utility
FS APPLICATION
LN.CNT 4519
INCL INCLM: 514/212.060
INCLS: 514/221.000; 514/220.000; 514/291.000; 540/496.000; 540/495.000; 540/521.000; 546/081.000
NCL NCLM: 514/212.060
NCLS: 514/221.000; 514/220.000; 514/291.000; 540/496.000; 540/495.000; 540/521.000; 546/081.000
IC [7]
ICM: C07D491-04
ICS: C07D471-04; A61K031-551; A61K031-55; A61K031-4745
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 289 OF 469 USPATFULL on STN
AN 2003:26240 USPATFULL
TI Methods of treating nitric oxide and cytokine mediated disorders
IN Singh, Inderjit, Mount Pleasant, SC, United States
PA Medical University of South Carolina, Charleston, SC, United States (U.S. corporation)
MUSC Foundation for Research Development, Charleston, SC, United States (U.S. corporation)
PI US 6511800 B1 20030128
AI US 2000-579791 20000525 (9)
RLI Continuation of Ser. No. WO 1998-US25360, filed on 25 Nov 1998
PRAI US 1997-66839P 19971125 (60)
DT Utility
FS GRANTED
LN.CNT 7562
INCL INCLM: 435/004.000
INCLS: 435/026.000
NCL NCLM: 435/004.000
NCLS: 435/026.000
IC [7]
ICM: C12Q001-00
EXF 435/4; 435/26; 514/440; 514/562; 514/563; 514/564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 290 OF 469 USPATFULL on STN
AN 2003:24336 USPATFULL
TI Secreted protein HFEAF41
IN Young, Paul, Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Duan, Roxanne, Bethesda, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Florence, Kimberly, Rockville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Lauie A., St. Paul, MN, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, VA, UNITED STATES
Lafleur, David W., Washington, DC, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2003018180 A1 20030123
AI US 2002-59395 A1 20020131 (10)
RLI Division of Ser. No. US 2001-966262, filed on 1 Oct 2001, PENDING
Continuation of Ser. No. US 1998-154707, filed on 17 Sep 1998, PENDING
Continuation-in-part of Ser. No. WO 1998-US5311, filed on 19 Mar 1998, UNKNOWN
PRAI US 1997-41277P 19970321 (60)
US 1997-42344P 19970321 (60)
US 1997-41276P 19970321 (60)
US 1997-41281P 19970321 (60)
US 1997-48094P 19970530 (60)
US 1997-48350P 19970530 (60)
US 1997-48188P 19970530 (60)
US 1997-48135P 19970530 (60)
US 1997-50937P 19970530 (60)
US 1997-48187P 19970530 (60)
US 1997-48099P 19970530 (60)
US 1997-48352P 19970530 (60)
US 1997-48186P 19970530 (60)
US 1997-48069P 19970530 (60)
US 1997-48095P 19970530 (60)
US 1997-48131P 19970530 (60)
US 1997-48096P 19970530 (60)
US 1997-48355P 19970530 (60)
US 1997-48160P 19970530 (60)
US 1997-48351P 19970530 (60)
US 1997-48154P 19970530 (60)
US 1997-54804P 19970805 (60)
US 1997-56370P 19970819 (60)
US 1997-60862P 19971002 (60)
DT Utility
FS APPLICATION

INCL INCLM: 536/023.200
INCLS: 530/350.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000
NCL NCLM: 536/023.200
NCLS: 530/350.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000
IC [7]
ICM: C07K014-435
ICS: C12P021-02; C12N005-06; C07H021-04; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 291 OF 469 USPATFULL on STN
AN 2003:20224 USPATFULL
TI Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Thompson, Richard C., Frankfort, IN, United States
Wilkie, Stephen C., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Huffman, George W., Carmel, IN, United States
Latimer, Lee H., Oakland, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6509331 B1 20030121
AI US 1999-337484 19990621 (9)
PRAI US 1998-155265P 19980622 (60)
DT Utility
FS GRANTED
LN.CNT 6167
INCL INCLM: 514/212.040
INCLS: 514/212.070; 540/522.000; 540/523.000
NCL NCLM: 514/212.040
NCLS: 514/212.070; 540/522.000; 540/523.000
IC [7]
ICM: C07D487-00
ICS: C07D491-00; C07D498-00; C07D513-00; A61K031-55
EXF 540/522; 540/523; 514/212.04; 514/212.07
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 292 OF 469 USPATFULL on STN
AN 2003:18018 USPATFULL
TI Composition, synthesis and therapeutic applications of polyamines
IN Murphy, Michael A., La Jolla, CA, UNITED STATES
MaLachowski, Mitchell R., San Diego, CA, UNITED STATES
PI US 2003013772 A1 20030116
AI US 2001-17235 A1 20011218 (10)
RLI Continuation-in-part of Ser. No. US 2000-486310, filed on 23 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-US17301, filed on 21 Aug 1998, UNKNOWN A 371 of International Ser. No. US 1997-915660, filed on 21 Aug 1997, GRANTED, Pat. No. US 5906996
DT Utility
FS APPLICATION
LN.CNT 3034
INCL INCLM: 514/674.000
INCLS: 564/512.000
NCL NCLM: 514/674.000
NCLS: 564/512.000
IC [7]
ICM: A61K031-13
ICS: C07C211-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 293 OF 469 USPATFULL on STN
AN 2003:13325 USPATFULL
TI Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Thorsett, Eugene D., Moss Beach, CA, United States
Porter, Warren J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
Audia, James E., Indianapolis, IN, United States
Droste, James, Indianapolis, IN, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.

Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6506782 B1 20030114
AI US 1998-32019 19980227 (9)
DT Utility
FS GRANTED
LN.CNT 9870
INCL INCLM: 514/364.000
NCL NCLM: 514/364.000
IC [7]
ICM: A61K031-4245
EXF 514/364
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 294 OF 469 USPATFULL on STN
AN 2003:3520 USPATFULL
TI 90 human secreted proteins
IN Ruben, Steven M., Olney, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Tewksbury, MA, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Janat, Fouad, Westerly, RI, UNITED STATES
PI US 2003003555 A1 20030102
AI US 2001-774639 A1 20010201 (9)
RLI Continuation of Ser. No. US 1999-244112, filed on 4 Feb 1999, ABANDONED
Continuation-in-part of Ser. No. WO 1998-US16235, filed on 4 Aug 1998, UNKNOWN
PRAI US 1997-55386P 19970805 (60)
US 1997-54807P 19970805 (60)
US 1997-55312P 19970805 (60)
US 1997-55309P 19970805 (60)
US 1997-54798P 19970805 (60)
US 1997-55310P 19970805 (60)
US 1997-54806P 19970805 (60)
US 1997-54809P 19970805 (60)
US 1997-54804P 19970805 (60)
US 1997-54803P 19970805 (60)
US 1997-54808P 19970805 (60)
US 1997-55311P 19970805 (60)
US 1997-55986P 19970818 (60)
US 1997-55970P 19970818 (60)
US 1997-56563P 19970819 (60)
US 1997-56557P 19970819 (60)
US 1997-56731P 19970819 (60)
US 1997-56365P 19970819 (60)
US 1997-56367P 19970819 (60)
US 1997-56370P 19970819 (60)
US 1997-56364P 19970819 (60)
US 1997-56366P 19970819 (60)
US 1997-56732P 19970819 (60)
US 1997-56371P 19970819 (60)
DT Utility
FS APPLICATION
LN.CNT 15472
INCL INCLM: 435/183.000
INCLS: 435/006.000; 435/069.100; 435/325.000; 435/320.100; 530/388.100; 536/023.200
NCL NCLM: 435/183.000
NCLS: 435/006.000; 435/069.100; 435/325.000; 435/320.100; 530/388.100; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12N005-06; C07K016-40; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 295 OF 469 USPATFULL on STN
AN 2002:343934 USPATFULL
TI Novel molecules of the PYRIN domain protein family and uses thereof
IN Bertin, John, Watertown, MA, UNITED STATES

PI US 2002197660 A1 20021226
AI US 2001-27629 A1 20011220 (10)
RLI Continuation-in-part of Ser. No. US 2001-964955, filed on 26 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2000-653901, filed on 1 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-506067, filed on 17 Feb 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4278
INCL INCLM: 435/007.920
NCL NCLM: 435/007.920
IC [7]
ICM: G01N033-53
ICS: G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 296 OF 469 USPATFULL on STN
AN 2002:326008 USPATFULL
TI Microsomal triglyceride transfer protein
IN Wetterau, II, John R., Langhorne, PA, United States
Sharp, Daru Young, Perrineville, NJ, United States
Gregg, Richard E., Pennington, NJ, United States
PA Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)
PI US 6492365 B1 20021210
AI US 1995-486929 19950607 (8)
RLI Division of Ser. No. US 1993-117362, filed on 3 Sep 1993, now patented, Pat. No. US 5595872 Continuation-in-part of Ser. No. US 1993-15449, filed on 22 Feb 1993, now abandoned Continuation-in-part of Ser. No. US 1992-847503, filed on 6 Mar 1992, now abandoned
DT Utility
FS GRANTED
LN.CNT 5043
INCL INCLM: 514/247.000
INCLS: 514/277.000
NCL NCLM: 514/247.000
NCLS: 514/277.000
IC [7]
ICM: C07D261-06
EXF 514/247; 514/277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 297 OF 469 USPATFULL on STN
AN 2002:323196 USPATFULL
TI Method for treating fibrotic diseases or other indications IIIC
IN Wagle, Dilip, New York, NY, UNITED STATES
Gall, Martin, Morristown, NJ, UNITED STATES
Bell, Stanley C., Narberth, PA, UNITED STATES
LaVoie, Edmond J., Princeton Junction, NJ, UNITED STATES
PI US 2002183365 A1 20021205
AI US 2001-36857 A1 20011231 (10)
PRAI US 2001-296246P 20010606 (60)
US 2001-259238P 20010102 (60)
US 2000-259294P 20001229 (60)
DT Utility
FS APPLICATION
LN.CNT 3334
INCL INCLM: 514/341.000
INCLS: 514/252.050; 514/255.050; 514/256.000; 514/242.000; 514/396.000; 514/406.000; 544/182.000; 544/238.000; 544/333.000; 544/405.000; 546/272.700; 546/275.400; 548/346.100; 548/377.100
NCL NCLM: 514/341.000
NCLS: 514/252.050; 514/255.050; 514/256.000; 514/242.000; 514/396.000; 514/406.000; 544/182.000; 544/238.000; 544/333.000; 544/405.000; 546/272.700; 546/275.400; 548/346.100; 548/377.100
IC [7]
ICM: A61K031-53
ICS: A61K031-506; A61K031-501; A61K031-497; A61K031-4439; C07D043-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 298 OF 469 USPATFULL on STN
AN 2002:323192 USPATFULL
TI Heterocyclic sulfonamide inhibitors of ***beta*** ***amyloid*** production
IN Kreft, Anthony F., Langhorne, PA, UNITED STATES

Woller, Kevin R., Ayer, MA, UNITED STATES
Stock, Joseph R., Monroe, NY, UNITED STATES
Diamantidis, George, Randolph, NJ, UNITED STATES
Kubrak, Dennis M., Philadelphia, PA, UNITED STATES
Kutterer, Kristina M., Westwood, NJ, UNITED STATES
Moore, William J., Marlborough, MA, UNITED STATES
Casebier, David S., Carlisle, MA, UNITED STATES
PA ArQule, Woburn, MA, 01801 (U.S. corporation)
PI US 2002183361 A1 20021205
US 6610734 B2 20030826
AI US 2001-14304 A1 20011211 (10)
PRAI US 2000-255105P 20001213 (60)
DT Utility
FS APPLICATION
LN.CNT 3972
INCL INCLM: 514/326.000
INCLS: 514/340.000; 514/381.000; 514/382.000; 514/397.000; 514/398.000; 546/210.000; 546/268.400; 548/315.400; 548/316.400
NCL NCLM: 514/445.000
NCLS: 514/342.000; 514/432.000; 514/444.000; 546/280.400; 549/013.000; 549/060.000; 549/065.000
IC [7]
ICM: C07D045-02
ICS: C07D041-02; A61K031-454; A61K031-4439; A61K031-4178
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 299 OF 469 USPATFULL on STN
AN 2002:315104 USPATFULL
TI Aromatic sulfone hydroxamic acid metalloprotease inhibitor
IN Barta, Thomas E., Evanston, IL, UNITED STATES
Becker, Daniel P., Glenview, IL, UNITED STATES
Bedell, Louis J., Mt. Prospect, IL, UNITED STATES
Boehm, Terri L., Ballwin, MO, UNITED STATES
Carroll, Jeffery N., Collinsville, IL, UNITED STATES
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES
Fobian, Yvette M., Labadie, MO, UNITED STATES
Freskos, John N., Clayton, MO, UNITED STATES
Getman, Daniel P., Chesterfield, MO, UNITED STATES
McDonald, Joseph J., Ballwin, MO, UNITED STATES
Hanson, Gunnar J., Skokie, IL, UNITED STATES
Hockerman, Susan L., Chicago, IL, UNITED STATES
Howard, Susan C., Fenton, MO, UNITED STATES
Kolodziej, Steve A., Ballwin, MO, UNITED STATES
Li, Hui, Vernon Hills, IL, UNITED STATES
Mischke, Deborah A., Defiance, MO, UNITED STATES
Rico, Joseph G., Ballwin, MO, UNITED STATES
Stehle, Nathan W., Ballwin, MO, UNITED STATES
Tollefson, Michael B., O'Fallon, MO, UNITED STATES
Vernier, William F., St. Louis, MO, UNITED STATES
Villamil, Clara I., Glenview, IL, UNITED STATES
PI US 2002177588 A1 20021128
US 6750233 B2 20040615
AI US 2001-954451 A1 20010917 (9)
RLI Division of Ser. No. US 1999-256948, filed on 24 Feb 1999, ABANDONED
PRAI US 1997-66007P 19971114 (60)
US 1998-95347P 19980804 (60)
US 1998-95501P 19980806 (60)
US 1998-101080P 19980918 (60)
DT Utility
FS APPLICATION
LN.CNT 16676
INCL INCLM: 514/211.010
INCLS: 514/217.110; 514/218.000; 514/227.500; 514/237.500; 514/255.010; 514/247.000; 514/327.000; 514/369.000; 514/385.000; 514/423.000
NCL NCLM: 514/336.000
NCLS: 514/342.000; 514/383.000; 514/432.000; 544/374.000; 546/280.100; 548/265.800; 549/028.000
IC [7]
ICM: A61K031-55
ICS: A61K031-553; A61K031-554; A61K031-551; A61K031-54; A61K031-535; A61K031-495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 300 OF 469 USPATFULL on STN
AN 2002:311025 USPATFULL

IN Ebner, Reinhard, Gaithersburg, MD, United States
Murphy, Marianne, Richmond, UNITED KINGDOM
Ruben, Steven M., Olney, MD, United States
Hu, Jing-Shan, Sunnyvale, CA, United States
Duan, D. Roxanne, Bethesda, MD, United States
Florence, Kimberly A., Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6486301 B1 20021126
AI US 1999-231788 19990115 (9)
RLI Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998
PRAI US 1997-52870P 19970716 (60)
US 1997-60140P 19970926 (60)
US 1997-55952P 19970818 (60)
DT Utility
FS GRANTED
LN.CNT 5643
INCL INCLM: 530/351.000
INCLS: 424/085.100
NCL NCLM: 530/351.000
NCLS: 424/085.100
IC [7]
ICM: C07K014-475
ICS: A61K038-19
EXF 530/351; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 301 OF 469 USPATFULL on STN
AN 2002:308378 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002173504 A1 20021121
AI US 2001-915519 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25650
INCL INCLM: 514/212.040
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/212.040
NCLS: 514/327.000; 514/424.000; 514/659.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 302 OF 469 USPATFULL on STN
AN 2002:301209 USPATFULL
TI In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases

Snow, Alan D., Lynnwood, WA, UNITED STATES
PI US 2002168753 A1 20021114
AI US 2001-7779 A1 20011130 (10)
RLI Continuation of Ser. No. US 1999-267795, filed on 12 Mar 1999, ABANDONED
PRAI US 1998-77924P 19980313 (60)
DT Utility
FS APPLICATION
LN.CNT 3150
INCL INCLM: 435/226.000
INCLS: 435/068.100
NCL NCLM: 435/226.000
NCLS: 435/068.100
IC [7]
ICM: C12P021-06
ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 303 OF 469 USPATFULL on STN
AN 2002:300827 USPATFULL
TI Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
IN McDonald, John R., Calgary, AB, UNITED STATES
Coggins, Philip J., Calgary, AB, UNITED STATES
PI US 2002168370 A1 20021114
AI US 2001-792793 A1 20010222 (9)
RLI Division of Ser. No. US 1999-453851, filed on 2 Dec 1999, PENDING
Division of Ser. No. US 1999-360242, filed on 22 Jul 1999, PENDING
Continuation of Ser. No. US 1998-120523, filed on 22 Jul 1998, ABANDONED
PRAI WO 1999-CA659 19990721
US 1998-155186P 19980722 (60)
DT Utility
FS APPLICATION
LN.CNT 7972
INCL INCLM: 424/178.100
INCLS: 514/012.000; 530/389.100; 536/023.530; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 424/178.100
NCLS: 514/012.000; 530/389.100; 536/023.530; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: A61K039-395
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 304 OF 469 USPATFULL on STN
AN 2002:295324 USPATFULL
TI Secreted protein HFEAF41
IN Young, Paul, Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Tewksburg, MA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Duan, Roxanne, Bethesda, MD, UNITED STATES
Hu, Jing-Shan, Sunnyvale, CA, UNITED STATES
Florence, Kimberly, Rockville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Lauie A., St. Paul, MN, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Lafleur, David W., Washington, DC, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
PI US 2002165374 A1 20021107
AI US 2001-984245 A1 20011029 (9)
RLI Division of Ser. No. US 1998-154707, filed on 17 Sep 1998, PENDING
Continuation-in-part of Ser. No. WO 1998-US5311, filed on 19 Mar 1998, UNKNOWN
PRAI US 1997-41277P 19970321 (60)
US 1997-42344P 19970321 (60)
US 1997-41276P 19970321 (60)
US 1997-41281P 19970321 (60)
US 1997-48094P 19970530 (60)
US 1997-48350P 19970530 (60)
US 1997-48188P 19970530 (60)
US 1997-48135P 19970530 (60)

US 1997-48187P 19970530 (60)
US 1997-48099P 19970530 (60)
US 1997-48352P 19970530 (60)
US 1997-48186P 19970530 (60)
US 1997-48069P 19970530 (60)
US 1997-48095P 19970530 (60)
US 1997-48131P 19970530 (60)
US 1997-48096P 19970530 (60)
US 1997-48355P 19970530 (60)
US 1997-48160P 19970530 (60)
US 1997-48351P 19970530 (60)
US 1997-48154P 19970530 (60)
US 1997-54804P 19970805 (60)
US 1997-56370P 19970819 (60)
US 1997-60862P 19971002 (60)
DT Utility
FS APPLICATION
LN.CNT 15075
INCL INCLM: 536/023.100
INCLS: 435/006.000; 435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000
NCL NCLM: 536/023.100
NCLS: 435/006.000; 435/007.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000
IC [7]
ICM: C07H021-04
ICS: C12Q001-68; G01N033-53; C12N009-00; C12N005-06; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 305 OF 469 USPATFULL on STN
AN 2002:294717 USPATFULL
TI Catalytically active recombinant memapsin and methods of use thereof
IN Lin, Xinli, Edmond, OK, UNITED STATES
Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
Tang, Jordan J.N., Edmond, OK, UNITED STATES
PA Oklahoma Medical Research Foundation
PI US 2002164760 A1 20021107
AI US 2001-795903 A1 20010228 (9)
RLI Division of Ser. No. US 2000-604608, filed on 27 Jun 2000, PENDING
PRAI US 1999-141363P 19990628 (60)
US 1999-168060P 19991130 (60)
US 2000-177836P 20000125 (60)
US 2000-178368P 20000127 (60)
US 2000-210292P 20000608 (60)
DT Utility
FS APPLICATION
LN.CNT 2440
INCL INCLM: 435/220.000
INCLS: 435/069.100; 435/252.300; 435/320.100
NCL NCLM: 435/220.000
NCLS: 435/069.100; 435/252.300; 435/320.100
IC [7]
ICM: C12N009-52
ICS: C12P021-02; C12N001-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 306 OF 469 USPATFULL on STN
AN 2002:291111 USPATFULL
TI Compounds for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Reel, Jon K., Carmel, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Folmer, Beverly K., Newark, DE, United States
Droste, James J., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 6476263 B1 20021105
AI US 2001-826412 20010403 (9)
RLI Continuation of Ser. No. US 1998-164448, filed on 30 Sep 1998, now patented, Pat. No. US 6211235 Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997, now patented, Pat. No. US 6191166
PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-108161P 19970228 (60)
US 1997-98558P 19970228 (60)
DT Utility
FS GRANTED
LN.CNT 12409
INCL INCLM: 564/152.000
INCLS: 564/153.000; 564/159.000; 564/160.000; 564/161.000; 564/041.000; 560/041.000; 562/450.000
NCL NCLM: 564/152.000
NCLS: 560/041.000; 562/450.000; 564/041.000; 564/153.000; 564/159.000; 564/160.000; 564/161.000
IC [7]
ICM: C07C233-00
EXF 564/152; 564/153; 564/159; 564/160; 564/161; 560/41; 562/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 307 OF 469 USPATFULL on STN
AN 2002:290742 USPATFULL
TI 94 Human Secreted Proteins
IN Ruben, Steven M., Olney, MD, United States
Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Wei, Ying-Fei, Berkeley, CA, United States
Young, Paul, Gaithersburg, MD, United States
Florence, Kimberly, Rockville, MD, United States
Soppet, Daniel R., Centreville, VA, United States
Brewer, Laurie A., St. Paul, MN, United States
Endress, Gregory A., Potomac, MD, United States
Carter, Kenneth C., Potomac, MD, United States
Mucenski, Michael, Cincinnati, OH, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Lafleur, David W., Washington, DC, United States
Olsen, Henrik, Gaithersburg, MD, United States
Shi, Yanggu, Gaithersburg, MD, United States
Moore, Paul A., Germantown, MD, United States
Komatsoulis, George, Silver Spring, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6475753 B1 20021105
AI US 1999-461325 19991214 (9)
RLI Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999
PRAI US 1998-89507P 19980616 (60)
US 1998-89508P 19980616 (60)
US 1998-89509P 19980616 (60)
US 1998-89510P 19980616 (60)
US 1998-90112P 19980622 (60)
US 1998-90113P 19980622 (60)
DT Utility
FS GRANTED
LN.CNT 18031
INCL INCLM: 435/069.100
INCLS: 435/069.400; 435/071.100; 435/252.300; 435/032.500; 435/320.100; 435/471.000; 536/023.500; 530/350.000
NCL NCLM: 435/069.100
NCLS: 435/069.400; 435/071.100; 435/252.300; 435/320.100; 435/325.000; 435/471.000; 530/350.000; 536/023.500
IC [7]
ICM: C12P021-02
ICS: C12N015-12; C12N005-10; C07K014-47
EXF 435/69.1; 435/69.4; 435/71.1; 435/91.1; 435/252.3; 435/325; 435/320.1; 435/471; 536/23.5; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 308 OF 469 USPATFULL on STN
AN 2002:290736 USPATFULL
TI Identification of agents that protect against inflammatory injury to neurons
IN Giulian, Dana, Houston, TX, United States

corporation)
PI US 6475745 B1 20021105
AI US 1997-922889 19970903 (8)
RLI Division of Ser. No. US 1996-717551, filed on 20 Sep 1996
DT Utility
FS GRANTED
LN.CNT 2755
INCL INCLM: 435/007.200
INCLS: 530/300.000; 530/350.000; 530/402.000
NCL NCLM: 435/007.200
NCLS: 530/300.000; 530/350.000; 530/402.000
IC [7]
ICM: G01N033-53
ICS: C07K007-00; C07K004-12
EXF 435/7.2; 435/7.1; 530/300; 530/350; 530/402; 424/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 309 OF 469 USPATFULL on STN
AN 2002:288118 USPATFULL
TI Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
IN Amitai, Gabriel, Rehovot, ISRAEL
Adani, Rachel, Moshav Gealia, ISRAEL
Rabinovitz, Ishai, Nes Ziona, ISRAEL
Sod-Moriah, Gali, Rehovot, ISRAEL
Meshulam, Haim, Bat Yam, ISRAEL
PA Israel Institute for Biological Research (non-U.S. corporation)
PI US 2002160988 A1 20021031
AI US 2001-906952 A1 20010716 (9)
PRAI US 2001-269343P 20010220 (60)
DT Utility
FS APPLICATION
LN.CNT 2876
INCL INCLM: 514/159.000
INCLS: 514/094.000; 514/063.000; 514/406.000
NCL NCLM: 514/159.000
NCLS: 514/094.000; 514/063.000; 514/406.000
IC [7]
ICM: A61K031-695
ICS: A61K031-675; A61K031-415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 310 OF 469 USPATFULL on STN
AN 2002:288114 USPATFULL
TI Fused tricyclic compounds, methods and compositions for inhibiting parp activity
IN Li, Jia-He, Cockeysville, MD, UNITED STATES
Zhang, Jie, Ellicott City, MD, UNITED STATES
PA Guilford Pharmaceuticals Inc. (U.S. corporation)
PI US 2002160984 A1 20021031
AI US 2002-109645 A1 20020401 (10)
RLI Continuation of Ser. No. US 1998-145184, filed on 1 Sep 1998, GRANTED, Pat. No. US 6380193 Continuation-in-part of Ser. No. US 1998-79510, filed on 15 May 1998, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3225
INCL INCLM: 514/080.000
INCLS: 514/295.000; 546/098.000; 546/023.000
NCL NCLM: 514/080.000
NCLS: 514/295.000; 546/098.000; 546/023.000
IC [7]
ICM: A61K031-675
ICS: C07D221-04; A61K031-473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 311 OF 469 USPATFULL on STN
AN 2002:283310 USPATFULL
TI Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
IN Schubert, David R., La Jolla, CA, United States
Liu, Yuanbin, San Diego, CA, United States
PA The Salk Institute for Biological Studies, La Jolla, CA, United States (U.S. corporation)
PI US 6472436 B1 20021029

T Utility
S GRANTED
N.CNT 1189
NCL INCLM: 514/731.000
INCLS: 514/453.000; 514/456.000
CL NCLM: 514/731.000
NCLS: 514/453.000; 514/456.000
C [7]
ICM: A61K031-05
ICS: A61K031-35
XF 514/731; 514/453; 514/456
AS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 312 OF 469 USPATFULL on STN
AN 2002:282980 USPATFULL
TI Methods for the prevention or treatment of alzheimer's disease
N Anderson, Stephen, Princeton, NJ, United States
PA Rutgers, the State University, New Brunswick, NJ, United States (U.S. corporation)
PI US 6471960 B1 20021029
AI US 2000-660954 20000913 (9)
LI Division of Ser. No. US 1999-388890, filed on 2 Sep 1999, now patented, Pat. No. US 6136548 Continuation of Ser. No. US 1996-686959, filed on 26 Jul 1996, now abandoned Continuation-in-part of Ser. No. WO 1995-US15007, filed on 22 Nov 1995 Continuation-in-part of Ser. No. US 1994-347144, filed on 22 Nov 1994, now patented, Pat. No. US 5589154
OT Utility
S GRANTED
LN.CNT 1730
INCL INCLM: 424/094.640
INCLS: 424/001.410; 424/001.490; 435/007.100; 435/172.100
NCL NCLM: 424/094.640
NCLS: 424/001.410; 424/001.490; 435/007.100; 435/455.000
IC [7]
ICM: A61K038-48
ICS: A61M036-14; G01N033-53; C12N013-00
EXF 424/1.41; 424/1.49; 424/94.64; 435/172.1; 435/7.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 313 OF 469 USPATFULL on STN
AN 2002:280605 USPATFULL
TI Carboxamine compounds, methods and compositions for inhibiting PARP activity
IN Li, Jia-He, Cockeysville, MD, UNITED STATES
Zhang, Jie, Ellicott City, MD, UNITED STATES
PA Guilford Pharmaceuticals Inc. (U.S. corporation)
PI US 2002156050 A1 20021024
AI US 2002-109646 A1 20020401 (10)
RLI Continuation of Ser. No. US 1998-145178, filed on 1 Sep 1998, GRANTED, Pat. No. US 6395749 Continuation-in-part of Ser. No. US 1998-79514, filed on 15 May 1998, ABANDONED
OT Utility
FS APPLICATION
LN.CNT 3539
INCL INCLM: 514/080.000
INCLS: 514/224.200; 514/230.500; 514/247.000; 514/266.200; 514/266.230; 514/266.240; 514/314.000; 514/312.000; 544/014.000; 544/105.000; 544/244.000; 544/284.000; 544/285.000; 546/153.000; 546/156.000
NCL NCLM: 514/080.000
NCLS: 514/224.200; 514/230.500; 514/247.000; 514/266.200; 514/266.230; 514/266.240; 514/314.000; 514/312.000; 544/014.000; 544/105.000; 544/244.000; 544/284.000; 544/285.000; 546/153.000; 546/156.000
IC [7]
ICM: A61K031-675
ICS: A61K031-5415; A61K031-538; A61K031-517; A61K031-4709
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 314 OF 469 USPATFULL on STN
AN 2002:280116 USPATFULL
TI "PRIONINS", HIGHLY SPECIFIC MARKERS FOR NONINVASIVE PRE-SYMPTOMATIC DETECTION OF TSE DISEASES, AND TARGETS FOR THERAPEUTIC REAGENTS TO PREVENT AND CONTROL TSE DISEASES IN ANIMALS AND HUMANS
IN BERGMANN, JOHANNA, HAMBURG, GERMANY, FEDERAL REPUBLIC OF
PREDDIE, ENRIQUE, MONTREAL, CANADA
PI US 2002155552 A1 20021024

WO 1998-EP3609 19980616
PRAI CA 1997-2206774 19970616
DT Utility
FS APPLICATION
LN.CNT 1040
INCL INCLM: 435/110.000
NCL NCLM: 435/110.000
IC [7]
ICM: C12P013-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 315 OF 469 USPATFULL on STN
AN 2002:279992 USPATFULL
TI Prevention and treatment of amyloid-associated disorders
IN Cordell, Barbara, Palo Alto, CA, UNITED STATES
Xu, Qiang, Cupertino, CA, UNITED STATES
Naidu, Asha, Fremont, CA, UNITED STATES
Paul, Steven M., Carmel, IN, UNITED STATES
Bales, Kelly R., Cloverdale, IN, UNITED STATES
PI US 2002155426 A1 20021024
AI US 2002-172268 A1 20020614 (10)
RLI Division of Ser. No. US 1999-447452, filed on 22 Nov 1999, GRANTED, Pat. No. US 6428950
PRAI US 1998-109910P 19981125 (60)
DT Utility
FS APPLICATION
LN.CNT 1484
INCL INCLM: 435/004.000
INCLS: 435/007.210
NCL NCLM: 435/004.000
NCLS: 435/007.210
IC [7]
ICM: C12Q001-00
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 316 OF 469 USPATFULL on STN
AN 2002:273410 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James A., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002151538 A1 20021017
US 6579867 B2 20030617
AI US 2001-915379 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26543
INCL INCLM: 514/212.040
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080
IC [7]
ICM: A61K031-55

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 317 OF 469 USPATFULL on STN
AN 2002:272761 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
Markland, William, Milford, MA, UNITED STATES
Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PI US 2002150881 A1 20021017
AI US 2001-781988 A1 20010214 (9)
RLI Continuation of Ser. No. US 1998-192067, filed on 16 Nov 1998, ABANDONED
Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED
Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED
Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED
Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, ABANDONED
PRAI WO 1989-US3731 19890901
DT Utility
FS APPLICATION
LN.CNT 15696
INCL INCLM: 435/005.000
INCLS: 435/006.000; 435/007.100; 435/235.100
NCL NCLM: 435/005.000
NCLS: 435/006.000; 435/007.100; 435/235.100
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; G01N033-53; C12N007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 318 OF 469 USPATFULL on STN
AN 2002:259529 USPATFULL
TI Discordant helix stabilization for prevention of amyloid formation
IN Johansson, Jan, Stockholm, SWEDEN
PI US 2002143105 A1 20021003
US 6716589 B2 20040406
AI US 2001-988842 A1 20011119 (9)
PRAI US 2000-253695P 20001120 (60)
US 2000-251662P 20001206 (60)
DT Utility
FS APPLICATION
LN.CNT 1541
INCL INCLM: 525/054.100
NCL NCLM: 435/007.200
IC [7]
ICM: C08H001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 319 OF 469 USPATFULL on STN
AN 2002:259408 USPATFULL
TI Gene expression profiles in liver cancer
IN Horne, Darci T., Gaithersburg, MD, UNITED STATES
Scherf, Uwe, Gaithersburg, MD, UNITED STATES
Vockley, Joseph, Damascus, MD, UNITED STATES
PI US 2002142981 A1 20021003
AI US 2001-880107 A1 20010614 (9)
PRAI US 2000-211379P 20000614 (60)
US 2000-237054P 20001002 (60)
DT Utility
FS APPLICATION
LN.CNT 15937
INCL INCLM: 514/044.000
INCLS: 435/006.000
NCL NCLM: 514/044.000
NCLS: 435/006.000
IC [7]
ICM: A61K048-00
ICS: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 320 OF 469 USPATFULL on STN
AN 2002:251785 USPATFULL

compositions comprising same, and methods for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002137738 A1 20020926
US 6559141 B2 20030506
AI US 2001-915564 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26049
INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080; 540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000; 540/527.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 321 OF 469 USPATFULL on STN
AN 2002:251784 USPATFULL
TI Lactams substituted by cyclic succinates as inhibitors of a beta protein production
IN Olson, Richard E., Wilmington, DE, UNITED STATES
PI US 2002137737 A1 20020926
US 6509333 B2 20030121
AI US 2001-871840 A1 20010601 (9)
PRAI US 2000-208536P 20000601 (60)
DT Utility
FS APPLICATION
LN.CNT 6581
INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 540/527.000; 546/216.000; 548/550.000
NCL NCLM: 514/221.000
NCLS: 540/509.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; C07D211-54; C07D223-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 322 OF 469 USPATFULL on STN
AN 2002:243133 USPATFULL
TI Peptide mutant of human ERAB or HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof
IN Abreo, Melwyn A., Jamul, CA, UNITED STATES
Agree, Charles S., San Diego, CA, UNITED STATES
Aust, Robert M., Alpine, CA, UNITED STATES
Kissinger, Charles R., San Diego, CA, UNITED STATES
Margosiak, Stephen, Escondido, CA, UNITED STATES
Meng, Jerry J., San Diego, CA, UNITED STATES
Pelletier, Laura A., Escondido, CA, UNITED STATES

Snowalter, Richard Edward, Santee, CA, UNITED STATES
Thomson, James Arthur, San Diego, CA, UNITED STATES
Tempczyk-Russell, Anna, Ramona, CA, UNITED STATES
Vanderpool, Darin, San Diego, CA, UNITED STATES
Villafranca, Jesus Ernesto, San Diego, CA, UNITED STATES
PI US 2002132319 A1 20020919
AI US 2001-931186 A1 20010817 (9)
PRAI US 2000-226123P 20000818 (60)
DT Utility
FS APPLICATION
LN.CNT 12914
INCL INCLM: 435/189.000
INCLS: 435/226.000; 536/023.200; 435/069.100; 702/019.000
NCL NCLM: 435/189.000
NCLS: 435/226.000; 536/023.200; 435/069.100; 702/019.000
IC [7]
ICM: C12N009-02
ICS: C12N009-64; G06F019-00; G01N033-48; G01N033-50; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 323 OF 469 USPATFULL on STN
AN 2002:237182 USPATFULL
TI Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
IN De La Monte, Suzanne, East Greenwich, RI, UNITED STATES
Wands, Jack R., Waban, MA, UNITED STATES
PI US 2002129391 A1 20020912
AI US 2001-964412 A1 20010928 (9)
RLI Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371 of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN
PRAI US 1997-38908P 19970226 (60)
DT Utility
FS APPLICATION
LN.CNT 2087
INCL INCLM: 800/012.000
INCLS: 800/018.000; 435/368.000; 435/320.100; 536/023.200
NCL NCLM: 800/012.000
NCLS: 800/018.000; 435/368.000; 435/320.100; 536/023.200
IC [7]
ICM: A01K067-027
ICS: C07H021-04; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 324 OF 469 USPATFULL on STN
AN 2002:228326 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002123486 A1 20020905
US 6632811 B2 20031014
AI US 2001-915342 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)

FS APPLICATION
LN.CNT 26177
INCL INCLM: 514/212.020
INCLS: 514/659.000
NCL NCLM: 514/220.000
NCLS: 514/221.000
IC [7]
ICM: A61K031-55
ICS: A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 325 OF 469 USPATFULL on STN
AN 2002:217305 USPATFULL
TI Alpha-(4-Ethoxyphenyl)-N-tert-butylnitrone, pharmaceutical compositions and their medical use
IN Kelleher, Judith A., Fremont, CA, United States
Maples, Kirk R., San Jose, CA, United States
Dykman, Alina, San Francisco, CA, United States
Zhang, Yong-Kang, Santa Clara, CA, United States
Wilcox, Allan L., Mountain View, CA, United States
Levell, Julian, Collegeville, PA, United States
PA Centaur Pharmaceuticals, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6441032 B1 20020827
AI US 2000-635527 20000809 (9)
RLI Division of Ser. No. US 2000-500650, filed on 9 Feb 2000 Continuation of Ser. No. US 1998-172763, filed on 15 Oct 1998, now patented, Pat. No. US 6046232
PRAI US 1997-62324P 19971017 (60)
US 1997-63736P 19971029 (60)
US 1998-90475P 19980624 (60)
DT Utility
FS GRANTED
LN.CNT 2317
INCL INCLM: 514/464.000
INCLS: 514/640.000; 514/645.000; 564/300.000; 564/265.000
NCL NCLM: 514/464.000
NCLS: 514/640.000; 514/645.000; 564/265.000; 564/300.000
IC [7]
ICM: A61K031-34
EXF 514/464; 514/640; 514/645; 564/300; 564/265; 564/434; 564/432
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 326 OF 469 USPATFULL on STN
AN 2002:214328 USPATFULL
TI Amyloid targeting imaging agents and uses thereof
IN Gervais, Francine, Ile Bizard, CANADA
Kong, Xianqi, Dollard-des-Ormeaux, CANADA
Chalifour, Robert, Ile Bizard, CANADA
Migneault, David, Laval, CANADA
PI US 2002115717 A1 20020822
AI US 2001-915092 A1 20010724 (9)
PRAI US 2000-220808P 20000725 (60)
DT Utility
FS APPLICATION
LN.CNT 2210
INCL INCLM: 514/553.000
INCLS: 424/001.110
NCL NCLM: 514/553.000
NCLS: 424/001.110
IC [7]
ICM: A61K031-185
ICS: A61K051-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 327 OF 469 USPATFULL on STN
AN 2002:214264 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES

Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002115652 A1 20020822
US 6541466 B2 20030401
AI US 2001-915362 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25618
INCL INCLM: 514/212.010
INCLS: 514/248.000; 514/258.000; 514/279.000; 514/410.000; 514/659.000
NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080; 540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000; 540/527.000
IC [7]
ICM: A61K031-55
ICS: A61K031-519; A61K031-5025; A61K031-4745; A61K031-407; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 328 OF 469 USPATFULL on STN
AN 2002:214213 USPATFULL
TI Inhibitors of memapsin 2 and use thereof
IN Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
Tang, Jordan J.N., Edmond, OK, UNITED STATES
Hong, Lin, Oklahoma City, OK, UNITED STATES
Ghosh, Arun K., River Forest, IL, UNITED STATES
PA Oklahoma Medical Research Foundation (U.S. corporation)
PI US 2002115600 A1 20020822
AI US 2001-845226 A1 20010430 (9)
RLI Division of Ser. No. US 2000-603713, filed on 27 Jun 2000, PENDING
PRAI US 1999-141363P 19990628 (60)
US 1999-168060P 19991130 (60)
US 2000-177836P 20000125 (60)
US 2000-178368P 20000127 (60)
US 2000-210292P 20000608 (60)
DT Utility
FS APPLICATION
LN.CNT 2377
INCL INCLM: 514/012.000
INCLS: 435/184.000; 530/326.000
NCL NCLM: 514/012.000
NCLS: 435/184.000; 530/326.000
IC [7]
ICM: A61K038-17
ICS: A61K038-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 329 OF 469 USPATFULL on STN
AN 2002:213843 USPATFULL
TI In vitro system for determining formation of ***abeta*** amyloid
IN Tanzi, Rudolph E., Hull, MA, UNITED STATES
Bush, Ashley I., Sommerville, MA, UNITED STATES
PA The General Hospital Corporation (U.S. corporation)
PI US 2002115223 A1 20020822
AI US 2002-41605 A1 20020110 (10)
RLI Division of Ser. No. US 1994-294819, filed on 26 Aug 1994, GRANTED, Pat. No. US 6365414
DT Utility
FS APPLICATION

INCL INCLM: 436/086.000
INCLS: 422/061.000
NCL NCLM: 436/086.000
NCLS: 422/061.000
IC [7]
ICM: G01N033-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 330 OF 469 USPATFULL on STN
AN 2002:209571 USPATFULL
TI Modulation of nitric oxide production
IN Vitek, Michael P., Apex, NC, United States
Colton, Carol A., Silver Spring, MD, United States
PA Duke University, Durham, NC, United States (U.S. corporation)
Georgetown University, Washington, DC, United States (U.S. corporation)
PI US 6436996 B1 20020820
AI US 1997-940594 19970930 (8)
DT Utility
FS GRANTED
LN.CNT 567
INCL INCLM: 514/565.000
INCLS: 514/506.000; 514/561.000; 514/625.000; 514/626.000; 514/627.000; 514/706.000; 514/742.000; 514/724.000; 514/747.000
NCL NCLM: 514/565.000
NCLS: 514/506.000; 514/561.000; 514/625.000; 514/626.000; 514/627.000; 514/706.000; 514/724.000; 514/742.000; 514/747.000
IC [7]
ICM: A61K031-195
ICS: A61K031-21; A61K031-16; A61K031-04
EXF 514/561; 514/742; 514/565; 514/724; 514/747; 514/706; 514/625; 514/626; 514/627; 514/506
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 331 OF 469 USPATFULL on STN
AN 2002:206646 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***beta*** - ***Amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Varghese, John, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002111343 A1 20020815
AI US 2001-915547 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25803
INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/212.030
NCLS: 514/327.000; 514/424.000; 514/659.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 332 OF 469 USPATFULL on STN
AN 2002:202241 USPATFULL
TI Death domain containing receptor-4
IN Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Pan, James G., Belmont, CA, United States
Gentz, Reiner L., Rockville, MD, United States
Dixit, Vishva M., Los Altos Hills, CA, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)
PI US 6433147 B1 20020813
AI US 2000-565918 20000505 (9)
RLI Continuation-in-part of Ser. No. US 1998-13895, filed on 27 Jan 1998, now patented, Pat. No. US 6342363
PRAI US 1999-132922P 19990506 (60)
US 1997-35722P 19970128 (60)
US 1997-37829P 19970205 (60)
DT Utility
FS GRANTED
LN.CNT 8675
INCL INCLM: 530/387.300
INCLS: 530/300.000; 530/350.000; 530/402.000; 536/023.100; 536/023.500; 435/069.100; 435/325.000; 435/252.300; 435/254.110; 424/178.100
NCL NCLM: 530/387.300
NCLS: 424/178.100; 435/069.100; 435/252.300; 435/254.110; 435/325.000; 530/300.000; 530/350.000; 530/402.000; 536/023.100; 536/023.500
IC [7]
ICM: C07K014-705
EXF 530/300; 530/350; 530/402; 530/387.3; 536/23.1; 536/23.5; 536/23.4; 435/69.1; 435/375; 435/252.3; 435/254.11; 424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 333 OF 469 USPATFULL on STN
AN 2002:202122 USPATFULL
TI .alpha.-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
IN Kelleher, Judith A., Fremont, CA, United States
Maples, Kirk R., San Jose, CA, United States
Dykman, Alina, San Fransisco, CA, United States
Zhang, Yong-Kang, San Jose, CA, United States
Wilcox, Allan L., Mountain View, CA, United States
Levell, Julian, Bridgewater, NJ, United States
PA Centaur Pharmaceuticals, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6433008 B1 20020813
AI US 2000-529555 20000718 (9)
PRAI US 1997-62324P 19971017 (60)
US 1997-63736P 19971029 (60)
US 1998-90475P 19980624 (60)
DT Utility
FS GRANTED
LN.CNT 2452
INCL INCLM: 514/464.000
NCL NCLM: 514/464.000
IC [7]
ICM: A61K031-36
EXF 514/464
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 334 OF 469 USPATFULL on STN
AN 2002:194690 USPATFULL
TI Assay to identify compounds that alter apolipoprotein E expression
IN Cordell, Barbara, Palo Alto, CA, United States
Xu, Qiang, Cupertino, CA, United States
Naidu, Asha, Fremont, CA, United States
Paul, Steven M., Carmel, IN, United States
Bales, Kelly R., Cloverdale, IN, United States
PA Scios Inc., Sunnyvale, CA, United States (U.S. corporation)
Eli Lilly & Co., Indianapolis, IN, United States (U.S. corporation)
PI US 6428950 B1 20020806
AI US 1999-447452 19991122 (9)
PRAI US 1998-109910P 19981125 (60)
DT Utility

LN.CNT 1499
INCL INCLM: 435/004.000
INCLS: 435/007.210; 435/070.300; 424/570.000; 424/572.000; 424/577.000; 514/001.000
NCL NCLM: 435/004.000
NCLS: 424/570.000; 424/572.000; 424/577.000; 435/007.210; 435/070.300; 514/001.000
IC [7]
ICM: C12Q001-00
ICS: G01N033-567; C12P021-04; A61K035-30; A61K035-12
EXF 424/562; 435/4; 435/7.21; 435/70.3; 514/1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 335 OF 469 USPATFULL on STN
AN 2002:193030 USPATFULL
TI Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
IN De La Monte, Suzanne, East Greenwich, RI, UNITED STATES
Wands, Jack R., Waban, MA, UNITED STATES
PI US 2002104108 A1 20020801
AI US 2001-964666 A1 20010928 (9)
RLI Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371 of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN
PRAI US 1997-38908P 19970226 (60)
DT Utility
FS APPLICATION
LN.CNT 2100
INCL INCLM: 800/012.000
INCLS: 800/018.000; 435/325.000; 435/368.000; 435/320.100; 536/023.200
NCL NCLM: 800/012.000
NCLS: 800/018.000; 435/325.000; 435/368.000; 435/320.100; 536/023.200
IC [7]
ICM: A01K067-027
ICS: C07H021-04; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 336 OF 469 USPATFULL on STN
AN 2002:192156 USPATFULL
TI Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
IN Sankaranarayanan, Alangudi, Ahmedabad, INDIA
PA TORRENT PHARMACEUTICALS LTD. (non-U.S. corporation)
PI US 2002103228 A1 20020801
AI US 2001-995731 A1 20011129 (9)
RLI Continuation-in-part of Ser. No. US 2000-590143, filed on 9 Jun 2000, PENDING Continuation of Ser. No. WO 1999-IB1687, filed on 15 Oct 1999, UNKNOWN Continuation of Ser. No. US 2001-939702, filed on 28 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-801778, filed on 9 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-598410, filed on 21 Jun 2000, PENDING Continuation-in-part of Ser. No. WO 1999-IB1683, filed on 15 Oct 1999, UNKNOWN
PRAI IN 1999-82899 19991006
IN 1999-82799 19991006
DT Utility
FS APPLICATION
LN.CNT 5800
INCL INCLM: 514/336.000
INCLS: 424/401.000; 514/354.000
NCL NCLM: 514/336.000
NCLS: 424/401.000; 514/354.000
IC [7]
ICM: A61K031-44
ICS: A61K007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 337 OF 469 USPATFULL on STN
AN 2002:191539 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2002102604 A1 20020801
AI US 2000-731872 A1 20001207 (9)
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)

FS APPLICATION
LN.CNT 28061
INCL INCLM: 435/007.100
INCLS: 536/023.100; 530/350.000
NCL NCLM: 435/007.100
NCLS: 536/023.100; 530/350.000
IC [7]
ICM: G01N033-53
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 338 OF 469 USPATFULL on STN
AN 2002:188403 USPATFULL
TI Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
IN Jackson, Paul F., Bel Air, MD, United States
Maclin, Keith M., Baltimore, MD, United States
Zhang, Jie, Ellicott City, MD, United States
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6426415 B1 20020730
AI US 1998-79508 19980515 (9)
RLI Continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997
DT Utility
FS GRANTED
LN.CNT 2307
INCL INCLM: 544/237.000
INCLS: 546/137.000
NCL NCLM: 544/237.000
NCLS: 546/137.000
IC [7]
ICM: C07D237-30
EXF 546/137; 544/237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 339 OF 469 USPATFULL on STN
AN 2002:178549 USPATFULL
TI Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
IN Chalifour, Robert, Ile Bizard, CANADA
Hebert, Lise, Brossard, CANADA
Kong, Xianqi, Dollard-des-Oremaux, CANADA
Gervais, Francine, Ile Bizard, CANADA
PI US 2002094335 A1 20020718
AI US 2001-867847 A1 20010529 (9)
RLI Continuation-in-part of Ser. No. US 2000-724842, filed on 28 Nov 2000, PENDING
PRAI US 1999-168594P 19991129 (60)
DT Utility
FS APPLICATION
LN.CNT 1946
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 340 OF 469 USPATFULL on STN
AN 2002:174785 USPATFULL
TI Assay for compounds which affect conformationally altered proteins
IN Prusiner, Stanley B., San Francisco, CA, United States
Supattapone, Surachai, San Francisco, CA, United States
Scott, Michael R., San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6419916 B1 20020716
AI US 1999-406972 19990928 (9)
RLI Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999, now patented, Pat. No. US 6214366
DT Utility
FS GRANTED
LN.CNT 1807
INCL INCLM: 424/078.320
INCLS: 424/078.350; 424/078.360; 424/078.370; 424/078.380; 424/DIG.016
NCL NCLM: 424/078.320

IC [7]
ICM: A61K031-785
EXF 424/78.16; 424/78.32; 424/78.35-78.38; 514/772.3-732.7; 435/238; 435/339; 523/105; 523/122
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 341 OF 469 USPATFULL on STN
AN 2002:157666 USPATFULL
TI Agents for use in the treatment of alzheimer's disease
IN Bush, Ashley I., Somerville, MA, UNITED STATES
Huang, Xudong, Cambridge, MA, UNITED STATES
Atwood, Craig S., Somerville, MA, UNITED STATES
Tanzi, Rudolph E., Canton, MA, UNITED STATES
PI US 2002082273 A1 20020627
AI US 2001-956980 A1 20010921 (9)
RLI Division of Ser. No. US 1998-38154, filed on 11 Mar 1998, PATENTED
DT Utility
FS APPLICATION
LN.CNT 4007
INCL INCLM: 514/291.000
INCLS: 514/298.000; 514/562.000; 514/566.000; 514/420.000; 514/707.000
NCL NCLM: 514/291.000
NCLS: 514/298.000; 514/562.000; 514/566.000; 514/420.000; 514/707.000
IC [7]
ICM: A61K031-4745
ICS: A61K031-473; A61K031-195; A61K031-198; A61K031-405; A61K031-105
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 342 OF 469 USPATFULL on STN
AN 2002:157080 USPATFULL
TI NARC8 programmed cell-death-associated molecules and uses thereof
IN Chiang, Lillian Wei-Ming, Cambridge, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2002081679 A1 20020627
AI US 2001-775009 A1 20010201 (9)
RLI Continuation-in-part of Ser. No. US 2000-692785, filed on 20 Oct 2000, PENDING
PRAI US 1999-161188P 19991022 (60)
DT Utility
FS APPLICATION
LN.CNT 4095
INCL INCLM: 435/183.000
INCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200; 435/226.000
NCL NCLM: 435/183.000
NCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200; 435/226.000
IC [7]
ICM: C12N009-00
ICS: C12N009-64; C07H021-04; C12N005-06; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 343 OF 469 USPATFULL on STN
AN 2002:152685 USPATFULL
TI Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
IN Vitek, Michael P., 205 Park Knoll La., Apex, NC, United States 27502
Cerami, Anthony, Ram Island Dr., Shelter Island, NY, United States 11964
Bucala, Richard J., 504 E. 63rd St. Apt. 33-0, New York, NY, United States 10021
Ulrich, Peter C., 148 DeWolf Rd., Old Tappan, NJ, United States 07675
Vlassara, Helen, Ram Island Dr., Shelter Island, NY, United States 11964
Zhang, Xini, 150 Fairhaven Dr. Apt. D1, Jericho, NY, United States 117534)
PI US 6410598 B1 20020625
AI US 1995-477364 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-457169, filed on 1 Jun 1995
Continuation-in-part of Ser. No. WO 1995-US1380, filed on 2 Feb 1995
Continuation-in-part of Ser. No. US 1994-311768, filed on 23 Sep 1994, now abandoned Continuation of Ser. No. US 1994-191579, filed on 3 Feb 1994, now abandoned
DT Utility
FS GRANTED
LN.CNT 2202
INCL INCLM: 514/632.000

NCL NCLM: 514/632.000
NCLS: 514/020.000; 514/229.800; 514/331.000; 514/634.000
IC [7]
ICM: A01N037-52
ICS: A61K031-155
EXF 514/632; 514/634; 514/400; 514/562; 514/866; 514/20; 514/45; 514/229.8; 514/331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 344 OF 469 USPATFULL on STN
AN 2002:133892 USPATFULL
TI Mitochondria protecting agents for treating mitochondria associated diseases
IN Ghosh, Soumitra S., San Diego, CA, UNITED STATES
Miller, Scott W., San Marcos, CA, UNITED STATES
Davis, Robert E., San Diego, CA, UNITED STATES
Moos, Walter H., Oakland, CA, UNITED STATES
PI US 2002068750 A1 20020606
AI US 2001-919684 A1 20010731 (9)
RLI Continuation of Ser. No. US 1999-461488, filed on 14 Dec 1999, ABANDONED
Division of Ser. No. US 1999-237999, filed on 26 Jan 1999, ABANDONED
PRAI US 1998-72484P 19980126 (60)
US 1998-72487P 19980126 (60)
US 1998-72483P 19980126 (60)
US 1998-72482P 19980126 (60)
DT Utility
FS APPLICATION
LN.CNT 1685
INCL INCLM: 514/311.000
INCLS: 514/456.000; 514/547.000; 514/634.000; 514/646.000; 514/658.000
NCL NCLM: 514/311.000
NCLS: 514/456.000; 514/547.000; 514/634.000; 514/646.000; 514/658.000
IC [7]
ICM: A61K031-47
ICS: A61K031-135; A61K031-155; A61K031-225
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 345 OF 469 USPATFULL on STN
AN 2002:133883 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002068741 A1 20020606
AI US 2001-915263 A1 20010726 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25726
INCL INCLM: 514/248.000
INCLS: 514/257.000; 514/258.000; 514/280.000; 514/290.000; 514/299.000; 514/410.000; 514/411.000
NCL NCLM: 514/248.000

514/410.000; 514/411.000
IC [7]
ICM: A61K031-517
ICS: A61K031-502; A61K031-498; A61K031-473; A61K031-403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 346 OF 469 USPATFULL on STN
AN 2002:129982 USPATFULL
TI N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting alpha- amyloid peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Whitesitt, Celia A., Greenwood, IN, United States
PA Athena Neurosciences, Inc., San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6399628 B1 20020604
AI US 1999-266908 19990312 (9)
RLI Continuation of Ser. No. US 1997-975977, filed on 21 Nov 1997, now patented, Pat. No. US 5965614
PRAI US 1996-104593P 19961122 (60)
DT Utility
FS GRANTED
LN.CNT 2944
INCL INCLM: 514/311.000
INCLS: 514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000; 514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000; 514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000; 548/540.000; 549/366.000; 549/439.000; 549/451.000; 549/496.000; 560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000
NCL NCLM: 514/311.000
NCLS: 514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000; 514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000; 514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000; 548/540.000; 549/366.000; 549/439.000; 549/451.000; 549/496.000; 560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000
IC [7]
ICM: C07D215-38
ICS: C07D277-82; C07D209-20; C07D319-14; C07D317-44; C07D307-02; C07C229-28
EXF 514/311; 514/367; 514/413; 514/423; 514/452; 514/465; 514/467; 514/471; 514/529; 514/533; 514/538; 514/550; 514/567; 546/171; 548/161; 548/496; 548/540; 549/366; 549/439; 549/451; 549/496; 560/43; 560/45; 560/161; 562/433; 562/457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 347 OF 469 USPATFULL on STN
AN 2002:129731 USPATFULL
TI Methods of detection of amyloidogenic proteins
IN Krishnamurthy, Girija, Chestnut Ridge, NY, United States
PA American Cyanamid Company, Madison, NY, United States (U.S. corporation)
PI US 6399314 B1 20020604
AI US 1999-474970 19991229 (9)
DT Utility
FS GRANTED
LN.CNT 1359
INCL INCLM: 435/007.100
INCLS: 514/001.000; 514/002.000; 530/387.100
NCL NCLM: 435/007.100
NCLS: 514/001.000; 514/002.000; 530/387.100
IC [7]
ICM: G01N033-53
ICS: A01N061-00; A61K031-00; C07K016-00
EXF 514/1; 514/2; 435/7.1; 530/387.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 348 OF 469 USPATFULL on STN
AN 2002:126782 USPATFULL
TI Mitochondria protecting agents for treating mitochondria associated

IN Ghosh, Soumitra S., San Diego, CA, UNITED STATES
Miller, Scott W., San Marcos, CA, UNITED STATES
Davis, Robert E., San Diego, CA, UNITED STATES
Moos, Walter H., Oakland, CA, UNITED STATES
PI US 2002065299 A1 20020530
AI US 2001-935845 A1 20010822 (9)
RLI Continuation of Ser. No. US 1999-461483, filed on 14 Dec 1999, ABANDONED
Division of Ser. No. US 1999-237999, filed on 26 Jan 1999, ABANDONED
PRAI US 1998-72484P 19980126 (60)
US 1998-72487P 19980126 (60)
US 1998-72483P 19980126 (60)
US 1998-72482P 19980126 (60)
DT Utility
FS APPLICATION
LN.CNT 1691
INCL INCLM: 514/311.000
INCLS: 514/456.000; 514/546.000; 514/534.000; 514/585.000; 514/727.000; 514/731.000
NCL NCLM: 514/311.000
NCLS: 514/456.000; 514/546.000; 514/534.000; 514/585.000; 514/727.000; 514/731.000
IC [7]
ICM: A61K031-47
ICS: A61K031-353; A61K031-192; A61K031-06; A61K031-05
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 349 OF 469 USPATFULL on STN
AN 2002:126781 USPATFULL
TI Mitochondria protecting agents for treating mitochondria associated diseases
IN Ghosh, Soumitra S., San Diego, CA, UNITED STATES
Miller, Scott W., San Marcos, CA, UNITED STATES
Davis, Robert E., San Diego, CA, UNITED STATES
Moos, Walter H., Oakland, CA, UNITED STATES
PI US 2002065298 A1 20020530
US 6511966 B2 20030128
AI US 2001-933911 A1 20010820 (9)
RLI Continuation of Ser. No. US 1999-461485, filed on 14 Dec 1999, ABANDONED
Division of Ser. No. US 1999-237999, filed on 26 Jan 1999, ABANDONED
PRAI US 1998-72484P 19980126 (60)
US 1998-72487P 19980126 (60)
US 1998-72483P 19980126 (60)
US 1998-72482P 19980126 (60)
DT Utility
FS APPLICATION
LN.CNT 1696
INCL INCLM: 514/311.000
INCLS: 514/456.000; 514/546.000; 514/634.000; 514/658.000
NCL NCLM: 514/034.000
NCLS: 514/312.000; 546/168.000
IC [7]
ICM: A61K031-47
ICS: A61K031-22; A61K031-353; A61K031-155; A61K031-135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 350 OF 469 USPATFULL on STN
AN 2002:126775 USPATFULL
TI Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity
IN Abreo, Melwyn A., Jamul, CA, UNITED STATES
Meng, Jerry J., San Diego, CA, UNITED STATES
Agree, Charles S., San Diego, CA, UNITED STATES
PI US 2002065292 A1 20020530
AI US 2001-931166 A1 20010817 (9)
PRAI US 2000-226123P 20000818 (60)
DT Utility
FS APPLICATION
LN.CNT 4718
INCL INCLM: 514/258.000
INCLS: 514/303.000; 544/262.000; 546/119.000
NCL NCLM: 514/258.000
NCLS: 514/303.000; 544/262.000; 546/119.000
IC [7]
ICM: C07D491-02
ICS: C07D471-02; A61K031-519; A61K031-4745

L4 ANSWER 351 OF 469 USPATFULL on STN
AN 2002:126344 USPATFULL
TI Novel proteases
IN Plowman, Gregory, San Carlos, CA, UNITED STATES
Whyte, David, Belmont, CA, UNITED STATES
Caenepeel, Sean, Oakland, CA, UNITED STATES
Charydczak, Glen, Kentfield, CA, UNITED STATES
Manning, Gerard, Menlo Park, CA, UNITED STATES
Sudarsanam, Sucha, Greenbrae, CA, UNITED STATES
PI US 2002064856 A1 20020530
AI US 2001-888615 A1 20010626 (9)
PRAI US 2000-214047P 20000626 (60)
DT Utility
FS APPLICATION
LN.CNT 8220
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200; 435/006.000
NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200; 435/006.000
IC [7]
ICM: C12N009-64
ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 352 OF 469 USPATFULL on STN
AN 2002:126316 USPATFULL
TI Method of controlling the binding of calmyrin to presenilin
IN Monteiro, Mervyn J., Columbia, MD, UNITED STATES
Stabler, Stacy, Baltimore, MD, UNITED STATES
PI US 2002064828 A1 20020530
AI US 2001-878454 A1 20010611 (9)
PRAI US 2000-210939P 20000612 (60)
DT Utility
FS APPLICATION
LN.CNT 2409
INCL INCLM: 435/069.100
INCLS: 435/252.300; 435/325.000; 435/410.000; 514/012.000; 530/350.000; 435/320.100; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/325.000; 435/410.000; 514/012.000; 530/350.000; 435/320.100; 536/023.500
IC [7]
ICM: A61K038-17
ICS: C07K014-435; C12P021-02; C12N005-04; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 353 OF 469 USPATFULL on STN
AN 2002:122647 USPATFULL
TI Carboxamide compounds, methods, and compositions for inhibiting PARP activity
IN Li, Jia-He, Cockeysville, MD, United States
Zhang, Jie, Ellicott City, MD, United States
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6395749 B1 20020528
AI US 1998-145178 19980901 (9)
RLI Continuation-in-part of Ser. No. US 1998-79514, filed on 15 May 1998, now abandoned
DT Utility
FS GRANTED
LN.CNT 3095
INCL INCLM: 514/310.000
INCLS: 514/082.000; 514/255.000; 514/307.000; 514/309.000; 514/311.000; 514/312.000; 514/313.000; 514/314.000; 544/337.000; 544/363.000; 546/021.000; 546/141.000; 546/143.000; 546/144.000; 546/146.000; 546/153.000; 546/157.000; 546/158.000; 546/165.000; 546/167.000; 546/169.000; 424/485.000; 424/486.000; 424/487.000
NCL NCLM: 514/310.000
NCLS: 424/485.000; 424/486.000; 424/487.000; 514/082.000; 514/253.060; 514/307.000; 514/309.000; 514/311.000; 514/312.000; 514/313.000; 514/314.000; 544/337.000; 544/363.000; 546/021.000; 546/141.000; 546/143.000; 546/144.000; 546/146.000; 546/153.000; 546/157.000; 546/158.000; 546/165.000; 546/167.000; 546/169.000
IC [7]

ICS: A61K031-47; C07F009-02; C07D217-22; C07D215-16
EXF 546/21; 546/141; 546/144; 546/153; 546/167; 546/143; 546/146; 546/157; 546/158; 546/165; 546/169; 544/337; 544/363; 514/82; 514/255; 514/307; 514/309; 514/312; 514/314; 514/310; 514/311; 514/313; 424/485; 424/486; 424/487
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 354 OF 469 USPATFULL on STN
AN 2002:109040 USPATFULL
TI Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
IN Zhang, Jie, Ellicott City, MD, United States
Tays, Kevin Leonard, Elkridge, MD, United States
Li, Jia-He, Cockevsville, MD, United States
PA Guilford Pharmaceuticals, Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6387902 B1 20020514
AI US 1998-224293 19981231 (9)
DT Utility
FS GRANTED
LN.CNT 2616
INCL INCLM: 514/249.000
INCLS: 544/347.000; 544/348.000
NCL NCLM: 514/249.000
NCLS: 544/347.000; 544/348.000
IC [7]
ICM: A61K031-50
ICS: C07D241-46
EXF 514/249; 544/347; 544/348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 355 OF 469 USPATFULL on STN
AN 2002:106291 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002055500 A1 20020509
AI US 2001-916440 A1 20010730 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25439
INCL INCLM: 514/212.030
INCLS: 514/327.000; 514/424.000; 514/659.000
NCL NCLM: 514/212.030
NCLS: 514/327.000; 514/424.000; 514/659.000
IC [7]
ICM: A61K031-55
ICS: A61K031-45; A61K031-4015; A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 356 OF 469 USPATFULL on STN
AN 2002:102627 USPATFULL

IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 6384208 B1 20020507
AI US 1999-354947 19990715 (9)
RLI Continuation of Ser. No. US 1995-482080, filed on 7 Jun 1995, now patented, Pat. No. US 6010849, issued on 4 Jan 2000 Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444, issued on 26 Nov 1996 Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014, issued on 10 Mar 1998 Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463, issued on 2 Dec 1997 Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS GRANTED
LN.CNT 5215
INCL INCLM: 536/024.100
INCLS: 536/023.100
NCL NCLM: 536/024.100
NCLS: 536/023.100
IC [7]
ICM: C07H021-04
EXF 435/6; 536/24.1; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 357 OF 469 USPATFULL on STN
AN 2002:99459 USPATFULL
TI Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production
IN Olson, Richard E., Wilmington, DE, UNITED STATES
Liu, Hong, Glen Mills, PA, UNITED STATES
Thompson III, Lorin A., Wilmington, DE, UNITED STATES
PI US 2002052360 A1 20020502
US 6503902 B2 20030107
AI US 2001-805645 A1 20010314 (9)
RLI Continuation-in-part of Ser. No. US 2000-661008, filed on 13 Sep 2000, PENDING
PRAI US 1999-153511P 19990913 (60)
US 2000-224388P 20000809 (60)
DT Utility
FS APPLICATION
LN.CNT 6949
INCL INCLM: 514/212.040
INCLS: 514/218.000; 514/220.000; 540/522.000; 540/523.000; 540/504.000
NCL NCLM: 514/221.000
NCLS: 540/509.000
IC [7]
ICM: A61K031-55
ICS: A61K031-5513; A61K031-551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 358 OF 469 USPATFULL on STN
AN 2002:99458 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, R. Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES

Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Bloomington, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002052359 A1 20020502
US 6544978 B2 20030408
AI US 2001-915480 A1 20010727 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 25908
INCL INCLM: 514/212.010
INCLS: 514/327.000; 514/424.000; 514/519.000; 514/529.000; 514/683.000; 514/676.000
NCL NCLM: 514/211.060
NCLS: 514/211.070; 514/212.040; 514/212.060; 514/212.070; 514/212.080; 540/488.000; 540/521.000; 540/522.000; 540/523.000; 540/524.000; 540/527.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-40; A61K031-215; A61K031-275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 359 OF 469 USPATFULL on STN
AN 2002:99421 USPATFULL
TI Methods and compounds for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis
IN Audia, James E., Indianapolis, IN, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Folmer, Beverly K., Newark, DE, UNITED STATES
Huffman, George W., Carmel, IN, UNITED STATES
Varghese, John, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Wu, Jing, San Mateo, CA, UNITED STATES
Eid, Clark Norman, Cheshire, CT, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
PI US 2002052322 A1 20020502
AI US 2001-789487 A1 20010220 (9)
RLI Continuation of Ser. No. US 1997-976289, filed on 21 Nov 1997, GRANTED, Pat. No. US 6191166
PRAI US 1996-108166P 19961122 (60)
US 1997-108161P 19970228 (60)
US 1997-98558P 19970228 (60)
US 1997-64859P 19970228 (60)
DT Utility
FS APPLICATION
LN.CNT 14911
INCL INCLM: 514/018.000
INCLS: 514/019.000; 514/400.000; 514/563.000; 514/419.000
NCL NCLM: 514/018.000
NCLS: 514/019.000; 514/400.000; 514/563.000; 514/419.000
IC [7]
ICM: A61K038-06
ICS: A61K031-05; A61K031-4172; A61K031-405; A61K031-198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 360 OF 469 USPATFULL on STN
AN 2002:95805 USPATFULL
TI Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
IN Jackson, Paul F., Bel Air, MD, United States
Maclin, Keith M., Baltimore, MD, United States
Zhang, Jie, Ellicott City, MD, United States
PA Guilford Pharmaceutical Inc., Baltimore, MD, United States (U.S. corporation)

AI US 2000-711953 20001115 (9)
RLI Continuation of Ser. No. US 1998-145166, filed on 1 Sep 1998, now patented, Pat. No. US 6197785 Continuation-in-part of Ser. No. US 1998-79508, filed on 15 May 1998 Continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997, now abandoned
DT Utility
FS GRANTED
LN.CNT 2724
INCL INCLM: 514/309.000
INCLS: 514/233.500; 546/141.000; 544/128.000
NCL NCLM: 514/309.000
NCLS: 514/233.500; 544/128.000; 546/141.000
IC [7]
ICM: A61K031-47
EXF 546/141; 514/309; 514/233.5; 544/128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 361 OF 469 USPATFULL on STN
AN 2002:95790 USPATFULL
TI Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
IN Li, Jia-He, Cockevsville, MD, United States
Zhang, Jie, Ellicott City, MD, United States
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6380193 B1 20020430
AI US 1998-145184 19980901 (9)
RLI Continuation-in-part of Ser. No. US 1998-79510, filed on 15 May 1998
DT Utility
FS GRANTED
LN.CNT 2371
INCL INCLM: 514/243.000
INCLS: 514/283.000; 514/249.000; 514/257.000; 514/286.000; 514/293.000; 514/296.000; 514/292.000; 544/182.000; 544/234.000; 544/233.000; 544/245.000; 544/247.000; 544/250.000; 546/048.000; 546/063.000; 546/086.000; 546/081.000; 546/084.000; 546/098.000
NCL NCLM: 514/243.000
NCLS: 514/249.000; 514/257.000; 514/283.000; 514/286.000; 514/292.000; 514/293.000; 514/296.000; 544/182.000; 544/233.000; 544/234.000; 544/245.000; 544/247.000; 544/250.000; 546/048.000; 546/063.000; 546/081.000; 546/084.000; 546/086.000; 546/098.000
IC [7]
ICM: A61K031-53
ICS: A61K031-44; A61K031-50; A61K031-505
EXF 546/81; 546/84; 546/98; 546/48; 546/63; 546/86; 514/292; 514/296; 514/243; 514/283; 514/249; 514/257; 514/286; 514/293; 544/182; 544/234; 544/233; 544/245; 544/247; 544/250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 362 OF 469 USPATFULL on STN
AN 2002:92777 USPATFULL
TI Catalytically active recombinant memapsin and methods of use thereof
IN Tang, Jordan J. N., Edmond, OK, UNITED STATES
Lin, Xinli, Edmond, OK, UNITED STATES
Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
Hong, Lin, Oklahoma City, OK, UNITED STATES
PI US 2002049303 A1 20020425
AI US 2001-796264 A1 20010228 (9)
RLI Division of Ser. No. US 2000-604608, filed on 27 Jun 2000, PENDING
PRAI US 1999-141363P 19990628 (60)
US 1999-168060P 19991130 (60)
US 2000-177836P 20000125 (60)
US 2000-178368P 20000127 (60)
DT Utility
FS APPLICATION
LN.CNT 2441
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/252.300; 435/320.100; 435/006.000; 435/069.200; 514/002.000; 530/387.900
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/252.300; 435/320.100; 435/006.000; 435/069.200; 514/002.000; 530/387.900
IC [7]
ICM: C12N015-09
ICS: C12N009-64; C12N015-74

L4 ANSWER 363 OF 469 USPATFULL on STN
AN 2002:85701 USPATFULL
TI Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ***beta*** - ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, UNITED STATES
Tung, Jay S., Belmont, CA, UNITED STATES
Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
Pleiss, Michael A., Sunnyvale, CA, UNITED STATES
Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Neitz, Jeffrey, San Francisco, CA, UNITED STATES
Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Freedman, Stephen, Walnut Creek, CA, UNITED STATES
Britton, Thomas C., Carmel, IN, UNITED STATES
Audia, James A., Indianapolis, IN, UNITED STATES
Reel, Jon K., Carmel, IN, UNITED STATES
Mabry, Thomas E., Indianapolis, IN, UNITED STATES
Dressman, Bruce A., Indianapolis, IN, UNITED STATES
Cwi, Cynthia L., Indianapolis, IN, UNITED STATES
Droste, James J., Indianapolis, IN, UNITED STATES
Henry, Steven S., New Palestine, IN, UNITED STATES
McDaniel, Stacey L., Indianapolis, IN, UNITED STATES
Scott, William Leonard, Indianapolis, IN, UNITED STATES
Stucky, Russell D., Indianapolis, IN, UNITED STATES
Porter, Warren J., Indianapolis, IN, UNITED STATES
PI US 2002045747 A1 20020418
AI US 2001-916282 A1 20010730 (9)
RLI Division of Ser. No. US 1997-996422, filed on 22 Dec 1997, PENDING
PRAI US 1996-64851P 19961223 (60)
DT Utility
FS APPLICATION
LN.CNT 26053
INCL INCLM: 540/450.000
INCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000
NCL NCLM: 540/450.000
NCLS: 540/496.000; 540/504.000; 514/220.000; 514/221.000
IC [7]
ICM: A61K031-551
ICS: C07D243-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 364 OF 469 USPATFULL on STN
AN 2002:78209 USPATFULL
TI Method of sterilizing
IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES
Supattapone, Surachai, San Francisco, CA, UNITED STATES
Scott, Michael R., San Francisco, CA, UNITED STATES
PI US 2002041862 A1 20020411
US 6517855 B2 20030211
AI US 2001-956705 A1 20010919 (9)
RLI Continuation of Ser. No. US 2000-494814, filed on 31 Jan 2000, GRANTED, Pat. No. US 6322802 Continuation-in-part of Ser. No. US 1999-447456, filed on 22 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999, GRANTED, Pat. No. US 6214366
DT Utility
FS APPLICATION
LN.CNT 1727
INCL INCLM: 424/078.270
INCLS: 422/028.000
NCL NCLM: 424/408.000
NCLS: 424/078.080; 424/078.180; 424/078.270; 424/078.350; 424/456.000; 424/DIG.016; 514/578.000; 523/105.000; 523/122.000; 525/410.000; 525/419.000; 528/363.000
IC [7]
ICM: A61K031-74
ICS: A61L009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 365 OF 469 USPATFULL on STN
AN 2002:69833 USPATFULL
TI Vitro system for determining formation of A. ***beta*** . ***amyloid***

Bush, Ashley L., Boston, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 6365414 B1 20020402
AI US 1994-294819 19940826 (8)
DT Utility
FS GRANTED
LN.CNT 1937
INCL INCLM: 436/086.000
INCLS: 436/164.000; 436/177.000; 436/811.000
NCL NCLM: 436/086.000
NCLS: 436/164.000; 436/177.000; 436/811.000
IC [7]
ICM: G01N021-75
ICS: G01N033-50
EXF 436/86; 436/164; 436/177; 436/811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 366 OF 469 USPATFULL on STN
AN 2002:67251 USPATFULL
TI Substituted 4,9-dihydrocyclopent a [imn] phenanthridine-5-ones, derivatives thereof and their uses
IN Li, Jia-He, Cockeysville, MD, UNITED STATES
Zhang, Jie, Ellicott City, MD, UNITED STATES
Kalish, Vincent J., Annapolis, MD, UNITED STATES
PI US 2002037904 A1 20020328
US 6545011 B2 20030408
AI US 2001-895262 A1 20010702 (9)
PRAI US 2000-218037P 20000713 (60)
DT Utility
FS APPLICATION
LN.CNT 2628
INCL INCLM: 514/288.000
INCLS: 546/066.000
NCL NCLM: 514/284.000
NCLS: 514/232.800; 514/253.020; 514/288.000; 544/125.000; 544/361.000; 546/062.000; 546/066.000; 546/070.000; 546/076.000
IC [7]
ICM: A61K031-4745
ICS: A61K031-4741; C07D471-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 367 OF 469 USPATFULL on STN
AN 2002:48621 USPATFULL
TI THIOALKYL COMPOUNDS, METHODS, AND COMPOSITIONS FOR INHIBITING PARP ACTIVITY
IN JACKSON, PAUL F., BEL AIR, MD, UNITED STATES
MACLIN, KEITH M., BALTIMORE, MD, UNITED STATES
ZHANG, JIE, ELLICOTT CITY, MD, UNITED STATES
PI US 2002028813 A1 20020307
AI US 1998-145179 A1 19980901 (9)
RLI Continuation-in-part of Ser. No. US 1998-79513, filed on 15 May 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2979
INCL INCLM: 514/248.000
INCLS: 514/309.000; 544/237.000; 546/141.000
NCL NCLM: 514/248.000
NCLS: 514/309.000; 544/237.000; 546/141.000
IC [7]
ICM: A61K031-502
ICS: A61K031-47; C07D217-22; C07D237-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 368 OF 469 USPATFULL on STN
AN 2002:48271 USPATFULL
TI Alpha-2-macroglobulin isotype diagnostic test for Alzheimer's disease
IN Tanzi, Rudolph E., Hull, MA, UNITED STATES
Blacker, Deborah L., Newton, MA, UNITED STATES
PA The General Hospital Corporation (U.S. corporation)
PI US 2002028462 A1 20020307
AI US 2001-925313 A1 20010810 (9)
RLI Division of Ser. No. US 1998-148503, filed on 4 Sep 1998, PENDING

US 1998-93297P 19980717 (60)
DT Utility
FS APPLICATION
LN.CNT 1955
INCL INCLM: 435/006.000
INCLS: 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/091.200
IC [7]
ICM: C12Q001-68
ICS: C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 369 OF 469 USPATFULL on STN
AN 2002:40045 USPATFULL
TI Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
IN O'Brien, Patrick Michael, Stockbridge, MI, United States
Picard, Joseph Armand, Canton, MI, United States
Sliskovic, Drago Robert, Saline, MI, United States
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)
PI US 6350885 B1 20020226
WO 2000006560 20000210
AI US 2001-719026 20010220 (9)
WO 1999-US12272 19990602
20010220 PCT 371 date
PRAI US 1998-94705P 19980730 (60)
DT Utility
FS GRANTED
LN.CNT 2382
INCL INCLM: 549/460.000
INCLS: 549/461.000; 514/468.000; 514/443.000
NCL NCLM: 549/460.000
NCLS: 549/461.000
IC [7]
ICM: C07D307-91
ICS: A61K031-38; A61K031-343
EXF 514/443; 514/468; 549/460; 549/461
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 370 OF 469 USPATFULL on STN
AN 2002:37916 USPATFULL
TI OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITY
IN LI, JIA-HE, COCKEYSVILLE, MD, UNITED STATES
TAYS, KEVIN LEONARD, ELKRIDGE, MD, UNITED STATES
ZHANG, JIE, ELLICOTT CITY, MD, UNITED STATES
PI US 2002022636 A1 20020221
AI US 1998-145180 A1 19980901 (9)
RLI Continuation-in-part of Ser. No. US 1998-79509, filed on 15 May 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3766
INCL INCLM: 514/307.000
INCLS: 514/308.000; 514/290.000; 514/298.000; 514/309.000
NCL NCLM: 514/307.000
NCLS: 514/308.000; 514/290.000; 514/298.000; 514/309.000
IC [7]
ICM: A61K031-44
ICS: A61K031-47; A61K031-415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 371 OF 469 USPATFULL on STN
AN 2002:33166 USPATFULL
TI TRANSGENIC NON-HUMAN MAMMALS WITH PROGRESSIVE NEUROLOGIC DISEASE
IN HSIAO, KAREN, NORTH OAKS, MN, UNITED STATES
BORCHELT, DAVID R., BALTIMORE, MD, UNITED STATES
SISODIA, SANGRAM, BALTIMORE, MD, UNITED STATES
PI US 2002019992 A1 20020214
US 6509515 B2 20030121
AI US 1999-260897 A1 19990302 (9)
RLI Continuation of Ser. No. US 1996-664872, filed on 17 Jun 1996, GRANTED,

Filed on 10 May 1996, ABANDONED Continuation-in-part of Ser. No. US 1994-189064, filed on 27 Jan 1994, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2655
INCL INCLM: 800/003.000
INCLS: 800/013.000; 800/014.000; 800/018.000
NCL NCLM: 800/012.000
NCLS: 800/003.000; 800/018.000
IC [7]
ICM: A01K067-027
ICS: G01N033-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 372 OF 469 USPATFULL on STN
AN 2002:32581 USPATFULL
TI Methods to treat alzheimer's disease
IN Hom, Roy, San Francisco, CA, UNITED STATES
Mamo, Shumeye S., Oakland, CA, UNITED STATES
Tung, Jay, Belmont, CA, UNITED STATES
Gailunas, Andrea, San Francisco, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES
PI US 2002019403 A1 20020214
AI US 2001-816876 A1 20010323 (9)
PRAI US 2000-191528P 20000323 (60)
DT Utility
FS APPLICATION
LN.CNT 8655
INCL INCLM: 514/256.000
INCLS: 514/519.000; 514/520.000; 514/534.000
NCL NCLM: 514/256.000
NCLS: 514/519.000; 514/520.000; 514/534.000
IC [7]
ICM: A61K031-505
ICS: A61K031-275; A61K031-277; A61K031-24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 373 OF 469 USPATFULL on STN
AN 2002:22538 USPATFULL
TI METHOD OF TREATING NEURODEGENERATIVE DISORDERS VIA INHIBITION OF ***AMYLOID*** ***BETA*** PEPTIDE BINDING
IN REITZ, ALLEN B., LANSDALE, PA, UNITED STATES
DEMETER, DAVID A., FISHERS, IN, UNITED STATES
LEE, DANIEL H.S., NORTHHAMPTON, PA, UNITED STATES
WANG, HOAU-YAN, PHILADELPHIA, PA, UNITED STATES
CHEN, ROBERT H., BELLE MEAD, NJ, UNITED STATES
ROSS, TINA MORGAN, AUDUBON, PA, UNITED STATES
SCOTT, MALCOLM K., LANSDALE, PA, UNITED STATES
PLATA-SALAMAN, CARLOS R., AMBLER, PA, UNITED STATES
PI US 2002013374 A1 20020131
US 6441049 B2 20020827
AI US 1999-320885 A1 19990527 (9)
PRAI US 1998-87577P 19980601 (60)
DT Utility
FS APPLICATION
LN.CNT 1507
INCL INCLM: 514/657.000
INCLS: 564/428.000; 564/429.000
NCL NCLM: 514/657.000
NCLS: 564/428.000; 564/429.000
IC [7]
ICM: A61K031-135
ICS: C07C211-42
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 374 OF 469 USPATFULL on STN
AN 2002:19174 USPATFULL
TI Alpha-2-macroglobulin diagnostic test
IN Tanzi, Rudolph E., Hull, MA, United States
Hyman, Bradley T., Swampscott, MA, United States
Rebeck, George W., Somerville, MA, United States
Blacker, Deborah L., Newton, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

AI US 1998-148503 19980904 (9)
PRAI US 1998-93297P 19980717 (60)
US 1997-57655P 19970905 (60)
DT Utility
FS GRANTED
LN.CNT 2070
INCL INCLM: 435/006.000
INCLS: 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/091.200
IC [7]
ICM: C12Q001-68
EXF 435/6; 435/91.2; 536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 375 OF 469 USPATFULL on STN
AN 2002:17315 USPATFULL
TI Mitochondria protecting agents for treating mitochondria associated diseases
IN Ghosh, Soumitra S., San Diego, CA, UNITED STATES
Miller, Scott W., San Marcos, CA, UNITED STATES
Davis, Robert E., San Diego, CA, UNITED STATES
Moos, Walter H., Oakland, CA, UNITED STATES
PI US 2002010195 A1 20020124
US 6498191 B2 20021224
AI US 2000-733271 A1 20001207 (9)
RLI Continuation of Ser. No. US 1999-237999, filed on 26 Jan 1999, ABANDONED
PRAI US 1998-72484P 19980126 (60)
US 1998-72487P 19980126 (60)
US 1998-72483P 19980126 (60)
US 1998-72482P 19980126 (60)
DT Utility
FS APPLICATION
LN.CNT 1688
INCL INCLM: 514/312.000
INCLS: 514/313.000; 514/456.000; 514/534.000; 514/543.000
NCL NCLM: 514/547.000
NCLS: 514/648.000; 514/721.000; 514/741.000
IC [7]
ICM: A61K031-47
ICS: A61K031-352; A61K031-216
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 376 OF 469 USPATFULL on STN
AN 2002:12546 USPATFULL
TI Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
IN Li, Jia-He, Cockeysville, MD, UNITED STATES
Kalish, Vincent J., Annapolis, MD, UNITED STATES
Zhang, Jie, Ellicott City, MD, UNITED STATES
Serdyuk, Larisa E., Baltimore, MD, UNITED STATES
Ferraris, Dana Victor, Towson, MD, UNITED STATES
Xiao, Ge, Baltimore, MD, UNITED STATES
Kletzly, Paul W., Arlington, VA, UNITED STATES
PI US 2002006927 A1 20020117
US 6723733 B2 20040420
AI US 2001-854455 A1 20010515 (9)
PRAI US 2000-205259P 20000519 (60)
DT Utility
FS APPLICATION
LN.CNT 2682
INCL INCLM: 514/253.030
INCLS: 514/290.000; 544/361.000; 546/108.000
NCL NCLM: 514/298.000
NCLS: 514/232.800; 514/253.030; 544/126.000; 544/361.000; 546/108.000
IC [7]
ICM: C07D221-12
ICS: C07D041-02; A61K031-496; A61K031-473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 377 OF 469 USPATFULL on STN
AN 2001:235319 USPATFULL
TI Kallikrein-binding "Kunitz domain" proteins and analogues thereof
IN Markland, William, Milford, MA, United States
Ladner, Robert Charles, Ijamsville, MD, United States

PI US 6333402 B1 20011225
AI US 1999-421097 19991019 (9)
RLI Division of Ser. No. US 1994-208264, filed on 10 Mar 1994, now patented, Pat. No. US 6057287 Continuation-in-part of Ser. No. US 1994-179964, filed on 11 Jan 1994, now abandoned
DT Utility
FS GRANTED
LN.CNT 3154
INCL INCLM: 536/023.500
INCLS: 536/023.200; 435/007.000; 435/252.300; 435/320.100; 530/317.000
NCL NCLM: 536/023.500
NCLS: 435/007.100; 435/252.300; 435/254.230; 435/320.100; 435/325.000; 530/317.000; 536/023.200
IC [7]
ICM: C07H021-04
ICS: A61K038-12; C12N001-20; C12N015-00; G01N033-53
EXF 435/7; 435/252.3; 435/320.1; 514/2; 530/317; 536/23.1; 536/23.2; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 378 OF 469 USPATFULL on STN
AN 2001:231143 USPATFULL
TI Arrays for identifying agents which mimic or inhibit the activity of interferons
IN Silverman, Robert H., Beachwood, OH, United States
Williams, Bryan R. G., Cleveland, OH, United States
Der, Sandy, Cleveland, OH, United States
PA The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S. corporation)
PI US 6331396 B1 20011218
AI US 1999-405438 19990923 (9)
PRAI US 1998-101497P 19980923 (60)
DT Utility
FS GRANTED
LN.CNT 9639
INCL INCLM: 435/006.000
INCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
NCL NCLM: 435/006.000
NCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
IC [7]
ICM: C12Q001-68
ICS: C12M001-36; C07H021-04
EXF 435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 379 OF 469 USPATFULL on STN
AN 2001:231048 USPATFULL
TI Food additives which affect conformationally altered proteins
IN Prusiner, Stanley B., 400 Pacheco St., San Francisco, CA, United States 94116
Supattapone, Surachai, 225 Buckingham Way #702, San Francisco, CA, United States 94132
Scott, Michael R., 1200 Clayton St., #9, San Francisco, CA, United States 94114
PI US 6331296 B1 20011218
AI US 1999-447456 19991122 (9)
RLI Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999, now patented, Pat. No. US 6214366
DT Utility
FS GRANTED
LN.CNT 1764
INCL INCLM: 424/078.080
INCLS: 424/078.170; 424/078.180; 424/078.270; 424/078.310; 424/078.320; 424/405.000; 424/439.000; 424/442.000; 424/438.000; 424/078.330; 424/078.340; 424/078.350; 426/271.000; 426/532.000; 525/512.000; 525/513.000; 525/514.000; 523/122.000
NCL NCLM: 424/078.080
NCLS: 424/078.170; 424/078.180; 424/078.270; 424/078.310; 424/078.320; 424/078.330; 424/078.340; 424/078.350; 424/405.000; 424/438.000; 424/439.000; 424/442.000; 426/271.000; 426/532.000; 523/122.000; 525/512.000; 525/513.000; 525/514.000
IC [7]
ICM: A01N025-10
EXF 424/DIG.76; 424/78.32; 424/78.35-78.38; 424/438-442; 424/405; 424/78.08; 424/78.17; 424/78.18; 424/78.27; 424/78.31; 514/772.3-772.7; 523/122;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 380 OF 469 USPATFULL on STN
AN 2001:226655 USPATFULL
TI Formamide compounds as therapeutic agents
IN Andrews, Robert Carl, Durham, NC, United States
Andersen, Marc Werner, Raleigh, NC, United States
Bubacz, Dulce Garrido, Cary, NC, United States
Chan, Joseph Howing, Chapel Hill, NC, United States
Cowan, David John, Hillsborough, NC, United States
Gaul, Michael David, Apex, NC, United States
McDougald, Daryl Lynn, Durham, NC, United States
Musso, David Lee, Raleigh, NC, United States
Rabinowitz, Michael Howard, Durham, NC, United States
Stanford, Jennifer Badiang, Cary, NC, United States
Wiethe, Robert William, Durham, NC, United States
PA Glaxo Wellcome Inc., Research Triangle Park, NC, United States (U.S. corporation)
PI US 6329400 B1 20011211
AI US 1999-382924 19990825 (9)
PRAI GB 1998-18608 19980826
US 1998-97958P 19980826 (60)
DT Utility
FS GRANTED
LN.CNT 3877
INCL INCLM: 514/336.000
INCLS: 514/352.000; 546/281.400; 546/309.000
NCL NCLM: 514/336.000
NCLS: 514/352.000; 546/281.400; 546/309.000
IC [7]
ICM: C07D409-12
ICS: C07D213-74; A61K031-4436; A61K031-4409
EXF 514/336; 514/337; 514/338; 514/352; 546/271.7; 546/281.1; 546/281.4; 546/282.4; 546/284.1; 546/283.4; 546/309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 381 OF 469 USPATFULL on STN
AN 2001:215066 USPATFULL
TI Agents for use in the treatment of Alzheimer's disease
IN Bush, Ashley I., Somerville, MA, United States
Huang, Xudong, Cambridge, MA, United States
Atwood, Craig S., Somerville, MA, United States
Tanzi, Rudolph E., Canton, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 6323218 B1 20011127
AI US 1998-38154 19980311 (9)
DT Utility
FS GRANTED
LN.CNT 4192
INCL INCLM: 514/311.000
INCLS: 514/244.000; 514/420.000; 514/707.000
NCL NCLM: 514/311.000
NCLS: 514/244.000; 514/420.000; 514/707.000
IC [7]
ICM: A61K031-47
ICS: A61K031-53; A61K031-40; A61K031-105
EXF 514/311; 514/244; 514/420; 514/707
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 382 OF 469 USPATFULL on STN
AN 2001:214671 USPATFULL
TI Method of sterilizing
IN Prusiner, Stanley B., San Francisco, CA, United States
Supattapone, Surachai, San Francisco, CA, United States
Scott, Michael R., San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6322802 B1 20011127
AI US 2000-494814 20000131 (9)
RLI Continuation-in-part of Ser. No. US 1999-447456, filed on 22 Nov 1999
Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999, now patented, Pat. No. US 6214366
DT Utility
FS GRANTED

INCL INCLM: 424/405.000
INCLS: 424/078.080; 424/078.180; 424/078.270; 424/078.350; 424/DIG.016; 528/363.000; 128/114.100; 128/832.000; 128/899.000; 600/003.000; 600/029.000; 600/030.000; 600/036.000; 600/372.000; 602/508.000; 604/890.100; 623/001.100; 623/920.000
NCL NCLM: 424/405.000
NCLS: 128/114.100; 128/832.000; 128/899.000; 422/027.000; 424/078.080; 424/078.180; 424/078.270; 424/078.350; 424/DIG.016; 528/363.000; 600/003.000; 600/029.000; 600/030.000; 600/036.000; 600/372.000; 604/890.100; 623/001.100; 623/920.000
IC [7]
ICM: A01N025-10
EXF 424/DIG.16; 424/405; 424/76.8; 424/78.07; 424/78.08; 424/78.17; 424/78.18; 424/78.26; 424/78.27; 424/78.31; 424/78.35; 424/78.37; 623/920; 623/11.11; 623/1.1; 623/2.1; 623/3.1; 623/4.1; 623/7; 623/9; 623/10; 604/890.1; 602/48; 602/508; 128/114.1; 128/832; 128/842; 128/899; 600/372; 600/478; 600/462; 600/488; 600/466; 600/3; 600/29; 600/30; 600/36
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 383 OF 469 USPATFULL on STN
AN 2001:200180 USPATFULL
TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
IN BARTA, THOMAS E, EVANSTON, IL, United States
BECKER, DANIEL P, GLENVIEW, IL, United States
BOEHM, TERRI L, BALLWIN, MO, United States
DECRESCENZO, GARY A, ST CHARLES, MO, United States
WILLAMI1, CLARA I, GLENVIEW, IL, United States
MCDONALD, JOSEPH J, BALLWIN, MO, United States
FRESKOS, JOHN N, CLAYTON, MO, United States
GETMAN, DANIEL P, CHESTERFIELD, MO, United States
HANSON, GUNNAR J, SKOKIE, IL, United States
PI US 2001039287 A1 20011108
AI US 1999-256948 A1 19990224 (9)
PRAI US 1997-66007P 19971114 (60)
US 1998-95347P 19980804 (60)
US 1998-95501P 19980806 (60)
US 1998-101080P 19980918 (60)
DT Utility
FS APPLICATION
LN.CNT 16461
INCL INCLM: 514/330.000
INCLS: 546/019.000; 546/094.000; 546/191.000; 546/159.000; 546/207.000; 546/227.000; 546/225.000; 544/147.000; 548/315.100; 548/311.100; 549/028.000; 549/419.000; 549/427.000
NCL NCLM: 514/330.000
NCLS: 546/019.000; 546/094.000; 546/191.000; 546/159.000; 546/207.000; 546/227.000; 546/225.000; 544/147.000; 548/315.100; 548/311.100; 549/028.000; 549/419.000; 549/427.000
IC [7]
ICM: C07D491-20
ICS: C07D211-08; C07D215-38; A61K031-445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 384 OF 469 USPATFULL on STN
AN 2001:158250 USPATFULL
TI Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
IN Li, Jia-He, Cockeysville, MD, United States
Zhang, Jie, Ellicott City, MD, United States
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6291425 B1 20010918
AI US 1999-387767 19990901 (9)
DT Utility
FS GRANTED
LN.CNT 2878
INCL INCLM: 514/008.000D
INCLS: 544/233.000; 544/232.000; 514/081.000; 514/080.000; 514/248.000
NCL NCLM: 514/080.000
NCLS: 514/081.000; 514/248.000; 544/232.000; 544/233.000
IC [7]
ICM: C07D491-04
ICS: C07D498-04; C07F009-141; A61K031-47; A61K031-50
EXF 544/233; 514/248

L4 ANSWER 385 OF 469 USPATFULL on STN
AN 2001:150648 USPATFULL
TI N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING ***BETA*** - ***AMYLOID*** PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
IN AUDIA, JAMES E., INDIANAPOLIS, IN, United States
FOLMER, BEVERLY K., NEWARK, DE, United States
JOHN, VARGHESE, SAN FRANCISCO, CA, United States
LATIMER, LEE H., OAKLAND, CA, United States
NISSEN, JEFFREY S., INDIANAPOLIS, IN, United States
PORTER, WARREN J., INDIANAPOLIS, IN, United States
THORSETT, EUGENE D., MOSS BEACH, CA, United States
WU, JING, SAN MATEO, CA, United States
PI US 2001020097 A1 20010906
US 6495693 B2 20021217
AI US 1999-280966 A1 19990330 (9)
RLI Continuation of Ser. No. US 1997-976191, filed on 21 Nov 1997, GRANTED, Pat. No. US 6096782
DT Utility
FS APPLICATION
LN.CNT 3729
INCL INCLM: 546/162.000
INCLS: 514/313.000; 514/367.000; 514/400.000; 514/419.000; 514/616.000; 514/620.000; 514/506.000; 514/399.000; 560/039.000; 560/043.000; 560/041.000; 564/156.000; 564/157.000; 564/163.000; 564/168.000; 548/161.000; 548/178.000; 548/338.100; 548/495.000; 546/163.000
NCL NCLM: 546/162.000
NCLS: 546/163.000; 548/161.000; 548/178.000; 548/338.100; 548/495.000; 560/039.000; 560/041.000; 560/043.000; 564/156.000; 564/157.000; 564/163.000; 564/168.000
IC [7]
ICM: C07D277-82
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 386 OF 469 USPATFULL on STN
AN 2001:150564 USPATFULL
TI Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
IN Zhang, Jie, Ellicott City, MD, United States
Serdyuk, Larisa E., Baltimore, MD, United States
Li, Jia-He, Cockeysville, MD, United States
PA GUILFORD PHARMACEUTICALS, INC. (U.S. corporation)
PI US 2001020013 A1 20010906
AI US 2000-745858 A1 20001226 (9)
RLI Continuation of Ser. No. US 1998-224294, filed on 31 Dec 1998, GRANTED, Pat. No. US 6201020
DT Utility
FS APPLICATION
LN.CNT 2874
INCL INCLM: 514/150.000
INCLS: 514/423.000; 514/427.000; 514/539.000; 514/456.000; 534/848.000
NCL NCLM: 514/150.000
NCLS: 514/423.000; 514/427.000; 514/539.000; 514/456.000; 534/848.000
IC [7]
ICM: A61K031-655
ICS: A61K031-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 387 OF 469 USPATFULL on STN
AN 2001:147440 USPATFULL
TI Method for identifying . ***beta*** .- ***amyloid*** peptide production inhibitors
IN Schenk, Dale B., Pacifica, CA, United States
Schlossmacher, Michael G., Vienna, Australia
Selkoe, Dennis J., Jamaica Plain, MA, United States
Seubert, Peter A., South San Francisco, CA, United States
Vigo-Pelfrey, Carmen, Mountain View, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)

AI US 1996-733202 19961018 (8)
RLI Division of Ser. No. US 1995-437067, filed on 9 May 1995, now patented, Pat. No. US 5593846 Continuation of Ser. No. US 1992-911647, filed on 10 Jul 1992, now abandoned Continuation-in-part of Ser. No. US 1992-911647, filed on 10 Jul 1992, now abandoned
DT Utility
FS GRANTED
LN.CNT 1410
INCL INCLM: 424/009.200
INCLS: 424/009.100; 800/018.000; 435/007.100
NCL NCLM: 424/009.200
NCLS: 424/009.100; 435/007.100; 800/018.000
IC [7]
ICM: A61K049-00
ICS: A01K067-027
EXF 424/9.1; 424/9.2; 424/9.34; 435/7.1; 435/7.2; 435/7.21; 435/7.92; 435/7.94; 435/7.95; 435/41; 435/69.1; 536/23.5; 800/2; 800/18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 388 OF 469 USPATFULL on STN
AN 2001:134239 USPATFULL
TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
IN BARTA, THOMAS E., EVANSTON, IL, United States
BECKER, DANIEL P., GLENVIEW, IL, United States
BOEHM, TERRI L., BALLWIN, MO, United States
DECRESCENZO, GARY A., ST.CHARLES, MO, United States
WILLAMIL, CLARA I., GLENVIEW, IL, United States
MCDONALD, JOSEPH J., BALLWIN, MO, United States
FRESKOS, JOHN N., CLAYTON, MO, United States
GETMAN, DANIEL P., CHESTERFIELD, MO, United States
HANSON, GUNNAR J., STOKIE, IL, United States
PI US 2001014688 A1 20010816
AI US 1998-191129 A1 19981113 (9)
PRAI US 1997-66007P 19971114 (60)
US 1998-95347P 19980804 (60)
US 1998-95501P 19980806 (60)
DT Utility
FS APPLICATION
LN.CNT 15774
INCL INCLM: 514/318.000
INCLS: 514/330.000; 514/328.000; 546/225.000; 549/220.000; 546/193.000
NCL NCLM: 514/318.000
NCLS: 514/330.000; 514/328.000; 546/225.000; 549/220.000; 546/193.000
IC [7]
ICM: A61K031-445
ICS: C07D211-30; C07F009-06; C07D211-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 389 OF 469 USPATFULL on STN
AN 2001:112599 USPATFULL
TI Transgenic mice expressing APP mutant at amino acids 717, 721 and 722
IN Hsiao, Karen, North Oaks, MN, United States
Borchelt, David R., Baltimore, MD, United States
Sisodia, Sangram S., Baltimore, MD, United States
PA Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)
PI US 6262335 B1 20010717
AI US 1998-19973 19980206 (9)
RLI Continuation of Ser. No. US 1994-189064, filed on 27 Jan 1994, now abandoned
DT Utility
FS GRANTED
LN.CNT 1104
INCL INCLM: 800/012.000
INCLS: 800/003.000; 800/018.000; 800/025.000
NCL NCLM: 800/012.000
NCLS: 800/003.000; 800/018.000; 800/025.000
IC [7]
ICM: A01K067-00
ICS: A01K067-027; G01N033-00; C12N015-00
EXF 800/3; 800/8; 800/12; 800/13; 800/14; 800/18; 800/25; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:112566 USPATFULL
TI N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
Eid, Clark N., Cheshire, CT, United States
Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., S. San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6262302 B1 20010717
AI US 1999-398211 19990917 (9)
RLI Continuation of Ser. No. US 1997-976295, filed on 21 Nov 1997, now patented, Pat. No. US 6153652
PRAI US 1996-98551P 19961122 (60)
US 1997-113671P 19970228 (60)
DT Utility
FS GRANTED
LN.CNT 4050
INCL INCLM: 564/152.000
INCLS: 564/155.000; 564/158.000; 564/168.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 549/303.000; 549/304.000; 548/471.000; 548/475.000; 546/309.000; 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000; 514/535.000; 514/539.000; 514/619.000
NCL NCLM: 564/152.000
NCLS: 546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/155.000; 564/158.000; 564/168.000
IC [7]
ICM: C07C229-38
ICS: C07C233-64; C07D307-00; C07D211-00; C07D213-00
EXF 560/43; 560/45; 560/47; 560/39; 560/41; 560/42; 514/349; 514/352; 514/357; 514/417; 514/470; 514/535; 514/539; 514/619; 564/152; 564/168; 564/155; 564/158; 549/303; 549/304; 548/471; 548/475; 546/309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 391 OF 469 USPATFULL on STN
AN 2001:105177 USPATFULL
TI VARIANT HUMAN ALPHA7 ACETYLCHOLINE RECEPTOR SUBNIT, AND METHODS OF PROD0U0CTION AND USES THEREOF
IN BRIGGS, CLARK A., LIBERTYVILLE, IL, United States
GOPALAKRISHNAN, MURALI, GRAYSLAKE, IL, United States
MC KENNA, DAVID G., MCHENRY, IL, United States
MONTEGGIA, LISA M., LINDERHURST, IL, United States
ROCH, JEAN-MARC, WAUKEGAN, IL, United States
SULLIVAN, JAMES P., DEERFIELD, IL, United States
TOUMA, EDWARD, NORTH CHICAGO, IL, United States
PI US 2001006796 A1 20010705
US 6323000 B2 20011127
AI US 1996-771737 A1 19961220 (8)
DT Utility
FS APPLICATION
LN.CNT 1634
INCL INCLM: 435/069.100
INCLS: 536/023.500; 435/325.000; 435/320.100; 530/350.000; 435/007.200; 514/002.000; 435/006.000; 530/387.900
NCL NCLM: 435/069.100
NCLS: 435/071.100; 435/254.200; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: A01N037-18
ICS: A61K038-00; C12Q001-68; G01N033-53; G01N033-567; C07H021-04; C12P021-06; C12N015-00; C12N015-09; C12N015-63
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 392 OF 469 USPATFULL on STN
AN 2001:86665 USPATFULL
TI Transgenic rodent comprising APP-Swedish
IN McLonlogue, Lisa C., San Francisco, CA, United States
Zhao, Jun, La Jolla, CA, United States
Sinha, Sukanto, San Francisco, CA, United States

corporation)
PI US 6245964 B1 20010612
AI US 1998-209647 19981210 (9)
RLI Continuation of Ser. No. US 1997-785943, filed on 22 Jan 1997, now patented, Pat. No. US 5850003 Continuation of Ser. No. US 1993-148211, filed on 1 Nov 1993, now patented, Pat. No. US 5612486 Continuation-in-part of Ser. No. US 1993-143697, filed on 27 Oct 1993, now patented, Pat. No. US 5604102
DT Utility
FS GRANTED
LN.CNT 2117
INCL INCLM: 800/012.000
INCLS: 800/003.000; 800/014.000; 800/018.000; 800/022.000
NCL NCLM: 800/012.000
NCLS: 800/003.000; 800/014.000; 800/018.000; 800/022.000
IC [7]
ICM: A01K067-00
ICS: A01K067-027; G01N033-00; C12N015-00
EXF 800/3; 800/12; 800/14; 800/18; 800/22; 424/9.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 393 OF 469 USPATFULL on STN
AN 2001:75401 USPATFULL
TI Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
IN Li, Jia-He, Cockeysville, MD, United States
Zhang, Jie, Ellicott City, MD, United States
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6235748 B1 20010522
AI US 2000-524750 20000314 (9)
RLI Division of Ser. No. US 1998-79509, filed on 15 May 1998, now abandoned Continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997, now abandoned
DT Utility
FS Granted
LN.CNT 2242
INCL INCLM: 514/285.000
INCLS: 546/062.000; 546/070.000; 428/451.000; 428/455.000; 428/464.000
NCL NCLM: 514/285.000
NCLS: 428/451.000; 428/455.000; 428/464.000; 546/062.000; 546/070.000
IC [7]
ICM: A61K031-4353
ICS: C07D221-18; C07D471-02
EXF 546/108; 546/62; 546/70; 514/285; 428/451; 428/455; 428/464; 534/560; 424/451; 424/463; 424/464; 424/474
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 394 OF 469 USPATFULL on STN
AN 2001:51793 USPATFULL
TI Methods for screening for inhibitors of Alzheimer .beta.-peptide filament formation
IN Potter, Huntington, Boston, MA, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 6214569 B1 20010410
AI US 1997-914694 19970819 (8)
RLI Continuation of Ser. No. US 1995-417937, filed on 6 Apr 1995, now patented, Pat. No. US 5780587 Continuation-in-part of Ser. No. US 1994-328491, filed on 25 Oct 1994, now abandoned Continuation-in-part of Ser. No. US 1994-290198, filed on 15 Aug 1994, now abandoned Continuation-in-part of Ser. No. US 1994-179574, filed on 10 Jan 1994, now patented, Pat. No. US 5506097 Continuation-in-part of Ser. No. US 1992-819361, filed on 13 Jan 1992, now patented, Pat. No. US 5338663 Continuation-in-part of Ser. No. US 572671, now abandoned
DT Utility
FS Granted
LN.CNT 1742
INCL INCLM: 435/007.800
NCL NCLM: 435/007.800
IC [7>]
ICM: G01N033-55
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 395 OF 469 USPATFULL on STN

TI Clearance and inhibition of conformationally altered proteins
IN Prusiner, Stanley B., San Francisco, CA, United States
Supattapone, Surachai, San Francisco, CA, United States
Scott, Michael, San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6214366 B1 20010410
AI US 1999-322903 19990601 (9)
DT Utility
FS Granted
LN.CNT 1037
INCL INCLM: 424/405.000
INCLS: 424/438.000; 424/442.000; 424/484.000; 424/DIG.016; 424/078.320; 424/078.350; 424/078.360; 424/078.370; 424/078.380; 514/772.300; 514/772.400; 514/772.500; 514/772.600; 514/772.700
NCL NCLM: 424/405.000
NCLS: 424/078.320; 424/078.350; 424/078.360; 424/078.370; 424/078.380; 424/438.000; 424/442.000; 424/484.000; 424/DIG.016; 514/772.300; 514/772.400; 514/772.500; 514/772.600; 514/772.700
IC [7]
ICM: A01N025-10
EXF 424/78.32; 424/78.35; 424/78.38; 424/405; 424/438; 424/442; 424/DIG.16; 514/772.3-772.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 396 OF 469 USPATFULL on STN
AN 2001:48108 USPATFULL
TI Compounds for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Reel, Jon K., Carmel, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
Folmer, Beverly K., Newark, DE, United States
Droste, James J., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IL, United States (U.S. corporation)
PI US 6211235 B1 20010403
AI US 1998-164448 19980930 (9)
RLI Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997
PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-98558P 19970228 (60)
DT Utility
FS Granted
LN.CNT 14056
INCL INCLM: 514/534.000
INCLS: 574/619.000; 560/041.000; 560/040.000; 564/163.000
NCL NCLM: 514/534.000
NCLS: 514/019.000; 514/619.000; 544/162.000; 546/233.000; 546/336.000; 548/479.000; 548/496.000; 560/040.000; 560/041.000; 564/163.000
IC [7]
ICM: A01N037-12
ICS: C07C229-00; C07C233-00
EXF 514/534; 514/619; 564/163; 560/40; 560/41
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 397 OF 469 USPATFULL on STN
AN 2001:44268 USPATFULL
TI Compounds for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis
IN Audia, James E., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Droste, James J., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
Huffman, George W., Carmel, IN, United States
John, Varghese, San Francisco, CA, United States

Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Tung, Jay S., Belmont, CA, United States
Wu, Jing, San Mateo, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6207710 B1 20010327
AI US 1998-164385 19980930 (9)
RLI Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997
PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-108161P 19970228 (60)
US 1997-98558P 19970228 (60)
DT Utility
FS Granted
LN.CNT 12026
INCL INCLM: 514/551.000
INCLS: 514/534.000; 514/563.000; 560/037.000; 560/038.000; 560/040.000; 560/041.000; 654/123.000; 654/155.000
NCL NCLM: 514/551.000
NCLS: 514/534.000; 514/563.000; 530/331.000; 560/037.000; 560/038.000; 560/040.000; 560/041.000; 564/123.000; 564/155.000
IC [7]
ICM: A01N037-12
ICS: C07C229-00; C07C233-00
EXF 514/551; 514/534; 514/563; 560/37; 560/38; 560/40; 560/41; 564/123; 564/155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 398 OF 469 USPATFULL on STN
AN 2001:36867 USPATFULL
TI Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
IN Zhang, Jie, Ellicott, MD, United States
Serdyuk, Larisa E., Baltimore, MD, United States
Li, Jia-He, Cockevsville, MD, United States
PA Guilford Pharmaceuticals, Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6201020 B1 20010313
AI US 1998-224294 19981231 (9)
DT Utility
FS Granted
LN.CNT 2960
INCL INCLM: 514/544.000
INCLS: 514/532.000; 514/538.000; 514/546.000; 514/551.000; 560/015.000; 560/029.000; 560/035.000; 560/064.000; 560/065.000; 560/073.000; 560/100.000; 560/103.000; 560/109.000; 560/125.000
NCL NCLM: 514/544.000
NCLS: 514/532.000; 514/538.000; 514/546.000; 514/551.000; 560/015.000; 560/029.000; 560/035.000; 560/064.000; 560/065.000; 560/073.000; 560/100.000; 560/103.000; 560/109.000; 560/125.000
IC [7]
ICM: A61K031-235
ICS: C07C069-035; C07C069-76
EXF 558/392; 558/396; 560/1; 560/15; 560/20; 560/19; 560/35; 560/25; 560/63; 560/64; 560/65; 560/100; 560/103; 560/109; 560/125; 560/56; 560/73; 560/121; 560/122; 560/123; 560/124; 514/529; 514/532; 514/538; 514/544; 514/546; 514/551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 399 OF 469 USPATFULL on STN
AN 2001:33282 USPATFULL
TI Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
IN Jackson, Paul F., Bel Air, MD, United States
Maclin, Keith M., Baltimore, MD, United States
Zhang, Jie, Ellicott City, MD, United States
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6197785 B1 20010306
AI US 1998-145166 19980901 (9)

said Ser. No. US 145166 And Ser. No. US 1997-922520, filed on 3 Sep 1997, now abandoned
DT Utility
FS Granted
LN.CNT 2403
INCL INCLM: 514/309.000
INCLS: 514/233.500; 514/299.000; 544/128.000; 546/141.000; 546/183.000
NCL NCLM: 514/309.000
NCLS: 514/233.500; 514/299.000; 544/128.000; 546/141.000; 546/183.000
IC [7]
ICM: C07D217-24
ICS: A61K031-47
EXF 514/309; 514/233.5; 546/141; 546/183; 544/128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 400 OF 469 USPATFULL on STN
AN 2001:25931 USPATFULL
TI Methods and compounds for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis
IN Audia, James E., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Droste, James J., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
Huffman, George W., Carmel, IN, United States
Varghese, John, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Tung, Jay S., Belmont, CA, United States
Wu, Jing, San Mateo, CA, United States
Eid, Clark Norman, Cheshire, CT, United States
Scott, William Leonard, Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6191166 B1 20010220
AI US 1997-976289 19971121 (8)
PRAI US 1996-108166P 19961122 (60)
US 1997-64859P 19970228 (60)
US 1997-108161P 19970228 (60)
US 1997-698556P 19970228 (60)
DT Utility
FS Granted
LN.CNT 12827
INCL INCLM: 514/534.000
INCLS: 514/535.000; 514/616.000; 514/619.000
NCL NCLM: 514/534.000
NCLS: 514/535.000; 514/616.000; 514/619.000
IC [7]
ICM: A01N037-12
EXF 574/534; 574/535; 574/616; 574/619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 401 OF 469 USPATFULL on STN
AN 2001:4738 USPATFULL
TI Formamides as therapeutic agents
IN Andrews, Robert Carl, Durham, NC, United States
Andersen, Marc Werner, Raleigh, NC, United States
Cowan, David John, Hillsborough, NC, United States
Deaton, David Norman, Cary, NC, United States
Dickerson, Scott Howard, Chapel Hill, NC, United States
Drewry, David Harold, Durham, NC, United States
Gaul, Michael David, Apex, NC, United States
Luzzio, Michael Joseph, Durham, NC, United States
Marron, Brian Edward, Durham, NC, United States
Rabinowitz, Michael Howard, Durham, NC, United States
PA Glaxo Wellcome Inc., Research Triangle Park, NC, United States (U.S. corporation)
PI US 6172064 B1 20010109
AI US 1999-382333 19990825 (9)
PRAI US 1998-97956P 19980826 (60)
DT Patent

LN.CNT 3155
INCL INCLM: 514/237.800
INCLS: 514/357.000; 514/428.000; 514/438.000; 514/575.000; 546/337.000; 546/168.000; 548/568.000; 549/076.000; 562/621.000; 562/623.000
NCL NCLM: 514/237.800
NCLS: 514/357.000; 514/428.000; 514/438.000; 514/575.000; 546/168.000; 546/337.000; 548/568.000; 549/076.000; 562/621.000; 562/623.000
IC [7]
ICM: C07D211-70
ICS: C07D207-08; C07D333-22; C07C259-04; A61K031-535; A61K031-40; A61K031-38; A61K031-19; A61K031-44
EXF 562/621; 562/623; 514/515; 514/438; 514/357; 514/237.8; 514/428; 549/76; 546/337; 546/168; 548/568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 402 OF 469 USPATFULL on STN
AN 2000:161048 USPATFULL
TI N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Latimer, Lee H., Oakland, CA, United States
Eid, Clark N., Cheshire, CT, United States
Audia, James E., Indianapolis, IN, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6153652 20001128
AI US 1997-976295 19971121 (8)
PRAI US 1996-1551P 19961122 (60)
US 1997-113671P 19970228 (60)
DT Utility
FS Granted
LN.CNT 3652
INCL INCLM: 514/619.000
INCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000; 514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000
NCL NCLM: 514/619.000
NCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000; 514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000
IC [7]
ICM: A01N037-18
ICS: A01N037-12; A01N037-44; A61K031-165
EXF 564/155; 564/158; 564/152; 564/168; 546/309; 548/471; 548/475; 549/303; 549/304; 560/39; 560/41; 560/42; 560/43; 514/349; 514/352; 514/357; 514/417; 514/470; 514/535; 514/539; 514/619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 403 OF 469 USPATFULL on STN
AN 2000:142115 USPATFULL
TI Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
IN Anderson, Stephen, Princeton, NJ, United States
PA Rutgers, The State University of New Jersey, New Brunswick, NJ, United States (U.S. corporation)
PI US 6136548 20001024
AI US 1999-388890 19990902 (9)
RLI Continuation of Ser. No. US 1996-686959, filed on 26 Jul 1996, now abandoned And a continuation-in-part of Ser. No. WO 1995-US15007, filed on 22 Nov 1995 which is a continuation-in-part of Ser. No. US 1994-347144, filed on 22 Nov 1994, now patented, Pat. No. US 5589154
DT Utility
FS Granted
LN.CNT 1820
INCL INCLM: 435/007.100
INCLS: 435/069.200; 435/172.100; 435/226.000; 436/086.000; 514/002.000
NCL NCLM: 435/007.100

IC [7]
ICM: G01N033-53
ICS: G01N033-00; C12N015-09; C12N009-64; A01N037-18
EXF 424/9.2; 424/184.1; 435/7.1; 435/7.8; 435/69.1; 435/69.2; 435/172.1; 435/359; 435/212; 435/215; 435/226; 530/350; 530/380; 530/381; 530/382; 514/2; 436/86; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 404 OF 469 USPATFULL on STN
AN 2000:125055 USPATFULL
TI Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
IN Jackson, Paul F., Bel Air, MD, United States
Maclin, Keith M., Baltimore, MD, United States
Zhang, Jie, Ellicott City, MD, United States
PA Guilford Pharmaceuticals, Inc., Baltimore, MD, United States (U.S. corporation)
PI US 6121278 20000919
AI US 1998-145185 19980901 (9)
RLI Continuation-in-part of Ser. No. US 1998-79510, filed on 15 May 1998, now abandoned And a continuation-in-part of Ser. No. US 1997-922520, filed on 3 Sep 1997
DT Utility
FS Granted
LN.CNT 2709
INCL INCLM: 514/292.000
INCLS: 514/081.000; 514/222.800; 514/224.500; 514/226.200; 514/229.200; 514/229.800; 514/243.000; 514/248.000; 514/267.000; 514/291.000; 514/293.000; 544/032.000; 544/066.000; 544/095.000; 544/183.000; 544/234.000; 544/250.000; 546/021.000; 546/081.000; 546/082.000; 546/083.000; 546/084.000
NCL NCLM: 514/292.000
NCLS: 514/081.000; 514/222.800; 514/224.500; 514/226.200; 514/229.200; 514/229.800; 514/243.000; 514/248.000; 514/267.000; 514/291.000; 514/293.000; 544/032.000; 544/066.000; 544/095.000; 544/183.000; 544/234.000; 544/250.000; 546/021.000; 546/081.000; 546/082.000; 546/083.000; 546/084.000
IC [7]
ICM: A61K031-4375
ICS: C07D471-06
EXF 546/21; 546/81; 514/81; 514/292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 405 OF 469 USPATFULL on STN
AN 2000:98466 USPATFULL
TI N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Wu, Jing, San Mateo, CA, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6096782 20000801
AI US 1997-976191 19971121 (8)
PRAI US 1996-77175P 19961122 (60)
DT Utility
FS Granted
LN.CNT 3343
INCL INCLM: 514/506.000
INCLS: 514/399.000; 548/335.500; 560/041.000
NCL NCLM: 514/506.000
NCLS: 514/399.000; 548/335.500; 560/041.000
IC [7]
ICM: A01N037-20
ICS: A01N043-50; C07C229-24; C07D233-61
EXF 560/41; 514/506; 514/399; 548/335.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 406 OF 469 USPATFULL on STN
AN 2000:91941 USPATFULL
TI Serine proteases, their activity and their synthetic inhibitors
IN Augustyns, Koen Jan Ludovicus, Minderhout, Belgium
Vanhoof, Greta Constantia, Mortsel, Belgium
Borloo, Marianne Jean Frieda, Deurne, Belgium
De Meester, Ingrid Anna Jozef, Wilrijk, Belgium
Goossens, Filip Jozef Anny, Lokeren, Belgium
Haemers, Achiel Jean-Marie, Gent, Belgium
Hendriks, Dirk Frans, Aartselaar, Belgium
Lambeir, Anne-Marie Virginie Renee, Heverlee, Belgium
Scharpe, Simon Lodewijk, Wieze, Belgium
PA FondaTech Benelux N.V., Belgium (non-U.S. corporation)
PI US 6090786 20000718
WO 9534538 19951221
AI US 1997-750484 19970219 (8)
WO 1995-EP2255 19950609
19970219 PCT 371 date
19970219 PCT 102(e) date
PRAI EP 1994-201668 19940610
EP 1994-203707 19941220
DT Utility
FS Granted
LN.CNT 1511
INCL INCLM: 514/019.000
INCLS: 514/020.000; 514/002.000; 530/330.000; 540/130.000
NCL NCLM: 514/019.000
NCLS: 514/002.000; 514/020.000; 530/330.000; 540/130.000
IC [7]
ICM: A61K038-05
ICS: C07K005-078
EXF 514/19; 514/20; 514/2; 530/330; 540/130
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 407 OF 469 USPATFULL on STN
AN 2000:54070 USPATFULL
TI Kallikrein-binding "Kunitz domain" proteins and analogues thereof
IN Markland, William, Milford, MA, United States
Ladner, Robert Charles, Ijamsville, MD, United States
PA Dyax Corp., Cambridge, MA, United States (U.S. corporation)
PI US 6057287 20000502
AI US 1994-208264 19940310 (8)
RLI Continuation-in-part of Ser. No. US 1994-179964, filed on 11 Jan 1994, now abandoned
DT Utility
FS Granted
LN.CNT 3820
INCL INCLM: 514/002.000
INCLS: 514/012.000; 530/300.000; 530/317.000; 530/324.000; 435/004.000; 435/007.400; 435/007.720; 435/069.100
NCL NCLM: 514/002.000
NCLS: 435/004.000; 435/007.400; 435/007.720; 435/069.100; 514/012.000; 530/300.000; 530/317.000; 530/324.000
IC [7]
ICM: A61K038-16
ICS: C07K014-00
EXF 530/317; 530/300; 530/324; 514/12; 514/2; 435/69.1; 435/4; 435/7.4; 435/7.72
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 408 OF 469 USPATFULL on STN
AN 2000:50364 USPATFULL
TI Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro
IN Lansbury, Jr., Peter T., Brookline, MA, United States
Han, Hogyu, Seoul, Korea, Republic of
Cho, Cheon-Gyu, Seoul, Korea, Republic of
Zhen, Weiguo, Waltham, MA, United States
Harper, James D., Cambridge, MA, United States
Davison, Alan, West Roxbury, MA, United States
PA Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
PI US 6054114 20000425
AI US 1997-852825 19970507 (8)
PRAI US 1996-16599P 19960508 (60)

DT Utility
FS Granted
LN.CNT 2848
INCL INCLM: 424/001.110
INCLS: 424/009.100; 534/010.000; 534/012.000; 534/014.000; 534/883.000; 556/045.000
NCL NCLM: 424/001.110
NCLS: 424/009.100; 534/010.000; 534/012.000; 534/014.000; 534/883.000; 556/045.000
IC [7]
ICM: A61K051-00
ICS: A61K049-00; C07F013-00
EXF 534/10; 534/12; 534/14; 534/670; 534/671; 534/883; 424/1.11; 424/1.37; 424/9.1; 556/45
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 409 OF 469 USPATFULL on STN
AN 2000:41077 USPATFULL
TI .alpha.-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
IN Kelleher, Judith A., Fremont, CA, United States
Maples, Kirk R., San Jose, CA, United States
Dykman, Alina, San Francisco, CA, United States
Zhang, Yong-Kang, Santa Clara, CA, United States
Wilcox, Allan L., Mountain View, CA, United States
Levell, Julian, Collegeville, PA, United States
PA Centaur Pharmaceuticals, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6046232 20000404
AI US 1998-172763 19981015 (9)
PRAI US 1997-62324P 19971017 (60)
US 1997-63736P 19971029 (60)
US 1998-90475P 19980624 (60)
DT Utility
FS Granted
LN.CNT 2793
INCL INCLM: 514/464.000
INCLS: 514/640.000; 514/645.000; 564/300.000; 564/265.000; 549/434.000
NCL NCLM: 514/464.000
NCLS: 514/640.000; 514/645.000; 549/434.000; 564/265.000; 564/300.000
IC [7]
ICM: A61K031-34
EXF 514/645; 514/640; 514/464; 564/300; 564/265; 549/434; 549/432
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 410 OF 469 USPATFULL on STN
AN 2000:37839 USPATFULL
TI Tyramine compounds and their neuronal effects
IN Giulian, Dana J., Houston, TX, United States
PA Baylor College of Medicine, Houston, TX, United States (U.S. corporation)
PI US 6043283 20000328
AI US 1997-870967 19970606 (8)
RLI Continuation-in-part of Ser. No. US 1996-717551, filed on 20 Sep 1996
DT Utility
FS Granted
LN.CNT 3153
INCL INCLM: 514/617.000
NCL NCLM: 514/617.000
IC [7]
ICM: A61K031-165
EXF 514/152; 514/617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 411 OF 469 USPATFULL on STN
AN 2000:31594 USPATFULL
TI Transgenic mouse expressing an . ***beta*** .- ***Amyloid*** transgene
IN Sato, Masahiro, Kawagoe, Japan
Kobayashi, Takashi, Fukuoka, Japan
Tada, Norihiro, Kawagoe, Japan
Shoji, Mikio, Gunma-gun, Japan
Kawarabayashi, Takeshi, Maebashi, Japan
PA Hoechst Japan Limited, Tokyo, Japan (non-U.S. corporation)
PI US 6037521 20000314

PRAI JP 1993-306026 19931112
DT Utility
FS Granted
LN.CNT 1316
INCL INCLM: 800/018.000
INCLS: 800/009.000; 800/012.000; 800/003.000; 424/009.100; 424/009.200
NCL NCLM: 800/018.000
NCLS: 424/009.100; 424/009.200; 800/003.000; 800/009.000; 800/012.000
IC [7]
ICM: A01K067-00
ICS: A01K067-027
EXF 800/2; 435/172.3; 424/9; 424/9.1; 424/9.2

L4 ANSWER 412 OF 469 USPATFULL on STN
AN 2000:28107 USPATFULL
TI .beta.-sheet nucleating peptidomimetics
IN Kelly, Jeffery W., 213 Chimney Hill Cir., College Station, TX, United States 77840
PI US 6034211 20000307
AI US 1996-664379 19960614 (8)
PRAI US 1996-18925P 19960603 (60)
DT Utility
FS Granted
LN.CNT 1635
INCL INCLM: 530/317.000
INCLS: 546/101.000
NCL NCLM: 530/317.000
NCLS: 546/101.000
IC [7]
ICM: C07K005-00
EXF 548/427; 546/101; 514/323-328; 530/317
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 413 OF 469 USPATFULL on STN
AN 2000:21390 USPATFULL
TI Methods of detecting Alzheimer's disease
IN Roses, Allen D., Durham, NC, United States
Strittmatter, Warren J., Durham, NC, United States
Salvesen, Guy S., Chapel Hill, NC, United States
Enghild, Jan, Durham, NC, United States
Schmechel, Donald E., Durham, NC, United States
PA Duke University, Durham, NC, United States (U.S. corporation)
PI US 6027896 20000222
AI US 1998-60459 19980415 (9)
RLI Continuation of Ser. No. US 1997-835503, filed on 8 Apr 1997, now patented, Pat. No. US 5767248 which is a continuation of Ser. No. US 1995-440900, filed on 15 May 1995, now abandoned which is a division of Ser. No. US 1994-227044, filed on 13 Apr 1994, now patented, Pat. No. US 5508167 which is a continuation-in-part of Ser. No. US 1993-114448, filed on 31 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-959992, filed on 13 Oct 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1614
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/091.200; 536/023.100; 536/024.300; 530/387.100; 530/350.000
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/091.200; 530/350.000; 530/387.100; 536/023.100; 536/024.300
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C12P019-34; C07H021-02
EXF 435/6; 435/7.1; 435/91.2; 536/23.1; 536/24.3; 530/387.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 414 OF 469 USPATFULL on STN
AN 2000:1862 USPATFULL
TI Vasoactive effects and free radical generation by . ***beta*** .-***amyloid*** peptides
IN Thomas, Thomas N., Palm Harbor, FL, United States
Mullan, Michael, Tampa, FL, United States
Arendash, Gary W., Lutz, FL, United States
Crawford, Fiona C., Tampa, FL, United States
Suo, Zhiming, Tampa, FL, United States

PI US 6011019 20000104
AI US 1996-747457 19961112 (8)
RLI Continuation-in-part of Ser. No. US 1996-615593, filed on 12 Mar 1996
DT Utility
FS Granted
LN.CNT 2634
INCL INCLM: 514/043.000
INCLS: 424/718.000; 424/094.400
NCL NCLM: 514/043.000
NCLS: 424/094.400; 424/718.000
IC [6]
ICM: A01N043-04
EXF 514/43; 424/718; 424/94.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 415 OF 469 USPATFULL on STN
AN 2000:1692 USPATFULL
TI Sequence-directed DNA binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood, CA, United States (U.S. corporation)
PI US 6010849 20000104
AI US 1995-482080 19950607 (8)
RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
LN.CNT 10022
INCL INCLM: 435/006.000
INCLS: 435/007.100
NCL NCLM: 435/006.000
NCLS: 435/007.100
IC [6]
ICM: C12Q001-68
ICS: G01N033-53
EXF 435/6; 435/7.1; 436/501; 536/23.1; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 416 OF 469 USPATFULL on STN
AN 1999:132524 USPATFULL
TI Diagnostic assay for Alzheimer's disease: assessment of A.beta. abnormalities
IN Tanzi, Rudolph E., Canton, MA, United States
Bush, Ashley I., Somerville, MA, United States
Moir, Robert D., Boston, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 5972634 19991026
WO 9612544 19960502
AI US 1997-817423 19970804 (8)
WO 1994-US11895 19941019
19970804 PCT 371 date
19970804 PCT 102(e) date
DT Utility
FS Granted
LN.CNT 2476
INCL INCLM: 435/007.940
INCLS: 435/007.100; 435/007.900; 435/007.920; 435/007.950; 435/975.000; 436/525.000; 436/164.000; 436/172.000
NCL NCLM: 435/007.940
NCLS: 435/007.100; 435/007.900; 435/007.920; 435/007.950; 435/975.000; 436/164.000; 436/172.000; 436/525.000
IC [6]
ICM: G01N033-53
EXF 435/7.1; 435/7.92; 435/7.94; 435/7.95; 435/975; 435/7.9; 436/525; 436/164; 436/172; 436/63

L4 ANSWER 417 OF 469 USPATFULL on STN
AN 1999:124950 USPATFULL
TI N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta*** .- ***amyloid*** peptide release and/or its synthesis by use of such compounds
IN Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Whitesitt, Celia A., Greenwood, IN, United States
PA Athena Neurosciences, Inc., United States (U.S. corporation)
PI US 5965614 19991012
AI US 1997-975977 19971121 (8)
PRAI US 1996-104593P 19961122 (60)
DT Utility
FS Granted
LN.CNT 2939
INCL INCLM: 514/538.000
INCLS: 514/508.000; 560/043.000; 560/035.000
NCL NCLM: 514/538.000
NCLS: 514/508.000; 560/035.000; 560/043.000
IC [6]
ICM: A01N037-12
ICS: A01N037-52; C07C229-28
EXF 514/538; 514/508; 560/43; 560/35
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 418 OF 469 USPATFULL on STN
AN 1999:117454 USPATFULL
TI Animal models of human amyloidoses
IN Snow, Alan D., Seattle, WA, United States
PA Board of Regents of the University of Washington Office of Technology, Seattle, WA, United States (U.S. corporation)
PI US 5958883 19990928
AI US 1995-461216 19950605 (8)
RLI Continuation of Ser. No. US 1992-969734, filed on 23 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-950417, filed on 23 Sep 1992, now abandoned
DT Utility
FS Granted
LN.CNT 4323
INCL INCLM: 514/016.000
INCLS: 514/017.000; 530/328.000; 530/329.000
NCL NCLM: 514/016.000
NCLS: 514/017.000; 530/328.000; 530/329.000
IC [6]
ICM: A61K038-08
ICS: C07K007-06
EXF 514/16; 514/17; 530/300; 530/328; 530/329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 419 OF 469 USPATFULL on STN
AN 1999:113631 USPATFULL
TI Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
IN Holmes, Todd, Somerville, MA, United States
Zhang, Shuguang, Cambridge, MA, United States
Rich, Alexander, Cambridge, MA, United States
DiPersio, C. Michael, Norton, MA, United States
Lockshin, Curtis, Lexington, MA, United States
PA Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
PI US 5955343 19990921
AI US 1994-293284 19940822 (8)
RLI Continuation-in-part of Ser. No. US 1992-973326, filed on 28 Dec 1992, now abandoned
DT Utility
FS Granted
LN.CNT 2516
INCL INCLM: 435/240.100

NCL NCLM: 435/325.000
NCLS: 435/378.000; 435/395.000; 435/401.000
IC [6]
ICM: C12N005-02
EXF 435/240.1; 435/240.2; 435/240.23; 435/240.241
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 420 OF 469 USPATFULL on STN
AN 1999:92643 USPATFULL
TI Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
IN Vitek, Michael P., East Norwich, NY, United States
Cerami, Anthony, Shelter Island, NY, United States
Bucala, Richard J., New York, NY, United States
Ulrich, Peter C., Old Tappan, NJ, United States
Vlassara, Helen, Shelter Island, NJ, United States
Zhang, Xini, Jericho, NJ, United States
PA The Picower Institute For Medical Research, Manhasset, NY, United States (U.S. corporation)
PI US 5935927 19990810
WO 9520979 19950810
AI US 1996-501127 19960810 (8)
WO 1995-US1380 19950202
19960810 PCT 371 date
19960810 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-311768, filed on 23 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-191579, filed on 3 Feb 1994, now abandoned
DT Utility
FS Granted
LN.CNT 2154
INCL INCLM: 514/012.000
INCLS: 514/023.000; 514/079.000; 514/091.000; 514/095.000; 514/359.000; 514/438.000; 514/439.000; 514/443.000; 514/569.000; 514/642.000; 514/647.000; 548/100.000; 548/121.000; 548/122.000; 530/300.000; 530/322.000; 536/001.110
NCL NCLM: 514/012.000
NCLS: 514/023.000; 514/079.000; 514/091.000; 514/095.000; 514/359.000; 514/438.000; 514/439.000; 514/443.000; 514/569.000; 514/642.000; 514/647.000; 530/300.000; 530/322.000; 536/001.110; 548/100.000; 548/121.000; 548/122.000
IC [6]
ICM: A61K038-00
ICS: A61K031-135; A61K031-70
EXF 530/300; 530/322; 514/2; 514/647; 514/12; 514/23; 514/569; 514/663; 514/665; 514/79; 514/91; 514/95; 514/359; 514/438; 514/439; 514/443; 514/642; 548/100; 548/121; 548/122; 536/1.11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 421 OF 469 USPATFULL on STN
AN 1999:67429 USPATFULL
TI Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
IN Cordell, Barbara, Palo Alto, CA, United States
PA Scios Inc., Mountain View, CA, United States (U.S. corporation)
PI US 5912410 19990615
AI US 1995-422333 19950413 (8)
RLI Continuation of Ser. No. US 1994-327381, filed on 21 Oct 1994, now abandoned which is a continuation-in-part of Ser. No. US 1991-716725, filed on 17 Jun 1991, now patented, Pat. No. US 5387742 which is a continuation-in-part of Ser. No. US 1990-538857, filed on 15 Jun 1990, now abandoned
DT Utility
FS Granted
LN.CNT 2702
INCL INCLM: 800/002.000
INCLS: 800/DIG.001; 424/009.200; 935/062.000
NCL NCLM: 800/012.000
NCLS: 424/009.200
IC [6]
ICM: C12N015-00
ICS: C12N005-00; A61K049-00
EXF 800/2; 800/DIG.1; 935/62; 424/9.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1999:27850 USPATFULL
TI Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
IN Hsiao, Karen, North Oaks, MN, United States
Borchelt, David R., Baltimore, MD, United States
Sisodia, Sangram S., Baltimore, MD, United States
PA Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)
PI US 5877399 19990302
AI US 1996-664872 19960617 (8)
RLI Continuation-in-part of Ser. No. US 1996-644691, filed on 10 May 1996, now abandoned which is a continuation of Ser. No. US 1994-189064, filed on 27 Jan 1994
DT Utility
FS Granted
LN.CNT 2823
INCL INCLM: 800/002.000
INCLS: 800/DIG.001; 424/009.200; 935/060.000
NCL NCLM: 800/003.000
NCLS: 424/009.200; 800/009.000; 800/012.000
IC [6]
ICM: C12N005-00
ICS: C12N015-00; A61K049-00
EXF 800/2; 800/DIG.1; 424/9.2; 435/320.1; 536/23.1; 935/60
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 423 OF 469 USPATFULL on STN
AN 1999:27412 USPATFULL
TI Screening methods to identify neurotoxin inhibitors
IN Yankner, Bruce A., Boston, MA, United States
PA The Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5876948 19990302
AI US 1991-737371 19910729 (7)
RLI Continuation-in-part of Ser. No. US 1990-559173, filed on 27 Jul 1990, now patented, Pat. No. US 5137873
DT Utility
FS Granted
LN.CNT 1037
INCL INCLM: 435/007.210
INCLS: 435/007.900; 435/007.950; 435/040.500; 435/960.000; 436/519.000; 436/811.000
NCL NCLM: 435/007.210
NCLS: 435/007.900; 435/007.950; 435/040.500; 435/960.000; 436/519.000; 436/811.000
IC [6]
ICM: G01N033-53
EXF 435/7.21; 435/7.9; 435/7.95; 435/29; 435/240.2; 435/960; 435/40.5; 436/518; 436/519; 436/811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 424 OF 469 USPATFULL on STN
AN 1999:18912 USPATFULL
TI Method of determining DNA sequence preference of a DNA-binding molecule
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5869241 19990209
AI US 1995-475228 19950607 (8)
RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented, Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992, now patented, Pat. No. US 5693463 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
LN.CNT 9840

INCLS: 435/911.000; 435/912.000; 935/077.000; 935/078.000
NCL NCLM: 435/006.000
NCLS: 435/091.100; 435/091.200
IC [6]
ICM: C12Q001-68
ICS: C12P019-34
EXF 435/6; 435/91.1; 435/91.2; 935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 425 OF 469 USPATFULL on STN
AN 1998:159959 USPATFULL
TI Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
IN Fisher, Abraham, Holon, Israel
Karton, Yishal, Ness-Ziona, Israel
Marciano, Daniele, Ramat-Hasharon, Israel
Barak, Dov, Rehovot, Israel
Meshulam, Haim, Bat Yam, Israel
PA Israel Institute for Biological Research, Nessziona, Israel (non-U.S. corporation)
PI US 5852029 19981222
AI US 1996-627222 19960118 (8)
RLI Continuation-in-part of Ser. No. US 1993-94855, filed on 20 Jul 1993, now patented, Pat. No. US 5534520 which is a continuation-in-part of Ser. No. US 1991-685397, filed on 9 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-507708, filed on 10 Apr 1990, now abandoned
DT Utility
FS Granted
LN.CNT 4189
INCL INCLM: 514/278.000
INCLS: 546/016.000; 546/019.000; 546/020.000
NCL NCLM: 514/278.000
NCLS: 546/016.000; 546/019.000; 546/020.000
IC [6]
ICM: C07D491-10
ICS: C07D491-20; A61K031-445; A61K031-46
EXF 546/19; 546/16; 546/20; 514/278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 426 OF 469 USPATFULL on STN
AN 1998:157599 USPATFULL
TI Transgenic rodents harboring APP allele having swedish mutation
IN McLonlogue, Lisa C., San Francisco, CA, United States
Zhao, Jun, San Diego, CA, United States
PA Athena Neurosciences, South San Francisco, CA, United States (U.S. corporation)
PI US 5850003 19981215
AI US 1997-785943 19970122 (8)
RLI Continuation of Ser. No. US 1993-148211, filed on 1 Nov 1993, now patented, Pat. No. US 5612486 which is a continuation-in-part of Ser. No. US 1993-143697, filed on 27 Oct 1993, now patented, Pat. No. US 5604102
DT Utility
FS Granted
LN.CNT 1766
INCL INCLM: 800/002.000
INCLS: 800/DIG.001; 935/062.000
NCL NCLM: 800/009.000
NCLS: 800/012.000; 800/014.000; 800/018.000
IC [6]
ICM: C12N005-00
ICS: C12N015-00
EXF 800/2; 800/DIG.1; 935/62
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 427 OF 469 USPATFULL on STN
AN 1998:147551 USPATFULL
TI Process for enhancing the activity of ***amyloid*** . ***beta*** . peptides
IN Hensley, Kenneth, Lexington, KY, United States
Butterfield, D. Allan, Lexington, KY, United States
Carney, John M., Lexington, KY, United States
Aksenov, Michael, Lexington, KY, United States
PA University of Kentucky Research Foundation, Lexington, KY, United States

PI US 5840838 19981124
AI US 1996-609090 19960229 (8)
DT Utility
FS Granted
LN.CNT 560
INCL INCLM: 530/324.000
INCLS: 530/326.000; 530/327.000; 530/328.000; 530/344.000
NCL NCLM: 530/324.000
NCLS: 530/326.000; 530/327.000; 530/328.000; 530/344.000
IC [6]
ICM: C07K007-00
ICS: C07K014-00
EXF 530/324; 530/326; 530/327; 530/328; 530/344
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 428 OF 469 USPATFULL on STN
AN 1998:144072 USPATFULL
TI Methods and compositions for the detection of soluble . ***beta*** .-***amyloid*** peptide
IN Schenk, Dale B., Pacifica, CA, United States
Schlossmacher, Michael G., Vienna, Austria
Selkoe, Dennis J., Jamaica Plain, MA, United States
Seubert, Peter A., South San Francisco, CA, United States
Vigo-Pelfrey, Carmen, Mountain View, CA, United States
PA Athena Neurosciences, Inc., So. San Francisco, CA, United States (U.S. corporation)
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 5837672 19981117
AI US 1995-456347 19950601 (8)
RLI Division of Ser. No. US 1995-437067, filed on 9 May 1995, now patented, Pat. No. US 5593846 And a continuation-in-part of Ser. No. US 1992-911647, filed on 10 Jul 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1445
INCL INCLM: 514/002.000
INCLS: 514/002.000; 514/042.000; 514/076.900; 514/222.200; 424/520.000; 435/007.900; 435/007.200; 436/518.000; 436/811.000
NCL NCLM: 514/002.000
NCLS: 424/520.000; 435/007.200; 435/007.900; 436/518.000; 436/811.000; 514/042.000; 514/169.000; 514/222.200
IC [6]
ICM: A61K031-00
ICS: A61K038-00
EXF 435/7.9; 435/4; 435/7.8; 435/6; 435/7.1; 435/7.2; 435/7.4; 436/518; 436/547; 436/548; 436/63; 436/811; 424/9.1; 424/184.1; 424/277.1; 424/520; 514/2; 514/42; 514/169; 514/222.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 429 OF 469 USPATFULL on STN
AN 1998:143904 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert Charles, Ijamsville, MD, United States
Gutterman, Sonia Kosow, Belmont, MA, United States
Roberts, Bruce Lindsay, Milford, MA, United States
Markland, William, Milford, MA, United States
Ley, Arthur Charles, Newton, MA, United States
Kent, Rachel Baribault, Boxborough, MA, United States
PA Dyax, Corp., Cambridge, MA, United States (U.S. corporation)
PI US 5837500 19981117
AI US 1995-415922 19950403 (8)
RLI Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, now patented, Pat. No. US 5403484 which is a division of Ser. No. US 1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409 which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now abandoned
DT Utility
FS Granted
LN.CNT 15973
INCL INCLM: 435/069.700
INCLS: 435/172.300; 530/350.000; 530/412.000; 536/023.400

NCLS: 435/091.100; 435/091.200; 435/471.000; 530/350.000; 530/412.000; 536/023.400
IC [6]
ICM: C12N015-62
ICS: C07K019-00
EXF 435/69.7; 435/172.3; 530/350; 530/412; 536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 430 OF 469 USPATFULL on STN
AN 1998:115560 USPATFULL
TI Methods and compositions for binding tau and MAP2c proteins
IN Strittmatter, Warren J., Durham, NC, United States
Roses, Allen D., Durham, NC, United States
Goedert, Michel, Cambridge, England
Weisgraber, Karl H., Walnut Creek, CA, United States
Saunders, Ann M., Durham, NC, United States
Schmechel, Donald E., Durham, NC, United States
PA Duke University, Durham, NC, United States (U.S. corporation)
PI US 5811243 19980922
AI US 7402325 19961025 (8)
RLI Division of Ser. No. 287218, filed on 8 Aug 1994 which is a continuation-in-part of Ser. No. 114910, filed on 31 Aug 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1122
INCL INCLM: 435/007.100
INCLS: 530/350.000
NCL NCLM: 435/007.100
NCLS: 530/350.000
IC [6]
ICM: C12Q001-00
ICS: G01N033-53; C07K014-00
EXF 530/350; 435/7.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 431 OF 469 USPATFULL on STN
AN 1998:88671 USPATFULL
TI Monoclonal ***antibody*** 369.2B specific for .beta. A4 peptide
IN Konig, Gerhard, Branford, CT, United States
Graham, Paul, New Haven, CT, United States
PA Bayer Corporation, Pittsburgh, PA, United States (U.S. corporation)
PI US 5786180 19980728
AI US 1995-388463 19950214 (8)
DT Utility
FS Granted
LN.CNT 926
INCL INCLM: 435/070.210
INCLS: 435/331.000; 436/547.000; 436/548.000; 530/327.000; 530/387.900; 530/388.100; 530/389.100
NCL NCLM: 435/070.210
NCLS: 435/331.000; 436/547.000; 436/548.000; 530/327.000; 530/387.900; 530/388.100; 530/389.100
IC [6]
ICM: A61K039-395
EXF 435/70.21; 435/240.27; 435/70.2; 435/326; 435/331; 530/388.1; 530/388.2; 530/327; 530/387.9; 530/389.1; 436/548; 436/547; 424/184.1; 424/185.1; 424/193.1; 424/194.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 432 OF 469 USPATFULL on STN
AN 1998:69161 USPATFULL
TI Apolipoprotein E isoform-specific monoclonal ***antibodies***
IN Roses, Allen D., Durham, NC, United States
Strittmatter, Warren J., Durham, NC, United States
Salvesen, Guy S., Chapel Hill, NC, United States
Enghild, Jan, Durham, NC, United States
Schmechel, Donald E., Durham, NC, United States
PA Duke University, Durham, NC, United States (U.S. corporation)
PI US 5767248 19980616
AI US 1997-835503 19970408 (8)
RLI Continuation of Ser. No. US 1995-440900, filed on 15 May 1995, now abandoned which is a division of Ser. No. US 1994-227044, filed on 13 Apr 1994, now patented, Pat. No. US 5508167 which is a continuation-in-part of Ser. No. US 1993-114448, filed on 31 Aug 1993,

1992-959992, filed on 13 Oct 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1603
INCL INCLM: 530/388.250
INCLS: 530/387.900; 530/388.100; 530/391.100; 530/391.300
NCL NCLM: 530/388.250
NCLS: 530/387.900; 530/388.100; 530/391.100; 530/391.300
IC [6]
ICM: C07K016-00
EXF 530/387.9; 530/388.1; 530/388.25; 530/391.1; 530/391.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 433 OF 469 USPATFULL on STN
AN 1998:68773 USPATFULL
TI Methods of screening for compounds which inhibit soluble .***beta***.- ***amyloid*** peptide production
IN Schlossmacher, Michael G., Vienna, Austria
Selkoe, Dennis J., Jamaica Plain, MA, United States
PA Athena Neurosciences, South San Francisco, CA, United States (U.S. corporation)
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5766846 19980616
AI US 1993-79511 19930617 (8)
RLI Division of Ser. No. US 1992-965972, filed on 26 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-911647, filed on 10 Jul 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1465
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/007.200; 435/007.210; 435/041.000; 435/069.100; 435/007.920; 435/007.940
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/007.200; 435/007.210; 435/007.920; 435/007.940; 435/041.000; 435/069.100
IC [6]
ICM: G01N033-53
EXF 435/6; 435/7.1; 435/7.2; 435/7.21; 435/29; 435/41; 435/69.1; 435/70.1; 435/70.3; 435/7.92; 435/7.94
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 434 OF 469 USPATFULL on STN
AN 1998:45106 USPATFULL
TI Methods for the detection of soluble ***amyloid*** . ***beta***.-protein (.beta.AP) or soluble transthyretin (TTR)
IN Goldgaber, Dmitry Y., Setauket, NY, United States
Schwarzman, Alexander L., St. James, NY, United States
Eisenberg-Grunberg, Moises, Port Jefferson Station, NY, United States
PA Research Foundation of State University of New York, Albany, NY, United States (U.S. corporation)
PI US 5744368 19980428
AI US 1993-148117 19931104 (8)
DT Utility
FS Granted
LN.CNT 1187
INCL INCLM: 436/501.000
INCLS: 435/007.800; 436/503.000; 436/504.000; 436/518.000; 436/804.000
NCL NCLM: 436/501.000
NCLS: 435/007.800; 436/503.000; 436/504.000; 436/518.000; 436/804.000
IC [6]
ICM: G01N033-566
ICS: G01N033-53
EXF 436/501; 436/504; 436/503; 436/518; 436/528; 436/531; 436/804; 435/7.93; 435/7.8; 435/7.9
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 435 OF 469 USPATFULL on STN
AN 1998:45071 USPATFULL
TI DNA encoding fused di-beta globins and production of pseudotetrameric hemoglobin
IN Hoffman, Stephen J., Denver, CO, United States
Looker, Douglas L., Lafayette, CO, United States
Rosendahl, Mary S., Broomfield, CO, United States

Wagenbach, Michael, Osaka, Japan
Anderson, David C., Lafayette, CO, United States
Mathews, Antony James, Louisville, CO, United States
Nagai, Kiyoshi, Cambridge, England
PA Somatogen, Inc., Boulder, CO, United States (U.S. corporation)
PI US 5744329 19980428
AI US 1995-444942 19950519 (8)
RLI Division of Ser. No. US 1991-789179, filed on 8 Nov 1991, now patented, Pat. No. US 5545727 which is a continuation-in-part of Ser. No. US 1991-671707, filed on 1 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-374161, filed on 30 Jun 1989, now abandoned Ser. No. Ser. No. US 1989-379116, filed on 13 Jul 1989, now abandoned And Ser. No. US 1989-349623, filed on 10 May 1989, now abandoned
DT Utility
FS Granted
LN.CNT 6645
INCL INCLM: 435/696.000
INCLS: 435/069.700; 435/069.100; 530/385.000; 536/023.400
NCL NCLM: 435/069.600
NCLS: 435/069.100; 435/069.700; 530/385.000; 536/023.400
IC [6]
ICM: C12P021-06
ICS: C07H017-00; C07K014-805
EXF 530/385; 536/23.1; 536/23.4; 435/69.1; 435/69.6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 436 OF 469 USPATFULL on STN
AN 1998:45052 USPATFULL
TI Bax promoter sequence and screening assays for indentifying agents that regulate bax gene expression
IN Reed, John C., Rancho Santa Fe, CA, United States
PA The Burnham Institute, La Jolla, CA, United States (U.S. corporation)
PI US 5744310 19980428
AI US 1996-688145 19960729 (8)
DT Utility
FS Granted
LN.CNT 1938
INCL INCLM: 435/006.000
INCLS: 435/691.000; 435/091.400; 435/325.000; 536/024.100
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/091.400; 435/325.000; 536/024.100
IC [6]
ICM: C12Q001-68
ICS: C12P021-00; C12N005-10; C07H021-04
EXF 435/6; 435/69.1; 435/91.1; 435/240.2; 435/91.4; 435/325; 536/24.1; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 437 OF 469 USPATFULL on STN
AN 1998:44877 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5744131 19980428
AI US 1995-476876 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
LN.CNT 5113
INCL INCLM: 424/078.080
INCLS: 436/501.000; 514/001.000
NCL NCLM: 424/078.080
NCLS: 436/501.000; 514/001.000
IC [6]
ICM: A61K031-74
ICS: G01N033-566; G01N033-558
EXF 536/23.1; 536/27.1; 546/109; 436/501; 514/1; 424/78.08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 438 OF 469 USPATFULL on STN
AN 1998:39383 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5738990 19980414
AI US 1995-475221 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
LN.CNT 5040
INCL INCLM: 435/006.000
INCLS: 435/691.000; 435/172.300; 435/320.100; 536/024.100; 935/036.000; 935/039.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 536/024.100
IC [6]
ICM: C12P021-02
ICS: C12N015-67; C07H021-04
EXF 435/172.1; 435/69.1; 435/6; 435/320.1; 435/172.3; 536/24.1; 935/36; 935/39
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 439 OF 469 USPATFULL on STN
AN 1998:25075 USPATFULL
TI Screening assay for the detection of DNA-binding molecules
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Watertown, MA, United States
Turin, Lisa M., Berkeley, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5726014 19980310
AI US 1993-123936 19930917 (8)
RLI Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
LN.CNT 5659
INCL INCLM: 435/006.000
INCLS: 435/091.200; 436/501.000
NCL NCLM: 435/006.000
NCLS: 435/091.200; 436/501.000
IC [6]
ICM: C12Q001-68
ICS: C12P019-34; G01N033-566
EXF 435/6; 435/235; 435/91.1; 435/91.2; 435/91.5; 536/23.1; 536/23.2; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 440 OF 469 USPATFULL on STN
AN 1998:19582 USPATFULL
TI In Vitro method for screening . ***beta*** .- ***amyloid*** deposition
IN Maggio, John E., Brookline, MA, United States
Mantyh, Patrick W., Edina, MN, United States
PA Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)
President and Fellows of Harvard College, Boston, MA, United States (U.S. corporation)
PI US 5721106 19980224
AI US 1994-304585 19940912 (8)
RLI Continuation-in-part of Ser. No. US 1991-744767, filed on 13 Aug 1991, now patented, Pat. No. US 5434050
DT Utility
FS Granted
LN.CNT 1977
INCL INCLM: 435/007.800

NCL NCLM: 435/007.800
NCLS: 435/007.100; 435/007.900; 436/501.000; 436/504.000
IC [6]
ICM: G01N033-53
EXF 435/4; 435/7.1; 435/7.21; 435/7.8; 435/7.9; 436/501; 436/86; 436/504
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 441 OF 469 USPATFULL on STN
AN 1998:14680 USPATFULL
TI Kit for detecting the ApoE4 allele, and for diagnosing the existence or risk of developing Alzheimer's disease
IN Roses, Allen D., Durham, NC, United States
Strittmatter, Warren J., Durham, NC, United States
Salvesen, Guy S., Chapel Hill, NC, United States
Enghild, Jan, Durham, NC, United States
Schmechel, Donald E., Durham, NC, United States
PA Duke University, Durham, NC, United States (U.S. corporation)
PI US 5716828 19980210
AI US 1995-441001 19950515 (8)
RLI Division of Ser. No. US 1994-227044, filed on 13 Apr 1994, now patented, Pat. No. US 5508167 which is a continuation-in-part of Ser. No. US 1993-114448, filed on 31 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-959992, filed on 13 Oct 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1604
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/810.000
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/810.000
IC [6]
ICM: C12Q001-68
ICS: G01N033-53
EXF 435/6; 435/7.1; 435/810; 204/182.8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 442 OF 469 USPATFULL on STN
AN 1998:14634 USPATFULL
TI Method of constructing sequence-specific DNA-binding molecules
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Watertown, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5716780 19980210
AI US 1995-484499 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
LN.CNT 4929
INCL INCLM: 435/006.000
INCLS: 436/501.000
NCL NCLM: 435/006.000
NCLS: 436/501.000
IC [6]
ICM: C12Q001-68
ICS: G01N033-566
EXF 435/6; 536/24.5; 935/33; 935/34; 935/36; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 443 OF 469 USPATFULL on STN
AN 97:112579 USPATFULL
TI Method of isolating .beta.A4 peptide species ending at carboxy-terminals residue 42 using monoclonal ***antibody*** 369.2B
IN Konig, Gerhard, Branford, CT, United States
Graham, Paul, New Haven, CT, United States
PA Bayer Corporation, West Haven, CT, United States (U.S. corporation)
PI US 5693753 19971202
AI US 1995-472627 19950607 (8)
RLI Division of Ser. No. US 1995-388463, filed on 14 Feb 1995
DT Utility

LN.CNT 924
INCL INCLM: 530/344.000
INCLS: 530/412.000; 530/413.000
NCL NCLM: 530/344.000
NCLS: 530/412.000; 530/413.000
IC [6]
ICM: C07K001-22
EXF 530/387.9; 530/388.1; 530/389.1; 530/391.1; 530/391.3; 530/391.5; 530/391.9; 530/344; 530/412; 530/413
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 444 OF 469 USPATFULL on STN
AN 97:112300 USPATFULL
TI Method of ordering sequence binding preferences of a DNA-binding molecule
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States4)
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5693463 19971202
AI US 1992-996783 19921223 (7)
RLI Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
LN.CNT 4908
INCL INCLM: 435/006.000
INCLS: 435/007.230; 536/023.100; 935/076.000; 935/077.000
NCL NCLM: 435/006.000
NCLS: 435/007.230; 536/023.100
IC [6]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-02; C12N015-00
EXF 435/6; 435/235; 536/23.1; 536/23.2; 514/44; 530/350; 530/351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 445 OF 469 USPATFULL on STN
AN 97:96730 USPATFULL
TI Methods of detecting .beta.A4 peptide species ending at carboxy-terminus residue 42 using monoclonal ***antibody*** 369.2B
IN Konig, Gerhard, Branford, CT, United States
Graham, Paul, New Haven, CT, United States
PA Bayer Corporation, West Haven, CT, United States (U.S. corporation)
PI US 5679531 19971021
AI US 1995-484969 19950607 (8)
RLI Division of Ser. No. US 1995-388463, filed on 14 Feb 1995
DT Utility
FS Granted
LN.CNT 932
INCL INCLM: 435/007.100
INCLS: 435/007.920; 435/007.950; 435/040.500; 435/040.520; 530/387.900; 530/388.100
NCL NCLM: 435/007.100
NCLS: 435/007.920; 435/007.950; 435/040.500; 435/040.520; 530/387.900; 530/388.100
IC [6]
ICM: G01N033-53
ICS: C07K016-18
EXF 435/70.21; 435/240.27; 435/387.9; 435/7.1; 435/7.21; 435/7.9; 435/40.52; 435/40.5; 435/7.92; 435/7.95; 530/388.1; 530/358.2; 530/327; 436/548; 424/184.1; 424/185.1; 424/193.1; 424/194.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 446 OF 469 USPATFULL on STN
AN 97:86591 USPATFULL
TI Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
IN Zhang, Shuguang, Cambridge, MA, United States
Lockshin, Curtis, Lexington, MA, United States
Rich, Alexander, Cambridge, MA, United States
Holmes, Todd, Cambridge, MA, United States
PA Massachusetts Insititute of Technology, Cambridge, MA, United States (U.S. corporation)

AI US 1994-346849 19941130 (8)
RLI Continuation of Ser. No. US 1992-973326, filed on 28 Dec 1992, now abandoned
DT Utility
FS Granted
LN.CNT 2210
INCL INCLM: 514/014.000
INCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000
NCL NCLM: 514/014.000
NCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000
IC [6]
ICM: A61K007-08
ICS: A61K014-00; C07K038-10; C07K038-16
EXF 530/300; 530/350; 514/12; 514/13; 514/14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 447 OF 469 USPATFULL on STN
AN 97:22926 USPATFULL
TI Transgenic animals harboring APP allele having swedish mutation
IN McConlogue, Lisa C., San Francisco, CA, United States
Zhao, Jun, San Diego, CA, United States
PA Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S. corporation)
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5612486 19970318
AI US 1993-148211 19931101 (8)
RLI Continuation-in-part of Ser. No. US 1993-143697, filed on 27 Oct 1993
DT Utility
FS Granted
LN.CNT 1759
INCL INCLM: 800/002.000
INCLS: 435/172.300; 536/023.500; 536/023.100
NCL NCLM: 800/012.000
NCLS: 536/023.100; 536/023.500; 800/018.000
IC [6]
ICM: C12N015-00
ICS: C07H021-04
EXF 800/2; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 448 OF 469 USPATFULL on STN
AN 97:15968 USPATFULL
TI Methods and compositions for monitoring cellular processing of ***beta*** - ***amyloid*** precursor protein
IN Seubert, Peter A., South San Francisco, CA, United States
Schenk, Dale B., Pacifica, CA, United States
Fritz, Lawrence C., San Francisco, CA, United States
PA Athena Neurosciences, Inc., South San Francisco, United States (U.S. corporation)
Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5605811 19970225
AI US 1995-440261 19950512 (8)
RLI Division of Ser. No. US 1992-965971, filed on 26 Oct 1992, now patented, Pat. No. US 5441870 which is a continuation-in-part of Ser. No. US 1995-868949, filed on 15 Apr 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1012
INCL INCLM: 435/029.000
INCLS: 435/023.000; 435/069.200; 424/009.200
NCL NCLM: 435/029.000
NCLS: 424/009.200; 435/023.000; 435/069.200
IC [6]
ICM: C12Q001-02
EXF 435/7.4; 435/23; 435/24; 435/29; 435/41; 435/69.2; 435/184; 424/9.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 449 OF 469 USPATFULL on STN
AN 96:120572 USPATFULL
TI Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease

PA Rutgers, The State University of New Jersey, Piscataway, NJ, United States (U.S. corporation)
PI US 5589154 19961231
AI US 1994-347144 19941122 (8)
DT Utility
FS Granted
LN.CNT 1362
INCL INCLM: 424/001.410
INCLS: 424/001.490; 424/001.690; 424/009.340; 424/009.600; 424/130.100; 424/145.100; 436/543.000; 436/547.000; 435/007.100; 530/380.000
NCL NCLM: 424/001.410
NCLS: 424/001.490; 424/001.690; 424/009.340; 424/009.600; 424/130.100; 424/145.100; 435/007.100; 436/543.000; 436/547.000; 530/380.000
IC [6]
ICM: A61K051-00
ICS: A61K039-395; A61K035-14; G01N033-53
EXF 424/1.49; 424/1.69; 424/1.41; 424/9.34; 424/9.6; 424/130.1; 424/145.1; 436/543; 436/547; 435/7.1; 530/380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 450 OF 469 USPATFULL on STN
AN 96:108816 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5578444 19961126
AI US 1993-171389 19931220 (8)
RLI Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993 which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
LN.CNT 5845
INCL INCLM: 435/006.000
INCLS: 435/007.230; 536/023.100; 935/076.000; 935/077.000
NCL NCLM: 435/006.000
NCLS: 435/007.230; 536/023.100
IC [6]
ICM: C12Q001-68
ICS: C12N015-00; G01N033-574; C07H021-02
EXF 435/6; 536/23.1; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 451 OF 469 USPATFULL on STN
AN 96:101466 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert C., Ijamsville, MD, United States
Guterman, Sonia K., Belmont, MA, United States
Roberts, Bruce L., Milford, MA, United States
Markland, William, Milford, MA, United States
Ley, Arthur C., Newton, MA, United States
Kent, Rachel B., Boxborough, MA, United States
PA Protein Engineering Corporation, Cambridge, MA, United States (U.S. corporation)
PI US 5571698 19961105
AI US 1993-57667 19930618 (8)
RLI Continuation of Ser. No. US 1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409 which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now abandoned
DT Utility
FS Granted
LN.CNT 15323
INCL INCLM: 435/069.700
INCLS: 435/006.000; 435/064.100; 435/172.300; 435/252.300; 435/320.100
NCL NCLM: 435/069.700
NCLS: 435/006.000; 435/069.100; 435/252.300; 435/320.100; 435/477.000
IC [6]

EXF 435/6; 435/64.1; 435/64.7; 435/172.3; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 452 OF 469 USPATFULL on STN
AN 96:92082 USPATFULL
TI Phospholipase A.sub.2 inhibitors
IN Clemens, James A., Indianapolis, IN, United States
Sofia, Michael J., Lawrenceville, NJ, United States
Stephenson, Diane T., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5563164 19961008
AI US 1995-464030 19950605 (8)
RLI Division of Ser. No. US 1993-173544, filed on 23 Dec 1993, now patented, Pat. No. US 5478857
DT Utility
FS Granted
LN.CNT 1858
INCL INCLM: 514/381.000
INCLS: 514/454.000; 514/455.000; 514/456.000; 514/457.000; 514/458.000; 514/568.000; 514/570.000; 514/571.000; 514/622.000
NCL NCLM: 514/381.000
NCLS: 514/454.000; 514/455.000; 514/456.000; 514/457.000; 514/458.000; 514/568.000; 514/570.000; 514/571.000; 514/622.000
IC [6]
ICM: A61K031-41
ICS: A61K031-35; A61K031-335; A61K031-19; A61K031-165
EXF 514/381; 514/454; 514/455; 514/456; 514/457; 514/458; 514/568; 514/570; 514/571; 514/622
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 453 OF 469 USPATFULL on STN
AN 96:80293 USPATFULL
TI Methods for treating a physiological disorder associated with . ***beta*** .- ***amyloid*** peptide
IN Lunn, William H. W., Indianapolis, IN, United States
Monn, James A., Indianapolis, IN, United States
Zimmerman, Dennis M., Mooresville, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5552426 19960903
AI US 1994-235400 19940429 (8)
DT Utility
FS Granted
LN.CNT 3104
INCL INCLM: 514/394.000
INCLS: 514/395.000; 548/304.400; 548/306.400; 548/306.700; 548/309.700; 548/310.100; 548/310.400; 548/310.700
NCL NCLM: 514/394.000
NCLS: 514/395.000; 548/304.400; 548/306.400; 548/306.700; 548/309.700; 548/310.100; 548/310.400; 548/310.700
IC [6]
ICM: A61K031-415
ICS: C07D235-18; C07D235-08
EXF 514/394; 514/395; 548/304.4; 548/304.7; 548/305.1; 548/305.4; 548/306.4; 548/306.7; 548/309.7; 548/310.1; 548/310.4; 548/310.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 454 OF 469 USPATFULL on STN
AN 96:31717 USPATFULL
TI Methods of screening for Alzheimer's disease
IN Roses, Allen D., Durham, NC, United States
Strittmatter, Warren J., Durham, NC, United States
Salvesen, Guy S., Chapel Hill, NC, United States
Enghild, Jan, Durham, NC, United States
Schmechel, Donald E., Durham, NC, United States
PA Duke University, Durham, NC, United States (U.S. corporation)
PI US 5508167 19960416
AI US 1994-227044 19940413 (8)
RLI Continuation-in-part of Ser. No. US 1993-114448, filed on 31 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-959992, filed on 13 Oct 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1653

INCLS: 435/004.000; 435/091.200; 435/091.520
NCL NCLM: 435/006.000
NCLS: 435/004.000; 435/091.200; 435/091.520
IC [6]
ICM: C12Q001-68
ICS: C12Q001-00; C12P019-34
EXF 435/4; 435/6; 435/91.2; 435/91.52; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 455 OF 469 USPATFULL on STN
AN 96:29429 USPATFULL
TI Method for inhibiting .beta.-protein enzymatic activity
IN Potter, Huntington, Boston, MA, United States
Kayyali, Usamah, Watertown, MA, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5506097 19960409
AI US 1994-179574 19940110 (8)
RLI Continuation-in-part of Ser. No. US 1992-819361, filed on 13 Jan 1992, now patented, Pat. No. US 5338663 which is a continuation-in-part of Ser. No. US 1990-572671, filed on 24 Aug 1990, now abandoned
DT Utility
FS Granted
LN.CNT 1041
INCL INCLM: 435/004.000
INCLS: 435/019.000; 435/020.000; 435/184.000
NCL NCLM: 435/004.000
NCLS: 435/019.000; 435/020.000; 435/184.000
IC [6]
ICM: C12Q001-00
ICS: C12Q001-46
EXF 435/4; 435/7.4; 435/19; 435/23; 435/183; 435/184; 435/210; 435/20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 456 OF 469 USPATFULL on STN
AN 96:5937 USPATFULL
TI Substituted 3-indolyl-5-pyrazolone compounds
IN Grant, Francine S., 800 Gateway Blvd., South San Francisco, CA, United States 94080
Fang, Lawrence Y., 800 Gateway Blvd., South San Francisco, CA, United States 94080
John, Varghese, 800 Gateway Blvd., South San Francisco, CA, United States 94080
Thorsett, Eugene D., 800 Gateway Blvd., South San Francisco, CA, United States 94080
PI US 5484940 19960116
AI US 1994-345973 19941128 (8)
DT Utility
FS Granted
LN.CNT 2464
INCL INCLM: 548/364.700
INCLS: 544/238.000; 544/284.000
NCL NCLM: 548/364.700
NCLS: 544/238.000; 544/284.000
IC [6]
ICM: C07D403-08
ICS: C07D403-14
EXF 548/364.7; 544/238; 544/284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 457 OF 469 USPATFULL on STN
AN 96:1451 USPATFULL
TI Method of providing enternal nutritional support to persons infected with human immunodeficiency virus
IN Cope, Frederick O., Worthington, OH, United States
DeWille, Normanella T., Upper Arlington, OH, United States
Richards, Ernest W., Columbus, OH, United States
Mazer, Terrence B., Reynoldsburg, OH, United States
Abbruzzese, Bonnie C., Dublin, OH, United States
Snowden, Gregory A., Pickerington, OH, United States
Chandler, Michael A., Gahanna, OH, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5480872 19960102
AI US 1993-69066 19930528 (8)
DT Utility

LN.CNT 1369
INCL INCLM: 514/021.000
INCLS: 426/648.000; 426/654.000; 426/656.000; 426/641.000; 426/657.000
NCL NCLM: 514/021.000
NCLS: 426/641.000; 426/648.000; 426/654.000; 426/656.000; 426/657.000
IC [6]
ICM: A23J003-16
ICS: A23L001-052; A61K038-17; A61K047-42
EXF 514/21; 514/23; 426/800; 426/656; 426/648; 426/654; 426/667; 426/641; 426/657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 458 OF 469 USPATFULL on STN
AN 95:114771 USPATFULL
TI Use of PLA.sub.2 inhibitors as treatment for alzheimer's disease
IN Clemens, James A., Indianapolis, IN, United States
Sofia, Michael J., Lawrenceville, NJ, United States
Stephenson, Diane T., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5478857 19951226
AI US 1993-173544 19931223 (8)
DT Utility
FS Granted
LN.CNT 1801
INCL INCLM: 514/381.000
INCLS: 514/454.000; 514/455.000; 514/456.000; 514/457.000; 514/458.000; 514/568.000; 514/570.000; 514/571.000; 514/622.000
NCL NCLM: 514/381.000
NCLS: 514/454.000; 514/455.000; 514/456.000; 514/457.000; 514/458.000; 514/568.000; 514/570.000; 514/571.000; 514/622.000
IC [6]
ICM: A61K031-41
ICS: A61K031-35; A61K031-335; A61K031-19; A61K031-165
EXF 514/381; 514/454; 514/455; 514/456; 514/457; 514/458; 514/568; 514/570; 514/571; 514/622
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 459 OF 469 USPATFULL on STN
AN 95:82203 USPATFULL
TI Chromosome 14 and familial Alzheimers disease genetic markers and assays
IN Schellenberg, Gerard D., Seattle, WA, United States
Bird, Thomas D., Seattle, WA, United States
Wijsman, Ellen M., Seattle, WA, United States
PA University of Washington, Seattle, WA, United States (U.S. corporation)
PI US 5449604 19950912
AI US 1992-964151 19921021 (7)
DT Utility
FS Granted
LN.CNT 3278
INCL INCLM: 435/006.000
INCLS: 435/091.200
NCL NCLM: 435/006.000
NCLS: 128/925.000; 435/091.200
IC [6]
ICM: C12Q001-68
ICS: C12P019-34
EXF 435/6; 435/91.2; 536/24.31; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 460 OF 469 USPATFULL on STN
AN 95:29628 USPATFULL
TI Nutritional product for persons infected with human immunodeficiency virus
IN Cope, Frederick O., Worthington, OH, United States
DeWille, Normanella T., Upper Arlington, OH, United States
Richards, Ernest W., Columbus, OH, United States
Mazer, Terrence B., Reynoldsburg, OH, United States
Abbruzzese, Bonnie C., Dublin, OH, United States
Snowden, Gregory A., Pickerington, OH, United States
Chandler, Michael A., Gahanna, OH, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5403826 19950404
AI US 1993-69269 19930528 (8)
DT Utility

LN.CNT 1375
INCL INCLM: 514/021.000
INCLS: 514/002.000; 514/023.000; 426/656.000; 426/800.000
NCL NCLM: 514/021.000
NCLS: 426/656.000; 426/800.000; 514/002.000; 514/023.000
IC [6]
ICM: A16K037-02
ICS: A16K031-70; A16K035-60
EXF 514/21; 514/23; 514/2; 426/800; 426/656; 426/648; 426/654; 426/607
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 461 OF 469 USPATFULL on STN
AN 95:29292 USPATFULL
TI Viruses expressing chimeric binding proteins
IN Ladner, Robert C., Ijamsville, MD, United States
Guterman, Sonia K., Belmont, MA, United States
Roberts, Bruce L., Milford, MA, United States
Markland, William, Milford, MA, United States
Ley, Arthur C., Newton, MA, United States
Kent, Rachel B., Boxborough, MA, United States
PA Protein Engineering Corporation, Cambridge, MA, United States (U.S. corporation)
PI US 5403484 19950404
AI US 1993-9319 19930126 (8)
RLI Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409 which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now abandoned
PRAI WO 1989-3731 19890901
DT Utility
FS Granted
LN.CNT 14368
INCL INCLM: 435/235.100
INCLS: 435/069.700; 435/172.300; 435/252.300; 435/320.100; 530/350.000; 536/023.400
NCL NCLM: 435/235.100
NCLS: 435/069.700; 435/252.300; 435/320.100; 530/350.000; 536/023.400
IC [6]
ICM: C07K013-00
ICS: C12N007-01
EXF 435/69.7; 435/172.3; 435/235.1; 435/320.1; 536/23.4; 530/380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 462 OF 469 USPATFULL on STN
AN 95:11757 USPATFULL
TI Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
IN Cordell, Barbara, Palo Alto, CA, United States
PA Scios Nova Inc., Mountain View, CA, United States (U.S. corporation)
PI US 5387742 19950207
AI US 1991-716725 19910617 (7)
RLI Continuation-in-part of Ser. No. US 1990-538857, filed on 15 Jun 1990, now abandoned
DT Utility
FS Granted
LN.CNT 2014
INCL INCLM: 800/002.000
INCLS: 424/009.000; 435/142.300; 536/023.500
NCL NCLM: 800/012.000
NCLS: 536/023.500; 800/018.000
IC [6]
ICM: A61K049-00
ICS: C12N015-00; C07H015-12
EXF 800/2; 435/6; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 463 OF 469 USPATFULL on STN
AN 94:70947 USPATFULL
TI Method of identifying inhibitors of .beta.-protein esterase activity
IN Potter, Huntington, Boston, MA, United States
Kayyali, Usamah, Somerville, MA, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5338663 19940816

RLI Continuation-in-part of Ser. No. US 1990-572671, filed on 24 Aug 1990, now abandoned
DT Utility
FS Granted
LN.CNT 875
INCL INCLM: 435/004.000
INCLS: 435/007.400; 435/019.000; 435/023.000; 435/219.000
NCL NCLM: 435/004.000
NCLS: 435/007.400; 435/019.000; 435/023.000; 435/219.000
IC [5]
ICM: C12Q001-00
ICS: C12Q001-44; C12Q001-37; C12N009-50
EXF 435/4; 435/7.4; 435/19; 435/23; 435/219; 436/86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 464 OF 469 USPATFULL on STN
AN 94:62434 USPATFULL
TI Method of impeding apoptosis of CD4 cells in persons infected with human immunodeficiency virus
IN Cope, Frederick O., Worthington, OH, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5330972 19940719
AI US 1993-69264 19930528 (8)
DT Utility
FS Granted
LN.CNT 1305
INCL INCLM: 514/002.000
INCLS: 514/021.000; 530/378.000; 426/044.000; 426/046.000; 426/656.000; 426/800.000; 426/658.000; 426/419.000
NCL NCLM: 514/002.000
NCLS: 426/044.000; 426/046.000; 426/419.000; 426/656.000; 426/658.000; 426/800.000; 514/021.000; 530/378.000
IC [5]
ICM: A61K037-02
EXF 514/2; 514/21; 426/656; 426/46; 426/44; 426/800; 426/658; 426/419; 530/378
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 465 OF 469 USPATFULL on STN
AN 93:61009 USPATFULL
TI ***Antibodies*** to A4 amyloid peptide
IN Majocha, Ron, Wayland, MA, United States
Marotta, Charles A., Cambridge, MA, United States
Zain, Sayeeda, Pittsford, NY, United States
PA The McLean Hospital, Belmont, MA, United States (U.S. corporation)
University of Rochester, Rochester, NY, United States (U.S. corporation)
PI US 5231000 19930727
AI US 1991-733375 19910722 (7)
RLI Continuation of Ser. No. US 1987-105751, filed on 8 Oct 1987
DT Utility
FS Granted
LN.CNT 687
INCL INCLM: 435/007.100
INCLS: 435/007.200; 435/007.210; 435/240.270; 530/388.100; 436/501.000; 436/506.000
NCL NCLM: 435/007.100
NCLS: 435/007.200; 435/007.210; 435/331.000; 436/501.000; 436/506.000; 530/388.100
IC [5]
ICM: G01N033-53
ICS: G01N033-564; G01N033-577; C12N005-20
EXF 530/387; 435/240.27; 435/7.1; 435/960; 435/7.2; 435/388.2; 436/518; 436/529-530; 436/548; 436/512; 436/501; 436/507; 424/85.8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 466 OF 469 USPATFULL on STN
AN 93:52487 USPATFULL
TI Directed evolution of novel binding proteins
IN Ladner, Robert C., Ijamsville, MD, United States
Guterman, Sonia K., Belmont, MA, United States
Roberts, Bruce L., Milford, MA, United States
Markland, William, Milford, MA, United States
Ley, Arthur C., Newton, MA, United States
Kent, Rachel B., Boxborough, MA, United States
PA Protein Engineering Corp., Cambridge, MA, United States (U.S.

PI US 5223409 19930629
AI US 1991-664989 19910301 (7)
RLI Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990, now abandoned And a continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988, now abandoned
DT Utility
FS Granted
LN.CNT 15410
INCL INCLM: 435/069.700
INCLS: 435/069.100; 435/172.300; 435/252.300; 435/320.100; 530/380.300; 530/387.500
NCL NCLM: 435/069.700
NCLS: 435/005.000; 435/069.100; 435/252.300; 435/320.100; 435/472.000; 530/387.300; 530/387.500
IC [5]
ICM: C12N015-09
ICS: C12N015-62; C12N015-63
EXF 435/69.1; 435/172.3; 435/252.3; 435/320.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 467 OF 469 USPATFULL on STN
AN 92:65951 USPATFULL
TI Substance P and tachykinin agonists for treatment of Alzheimer's disease
IN Yankner, Bruce A., Boston, MA, United States
PA The Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5137873 19920811
AI US 1990-559173 19900727 (7)
DT Utility
FS Granted
LN.CNT 376
INCL INCLM: 514/015.000
INCLS: 514/002.000; 530/327.000; 530/839.000
NCL NCLM: 514/015.000
NCLS: 514/002.000; 530/327.000; 530/839.000
IC [5]
ICM: A61K037-42
ICS: A61K037-02; C07K007-06; C07K007-22
EXF 514/14; 514/15; 514/18; 530/327; 530/328; 530/331; 530/839; 436/811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 468 OF 469 USPAT2 on STN
AN 2002:141109 USPAT2
TI Death domain containing receptor 5
IN Ni, Jian, Rockville, MD, United States
Gentz, Reiner L., Rockville, MD, United States
Yu, Guo-Liang, Berkeley, CA, United States
Rosen, Craig A., Laytonsville, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6743625 B2 20040601
AI US 2001-874138 20010606 (9)
RLI Continuation of Ser. No. US 2000-565009, filed on 4 May 2000
Continuation-in-part of Ser. No. US 1998-42583, filed on 17 Mar 1998
PRAI US 1999-148939P 19990813 (60)
US 1999-133238P 19990507 (60)
US 1999-132498P 19990504 (60)
US 1998-42583P 19980317 (60)
US 1997-54021P 19970729 (60)
US 1997-40846P 19970317 (60)
DT Utility
FS GRANTED
LN.CNT 8567
INCL INCLM: 435/325.000
INCLS: 530/350.000; 536/023.100; 536/023.400; 536/023.500; 435/069.100; 435/252.300; 435/254.110
NCL NCLM: 435/325.000
NCLS: 435/069.100; 435/252.300; 435/254.110; 530/350.000; 536/023.100; 536/023.400; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C12N005-10; C12N015-12
EXF 530/350; 536/23.1; 536/23.5; 536/23.4; 435/320.1; 435/69.1; 435/325; 435/252.3; 435/254.11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 469 OF 469 USPAT2 on STN
AN 2002:37941 USPAT2
TI Methods for treating multiple sclerosis
IN Shankar, L. Sai Latha, 323 E. 88th St., Apt. 19, New York, NY, United States 10128
Tatton, William G., 8 Halliday Ct., Purchase, NY, United States 10577
Tatton, Nadine A., 8 Halliday Ct., Purchase, NY, United States 10577
PI US 6492427 B2 20021210
AI US 1999-416010 19991008 (9)
PRAI US 1998-103742P 19981009 (60)
DT Utility
FS GRANTED
LN.CNT 4782
INCL INCLM: 514/646.000
INCLS: 514/647.000; 514/654.000
NCL NCLM: 514/646.000
NCLS: 514/647.000; 514/654.000
IC [7]
ICM: A61K031-135
EXF 514/646; 514/647; 514/651; 514/654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
STN INTERNATIONAL LOGOFF AT 16:00:41 ON 31 AUG 2004